From 41211867b0c1fa6d073fb3b2efea16892066456b Mon Sep 17 00:00:00 2001 From: Fuyuan Wang <60631776+wfy1997@users.noreply.github.com> Date: Mon, 30 Sep 2024 09:58:49 -0400 Subject: [PATCH 01/23] update to split the image node --- model-desc/cds-model-props.yml | 1325 ++++++++++++++++++-------------- model-desc/cds-model.yml | 178 +++-- 2 files changed, 875 insertions(+), 628 deletions(-) diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index 42a81cb..40fc401 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -1,11 +1,11 @@ PropDefinitions: - #crdc_id + # crdc_id crdc_id: Desc: The crdc_id is a unique identifier that is generated by Data Hub Type: string Tags: Template: 'No' - #image + # image study_link_id: Desc: The study_link_id is ID property for the node image. It should consist of a string and a number. Req: true @@ -187,925 +187,1088 @@ PropDefinitions: Code: '6161035' Value: ICD-O Origin of Disease Anatomic Site Version: '1.00' - performed_imaging_study_description: - Desc: The textual representation of the certain or salient aspects, characteristics, or features of the imaging study. [Adapted from www.businessdictionary.com] - Req: true - Type: string - Term: - - Origin: caDSR - Original Source: DICOM - Code: '2182389' - Value: Image Study Description 64 Character Text - Version: '2.10' - performed_imaging_study_admittingDiagnosisCode: - Desc: The identified disease(s) or illness(es) at the time of the admission during which imaging was performed. - Req: true - Type: string - Term: - - Origin: caDSR - Original Source: DICOM - Code: '2902328' - Value: Image Study Admitting Diagnosis Description 64 Character Text - Version: '1.00' - performed_imaging_study_nonAcquisitionModalitiesInStudyCode: - Desc: A coded value specifying the type of equipment that created the images in this imaging study other than that used to acquire the original data. + performed_imaging_study_typeCode: + Desc: A coded value specifying the kind of algorithm used when reconstructing the image from the data acquired during the acquisition process. Req: true Type: string Term: - Origin: caDSR - Original Source: DSS - Code: '12137353' - Value: Imaging Technology DICOM Modality Type + Original Source: CDS + Code: "14617551" + Value: Imaging Reconstruction Protocol Type Code" Version: '1.00' - performed_imaging_study_lossyImageCompressionIndicator: - Desc: Specifies whether any images in the study are irreversibly altered during encoding at any time during its life. - Req: true - Enum: - - "0" - - "1" + longitudinal_temporal_event_type: + Desc: The type of event to which Longitudinal Temporal Offset from Event is relative. + Type: number Term: - Origin: caDSR - Code: '2659474' - Value: Image Lossy Compression Code + Original Source: CDS + Code: '14670294' + Value: Longitudinal Study Temporal Event Type Version: '1.00' - performed_imaging_study_summary: - Desc: A brief statement about the characteristics of this element, which is intended for use by the radiologist, technologist and/or physicist during management of the imaging protocol to understand the characteristics of the element in the protocol. - Req: true - Type: string + longitudinal_temporal_event_offset: + Desc: An offset in days from a particular event of significance. May be fractional. In the context of a clinical trial, this is often the days since enrollment, or the baseline imaging Study. + Type: number Term: - Origin: caDSR Original Source: CDS - Code: '14670299' - Value: Imaging Study Process Protocol Element Summary Text + Code: '14612661' + Value: Longitudinal Study Temporal Offset Number Version: '1.00' - performed_imaging_study_primaryAnatomicSiteCode: - Desc: A coded value specifying the anatomic location that is the focus of this imaging process protocol element. + #MultiplexMicroscopy: + MultiplexMicroscopy_id: + Desc: MultiplexMicroscopy identifier + Type: string Req: true + Key: true + acquisition_method_type: + Desc: Records the method of acquisition or source for the specimen under consideration Type: string Term: - Origin: caDSR - Original Source: CDS - Code: '14612662' - Value: Image Study Primary Anatomic Site Sequence of Items Text - Version: '1.00' - performed_imaging_study_acquisitionTypeCode: - Desc: A coded value specifying spatial aspects of the mechanism of data collection. - Req: true + Original Source: MCL/HTAN + Code: '6626651' + Value: Biospecimen Acquisition Method Type + Version: '2.00' + tumor_tissue_type: + Desc: Text that describes the kind of disease present in the tumor specimen as related to a specific timepoint (add rows to select multiple values along with timepoints) Type: string Term: - Origin: caDSR - Original Source: CDS - Code: '14670301' - Value: Image Study Spatial Acquisition Type Code + Original Source: HTAN + Code: '3288124' + Value: Tumor Tissue Disease Description Type Version: '1.00' - performed_imaging_study_cardiacSynchronizationTechniqueCode: - Desc: The means used to coordinate the collection or reconstruction of data with the cardiac cycle. + tissue_fixative: + Desc: A compound that preserves tissues and cells for microscopic study. + Req: true Enum: - - REALTIME - - PROSPECTIVE - - RETROSPECTIVE - - PACED - - NONE + - 95% Ethanol + - Acetone + - Alcohol + - Carbodiimide + - Carnoy's Solution + - CryoStor + - Diimidoester + - Dimethylacetamide + - Formalin + - Glutaraldehyde + - Methacarn + - Not applicable + - Not recorded + - NP40 Lysis Buffer + - OCT media + - Other + - Para-benzoquinone + - PAXgene Tissue + - Poloxamer + - RNAlater + - Saline + - TCL Lysis Buffer + - Unknown Term: - Origin: caDSR - Original Source: CDS - Code: '14617521' - Value: Image Study Cardiac Synchronization Technique Code Name - Version: '1.00' - performed_imaging_study_dataCollectionDiameter: - Desc: The diameter of the region over which information is acquired. + Original Source: NCI Standard + Code: '65078' + Value: Specimen Fixative Type + Version: '4.00' + embedding_medium: + Desc: A material that infiltrates and supports a specimen and preserves its shape and structure for sectioning and microscopy. Req: true - Type: string + Enum: + - Paraffin wax + - Carbowax + - Methacrylate + - Epoxy Resin (Araldite) + - Agar embedding + - Celloidin media + - Gelatin + - Other + - None + - Unknown Term: - Origin: caDSR - Original Source: CDS - Code: '14612665' - Value: Image Acquisition Data Collection Location Diameter Number + Original Source: HTAN + Code: '8037927' + Value: Biospecimen Collection Medium Type Version: '1.00' - performed_imaging_study_respiratoryMotionTechniqueCode: - Desc: The means to be used to coordinate the collection or reconstruction of data with breathing. + staining_method: + Desc: Any of the various methods that use a dye, reagent, or other material for producing coloration in tissues or microorganisms for microscopic examination. Req: true Enum: - - BREATH-HOLD - - REALTIME - - GATING - - TRACKING - - RETROSPECTIVE - - CORRECTION - - NONE + - CODEX + - GeoMX-DSP + - H&E + - IHC + - IMC + - MIBI + - mIHC + - MxIF + - SABER + - t-CyCIF Term: - Origin: caDSR - Original Source: CDS - Code: '14617522' - Value: Image Study Respiratory Motion Technique Code Name + Original Source: HTAN + Code: '7789196' + Value: Imaging Assay Technology Type Version: '1.00' - performed_imaging_study_bodyPositionCode: - Desc: A coded value specifying the 3-dimensional spatial orientation of a subject during this imaging acquisition protocol element. - Enum: - - Supine - - Trendelenburg - - Standing + objective: + Desc: "An\_objective\_is an optical element that gathers light from an object being observed and\_focuses\_the\_light rays\_from it to produce a\_real image\_of the object." + Type: string Term: - Origin: caDSR - Original Source: CDS - Code: '14617523' - Value: Image Study Body Position Name + Code: '7788935' + Value: Microscope Device Objective Lens Text Version: '1.00' - performed_imaging_study_typeCode: - Desc: A coded value specifying the kind of algorithm used when reconstructing the image from the data acquired during the acquisition process. - Req: true + nominal_magnification: + Desc: The magnification of the lens as specified by the manufacturer - i.e. '60' is a 60X lens. floating point value > 1(no units) Type: string Term: - Origin: caDSR - Original Source: CDS - Code: "14617551" - Value: Imaging Reconstruction Protocol Type Code" + Original Source: HTAN + Code: '7788940' + Value: Microscope Device Nominal Magnification Float Value Version: '1.00' - performed_imaging_study_algorithmCode: - Desc: A coded value specifying the algorithm to use when reconstructing the image from the data acquired during the acquisition process - Req: true + immersion: + Desc: Immersion medium Type: string Term: - Origin: caDSR - Code: '14617557' - Value: Imaging Reconstruction Protocol Algorithm Code Text + Original Source: HTAN + Code: '8058286' + Value: Microscope Device Immersion Medium Type Version: '1.00' - performed_imaging_study_reconstructionFieldOfViewHeight: - Desc: The vertical dimension of the rectangular region from which data is used in creating the reconstruction of the image. - Req: true + lens_numerical_aperture: + Desc: The numerical aperture of the lens. Floating point value > 0. Type: string Term: - Origin: caDSR - Code: '14612672' - Value: Imaging Reconstruction Protocol Field of View Height Number + Original Source: HTAN + Code: '7788942' + Value: Microscope Device Lens Numerical Aperture Float Value Version: '1.00' - performed_imaging_study_reconstructionFieldOfViewWidth: - Desc: The horizontal dimension of the rectangular region from which data is used in creating the reconstruction of the image. - Req: true + working_distance: + Desc: The working distance of the lens, expressed as a floating point number. Floating point > 0. Size needs to be specified in microns (um) Type: string Term: - Origin: caDSR - Code: '14612674' - Value: Imaging Reconstruction Protocol Field of View Width Number + Original Source: HTAN + Code: '7788943' + Value: Microscope Device Working Distance Float Value Version: '1.00' - performed_imaging_study_reconstructionDiameter: - Desc: The diameter of the region from which data is used in creating the reconstruction of the image. + imaging_assay_type: + Desc: Type of imaging assay Req: true Type: string Term: - Origin: caDSR - Code: '2182085' - Value: Reconstruction Diameter in Millimeter(s) + Original Source: HTAN + Code: '7789196' + Value: Imaging Assay Technology Type Version: '1.00' - performed_imaging_study_sliceThickness: - Desc: The cross plane dimension of the reconstructed image. - Req: true + pyramid: + Desc: The data file contains an image pyramid Type: string Term: - Origin: caDSR - Code: '3113185' - Value: Image Plane Slice Thickness Float or Fixed-point Millimeter Number - Version: '2.00' - performed_imaging_study_reconstructionInterval: - Desc: The cross plane distance between the centers of adjacent, parallel reconstructed images. - Req: true + Original Source: HTAN + Code: '7788945' + Value: Image Processing Pyramid Representation True False Indicator + Version: '1.00' + physical_size_x: + Desc: Physical size (X-dimension) of a pixel. Floating point value > 0. Size needs to be specified in microns (um) Type: string Term: - Origin: caDSR - Code: '14612682' - Value: Imaging Reconstruction Protocol Reconstruction Interval Millimeter Number + Original Source: HTAN + Code: '7786584' + Value: Image Processing Pyramid Representation True False Indicator Version: '1.00' - longitudinal_temporal_event_type: - Desc: The type of event to which Longitudinal Temporal Offset from Event is relative. - Type: number + physical_size_y: + Desc: Physical size (Y-dimension) of a pixel. Floating point value > 0. Size needs to be specified in microns (um) + Type: string Term: - Origin: caDSR - Original Source: CDS - Code: '14670294' - Value: Longitudinal Study Temporal Event Type + Original Source: HTAN + Code: '7786585' + Value: Pixel Y-Dimension Float Value Version: '1.00' - longitudinal_temporal_event_offset: - Desc: An offset in days from a particular event of significance. May be fractional. In the context of a clinical trial, this is often the days since enrollment, or the baseline imaging Study. - Type: number + physical_size_z: + Desc: Physical size (Z-dimension) of a pixel. Floating point value > 0. Size needs to be specified in microns (um) + Type: string Term: - Origin: caDSR - Original Source: CDS - Code: '14612661' - Value: Longitudinal Study Temporal Offset Number + Original Source: HTAN + Code: '7786586' + Value: Pixel Z-Dimension Float Value Version: '1.00' - CTAquisitionProtocolElement_singleCollimationWidth: - Desc: The width of a single row of acquired data. The units are of linear distince, e.g. mm. + size_c: + Desc: Number of channels. Integer >= 1 Type: string Term: - Origin: caDSR - Code: '2903347' - Value: Image Single Collimation Width 8 Byte Millimeter Number + Code: '7794859' + Value: OME TIFF Channel Count Version: '1.00' - CTAquisitionProtocolElement_totalCollimationWidth: - Desc: The width of the total collimation over the area of active x-ray detection. The units are of linear distince, e.g. mm. - Req: true + size_t: + Desc: Number of time points. Integer >= 1 Type: string Term: - Origin: caDSR - Code: '2903328' - Value: Image Total Collimation Width 8 Byte Millimeter Number + Code: '7794860' + Value: OME TIFF Timepoint Count Version: '1.00' - CTAquisitionProtocolElement_gantryDetectorTilt: - Desc: Nominal angle of tilt in degrees of the scanning gantry. The units are of plane angle , e.g. degrees. Zero degrees means the gantry is not tilted, negative degrees are when the top of the gantry is tilted away from where the table enters the gantry. - Req: true + size_x: + Desc: 'Size of image: X dimension (in pixels). Integer >= 1' Type: string Term: - Origin: caDSR - Original Source: caDSR - Code: '2656117' - Value: Image Gantry Detector Tilt 16 Character Number + Code: '7788567' + Value: OME TIFF X-Dimension Pixel Measurement Version: '1.00' - CTAquisitionProtocolElement_spiralPitchFactor: - Desc: Ratio of the distance that the table moves during a complete revolution of the source around the gantry orbit, to the width of the total collimation over the area of active x-ray detection. The units are of unity. - Req: true + size_y: + Desc: 'Size of image: Y dimension (in pixels). Integer >= 1' Type: string Term: - Origin: caDSR - Code: '2414556' - Value: Computed Tomography Pitch Factor Number + Code: '7788568' + Value: OME TIFF Y-Dimension Pixel Measurement Version: '1.00' - CTAquisitionProtocolElement_ctdiVol: - Desc: The average dose over the total volume scanned for the selected CT conditions of operation (calculated according to IEC 60601-2-44, Ed.2.1 (Clause 29.1.103.4)). The units are energy dose, e.g. mGy. - Req: true + size_z: + Desc: 'Size of image: Z dimension (in pixels). Integer >= 1' Type: string Term: - Origin: caDSR - Code: '3882991' - Value: Computed Tomography Dose Index Volume Quantity 8 Byte Number + Code: '7788569' + Value: OME TIFF Z-Dimension Pixel Measurement Version: '1.00' - CTAquisitionProtocolElement_ctdiPhantomTypeCode: - Desc: The type of phantom to use for CTDI measurement according to IEC 60601-2-44 + channel_metadata_filename: + Desc: File name of uploaded companion CSV file containing channel-level metadata details Req: true Type: string Term: - Origin: caDSR - Code: '14612683' - Value: Imaging Technique CTDI Phantom Type Sequence of Items Text + Original Source: HTAN + Code: '7787678' + Value: Channel Analysis Metadata Electronic File Name Text Version: '1.00' - CTAquisitionProtocolElement_kVp: - Desc: Peak kilovoltage output of the x-ray generator. The units are of electrical potential. - Req: true + channel_metadata_file_url_in_cds: + Desc: '' Type: string Term: - Origin: caDSR - Code: '2904496' - Value: Image Kilovolt Peak Float 16 Number + Original Source: CDS + Code: '11556141' + Value: Electronic File Pathname Text Version: '1.00' - CTAquisitionProtocolElement_exposureModulationType_Code: - Desc: The manner in which tube current is varied in order to limit the dose. - Enum: - - NONE - - ANGULAR - - LONGITUDINAL - - ECG-BASED - - ORGAN-BASED + channel_id: + Desc: The unique channel identifier for each channel in this image must match the corresponding field in the OME-TIFF header + Req: true + Type: string Term: - Origin: caDSR - Code: '14617524' - Value: Imaging Technique Exposure Modulation Type + Code: '14765171' + Value: OME Tagged Image File Format Channel Identifier Version: '1.00' - CTImageReconstructionProtocolElement_convolutionKernel: - Desc: A label describing the mathematical operations used to reconstruct images from the acquired data. The values for this attribute are vendor specific and not coded. + channel_name: + Desc: Channel label for each channel in this image must match the corresponding field in the OME-TIFF header + Req: true Type: string Term: - Origin: caDSR - Code: '2656119' - Value: Image Convolution Kernel 16 Character Text + Code: '14765172' + Value: OME Tagged Image File Format Channel Name Version: '1.00' - CTImageReconstructionProtocolElement_convolutionKernelGroupCode: - Desc: A coded value specifying the family of mathematical operations to use to reconstruct images from the acquired data + cycle_number: + Desc: 'the cycle # in which the co-listed reagent(s) was(were) used' Type: string Term: - Origin: caDSR - Code: '14617525' - Value: Imaging Technique Convolution Kernel Group Name + Original Source: CDS + Code: '14765176' + Value: Multiplex Imaging Reagent Cycle Number Integer Version: '1.00' - MRImageAcquisitionProtocolElement_echoPulseSequenceCategoryCode: - Desc: A coded value specifying an echo category of pulse sequences. - Enum: - - SPIN - - GRADIENT - - BOTH + sub_cycle_number: + Desc: 'sub-cycle #' + Type: string Term: - Origin: caDSR Original Source: CDS - Code: '14645641' - Value: Image Acquisition Spin-Echo Pulse Sequence Code Category + Code: '14765180' + Value: Multiplex Imaging Reagent Sub-Cycle Number Integer Version: '1.00' - MRImageAcquisitionProtocolElement_diffusionBValue: - Desc: The factor by which the acquisition is sensitized to the Brownian motion of water molecules. The units are of time/area, e.g. s/mm2 + target_name: + Desc: short descriptive name (abbreviation) for this target (antigen) Type: string Term: - Origin: caDSR - Code: '14607706' - Value: Imaging Technique MR Diffusion B Value Number + Original Source: CDS + Code: "14765180" + Value: "Multiplex Imaging Reagent Sub-Cycle Number Integer" Version: '1.00' - MRImageAcquisitionProtocolElement_diffusionDirectionalityCode: - Desc: A coded value specifying whether diffusion conditions for the frame are directional, or isotropic with respect to direction - Enum: - - DIRECTIONAL - - BMATRIX - - ISOTROPIC - - NONE + antibody_name: + Desc: short descriptive name for this antibody + Type: string Term: - Origin: caDSR - Code: '14616426' - Value: Imaging Technique Diffusion Directionality Type + Original Source: CDS + Code: '14765184' + Value: Tissue Slide IHC Antibody Used Type Version: '1.00' - MRImageAcquisitionProtocolElement_magneticFieldStrength: - Desc: "A vector quantity indicating the ability of a magnetic field to exert a force on moving electric charges. [The American Heritage\xAE Science Dictionary]. The units are of magnetic flux density, e.g. tesla." + rrid_identifier: + Desc: Research Resource Identifier Type: string Term: - Origin: caDSR - Code: '14607707' - Value: Imaging Technique Magnetic Field Strength Number + Original Source: CDS + Code: '14767247' + Value: Multiplex Imaging Research Resource Identifier Text Version: '1.00' - MRImageAcquisitionProtocolElement_resonantNucleusCode: - Desc: A coded value specifying the atomic nucleus that is the target of the acquisition - Enum: - - 1H - - 3HE - - 7LI - - 13C - - 19F - - 23NA - - 31P - - 129XE + fluorophore: + Desc: Fluorescent dye label + Type: string Term: - Origin: caDSR - Code: '14616427' - Value: Image Acquisition Resonant Nucleus Type + Original Source: CDS + Code: '14767255' + Value: Multiplex Imaging Fluorescent Dye Text Version: '1.00' - MRImageAcquisitionProtocolElement_acquisitionContrastCode: - Desc: A coded value specifying the inherent (as opposed to exogenous) contrast in the acquisition. - Enum: - - DIFFUSION - - FLOW_ENCODED_Flow Encoded contrast - - FLUID_ATTENUATED_Fluid Attenuated T2 weighted contrast - - PERFUSION_Perfusion weighted contrast - - PROTON_DENSITY_Proton Density weighted contrast - - STIR_Short Tau Inversion Recovery - - TAGGING_Superposition of thin saturation bands onto image - - T1_T1 weighted contrast - - T2_T2 weighted contrast - - T2_STAR_T2* weighted contrast - - TOF_Time Of Flight weighted contrast + clone: + Desc: Unique clone identifier + Type: string Term: - Origin: caDSR - Code: '14616428' - Value: Image Acquisition Contrast Type + Original Source: CDS + Code: '14767258' + Value: Multiplex Imaging Clone Unique Identifier Version: '1.00' - MRImageAcquisitionProtocolElement_inversionRecoveryIndicator: - Desc: Specifies whether an inversion recovery preparatory sequence is used in the acquisition. + lot: + Desc: lot number from vendor Type: string Term: - Origin: caDSR - Code: '14607722' - Value: Image Acquisition Inversion Recovery Indicator + Original Source: CDS + Code: '14769695' + Value: Multiplex Imaging Vendor Lot Number Text Version: '1.00' - MRImageAcquisitionProtocolElement_pulseSequenceName: - Desc: Name of the pulse sequence that is used for the acquisition. This is usually a vendor-specific name. + catalog_number: + Desc: catalog number from vendor Type: string Term: - Origin: caDSR - Code: '14608594' - Value: Image Acquisition Pulse Sequence Name Text + Original Source: CDS + Code: '14767261' + Value: Multiplex Imaging Vendor Catalog Number Text Version: '1.00' - MRImageAcquisitionProtocolElement_multipleSpinEchoIndicator: - Desc: Specifies whether different lines in k-space are collected for a single frame. + excitation_wavelength: + Desc: center/peak of the excitation spectrum (nm) Type: string Term: - Origin: caDSR - Code: '14608595' - Value: Imaging Technique Multiple Spin Echo Indicator + Original Source: CDS + Code: '14765187' + Value: Multiplex Imaging Excitation Wavelength Number Version: '1.00' - MRImageAcquisitionProtocolElement_phaseContrastIndicator: - Desc: Specifies whether this is a pulse sequence in which the flowing spins are velocity encoded in phase. + emission_wavelength: + Desc: center/peak of the emission spectrum (nm) Type: string Term: - Origin: caDSR - Code: '14608601' - Value: Image Phase Contrast Indicator + Original Source: CDS + Code: '14767264' + Value: Multiplex Imaging Emission Wavelength Number Version: '1.00' - MRImageAcquisitionProtocolElement_timeOfFlightContrastIndicator: - Desc: Specifies whether contrast is created by the inflow of blood in the saturated plane. + excitation_bandwidth: + Desc: nominal width of excitation spectrum (nm) Type: string Term: - Origin: caDSR - Code: '14608649' - Value: Imaging Technique Time of Flight Contrast Indicator + Original Source: CDS + Code: '14765190' + Value: Multiplex Imaging Excitation Bandwidth Number Version: '1.00' - MRImageAcquisitionProtocolElement_arterialSpinLabelingContrastCode: - Desc: A coded value specifying how arterial water is used as a diffusable tracer. + emission_bandwidth: + Desc: nominal width of emission spectrum (nm) Type: string Term: - Origin: caDSR - Code: '14616429' - Value: Imaging Technique Arterial Spin Labeling Contrast Name + Original Source: CDS + Code: '14765193' + Value: Multiplex Imaging Emission Bandwidth Number Version: '1.00' - MRImageAcquisitionProtocolElement_steadyStatePulseSequenceCode: - Desc: A coded value specifying how residual transverse magnetization is maintained during the acquisition. - Enum: - - FREE PRECESSION - - TRANSVERSE - - TIME REVERSED - - LONGITUDINAL - - NONE + metal_isotope_element_abbreviation: + Desc: Element abbreviation + Type: string Term: - Origin: caDSR - Code: '14616430' - Value: Image Acquisition Steady State Pulse Sequence Type + Original Source: CDS + Code: '14765198' + Value: Multiplex Imaging Isotope Abbreviation Name Version: '1.00' - MRImageAcquisitionProtocolElement_echoPlanarPulseSequenceIndicator: - Desc: Specifies whether multiple echos of different phase steps are acquired using rephasing gradients instead of repeated 180-degree pulses. + metal_isotope_element_mass: + Desc: Element mass number Type: string Term: - Origin: caDSR - Code: '14612651' - Value: Image Acquisition Echo Planar Pulse Sequence Indicator + Original Source: CDS + Code: '14765201' + Value: Multiplex Imaging Isotope Element Number Identifier Version: '1.00' - MRImageAcquisitionProtocolElement_saturationRecoveryIndicator: - Desc: Specifies whether a saturation recovery pulse sequence is used + oligo_barcode_upper_strand: + Desc: DNA barcode used for labeling Type: string Term: - Origin: caDSR - Code: '14612652' - Value: Imaging Technique Saturation Recovery Indicator + Original Source: CDS + Code: '14765205' + Value: Multiplex Imaging Oligonucleotide Barcode Upper Strand Text Version: '1.00' - MRImageAcquisitionProtocolElement_spectrallySelectedSuppressionCode: - Desc: A coded value specifying the type of substance-specific signal suppression is used. - Enum: - - FAT - - WATER - - FAT AND WATER - - SILICON GEL - - NONE + oligo_barcode_lower_strand: + Desc: DNA barcode used for labeling + Type: string Term: - Origin: caDSR - Code: '14616431' - Value: Imaging Technique Spectrally Selected Suppression Type + Original Source: CDS + Code: '14765208' + Value: Multiplex Imaging Oligonucleotide Barcode Lower Strand Text Version: '1.00' - MRImageReconstructionProtocolElement_complexImageComponentCode: - Desc: A coded value specifying the channel of the quadrature detected data, or the combination derived from those channels, used to reconstruct the image - Enum: - - REAL - - IMAGINARY - - PHASE - - MAGNITUDE + dilution: + Desc: Final dilution ratio used in experiment + Type: string Term: - Origin: caDSR - Code: '14616432' - Value: Imaging Technique Complex Image Component Type + Code: '14767270' + Value: Multiplex Imaging Final Dilution Ratio Number Version: '1.00' - PETImagingAcquisitionProtocolElement_gantryDetectorTilt: - Desc: Nominal angle of tilt in degrees of the scanning gantry. The units are of plane angle , e.g. degrees. Zero degrees means the gantry is not tilted, negative degrees are when the top of the gantry is tilted away from where the table enters the gantry. + concentration: + Desc: Final concentration used in experiment Type: string Term: - Origin: caDSR - Code: '2656117' - Value: Image Gantry Detector Tilt 16 Character Number + Original Source: CDS + Code: '14768386' + Value: Multiplex Imaging Final Concentration Number Version: '1.00' - Radiopharmaceutical_radionuclideCode: - Desc: A coded value that specifies the radioactive isotope in the radiophamaceutical. + # NonDICOMradiologyAllModalities: + NonDICOMradiologyAllModalities_id: + Desc: NonDICOMradiologyAllModalities identifier + Type: string + Req: true + Key: true + performed_imaging_study_description: + Desc: The textual representation of the certain or salient aspects, characteristics, or features of the imaging study. [Adapted from www.businessdictionary.com] + Req: true Type: string Term: - Origin: caDSR - Code: '14612653' - Value: Imaging Technique Radionuclide Code Text + Original Source: DICOM + Code: '2182389' + Value: Image Study Description 64 Character Text + Version: '2.10' + performed_imaging_study_admittingDiagnosisCode: + Desc: The identified disease(s) or illness(es) at the time of the admission during which imaging was performed. + Req: true + Type: string + Term: + - Origin: caDSR + Original Source: DICOM + Code: '2902328' + Value: Image Study Admitting Diagnosis Description 64 Character Text Version: '1.00' - acquisition_method_type: - Desc: Records the method of acquisition or source for the specimen under consideration + performed_imaging_study_nonAcquisitionModalitiesInStudyCode: + Desc: A coded value specifying the type of equipment that created the images in this imaging study other than that used to acquire the original data. + Req: true Type: string Term: - Origin: caDSR - Original Source: MCL/HTAN - Code: '6626651' - Value: Biospecimen Acquisition Method Type - Version: '2.00' - tumor_tissue_type: - Desc: Text that describes the kind of disease present in the tumor specimen as related to a specific timepoint (add rows to select multiple values along with timepoints) + Original Source: DSS + Code: '12137353' + Value: Imaging Technology DICOM Modality Type + Version: '1.00' + performed_imaging_study_lossyImageCompressionIndicator: + Desc: Specifies whether any images in the study are irreversibly altered during encoding at any time during its life. + Req: true + Enum: + - "0" + - "1" + Term: + - Origin: caDSR + Code: '2659474' + Value: Image Lossy Compression Code + Version: '1.00' + performed_imaging_study_summary: + Desc: A brief statement about the characteristics of this element, which is intended for use by the radiologist, technologist and/or physicist during management of the imaging protocol to understand the characteristics of the element in the protocol. + Req: true Type: string Term: - Origin: caDSR - Original Source: HTAN - Code: '3288124' - Value: Tumor Tissue Disease Description Type + Original Source: CDS + Code: '14670299' + Value: Imaging Study Process Protocol Element Summary Text Version: '1.00' - tissue_fixative: - Desc: A compound that preserves tissues and cells for microscopic study. + performed_imaging_study_primaryAnatomicSiteCode: + Desc: A coded value specifying the anatomic location that is the focus of this imaging process protocol element. Req: true + Type: string + Term: + - Origin: caDSR + Original Source: CDS + Code: '14612662' + Value: Image Study Primary Anatomic Site Sequence of Items Text + Version: '1.00' + performed_imaging_study_acquisitionTypeCode: + Desc: A coded value specifying spatial aspects of the mechanism of data collection. + Req: true + Type: string + Term: + - Origin: caDSR + Original Source: CDS + Code: '14670301' + Value: Image Study Spatial Acquisition Type Code + Version: '1.00' + performed_imaging_study_cardiacSynchronizationTechniqueCode: + Desc: The means used to coordinate the collection or reconstruction of data with the cardiac cycle. Enum: - - 95% Ethanol - - Acetone - - Alcohol - - Carbodiimide - - Carnoy's Solution - - CryoStor - - Diimidoester - - Dimethylacetamide - - Formalin - - Glutaraldehyde - - Methacarn - - Not applicable - - Not recorded - - NP40 Lysis Buffer - - OCT media - - Other - - Para-benzoquinone - - PAXgene Tissue - - Poloxamer - - RNAlater - - Saline - - TCL Lysis Buffer - - Unknown + - REALTIME + - PROSPECTIVE + - RETROSPECTIVE + - PACED + - NONE Term: - Origin: caDSR - Original Source: NCI Standard - Code: '65078' - Value: Specimen Fixative Type - Version: '4.00' - embedding_medium: - Desc: A material that infiltrates and supports a specimen and preserves its shape and structure for sectioning and microscopy. + Original Source: CDS + Code: '14617521' + Value: Image Study Cardiac Synchronization Technique Code Name + Version: '1.00' + performed_imaging_study_dataCollectionDiameter: + Desc: The diameter of the region over which information is acquired. + Req: true + Type: string + Term: + - Origin: caDSR + Original Source: CDS + Code: '14612665' + Value: Image Acquisition Data Collection Location Diameter Number + Version: '1.00' + performed_imaging_study_respiratoryMotionTechniqueCode: + Desc: The means to be used to coordinate the collection or reconstruction of data with breathing. Req: true Enum: - - Paraffin wax - - Carbowax - - Methacrylate - - Epoxy Resin (Araldite) - - Agar embedding - - Celloidin media - - Gelatin - - Other - - None - - Unknown + - BREATH-HOLD + - REALTIME + - GATING + - TRACKING + - RETROSPECTIVE + - CORRECTION + - NONE + Term: + - Origin: caDSR + Original Source: CDS + Code: '14617522' + Value: Image Study Respiratory Motion Technique Code Name + Version: '1.00' + performed_imaging_study_bodyPositionCode: + Desc: A coded value specifying the 3-dimensional spatial orientation of a subject during this imaging acquisition protocol element. + Enum: + - Supine + - Trendelenburg + - Standing + Term: + - Origin: caDSR + Original Source: CDS + Code: '14617523' + Value: Image Study Body Position Name + Version: '1.00' + performed_imaging_study_algorithmCode: + Desc: A coded value specifying the algorithm to use when reconstructing the image from the data acquired during the acquisition process + Req: true + Type: string + Term: + - Origin: caDSR + Code: '14617557' + Value: Imaging Reconstruction Protocol Algorithm Code Text + Version: '1.00' + performed_imaging_study_reconstructionFieldOfViewHeight: + Desc: The vertical dimension of the rectangular region from which data is used in creating the reconstruction of the image. + Req: true + Type: string + Term: + - Origin: caDSR + Code: '14612672' + Value: Imaging Reconstruction Protocol Field of View Height Number + Version: '1.00' + performed_imaging_study_reconstructionFieldOfViewWidth: + Desc: The horizontal dimension of the rectangular region from which data is used in creating the reconstruction of the image. + Req: true + Type: string + Term: + - Origin: caDSR + Code: '14612674' + Value: Imaging Reconstruction Protocol Field of View Width Number + Version: '1.00' + performed_imaging_study_reconstructionDiameter: + Desc: The diameter of the region from which data is used in creating the reconstruction of the image. + Req: true + Type: string Term: - Origin: caDSR - Original Source: HTAN - Code: '8037927' - Value: Biospecimen Collection Medium Type + Code: '2182085' + Value: Reconstruction Diameter in Millimeter(s) Version: '1.00' - staining_method: - Desc: Any of the various methods that use a dye, reagent, or other material for producing coloration in tissues or microorganisms for microscopic examination. + performed_imaging_study_sliceThickness: + Desc: The cross plane dimension of the reconstructed image. Req: true - Enum: - - CODEX - - GeoMX-DSP - - H&E - - IHC - - IMC - - MIBI - - mIHC - - MxIF - - SABER - - t-CyCIF + Type: string Term: - Origin: caDSR - Original Source: HTAN - Code: '7789196' - Value: Imaging Assay Technology Type - Version: '1.00' - objective: - Desc: "An objective is an optical element that gathers light from an object being observed and focuses the light rays from it to produce a real image of the object." + Code: '3113185' + Value: Image Plane Slice Thickness Float or Fixed-point Millimeter Number + Version: '2.00' + performed_imaging_study_reconstructionInterval: + Desc: The cross plane distance between the centers of adjacent, parallel reconstructed images. + Req: true Type: string Term: - Origin: caDSR - Code: '7788935' - Value: Microscope Device Objective Lens Text + Code: '14612682' + Value: Imaging Reconstruction Protocol Reconstruction Interval Millimeter Number Version: '1.00' - nominal_magnification: - Desc: The magnification of the lens as specified by the manufacturer - i.e. '60' is a 60X lens. floating point value > 1(no units) + # NonDICOMCTimages : + NonDICOMCTimages_id: + Desc: NonDICOMCTimages identifier + Type: string + Req: true + Key: true + CTAquisitionProtocolElement_singleCollimationWidth: + Desc: The width of a single row of acquired data. The units are of linear distince, e.g. mm. Type: string Term: - Origin: caDSR - Original Source: HTAN - Code: '7788940' - Value: Microscope Device Nominal Magnification Float Value + Code: '2903347' + Value: Image Single Collimation Width 8 Byte Millimeter Number Version: '1.00' - immersion: - Desc: Immersion medium + CTAquisitionProtocolElement_totalCollimationWidth: + Desc: The width of the total collimation over the area of active x-ray detection. The units are of linear distince, e.g. mm. + Req: true Type: string Term: - Origin: caDSR - Original Source: HTAN - Code: '8058286' - Value: Microscope Device Immersion Medium Type + Code: '2903328' + Value: Image Total Collimation Width 8 Byte Millimeter Number Version: '1.00' - lens_numerical_aperture: - Desc: The numerical aperture of the lens. Floating point value > 0. + CTAquisitionProtocolElement_gantryDetectorTilt: + Desc: Nominal angle of tilt in degrees of the scanning gantry. The units are of plane angle , e.g. degrees. Zero degrees means the gantry is not tilted, negative degrees are when the top of the gantry is tilted away from where the table enters the gantry. + Req: true Type: string Term: - Origin: caDSR - Original Source: HTAN - Code: '7788942' - Value: Microscope Device Lens Numerical Aperture Float Value + Original Source: caDSR + Code: '2656117' + Value: Image Gantry Detector Tilt 16 Character Number Version: '1.00' - working_distance: - Desc: The working distance of the lens, expressed as a floating point number. Floating point > 0. Size needs to be specified in microns (um) + CTAquisitionProtocolElement_spiralPitchFactor: + Desc: Ratio of the distance that the table moves during a complete revolution of the source around the gantry orbit, to the width of the total collimation over the area of active x-ray detection. The units are of unity. + Req: true Type: string Term: - Origin: caDSR - Original Source: HTAN - Code: '7788943' - Value: Microscope Device Working Distance Float Value + Code: '2414556' + Value: Computed Tomography Pitch Factor Number Version: '1.00' - imaging_assay_type: - Desc: Type of imaging assay + CTAquisitionProtocolElement_ctdiVol: + Desc: The average dose over the total volume scanned for the selected CT conditions of operation (calculated according to IEC 60601-2-44, Ed.2.1 (Clause 29.1.103.4)). The units are energy dose, e.g. mGy. Req: true Type: string Term: - Origin: caDSR - Original Source: HTAN - Code: '7789196' - Value: Imaging Assay Technology Type + Code: '3882991' + Value: Computed Tomography Dose Index Volume Quantity 8 Byte Number Version: '1.00' - pyramid: - Desc: The data file contains an image pyramid + CTAquisitionProtocolElement_ctdiPhantomTypeCode: + Desc: The type of phantom to use for CTDI measurement according to IEC 60601-2-44 + Req: true Type: string Term: - Origin: caDSR - Original Source: HTAN - Code: '7788945' - Value: Image Processing Pyramid Representation True False Indicator + Code: '14612683' + Value: Imaging Technique CTDI Phantom Type Sequence of Items Text Version: '1.00' - physical_size_x: - Desc: Physical size (X-dimension) of a pixel. Floating point value > 0. Size needs to be specified in microns (um) + CTAquisitionProtocolElement_kVp: + Desc: Peak kilovoltage output of the x-ray generator. The units are of electrical potential. + Req: true Type: string Term: - Origin: caDSR - Original Source: HTAN - Code: '7786584' - Value: Image Processing Pyramid Representation True False Indicator + Code: '2904496' + Value: Image Kilovolt Peak Float 16 Number Version: '1.00' - physical_size_y: - Desc: Physical size (Y-dimension) of a pixel. Floating point value > 0. Size needs to be specified in microns (um) - Type: string + CTAquisitionProtocolElement_exposureModulationType_Code: + Desc: The manner in which tube current is varied in order to limit the dose. + Enum: + - NONE + - ANGULAR + - LONGITUDINAL + - ECG-BASED + - ORGAN-BASED Term: - Origin: caDSR - Original Source: HTAN - Code: '7786585' - Value: Pixel Y-Dimension Float Value + Code: '14617524' + Value: Imaging Technique Exposure Modulation Type Version: '1.00' - physical_size_z: - Desc: Physical size (Z-dimension) of a pixel. Floating point value > 0. Size needs to be specified in microns (um) + CTImageReconstructionProtocolElement_convolutionKernel: + Desc: A label describing the mathematical operations used to reconstruct images from the acquired data. The values for this attribute are vendor specific and not coded. Type: string Term: - Origin: caDSR - Original Source: HTAN - Code: '7786586' - Value: Pixel Z-Dimension Float Value + Code: '2656119' + Value: Image Convolution Kernel 16 Character Text Version: '1.00' - size_c: - Desc: Number of channels. Integer >= 1 + CTImageReconstructionProtocolElement_convolutionKernelGroupCode: + Desc: A coded value specifying the family of mathematical operations to use to reconstruct images from the acquired data Type: string Term: - Origin: caDSR - Code: '7794859' - Value: OME TIFF Channel Count + Code: '14617525' + Value: Imaging Technique Convolution Kernel Group Name Version: '1.00' - size_t: - Desc: Number of time points. Integer >= 1 + # NonDICOMMRimages: + NonDICOMMRimages_id: + Desc: NonDICOMMRimages identifier Type: string + Req: true + Key: true + MRImageAcquisitionProtocolElement_echoPulseSequenceCategoryCode: + Desc: A coded value specifying an echo category of pulse sequences. + Enum: + - SPIN + - GRADIENT + - BOTH Term: - Origin: caDSR - Code: '7794860' - Value: OME TIFF Timepoint Count + Original Source: CDS + Code: '14645641' + Value: Image Acquisition Spin-Echo Pulse Sequence Code Category Version: '1.00' - size_x: - Desc: 'Size of image: X dimension (in pixels). Integer >= 1' + MRImageAcquisitionProtocolElement_diffusionBValue: + Desc: The factor by which the acquisition is sensitized to the Brownian motion of water molecules. The units are of time/area, e.g. s/mm2 Type: string Term: - Origin: caDSR - Code: '7788567' - Value: OME TIFF X-Dimension Pixel Measurement + Code: '14607706' + Value: Imaging Technique MR Diffusion B Value Number Version: '1.00' - size_y: - Desc: 'Size of image: Y dimension (in pixels). Integer >= 1' - Type: string + MRImageAcquisitionProtocolElement_diffusionDirectionalityCode: + Desc: A coded value specifying whether diffusion conditions for the frame are directional, or isotropic with respect to direction + Enum: + - DIRECTIONAL + - BMATRIX + - ISOTROPIC + - NONE Term: - Origin: caDSR - Code: '7788568' - Value: OME TIFF Y-Dimension Pixel Measurement + Code: '14616426' + Value: Imaging Technique Diffusion Directionality Type Version: '1.00' - size_z: - Desc: 'Size of image: Z dimension (in pixels). Integer >= 1' + MRImageAcquisitionProtocolElement_magneticFieldStrength: + Desc: "A vector quantity indicating the ability of a magnetic field to exert a force on moving electric charges. [The American Heritage\xAE Science Dictionary]. The units are of magnetic flux density, e.g. tesla." Type: string Term: - Origin: caDSR - Code: '7788569' - Value: OME TIFF Z-Dimension Pixel Measurement + Code: '14607707' + Value: Imaging Technique Magnetic Field Strength Number Version: '1.00' - channel_metadata_filename: - Desc: File name of uploaded companion CSV file containing channel-level metadata details - Req: true - Type: string + MRImageAcquisitionProtocolElement_resonantNucleusCode: + Desc: A coded value specifying the atomic nucleus that is the target of the acquisition + Enum: + - 1H + - 3HE + - 7LI + - 13C + - 19F + - 23NA + - 31P + - 129XE Term: - Origin: caDSR - Original Source: HTAN - Code: '7787678' - Value: Channel Analysis Metadata Electronic File Name Text + Code: '14616427' + Value: Image Acquisition Resonant Nucleus Type Version: '1.00' - channel_metadata_file_url_in_cds: - Desc: '' + MRImageAcquisitionProtocolElement_acquisitionContrastCode: + Desc: A coded value specifying the inherent (as opposed to exogenous) contrast in the acquisition. + Enum: + - DIFFUSION + - FLOW_ENCODED_Flow Encoded contrast + - FLUID_ATTENUATED_Fluid Attenuated T2 weighted contrast + - PERFUSION_Perfusion weighted contrast + - PROTON_DENSITY_Proton Density weighted contrast + - STIR_Short Tau Inversion Recovery + - TAGGING_Superposition of thin saturation bands onto image + - T1_T1 weighted contrast + - T2_T2 weighted contrast + - T2_STAR_T2* weighted contrast + - TOF_Time Of Flight weighted contrast + Term: + - Origin: caDSR + Code: '14616428' + Value: Image Acquisition Contrast Type + Version: '1.00' + MRImageAcquisitionProtocolElement_inversionRecoveryIndicator: + Desc: Specifies whether an inversion recovery preparatory sequence is used in the acquisition. Type: string Term: - Origin: caDSR - Original Source: CDS - Code: '11556141' - Value: Electronic File Pathname Text + Code: '14607722' + Value: Image Acquisition Inversion Recovery Indicator Version: '1.00' - channel_id: - Desc: The unique channel identifier for each channel in this image must match the corresponding field in the OME-TIFF header - Req: true + MRImageAcquisitionProtocolElement_pulseSequenceName: + Desc: Name of the pulse sequence that is used for the acquisition. This is usually a vendor-specific name. Type: string Term: - Origin: caDSR - Code: '14765171' - Value: OME Tagged Image File Format Channel Identifier + Code: '14608594' + Value: Image Acquisition Pulse Sequence Name Text Version: '1.00' - channel_name: - Desc: Channel label for each channel in this image must match the corresponding field in the OME-TIFF header - Req: true + MRImageAcquisitionProtocolElement_multipleSpinEchoIndicator: + Desc: Specifies whether different lines in k-space are collected for a single frame. Type: string Term: - Origin: caDSR - Code: '14765172' - Value: OME Tagged Image File Format Channel Name + Code: '14608595' + Value: Imaging Technique Multiple Spin Echo Indicator Version: '1.00' - cycle_number: - Desc: 'the cycle # in which the co-listed reagent(s) was(were) used' + MRImageAcquisitionProtocolElement_phaseContrastIndicator: + Desc: Specifies whether this is a pulse sequence in which the flowing spins are velocity encoded in phase. Type: string Term: - Origin: caDSR - Original Source: CDS - Code: '14765176' - Value: Multiplex Imaging Reagent Cycle Number Integer + Code: '14608601' + Value: Image Phase Contrast Indicator Version: '1.00' - sub_cycle_number: - Desc: 'sub-cycle #' + MRImageAcquisitionProtocolElement_timeOfFlightContrastIndicator: + Desc: Specifies whether contrast is created by the inflow of blood in the saturated plane. Type: string Term: - Origin: caDSR - Original Source: CDS - Code: '14765180' - Value: Multiplex Imaging Reagent Sub-Cycle Number Integer + Code: '14608649' + Value: Imaging Technique Time of Flight Contrast Indicator Version: '1.00' - target_name: - Desc: short descriptive name (abbreviation) for this target (antigen) + MRImageAcquisitionProtocolElement_arterialSpinLabelingContrastCode: + Desc: A coded value specifying how arterial water is used as a diffusable tracer. Type: string Term: - Origin: caDSR - Original Source: CDS - Code: "14765180" - Value: "Multiplex Imaging Reagent Sub-Cycle Number Integer" + Code: '14616429' + Value: Imaging Technique Arterial Spin Labeling Contrast Name Version: '1.00' - antibody_name: - Desc: short descriptive name for this antibody - Type: string + MRImageAcquisitionProtocolElement_steadyStatePulseSequenceCode: + Desc: A coded value specifying how residual transverse magnetization is maintained during the acquisition. + Enum: + - FREE PRECESSION + - TRANSVERSE + - TIME REVERSED + - LONGITUDINAL + - NONE Term: - Origin: caDSR - Original Source: CDS - Code: '14765184' - Value: Tissue Slide IHC Antibody Used Type + Code: '14616430' + Value: Image Acquisition Steady State Pulse Sequence Type Version: '1.00' - rrid_identifier: - Desc: Research Resource Identifier + MRImageAcquisitionProtocolElement_echoPlanarPulseSequenceIndicator: + Desc: Specifies whether multiple echos of different phase steps are acquired using rephasing gradients instead of repeated 180-degree pulses. Type: string Term: - Origin: caDSR - Original Source: CDS - Code: '14767247' - Value: Multiplex Imaging Research Resource Identifier Text + Code: '14612651' + Value: Image Acquisition Echo Planar Pulse Sequence Indicator Version: '1.00' - fluorophore: - Desc: Fluorescent dye label + MRImageAcquisitionProtocolElement_saturationRecoveryIndicator: + Desc: Specifies whether a saturation recovery pulse sequence is used Type: string Term: - Origin: caDSR - Original Source: CDS - Code: '14767255' - Value: Multiplex Imaging Fluorescent Dye Text + Code: '14612652' + Value: Imaging Technique Saturation Recovery Indicator Version: '1.00' - clone: - Desc: Unique clone identifier - Type: string + MRImageAcquisitionProtocolElement_spectrallySelectedSuppressionCode: + Desc: A coded value specifying the type of substance-specific signal suppression is used. + Enum: + - FAT + - WATER + - FAT AND WATER + - SILICON GEL + - NONE Term: - Origin: caDSR - Original Source: CDS - Code: '14767258' - Value: Multiplex Imaging Clone Unique Identifier + Code: '14616431' + Value: Imaging Technique Spectrally Selected Suppression Type Version: '1.00' - lot: - Desc: lot number from vendor - Type: string + MRImageReconstructionProtocolElement_complexImageComponentCode: + Desc: A coded value specifying the channel of the quadrature detected data, or the combination derived from those channels, used to reconstruct the image + Enum: + - REAL + - IMAGINARY + - PHASE + - MAGNITUDE Term: - Origin: caDSR - Original Source: CDS - Code: '14769695' - Value: Multiplex Imaging Vendor Lot Number Text + Code: '14616432' + Value: Imaging Technique Complex Image Component Type Version: '1.00' - catalog_number: - Desc: catalog number from vendor + # NonDICOMPETimages: + NonDICOMPETimages_id: + Desc: NonDICOMPETimages identifier + Type: string + Req: true + Key: true + PETImagingAcquisitionProtocolElement_gantryDetectorTilt: + Desc: Nominal angle of tilt in degrees of the scanning gantry. The units are of plane angle , e.g. degrees. Zero degrees means the gantry is not tilted, negative degrees are when the top of the gantry is tilted away from where the table enters the gantry. Type: string Term: - Origin: caDSR - Original Source: CDS - Code: '14767261' - Value: Multiplex Imaging Vendor Catalog Number Text + Code: '2656117' + Value: Image Gantry Detector Tilt 16 Character Number Version: '1.00' - excitation_wavelength: - Desc: center/peak of the excitation spectrum (nm) + Radiopharmaceutical_radionuclideCode: + Desc: A coded value that specifies the radioactive isotope in the radiophamaceutical. Type: string Term: - Origin: caDSR - Original Source: CDS - Code: '14765187' - Value: Multiplex Imaging Excitation Wavelength Number + Code: '14612653' + Value: Imaging Technique Radionuclide Code Text Version: '1.00' - emission_wavelength: - Desc: center/peak of the emission spectrum (nm) + # NonDICOMpathologyImages: + NonDICOMpathologyImages_id: + Desc: NonDICOMpathologyImages identifier + Type: string + Req: true + Key: true + acquisition_method_type: + Desc: Records the method of acquisition or source for the specimen under consideration Type: string Term: - Origin: caDSR - Original Source: CDS - Code: '14767264' - Value: Multiplex Imaging Emission Wavelength Number - Version: '1.00' - excitation_bandwidth: - Desc: nominal width of excitation spectrum (nm) + Original Source: MCL/HTAN + Code: '6626651' + Value: Biospecimen Acquisition Method Type + Version: '2.00' + tumor_tissue_type: + Desc: Text that describes the kind of disease present in the tumor specimen as related to a specific timepoint (add rows to select multiple values along with timepoints) Type: string Term: - Origin: caDSR - Original Source: CDS - Code: '14765190' - Value: Multiplex Imaging Excitation Bandwidth Number + Original Source: HTAN + Code: '3288124' + Value: Tumor Tissue Disease Description Type Version: '1.00' - emission_bandwidth: - Desc: nominal width of emission spectrum (nm) - Type: string + tissue_fixative: + Desc: A compound that preserves tissues and cells for microscopic study. + Req: true + Enum: + - 95% Ethanol + - Acetone + - Alcohol + - Carbodiimide + - Carnoy's Solution + - CryoStor + - Diimidoester + - Dimethylacetamide + - Formalin + - Glutaraldehyde + - Methacarn + - Not applicable + - Not recorded + - NP40 Lysis Buffer + - OCT media + - Other + - Para-benzoquinone + - PAXgene Tissue + - Poloxamer + - RNAlater + - Saline + - TCL Lysis Buffer + - Unknown Term: - Origin: caDSR - Original Source: CDS - Code: '14765193' - Value: Multiplex Imaging Emission Bandwidth Number - Version: '1.00' - metal_isotope_element_abbreviation: - Desc: Element abbreviation - Type: string + Original Source: NCI Standard + Code: '65078' + Value: Specimen Fixative Type + Version: '4.00' + embedding_medium: + Desc: A material that infiltrates and supports a specimen and preserves its shape and structure for sectioning and microscopy. + Req: true + Enum: + - Paraffin wax + - Carbowax + - Methacrylate + - Epoxy Resin (Araldite) + - Agar embedding + - Celloidin media + - Gelatin + - Other + - None + - Unknown Term: - Origin: caDSR - Original Source: CDS - Code: '14765198' - Value: Multiplex Imaging Isotope Abbreviation Name + Original Source: HTAN + Code: '8037927' + Value: Biospecimen Collection Medium Type Version: '1.00' - metal_isotope_element_mass: - Desc: Element mass number - Type: string + staining_method: + Desc: Any of the various methods that use a dye, reagent, or other material for producing coloration in tissues or microorganisms for microscopic examination. + Req: true + Enum: + - CODEX + - GeoMX-DSP + - H&E + - IHC + - IMC + - MIBI + - mIHC + - MxIF + - SABER + - t-CyCIF Term: - Origin: caDSR - Original Source: CDS - Code: '14765201' - Value: Multiplex Imaging Isotope Element Number Identifier + Original Source: HTAN + Code: '7789196' + Value: Imaging Assay Technology Type Version: '1.00' - oligo_barcode_upper_strand: - Desc: DNA barcode used for labeling + objective: + Desc: "An_objective_is an optical element that gathers light from an object being observed and_focuses_the_light rays_from it to produce a_real image_of the object." Type: string Term: - Origin: caDSR - Original Source: CDS - Code: '14765205' - Value: Multiplex Imaging Oligonucleotide Barcode Upper Strand Text + Code: '7788935' + Value: Microscope Device Objective Lens Text Version: '1.00' - oligo_barcode_lower_strand: - Desc: DNA barcode used for labeling + nominal_magnification: + Desc: The magnification of the lens as specified by the manufacturer - i.e. '60' is a 60X lens. floating point value > 1(no units) Type: string Term: - Origin: caDSR - Original Source: CDS - Code: '14765208' - Value: Multiplex Imaging Oligonucleotide Barcode Lower Strand Text + Original Source: HTAN + Code: '7788940' + Value: Microscope Device Nominal Magnification Float Value Version: '1.00' - dilution: - Desc: Final dilution ratio used in experiment + immersion: + Desc: Immersion medium Type: string Term: - Origin: caDSR - Code: '14767270' - Value: Multiplex Imaging Final Dilution Ratio Number + Original Source: HTAN + Code: '8058286' + Value: Microscope Device Immersion Medium Type Version: '1.00' - concentration: - Desc: Final concentration used in experiment + lens_numerical_aperture: + Desc: The numerical aperture of the lens. Floating point value > 0. Type: string Term: - Origin: caDSR - Original Source: CDS - Code: '14768386' - Value: Multiplex Imaging Final Concentration Number + Original Source: HTAN + Code: '7788942' + Value: Microscope Device Lens Numerical Aperture Float Value Version: '1.00' + # file checksum_value: Desc: checksum (hash) for file (using checksum_algorithm) - if you want to use a checksum other than md5 diff --git a/model-desc/cds-model.yml b/model-desc/cds-model.yml index 69bc20e..75b6f8d 100644 --- a/model-desc/cds-model.yml +++ b/model-desc/cds-model.yml @@ -231,55 +231,19 @@ Nodes: - imaging_sofware - imaging_protocol - organ_or_tissue - - performed_imaging_study_description - - performed_imaging_study_admittingDiagnosisCode - - performed_imaging_study_nonAcquisitionModalitiesInStudyCode - - performed_imaging_study_lossyImageCompressionIndicator - - performed_imaging_study_summary - - performed_imaging_study_primaryAnatomicSiteCode - - performed_imaging_study_acquisitionTypeCode - - performed_imaging_study_cardiacSynchronizationTechniqueCode - - performed_imaging_study_dataCollectionDiameter - - performed_imaging_study_respiratoryMotionTechniqueCode - - performed_imaging_study_bodyPositionCode - performed_imaging_study_typeCode - - performed_imaging_study_algorithmCode - - performed_imaging_study_reconstructionFieldOfViewHeight - - performed_imaging_study_reconstructionFieldOfViewWidth - - performed_imaging_study_reconstructionDiameter - - performed_imaging_study_sliceThickness - - performed_imaging_study_reconstructionInterval - longitudinal_temporal_event_type - longitudinal_temporal_event_offset - - CTAquisitionProtocolElement_singleCollimationWidth - - CTAquisitionProtocolElement_totalCollimationWidth - - CTAquisitionProtocolElement_gantryDetectorTilt - - CTAquisitionProtocolElement_spiralPitchFactor - - CTAquisitionProtocolElement_ctdiVol - - CTAquisitionProtocolElement_ctdiPhantomTypeCode - - CTAquisitionProtocolElement_kVp - - CTAquisitionProtocolElement_exposureModulationType_Code - - CTImageReconstructionProtocolElement_convolutionKernel - - CTImageReconstructionProtocolElement_convolutionKernelGroupCode - - MRImageAcquisitionProtocolElement_echoPulseSequenceCategoryCode - - MRImageAcquisitionProtocolElement_diffusionBValue - - MRImageAcquisitionProtocolElement_diffusionDirectionalityCode - - MRImageAcquisitionProtocolElement_magneticFieldStrength - - MRImageAcquisitionProtocolElement_resonantNucleusCode - - MRImageAcquisitionProtocolElement_acquisitionContrastCode - - MRImageAcquisitionProtocolElement_inversionRecoveryIndicator - - MRImageAcquisitionProtocolElement_pulseSequenceName - - MRImageAcquisitionProtocolElement_multipleSpinEchoIndicator - - MRImageAcquisitionProtocolElement_phaseContrastIndicator - - MRImageAcquisitionProtocolElement_timeOfFlightContrastIndicator - - MRImageAcquisitionProtocolElement_arterialSpinLabelingContrastCode - - MRImageAcquisitionProtocolElement_steadyStatePulseSequenceCode - - MRImageAcquisitionProtocolElement_echoPlanarPulseSequenceIndicator - - MRImageAcquisitionProtocolElement_saturationRecoveryIndicator - - MRImageAcquisitionProtocolElement_spectrallySelectedSuppressionCode - - MRImageReconstructionProtocolElement_complexImageComponentCode - - PETImagingAcquisitionProtocolElement_gantryDetectorTilt - - Radiopharmaceutical_radionuclideCode + + MultiplexMicroscopy: + Tags: + Category: data_file + Assignment: core + Class: primary + Template: 'Yes' + Desc: "" + Props: + - MultiplexMicroscopy_id - acquisition_method_type - tumor_tissue_type - tissue_fixative @@ -323,7 +287,111 @@ Nodes: - oligo_barcode_lower_strand - dilution - concentration - - crdc_id + + NonDICOMCTimages: + Tags: + Category: data_file + Assignment: core + Class: primary + Template: 'Yes' + Desc: "" + Props: + - NonDICOMCTimages_id + - CTAquisitionProtocolElement_singleCollimationWidth + - CTAquisitionProtocolElement_totalCollimationWidth + - CTAquisitionProtocolElement_gantryDetectorTilt + - CTAquisitionProtocolElement_spiralPitchFactor + - CTAquisitionProtocolElement_ctdiVol + - CTAquisitionProtocolElement_ctdiPhantomTypeCode + - CTAquisitionProtocolElement_kVp + - CTAquisitionProtocolElement_exposureModulationType_Code + - CTImageReconstructionProtocolElement_convolutionKernel + - CTImageReconstructionProtocolElement_convolutionKernelGroupCode + + NonDICOMMRimages: + Tags: + Category: data_file + Assignment: core + Class: primary + Template: 'Yes' + Desc: "" + Props: + - NonDICOMMRimages_id + - MRImageAcquisitionProtocolElement_echoPulseSequenceCategoryCode + - MRImageAcquisitionProtocolElement_diffusionBValue + - MRImageAcquisitionProtocolElement_diffusionDirectionalityCode + - MRImageAcquisitionProtocolElement_magneticFieldStrength + - MRImageAcquisitionProtocolElement_resonantNucleusCode + - MRImageAcquisitionProtocolElement_acquisitionContrastCode + - MRImageAcquisitionProtocolElement_inversionRecoveryIndicator + - MRImageAcquisitionProtocolElement_pulseSequenceName + - MRImageAcquisitionProtocolElement_multipleSpinEchoIndicator + - MRImageAcquisitionProtocolElement_phaseContrastIndicator + - MRImageAcquisitionProtocolElement_timeOfFlightContrastIndicator + - MRImageAcquisitionProtocolElement_arterialSpinLabelingContrastCode + - MRImageAcquisitionProtocolElement_steadyStatePulseSequenceCode + - MRImageAcquisitionProtocolElement_echoPlanarPulseSequenceIndicator + - MRImageAcquisitionProtocolElement_saturationRecoveryIndicator + - MRImageAcquisitionProtocolElement_spectrallySelectedSuppressionCode + - MRImageReconstructionProtocolElement_complexImageComponentCode + + NonDICOMpathologyImages: + Tags: + Category: data_file + Assignment: core + Class: primary + Template: 'Yes' + Desc: "" + Props: + - NonDICOMpathologyImages_id + - acquisition_method_type + - tumor_tissue_type + - tissue_fixative + - embedding_medium + - staining_method + - objective + - nominal_magnification + - immersion + - lens_numerical_aperture + + NonDICOMPETimages: + Tags: + Category: data_file + Assignment: core + Class: primary + Template: 'Yes' + Desc: "" + Props: + - NonDICOMPETimages_id + - PETImagingAcquisitionProtocolElement_gantryDetectorTilt + - Radiopharmaceutical_radionuclideCode + + NonDICOMradiologyAllModalities: + Tags: + Category: data_file + Assignment: core + Class: primary + Template: 'Yes' + Desc: "" + Props: + - NonDICOMradiologyAllModalities_id + - performed_imaging_study_description + - performed_imaging_study_admittingDiagnosisCode + - performed_imaging_study_nonAcquisitionModalitiesInStudyCode + - performed_imaging_study_lossyImageCompressionIndicator + - performed_imaging_study_summary + - performed_imaging_study_primaryAnatomicSiteCode + - performed_imaging_study_acquisitionTypeCode + - performed_imaging_study_cardiacSynchronizationTechniqueCode + - performed_imaging_study_dataCollectionDiameter + - performed_imaging_study_respiratoryMotionTechniqueCode + - performed_imaging_study_bodyPositionCode + - performed_imaging_study_algorithmCode + - performed_imaging_study_reconstructionFieldOfViewHeight + - performed_imaging_study_reconstructionFieldOfViewWidth + - performed_imaging_study_reconstructionDiameter + - performed_imaging_study_sliceThickness + - performed_imaging_study_reconstructionInterval Relationships: of_program: @@ -368,6 +436,22 @@ Relationships: - Src: image Dst: file Mul: one_to_one + of_image: + Props: null + Mul: one_to_one + Ends: + - Src: MultiplexMicroscopy + Dst: image + - Src: NonDICOMCTimages + Dst: image + - Src: NonDICOMpathologyImages + Dst: image + - Src: NonDICOMMRimages + Dst: image + - Src: NonDICOMradiologyAllModalities + Dst: image + - Src: NonDICOMPETimages + Dst: image associated_with: Props: null Mul: many_to_one From 6a0d8ef842f490728926c7be6a61703876fe007d Mon Sep 17 00:00:00 2001 From: Fuyuan Wang <60631776+wfy1997@users.noreply.github.com> Date: Mon, 7 Oct 2024 15:54:45 -0400 Subject: [PATCH 02/23] Update to add 2 new nodes(proteomic, data_version) and add descriptions to the new nodes --- model-desc/cds-model-props.yml | 78 +++++++++++++++++++++++++++++++++- model-desc/cds-model.yml | 44 ++++++++++++++++--- 2 files changed, 115 insertions(+), 7 deletions(-) diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index 40fc401..a20b179 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -11049,4 +11049,80 @@ PropDefinitions: Original Source: DSS Code: "11459801" Value: Program Short Name Text - Version: '1.00' \ No newline at end of file + Version: '1.00' + # proteomic + aliquot_id: + Desc: Software that was used to de-identify the images (if used) + Req: true + Key: true + Term: + - Origin: caDSR + Original Source: CRDC + Code: "15105438" + Value: Specimen Aliquot Identifier + analytical_fractions: + Desc: The portion of a specimen that was isolated from the whole and collected via a fractionation process to be subjected to further analysis. + Type: string + Term: + - Origin: caDSR + Original Source: CRDC + Code: "15112968" + Value:Laboratory Procedure Proteomic Profiling Analytical Fraction Type + Version: '1.00' + experimental_strategy: + Desc: The type of systematic investigation using controlled observations and measurements to test hypotheses or develop a plan of action based on the facts discovered. + Type: string + Term: + - Origin: caDSR + Original Source: CRDC + Code: "12373576" + Value: Research Activity Experimental Method Experimental Method Type + Version: '1.00' + instrument_make: + Desc: The words that describe an entity that produces finished goods used to perform a diagnostic, therapeutic or research activity. + Type: string + Term: + - Origin: caDSR + Original Source: CRDC + Code: "2866141" + Value: Equipment Manufacturer Name Text + Version: '1.00' + instrument_model: + Desc: The words that describe the style or design of an entity"s finished goods used to perform a diagnostic, therapeutic or research activity. + Type: string + Term: + - Origin: caDSR + Original Source: CRDC + Code: "2413274" + Value: Equipment Manufacturer Model Name Text + Version: '2.10' + proteomic_design_description: + Desc: The description of the analysis of proteins using a combination of techniques to quantify and to characterize proteins. + Type: string + Term: + - Origin: caDSR + Original Source: CRDC + Code: "15089939" + Value: Research Activity Proteomics Study Design Description Text + Version: '1.00' + # data_version + data_version_id: + Desc: A static data version ID that is used primarily to assist in data loading. This ID will be used as a reference to update the existing data_version node instead of creating a new one with each version change. + Type: string + Key: true + Req: true + version: + Desc: The version of the data that has been loaded. This should be similar to semantic versioning format (major.minor.patch). + Type: string + Req: true + datetime: + Desc: An ISO8601 formatted datetime that records when the dataset was last edited. + Type: string + Req: true + model_version: + Desc: The version of the model used to load the data + Type: string + Req: true + description: + Desc: Any additional information about the dataset that might be relevant formatted as a short sentence or paragraph + Type: string \ No newline at end of file diff --git a/model-desc/cds-model.yml b/model-desc/cds-model.yml index 75b6f8d..799b577 100644 --- a/model-desc/cds-model.yml +++ b/model-desc/cds-model.yml @@ -241,7 +241,7 @@ Nodes: Assignment: core Class: primary Template: 'Yes' - Desc: "" + Desc: "non DICOM standard multiplex images to analyze cellular interactions and spatial context in biological samples" Props: - MultiplexMicroscopy_id - acquisition_method_type @@ -294,7 +294,7 @@ Nodes: Assignment: core Class: primary Template: 'Yes' - Desc: "" + Desc: "non DICOM standard computed tomography images" Props: - NonDICOMCTimages_id - CTAquisitionProtocolElement_singleCollimationWidth @@ -314,7 +314,7 @@ Nodes: Assignment: core Class: primary Template: 'Yes' - Desc: "" + Desc: "non DICOM standard magnetic resonance images" Props: - NonDICOMMRimages_id - MRImageAcquisitionProtocolElement_echoPulseSequenceCategoryCode @@ -341,7 +341,7 @@ Nodes: Assignment: core Class: primary Template: 'Yes' - Desc: "" + Desc: "non DICOM standard used for the study of examination of tissue samples and histological features" Props: - NonDICOMpathologyImages_id - acquisition_method_type @@ -360,7 +360,7 @@ Nodes: Assignment: core Class: primary Template: 'Yes' - Desc: "" + Desc: "non DICOM standard positron emission tomography used to study metabolic processes in tissues" Props: - NonDICOMPETimages_id - PETImagingAcquisitionProtocolElement_gantryDetectorTilt @@ -372,7 +372,7 @@ Nodes: Assignment: core Class: primary Template: 'Yes' - Desc: "" + Desc: "non DICOM standard radiology images" Props: - NonDICOMradiologyAllModalities_id - performed_imaging_study_description @@ -393,6 +393,35 @@ Nodes: - performed_imaging_study_sliceThickness - performed_imaging_study_reconstructionInterval + proteomic: + Tags: + Category: data_file + Assignment: core + Class: primary + Template: 'Yes' + Desc: "proteo-genomic data submitted to CDS" + Props: + - aliquot_id + - analytical_fractions + - experimental_strategy + - instrument_make + - instrument_model + - proteomic_design_description + + data_version: + Tags: + Category: data_file + Assignment: core + Class: primary + Template: 'Yes' + Desc: "version of the data being uploaded for release" + Props: + - data_version_id + - version + - datetime + - model_version + - description + Relationships: of_program: Props: null @@ -436,6 +465,9 @@ Relationships: - Src: image Dst: file Mul: one_to_one + - Src: proteomic + Dst: file + Mul: one_to_one of_image: Props: null Mul: one_to_one From f4794d12dce9176a2e7c5b774d8d4ee90caddfe1 Mon Sep 17 00:00:00 2001 From: Fuyuan Wang <60631776+wfy1997@users.noreply.github.com> Date: Mon, 7 Oct 2024 16:32:42 -0400 Subject: [PATCH 03/23] update model version --- model-desc/cds-model.yml | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/model-desc/cds-model.yml b/model-desc/cds-model.yml index 799b577..f76c330 100644 --- a/model-desc/cds-model.yml +++ b/model-desc/cds-model.yml @@ -1,5 +1,5 @@ Handle: CDS -Version: v4.0.2 +Version: v5.0.0 Nodes: program: Desc: "Program in the Cancer Data Service refer to a broad framework of goals under which related projects or other research activities are grouped. Example - Clinical Proteomic Tumor Analysis Consortium (CPTAC)" From 602eda7aed674b9feaa10e9b0b5113c97e3a6705 Mon Sep 17 00:00:00 2001 From: Austin Mueller <64418315+AustinSMueller@users.noreply.github.com> Date: Tue, 8 Oct 2024 09:20:06 -0400 Subject: [PATCH 04/23] Fixing YAML formatting error The missing space here between the key and the value is causing a yaml parsing error in the data loader --- model-desc/cds-model-props.yml | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index a20b179..f6ab17d 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -11067,7 +11067,7 @@ PropDefinitions: - Origin: caDSR Original Source: CRDC Code: "15112968" - Value:Laboratory Procedure Proteomic Profiling Analytical Fraction Type + Value: Laboratory Procedure Proteomic Profiling Analytical Fraction Type Version: '1.00' experimental_strategy: Desc: The type of systematic investigation using controlled observations and measurements to test hypotheses or develop a plan of action based on the facts discovered. From aa32715844fa379b1daabedcfddda5067b4f56f6 Mon Sep 17 00:00:00 2001 From: wfy1997 <60631776+wfy1997@users.noreply.github.com> Date: Thu, 10 Oct 2024 15:38:50 -0400 Subject: [PATCH 05/23] update to change the node "data_version" to "version" and change property "version" to "data_version" --- model-desc/README.md | 54 +++++++++++++++++++++++++++++++ model-desc/cds-file-examples.zip | Bin 0 -> 90143 bytes model-desc/cds-model-props.yml | 6 ++-- model-desc/cds-model.yml | 4 +-- model-desc/navigator-icon.png | Bin 0 -> 7798 bytes 5 files changed, 59 insertions(+), 5 deletions(-) create mode 100644 model-desc/README.md create mode 100644 model-desc/cds-file-examples.zip create mode 100644 model-desc/navigator-icon.png diff --git a/model-desc/README.md b/model-desc/README.md new file mode 100644 index 0000000..4637e14 --- /dev/null +++ b/model-desc/README.md @@ -0,0 +1,54 @@ +### The Graph-Based Data Model + +The CDS data model is graph-based, where nodes correspond functionally to tables in a traditional relational database. Each node contains properties that represent columns or fields in the respective table, with relationships stored at the level of individual records. This flexible data model is developed to accommodate genomic and imaging cancer data submitted to CDS, enabling the exploration of biological questions in basic cancer research. Nodes are designed to capture specific information relevant to each study and data type, recognizing variations between submissions. + +### Node Categories + +All nodes are categorized into several groups, each representing a family of interconnected nodes that collectively define higher-level entities within the data model. For example, the **Participant** category encompasses a small set of nodes that comprehensively describe CDS study participants/subjects. The **Study** category includes nodes that collectively define various aspects of studies. Meanwhile, the **Sequencing** category contains nodes where genomic experimental observations related to various cancer conditions can be represented + +### Assignment: Core nodes versus Extended nodes + +CDS is data type agnostic, and within its data model, there are nodes that are consistently or frequently populated with data, irrespective of the study type. These nodes, positioned at the core of the data model, are classified as 'Core' nodes. Surrounding the core is the extended data model, which includes numerous nodes that currently have lower data density. This division aims to guide users, especially data submitters, towards focusing on the nodes and properties crucial for defining any study, regardless of its specific nature. + +### Class: Required nodes versus Optional nodes + +Within the core data model and its extended counterpart, certain nodes are more crucial and therefore more densely populated. These nodes include fields designated as 'Required,' distinguishing them from less populated nodes with 'Optional' fields. Core nodes are essential components that form the backbone of any study, containing numerous required properties. It's important to note that each node contains both required and optional fields. Optional fields may contain valuable accessory data relevant to some studies but not necessarily all. + + + +### Facet-Based Filtering + +The facet-based filtering options available in the left-hand sidebar of the Data Model Navigator allow users to filter nodes based on several criteria: Category, Assignment, and Class designations; properties marked as Required, or Optional; and properties displayed in the application’s user interface (UI). Using these filtering criteria, users can efficiently segment the data model into smaller sets of nodes and identify nodes of specific interest. It's important to note that these filters apply to both the Graph View and the Table View, and selected filters remain active when switching between these viewing modes. + +### Graph View + +In Graph View mode, the Data Model Navigator offers users an interactive, graphical representation of the data model. Users can apply filters, as described previously, to pinpoint nodes and their associated properties that are most relevant or interesting. Selecting a node activates a Properties Dialogue box, which displays the node’s Assignment and Class designations and quantifies the number of properties categorized as Required, and Optional. + +### Table View + +In Table View mode, the Data Model Navigator displays detailed tabular views of each node, which fully-define the properties within them, inclusive of the applicable controlled vocabularies of acceptable terms for enumerated properties. The tabular views also clearly identify which properties are Required versus those that are Preferred or Optional; the acceptable data type for each property; which properties are displayed within the application’s UI; and the labels via which such properties are displayed. Note that many properties displayed within the UI are renamed with labels which are more intuitive than the property names themselves, and that some properties are displayed via more than one label. As described below, comprehensive documentation of the data model’s nodes and property requirements can be downloaded in PDF format via the Table View, alongside node-specific data loading templates into which data submitters can insert the relevant data values and thereby create loading-ready data files. + +### Required, Preferred and Optional Properties + +Each property is assigned one of three requirement levels - Required, or Optional. + +- **Required** properties are largely self-explanatory, i.e. data destined for a node which contains required properties must include values for all such properties, and values must be compliant with the acceptable values for properties which are both required and enumerated. Controlled vocabularies for such properties typically include terms such as “Not Applicable”, “Not Reported” and “Unknown” to accommodate situations where data values aren’t relevant or weren’t collected, either by design or otherwise. Notably, for nodes into which a data submitter is not propagating any data values, required fields are no longer relevant, and can be ignored. +- **Optional** properties are precisely that and null values are allowed. + + + +### Key Properties + +Many nodes contain a single property visually identified as a Key Property by a **blue key icon** displayed next to the name of the appropriate property. In addition to several nodes that require one in support of data updates, all nodes which act as parents of child nodes will likewise have a single property within them identified as a Key Property. During data loading, **_child records_** are associated with their correct **_parents_** by virtue of data loading files which contain the appropriate values for the property identified as their parents’ Key Property. For example, files via which sample records are loaded will contain a column into which values of "Participant ID" must be inserted, such that samples can be associated with the appropriate participant from which they were derived, with “Participant ID” being designated as the Key Property within the **Participant** node. Key Properties are therefore functionally equivalent to foreign keys in traditional relational databases. + +### PDF Documentation + +Detailed documentation of the data model’s nodes and property requirements can be downloaded as PDF exports, either in the form of a comprehensive data dictionary inclusive of all nodes, invoked via the upper-level “Available Downloads” option, or from within the Table View, and invoked on a node-by-node basis. Used alongside the corresponding data loading templates described below, these node-specific PDF exports function as user guides for data preparation and submission. See the associated [Data Submission Guidelines](/#/submit) + +### Data Loading Templates + +In support of data submission, data loading templates can be downloaded, either in the form of a zip file containing copies of all available templates, invoked via the upper-level “Available Downloads” option, or from within the Table View, and invoked on a node-by-node basis. Templates include columns into which the data values required to associate child records with their parents can be inserted. Notably, each template will include a **mapping column** for each potential parent, but although \*all child records must be mapped to **at least one parent\***, submitters are not required to provide a mapping value for each and every potential parent, _only the_ **_most appropriate parent(s)_**. Guided by the corresponding node-specific PDF exports described above, data submitters can insert the relevant data values into these data loading templates, and thereby create loading-ready data files that can be handed off to the CDS Data Team. + +### Controlled Vocabularies + +In the interests of data quality and consistency, the CDS data model makes extensive use of enumerated properties and controlled vocabularies of acceptable terms. All such controlled vocabularies can be viewed via Table View mode, and value sets are included in full in the appropriate PDF exports. Furthermore, in support of data submitters pre-validating their templated data, all controlled vocabularies can be exported in machine readable JSON and TSV formats, either in the form of a zip file containing copies of controlled vocabularies for all enumerated properties, invoked via the upper-level “Available Downloads” option, or from within the Table View, and invoked on a property-by-property basis. As more studies are added to the CDS, many of these controlled vocabularies will continue to evolve, and will be updated by the CDS Data Team during study on-boarding, in order to accommodate additional terms not yet encountered. diff --git a/model-desc/cds-file-examples.zip b/model-desc/cds-file-examples.zip new file mode 100644 index 0000000000000000000000000000000000000000..0008d6f510ec0716215097530ed5d616af0cb00c GIT binary patch literal 90143 zcmd41V~l6tx9_PKkXlYNu@Kj*$UE14@R znaLV+JoCvMW975tBtbw?0RLQ}Ruby}_VDjF8UO)6NLW!xsSISo3$lS(MSIOAg z&Pw0O*iqMog^q!aS=Y(ISl`Lo*v5%oSqT;Z5sLt6`ag!V+YbN`XhGpMEa(|LuDsm8 zMS=uC{!fumfB*p2zmarxr3Hj!71ikJbpM5*|5MD2zp?+9n1*_&hNgN3dNlq}u^1ra2-rZk#021Xm?9XVz|n++0tjeo!)OFD{EB^`sLy(OJF-*Li;^@HBjStW z(o$3YBi}#}s zIqF*58d~Za{oN{BQ)3%jYjZNkt|-;pdjJ(k4%0P6NMQ znI95=(vsYn?ho3!%9bA;G<@H*=v9{=i$_fqb#>{kRw}k8_~`j&Q%*g6>i<+HTQPQP z$u7BOv#viHY5I0~e*9j%^w8k*(WE~!e?e!97=5y6>@vA0{mfrK_h|ie>P%n!(bU;q zs{WF8e_H%{XYpvxYp8lJqP>UQ)tYH_2CKQHqq}r2TV5`E?!mNPGkTrf|Lv`@Fh0Fb zZ`JnJsUyqF_jNOPVB_5WdHwC->GB}L`LxbA72)cda{gMu-u>Meo-yjBJq>qu7>Vo6 z@#T?@VPBVC=KHBRAlj9uc-TR8 zf^Bf}^39~N6rRrZIKsMC8#Uqd0WHQ|z?Ucgn61<#TDb z)^k*zob^E?Z7rE4MTLY(`auir%r4Hn?^ccKs))g}?ZG>jwvy8j>7oazde+Bon^7aXno+0DHLDZ!?HNxOPicBUC*5~nG~Lwdphw*X z=Cn*LS^c2Jn=I$;S>4u*Y}e{m)%jlAmXG@6N_jK+arO7Je5uT_+?dQ72@=VlN2&2} zN*#}>iupo?>BiG{6JcBVc+^fl`a~5DYcVo02mQ1n_$v2O(EXt#8 zmtAO|64!%myMn&{ZzrJQhB%G|yk+smg=sELO38ob)zKb%y*SFhOZIUYK0klo^Qh0w zZ!LgT9Hd!yY|N*Fil3*F^If-41{n=SD2&ev2AdEbyGnAhbdp0{tBy}Yn4;)juaBK( zn7Tgwm>3`v8-pf?}Wx(z13)50i{V3EuDz zX&s5@4w$K8>AEM>#pUDJ+cI{4IV)h-rKRW}b5qMEIPEZuSCvwWMj5h)=H$YE$_qv& z_hf$)Boi&Fp@~+JJjm>&3D4I~{e0;-U%gBmm_EyJ?j)3DG>;@;I&e}BFHys-B-jrRGx(c@R_kU!w%t>&GiTalkhu=dX0F@DV9=1m}#7Xk_5j zvJ5Z!BgFupjUYz0NG$ORFet7~trLG_kvm={VkwIL;;6lIejnjojXtp-*l=Ocs56h9 zK72fAsz_o%&4eJ?8jMotIN_lfUmDpu)RTCON4cSxQ{SJz{7_R=eN?{p@o+&D13Xw< zMk29hK)D<{molP(7#g+4%yRjvQMtODbyUJjTr#zUvOgCq5jDob zVB98~m~mC7WANf8<|kbEQ%b?BxPcaNi&OI~cx|FYm`^nf(7~&kGhfj~j;Bp1Uyg$u zzLz6G0ASLI8mt65n-tpb&AKD#_Q{IuEWp8m7mh0_r9c2)v#>t(7k-_4m-h@V;yJF~ z?*1CCrwG+CbpF$rM1bc^BwvUiph!mMOo?(Ij58Bz0H@&V!{y;(38rU@t3;8R{^hO1 zmpGFm=y5<*MBUr4Q#fBBS$1G}XlLi~aJ#I#eLXV(X+5T4j($5r879%6MgoQee(4}M zs!*o&*yvh}Kb>A%og!31geOQUZ^}{cvW%)Wo0~+fEop4cl9_GEK0L{=a(YY1mA)~7 z9%1V#t!qSnOF$Jyb=TMj6vkG_6zQmb7JPI4{;O^kaI)@YNY>6I)W6H5CeA%2nx_Sn zdMlOhn(Sb8$dz^baPf#NYUlLw6vNrvukAsu(Z{yjHZo@0Equ^{+FI9^M#%VHuf16SQqnI*CJakK z<>aqACD_5$20C+ZzuAoT!3P`3w$4CntK*b%bv|MpCVgHJCJ}rjp52Gg&nl7l7>bLX zk3oAgav#y{*ijm``^%5#*C#sb8|vpuntenNq@*Gu$FczAT+LNWbrr+;i5-+n-lNs! zit9jL%;P*G?nwSTl^mc1uheJKR%3_|9$@+3N|i$rNWX~cxQg6jgN1{Bp-1(Vn24u= zxK_1a=;9OQSe!GOBZThEYY4!G|AH`88=|%r)uF=U09hRUBE? zbil85aiX){Oh@1RH{lyMZkyv-zuX4_OuI=RJNO(@(Y*P6!RyQaN ztv+f8-6WR|n-J4)+w4`}YVoLOQBW}yKfh-qV%Cj{yu=RVk9VAV_xTWz(CIgErP;|6 zT2dx5hKbz>+;(ILa}w(b_;y0X4YJl-`9J)_C24zd#KR-QdqWLai7okLuyP4~BA;*l z_WLulAZ*H0yFYPbYGX?(C{W}B(#CRyrdxZ&=6}9;3;=Zvu6c$^?a2dBjs?8V1zL&y zfXztl7hpa+@Kx45MF^G8AeiQFODV(pC@C}e~GKQ1S1a> zr;|`ERBgx3D;}WG+NpCUkpFtAwN57E6(y1vN&8J!eT|w$tuf~=De^OK`XDdJuX&hE z138;IuB0vzF`jcin@GIwfs|fgON1|mg;yUKzu5%onY~&91~FoZWBL{j--rdH?y6%n zK1?=QOo>oYFr^bxWlu`^4AB|80GdaK^}^!z{gg>5JB)9s_89r&IBdm<2&Ogey*e&gmbEx^bI$Pv9gpa14YvNx&7b zsAG64ZMAYdQW@?!p*}LdUE&fVM+T0INzVQl2gC5k28sD)V?DU%1H;PsYZPh9Y#Y(# zq`g#R3y;nQRhb*J6Bt+Z!;GtWV5Z(>ZqHasp+T(kdDtc}-ljr_QFWh-vXlwtH$4>X zqk7kVg!zR>K`4nWm`!%L=E4w@-Y4N%oA|NL&tz|{fz3l8Rz(e0(y;1K9rdn}0;kpO z!A&G$J{igTIcy1KTJ8f;BmL9`GSN&zbxRTEK>Gu3&NBHsestYH*MRkwA1zFS5E#Wm zN*Q{r*eIwI3wQF!&9>Xr&?>vvY0n-NsWE=uy1xNlnf1z;x*}dDDBLJ<+V0?`V>?d) z=n2EB8FHg+C_TEcMEmv>%27Qg2pT*4Er9}~qO~Mdq3qz`+kcNuDgRdp`%9(&wsTCH zy?REC+D!bToKrOETHoK(*mU7X(^X*;?sqH{6?XP*JcVd=Kn{BZv0^Q7Ww0Ry6aV;o zIwGrG$kE0uX7*(~MbjVlFtA`8YMr1XyUqM*ywszHCAJzL%4Rl~+ZCWNED?O2>!EP= zc@-CuSC6G~yu6H$xQvKt197DUWehv!a%jiWx%rfo`?QO`7Cd4$^y~@F18l%1&xw@8 z25A&8!Jkn5YSN17{h?wtwMh^iNd{=cd#*nkNllI)H#R_;XUm$JgjgC6x_h(x34ae2xD&Se=oEd34$I4e*Dm)BdLPe;Y1^~WE0e<25?zy z{5rsvE436sj;HHaQ5Ac}U$V&&{y1I0cJ!*4z|sf!gy+U@V^H&@-qSfvO1YZ=*drFCB4SW zy`%+xe|KS>H*}y&(Le2vjXH)s3*CQpPI6d5{E}51J5J%*0&i z$cp0K&u{ zPPp-^AuKhMo!jQ*acui>Km?dys16PyA9Av!#*$xAFo$b8g2%XiRTSPsus|3%nn18L z7IOjqPoIUwzVj&;zMHS0N67f|4vGk{jo;=TXCkhVnJcPFBV13EjeTlCr*w&zY?6GO zA3?2!9Z(!@zU>hOlJds}uoSJDYWd zn{jQbpj-XH#RP)!Z}XG=XiU(!Jo|bJrvpeY{OAt_*Ui;fL1JP(Jsk$K^wZp6*hYM7 z<>)hgSHp@?_k-RKT;qWg{3={cY9Ht-)m+EvVu8QD8D>`Zdg>MxSxAxR=ou2!psHAp zYVp?s&WiW<4oqDw6+u^p+9;9h=;M`93p4QeO;KmCbknCsRVB&a=d~)Pqm|QQ6a5nc zk(hsHp_$sjhe`mHPwHrnUa7|L5jn>Kh5e0SH$8zfI+WzBqZJH~O*`SUKls0J>5vsb zoJcjHGcIj{VIp9uf3JOF2*BM0pQxF5CpR5v*^e6w29q&Uu1xtw`i!CVvDk))h5_J`aE~7%u zF^I?fUn7bYCuS3gJDu{z18Jn+{O&cOIWKI=+lnPAk(t%@J+fiQ3Xl|-;+->@fkMZ) zULa4?;n=Ze2vj4z;U6YFy2}D#U_nQ4f{D{uajY?uukd){pI{W)1=(y9d~iEC+)}#J zE07d)!G_GyS|=M)u?G=c)3!SAldd78`Jk zVx*ilPa@J$be*7~R6tdP>XSUiF^Q5EVFzP&o1C|6`g*sXY+l(6e{f*SXvz&26apT zVxA>lrvPyuBj7|o!oZb)cmgP`GzEMs<9X|XW?UCnugnRw@>4#6H&=Dr5mRtI8oTdG zlh1fx$E4WP_=@CQk7>|V`lnP##qipgH@?&G$byuKao`bW;4S_-otB;^I?Bvq&Hgg< z3TLk^@I{5~lk$UVWCw$I5%uBNcEm&&;`+FzMhGjGS|FrVRyhk3n}k`YR>oA~Oz5bO zF$We@&K%c2A*fH(n6j4nJPoO*fjH4dv}iEM5t)g+mSY3_q(H3ovohc&+MbrHdrR22m#b76JBK}BZTuS{6e z{OD?+GV#UU)vZDepl<#~0z*`%Cp+gi5tYqxvvy!lK-gkBzMqMb< zzzDzUH2h*CyQr`iqVgszqz)m9EoiMpD=%!_B|pf3{vHUnHQv!sn5p!}K~=Bv`QSzJ z*0@Ca4HV=+9pXJ`j8^(E_W?NZ@_te$j>lHdqht@AxnsNu+6jLCm{uN}`g$15aa=_< z+og5y2OXlea8sUimg%4rkw%RW#j+<7JuQtZu-0 zq{31`A%_4ygx^P~$ZY{Jis|`B+!~`j6$L?399Aq-;-ltBa;Wi*;GY6yG-wW4=9V?n zwhLMQ=CVQ@h2|h8e1oVNeoe6zp!l)*)hhgjQu}hVC31XeWQR4gxQ~ve>!2T?o*V7f)0s(UWMFadYdbFnd>xxaeUaA*RxH0vknfb@VQJfRf`FJ1LfzNxYe$)jVsMj; zbSwQ?38lfZ^IRT)&_IK@mDd=eR%i3NCzY{F{XDpw1fRkM+ljPYUrHo~19$lShx7UY z^!-a7o-J_9=*U)rz>;;~rGH3lM^PyvE0v;*ry-k;V^w0~`kScYS zh>edmqE4m()~4vn58cE)WCx8T=co|pZ1Wz=GUrB=!yPVmYY7Z+X*|^SQ0BCw7FLEi zmVZ1evWgJAFSu}X1RGJDGm2;&(GIi(gC*-EEXM4_3#nKj?Q8@*pZjvhvIpZX{?;UP z3l11bL0Hn~00%E(xwTWfr)z}I&sQr0_?k}1kpS`JJ0LQavP2-#`CogNBLX0vbsxC4 z;{In=vd-Kov4?w4gFcKjM9<*x>r}dJQ^ZiTEx&Bf{`_-P1j{%Igz?ZvsErpmVGmsmJO-|peS75g|Jo*oJ|Fv$Z1(NN_OwsChdWS zoS%^ipo+4~WeE~NARc}9O%@DFj+n4GK&}CeN8Ml$wa+b>n6@~o8FgRC%Qcr5nisJ= zZApQm%=V+w)AlR2jLt-9@#%n;oUkfRtSelu3=sk11>z=9r$Jak)0PDGbgO72C_Ia2 z;Ul!(Y4Ln2HMGVj3j$w;u z%uIwx6RD&a3Z3krKt|sC@(w0*{SxP|6H~bhR}y6ucumN)8x+@D%%{i7p$Z~QB2!t* zB!$cNGmNv+%j;DU(@gSD9BQyJ#aKKhX9nTEx{W?zoVrLvnxU@fV^aH5+|#M!5mPFL zVmRDxt%tQZr~N_B6GlIm3#u1uL>WU+Ja8f_xv-5QDrumq(i&pz5Q7`WNaMkw5CM7+ zZdB_zo?27GZ+M;j%Pci2Eq-rn-p3*;FFZtrfSQy{i=)18H}F?mvGd|L#6J*lXNzRk z8XExk2lf5e5U}PiB2@m*Q1o9wqJIJEf0GCP!%P1qW@?X%@cRY(-;t>tnb-YLA!twx0O04p2tw)p;%Y@FTLA%Cj8@0x5utgELZT&t#x(Qa&pK%UB{b5Od#rBNItHqv&GDstlAou&?OCVyJqjf4y zYQGx@C3_Tkw!Nt@ba7=ajX!p+XI(9qAI;FdA65IbpTSR_o_EiQJpa)AG@}gbZ#D_j{~bqq}Cm7yGjC zJ!iK|Z+9T9XBIZf`d-oV`Fu*;`?zZ0ynSBTovEVV7PX3LcC1$|9e3lwuQ?6NZti)z zYJAVLbuUdZ&`-Iw^JaCMc6y=QkG~!_w~vcAz2574pJl+W?|11|@m0MqmMFaoo`qZ% zUtWzr5smRg5IwjqYv~RvWl9J^S{GDf?Kb zX{M(YBMF%(vR^Mb4?SSNKuFo3XO~Fv)25%3iFiZot9N6&p&|oQiUT~6%+TMzA&qiB zz$^W*zp!@S#&|fs`&{xCWYK4H~QR9UQgT`7YxfTQ|QVSCXf% zUfSZzY}}#+1?5!DfEZcQN@0LY@=z?}+!!Veqyk2EIiAd!6m2kqYi7tfmfl3CUHZ{S zY5Md+Iw*u1hzvi+A4{JA(`ZWfom~ckin7hl*$AysMkY{3Do|L-(c%8Ip>U1h21 zjjn!cXMJw7OyfP-oeX|+|9xy>*s>1W(#cjh|9#!=pF`nTt0gEI~&2PrsTY5or;yZ#0pM!Eh!47t`Y4s|f;i163~f>740-gQ;6Kb%~m zE(=7%?nc-IaUTuS^bakueE|68iNCmPS0Ye%hA>Ure{+71h|>Bj{-Ow1q0#Ra<}k&FI3C-<;P%#r2`OW!E^F;uQv2$Yq0J}3NKF)AIN zA4XM>P^T@Oq%H^DJejIs%#yel;ZlP|s%YF9AI}*_V!@ec;%7jWtER;}ttD=XmF#ZR zELfU+h{ZWwYdz^;nUTaknIxRiJ$S=9F56mjbM;AxgE~=ygl!mo;l;)b- zT4y^tR>W3cihTT?or~;^(%%WGG4qoa9EL<4Hh&B=$4%6X{Gr}#wE{XT0W>_}uTeQP zz@^m$J>M6gL3HB1#=sT=XKpJzr>yQnq#E`hF-e_E6&`X6{bBxo=Xv@M*^fFKL4}H-|1LM_!==6v$s-0@ zfnv_lz6Y>KNSF72`x%i)7P*!(uz*I{G=>8Oi6vK*d+QH)!%b8~D5WB0)xm*!$12CD zxAujeCc(m+bQA~8J~Uu3#2#djZ*D<>fX9D86QPGS@%MCzuy-jNTsGDu3gW zy!&S&DF9#dWo9XM_cTdU!>vp%c~$Y}@qH5TD!O@!9ZQ@oP&V0MD3G~CVEuI4ZHXx_ z@9!Kd6NnFr+b*E`U)E{lL3->e%-}R7eT)H%GO*x*0QaCp2 zBLPIBgah*0WxEUv)C7Ty7jw{z*jjdF#YO!cD4OQ9SR$>iv7 zzOUxOymBhpAS8ma8-=F{IXEkN`5#c4N@c(L+9!C96?>|4nGR-t;`6OXnF%@%Opd%Y zwd(j>1)Dnw(f9bAi7dpJ;m4|9+B{YWZ+f;n}uSZN`-6yzG^aT-PmhuWltf`7R>7bT@Ernm;Mv zU*Al8N8pFO>&nNabv%8SeT;SS!b!TRZSHx;ocxrz}2!f0=00#5hN7%c#8ee;vt1 zd7J;ahG*L@du)5VZ;_nH?y@cCYi8R-YdDAV>3R)2;`%=4>!@tmEcUxTV|Ps?_%$tgW)S&F^WJi7$T-X$w%CCz9UMCdU`Q3p*G^)g%iq zJ}^#S7%XCWkM}A=>T~Whg8se&@)3y6&In(jGHZtZW1d!bpy{Kzzy@~F{{<=e`dqv5 z{jSzSwiL3@N*~Y6j{KtaF4Cnji9( ziZGG%8lz&5^)-<$%ew6G^!_0Hh-Fq|K4pT>^qy_{<|ce`uS_GeUjS`fNRULfKq7%Y z%9<>2bOlCxe;gVJXFbxnd|6S>ee7cAa%~ET3 z#}$Sy4e!zUoz0KtE0R}@EwapngH39+^|^}5k7^fVJv+`y|86$dOTT|VBb%pDPF2o%QX=Z_y4?qtM6CJ zII)-ettVVJEc#1fiDb=$biDlL3SmY3CYh>UWH{o_>k~CHq(bAnw!l9tcxW}`KU{5f z-@1XWl&p}2o1x+n1VtP&mYZKEk-naguC|!AapBoC??Vo(-8K8$;1=z#FMo4Puw|^j z<*xM|b_j+fdg%mUi^R0Jfju+qmRiZ6Tx}r1Cy+?UgQrwIMkt;uVbUbIiKdUTG-0h) z{-Pw*_icLhfii_|g3K=4z&X#b-65Wop0MrxPI9%wU~4yMr-GX_UAf#Dxm$Oh)hKP8 zG%=<}OKEp#*FcZBH-Ie%OL;S}|2lQBhZ?ql<9Pwm+88|cxILYG6~Aj*Ik{19}GfjkRD8dz139Q}I*ek2pW;R-SzI z1z;x6>aaZSKP}+!gKZi-7q>Hnzxp7yt9mfPw|Lm6eNld5`QGWjS5Bpze~5Yl@hVfl z=-XYNG*)d6f5JXu>7uyN)%=jhyFxcb;AE`p^3vVfWP@mM)8y9^f_Sdg%H`=8Jr9(?yb9qG z(W2HRm54>eXLacZ69-irh{UF2##%?P-ltZ?@j3U_p|LGDrv`9P~` zaUOeTJ!wFET6|OMQTb%Q0h1W7AMRE ziB1)8P$xx>@_pp>|Onw1A1Q#esGCCF#xttlK39&5a%JPP$gQ z>I~ZM#rmA3d4Fejac@t5|8qse{sT^OM3+@}>mUlb&70}9mOE}?UCQlpMZzLxY=c+&e6T{;t{x77Ed=&8p12i-X#7&flydHyH zbaKG@J#ioZ%d1e9S1;J{B%(`*E&YNrP&P{b;57&69=HBZMGxKY7(=2Upk}+C#5hRc z13v&ILB6VSV@C)sXiO*I!MrY86_*&IAXhddJv~}BVNxX!;*uV`o)`Ke?Tb<2$Kvx9Ke9ur z1>7>(3G%FxNoad}odVByA*&GiuXL!(FOc^H#&pob&bhlHVhlxVN3?6}xVhZoUhc9TWyi`{ z3xDkdObu{ODAGr;`H+$kGS1|ded}bg8pv$t#QYm;)Xhk!1WZAYL41)yr|aXHaeK%A zX@aX`uX-1_r`1;o#4M%T4;4S!&)|+$_@jBtb%s}FXG70*$(?BD$Qy89%4UaEBcOvc zkd7stLL7M!tVfkg!vKs+Yb^JpAvF(LiUK^0{0HFaV|wRJbv$IK-P`T+>tX*^Zv(q1 zz_;UjgA4{|3cp9S3p@f=hVLflBRESHgpj}|iZUbaD> z)yey9_lk213Oi=ax(X68WfTi)WKIK>gBEKp!;z5R#HHYCk&s@0h)6SO)MQtKduGv- zoPC}AdaC*xRwd&8-OE$ekMjHZ79#N0`F&YmbQZvUvDB++E6RXrmo_km!>NZQ&Abr} zh$2P00vREW2&5pq?B|GRzDvSL4co)tWXK9nf&w7{688E#wsWby=F}{OA zdfXknw)ealz&gZklD?n8e0X>v!WY8s|9x@%nQI5Ph4VnV^>ye?q_mdSDPRP46vlnC z4<)WlPK4g%+4a}IwM7O$N{Z+Gy(~L@ErtKrt5`Qmu*KKD|GKyEM& z5}>?Hc{}x@y^QEz&)3;=X$M9V*$UX&RYL}DCVol!bIYcK6Od@7AEx^Rs6U1RV!l}? zrSkAW3$agQgtX3A9>xU!to?vWUby&Gjh7^VazS-b1?d_!5-xJ5E9L@_G5UHm;!H+n zQjLhGMDH&Xt*+UyK2^(xCIbb6he`#G2CDWNj zFE5a#OUytyl6?V<7}u_)=}t29@kfTVPY{AiSy56urk|F!$9Vb;xuhIatt~^Y)=kNF z#?Hh}Irxz@eu8U=hA9sTo*s#^!dhZ;^Cc4n5kCxp{ z`=wmfG$?e(bunSD{f7t+_&Q5Y%nky~(@NeyMXa9T8`zhq_fT@1QP^@}VlkW`MA;#) zUb|0U0Iq=+!Q;hwBSz%2Q|(#ciMk?5FPsm_k@9H?U}o|==f`+23ei0eXjE1(^;Zqb zdRaekyZCX38FQR~7TxuI(?{G#)9(bW%tZvV9!+P_BRVnF^L81Q*$!J-XgMOrwEM^g zRZ+{MZK< zQvE ze3v4`hkv<@D%6`>%o%bT`gAJ&t<;k~>qom3C4(}YSAi$D$zGcYvi zrL2^tifUf6b_MEU5iZ;9P$$b1SpdIevyMx&I!g*O#|!(N)6?5b3^> zfE#^xNMTqxMr@wtx;&~XJb4y<<1{?fPw#^z=}xx)f!05;VGs|)&GAw&&8B(?^oj7% zP0c=)0fMs&yEJ;2(GNmmp!sps7D$^;*ZR|C-(f|+5taI+*d(P#?9Rg$lftjS6KvUK z8wOLPxVB3HobI>Z;>Vm1kX+Pd3K(DH?-UGrW9fM`8Q$vgc4%G%wWZCri=TDf8^@N4 z%@QqUVxr4Y2|JRZ_3Hio?um{hO38Y+z2mn=C@BsRz9@Q8i9Av6GZoY&l`ekmqj6J& z-t62Ym~Qwtew%S$He+zylfh9)s=N?}IYfagcFl&8_5(z;p+v})HCJQp;fNJx@UC5@ zj_WkG1uWbn;eklfF?f!AB+>#V5=z-?A-u5j*))#ayke&YlD8gOT0Jt{hbGZZ44x;w zM0Zn)o++_2h#rw)-DV*yR$5rLu%%H7KtB>{F%FKTJ5zt8N$tV$--y9T`Lx=1?{8RUwUoWwNZaz(;5z~gsJ%A zKEU){^@?%5fjw(JI|i;r18T$7y;Xl1YI6wSm?$BAJy4*QfOSvqd0X0OPSG(m4c5)l zzj}#u)cxQWKl0@}a@PKYdSwzaJx5~QPqRTLRal%}YT1E;z+ot+#&4ewXuHEA^-~a~ zW<~zlR6W?Gg)1G?3Hz0c+VHE!&1I3{gA+reDyx5yBK&&CH+8wmoSv7CBfnu9YZ(EL zGEP7bQU0saE|W+i&Tv)|E+G6$>Bd#+Y+KLtTu8?T-FE}sjcqM8EadE#4t&?_2F!1> z*w?GgBkbGr_3KkyEoC5Yos0E=;w6c8lqgi9pUik?!y5+=wkLo~w4?;zk32$%{1`s8 zS>Ilid)6?c6WzHch@8&VEiyPMH47pKf_1CB%bJ;{o_h=L!{JTM_u(5Tp9yMud!`a#V<;q8j!t(+Z;m4dvI>hUD|eWuGq-r zb&xek&T9@w4)rE?g>1=#dvK3uyZKZ_SPemeU@}uXLZ<~pMOrGePn{vs^YSudM?WLE z)BV!Kxdd?Z8LleyPo%-E7IYS-uE3HzxN!Jw20U!?QnBT{NTYI(5FJEIC_bZzJ05rB z6-qvReGc7QB%TN4x`)@Iu~2?rO+T%pP1B`hcECq)Y^mY#t_=kaPp7fAkW(0Eq%=u+ z$L|!3dd46Ws-p<8z#@A6grc+wX6p$8YsK}as<-pb!fu~pBo=(UPeyMWu z3BuAfp0|SSWxp_@YZ(&^DGc_VjY}!eUOR#T^NgxAv@nKLlLUC85ik7N2{KdA{Y1*5M%ilX;_l4fNGx+kQ$DKLKaRgR4BEOnW6;Mi z#Kn%-q?z!__ryfS<`l#^PeA#mnmz83ulo0_z&z8cC-t{~S{qzs`9m-Ced~&^Wzmv+fb9WOvoDuQx4k->E%0`t-@# z(7}*f+P47$8#?G660X1x_BRe%VF)MnWH@j<2XAf*W~1gtBvYOGxN zH2Pbn46g(4p7(=We;L-&N80K(5gS#c5ju7x7DbLTKq(Vn!l^!vo5jmtJKmp^vU`CS z<*sfoC|!?S6?a>!>T^5dZZTJw@2mfOpo(+WhC5Ko6@ZrJp{rp0C5G%I;q@Y(r>H-N zI!0h#7&A>heG$wm01^N>n;rhlqHw65+`HB|KBNm{sh^cutFSXMi- zV94zon|m9r6ZuHdo=)hO8*Q~%`FMq+w{!)4UB?lj)O2)A>_lJA@1|3){$ppGS-et1 zZTd^!m`KT4Dbj$#dovcLq4n*`;efw8J<%EP~pK+~7e`3|JaDTJ+uPJ2! zU_DoC@A368P0#T~f;<-^;TkVci9%1Ib=abqrEXX-OGODKh>D_i!ON5%-ZV1Fz;d~< zc}8{Oyk($WJl(+$!KN{M-T zQCC^<$F05dTjwsTX{|MA=4mesTPw;pQ|m;TTh!2tUu)q&;cgO|g+^sMfz0I;LUmFq zxTvBV1hac2@+KN5;s&4!QZK}licXZRRHK9>bXvkhQmCbDcjsz%c$-Mkqy%22NU`h+ zjH*QEXwGtQd6C2CixFjyippVsVG^%iPi7?)gFv@+GkwJk#Zw&` zImEv0&TgSHn6yn(Q*$gN*^b5uUHQzEFf9g}k$6UPIuEQhebG8P71^({?K$j=SxjTQ zz)5&W4PaG`dvO-A@;`);c%Amq7T!TNaP?k+&x4|dA~#zgdd*VCof9TYI&<8+gKSpd zwKBQ_tWiWH8OIvM&3_qrmDradaLAch%z$h_RR{FU@3c88+Rgz2q>a7B^psbAnhMbV z8A**$L^FaCK`s0&I@#CrU|4W%+EyJWn`Lb|`{~6rK5$QfU4TNG%q~37-s4iO87fEY zXhnP__4{*=){#zIcocpN_SzVybX2xA%SI{pJ#)5oXg{|!%hw;_5t9i0DAx=Jz<@qY z2Mrlyix++ztZ4Kw_`xsT0v+QPPWel`Pne%vSzf7%XDSmz56$clrYc?MV%^RAi1F6X)30jtN)KN^Vyn8GbOy=+XAdX3s^`jz82GmCW^ zbof_x6dF5n;^UQqGTgF&kz4gWfgL46%pW+BNVC5kFv1!6O^DSu63avkZ7YL1dSq{* zy}C|acRJhr)|J0W0|qrO3>RXf!I=(t6pS^3> zuBsCzIT8}=O}Oj>KsuJLZ-$*1$}Za>#PD+q=vMNfNd44l)MR8vX1{GD6B+!sLuE}i zjnc<0SzqjWw1EgN9981eJ&bt?_?;8tZ;8SjjOxk&^vP^^YNXy#ssqc=81;>UxPiP+ zO&0x&e0Z-7D#n({W}bJ6dsL14F#T(aO=qAaq4C>^N9dX2xQw8rBH>f#rw1J@r)bqr zoPd7UI%E=N;nHo$Q5W%SB{PgLQ)i6aRPJO_@sf14?Reg0tSu22BFYV{fgztU(?r&i zRI|7~LS>ay=RJJ3O!(B_7CUM8ZM?@NpmY}s03|Nka-+v2H<0JL18PFUd62R8A{G!N zaR2^1tBh%@WI(4e>Btr#Ih)}kyx;EHKzN}GbOt#?6Gc)j+{vu(4pZNwfx;dPOFB+c z;j~Jo>Bo-3_Ol~wN2>UpG+?+=f_>o3afrN0)L2b4PQGI|Xs}Aragm=5=E=XgMH9wK zU+@s-JUGhO-zooo;FVy+vR0G6x*&R7w$RU0J>ldMT*CF>-)q0_d&6SSHsk#qIcids zQ931PFH!g-1?zlSCOM+S9Awv9y;_)$MOlVD7sc0Kyo{yN4I!pD>7;1Gxs_3lO$#QN zKdV(fnLjB)cqJ}ua3-~WEqO#8x@m9|)jrJ3i08PPL~$^`D)9#(&5%(pY68fsSn?ii zlvHgmppR!k0`l1D#{&(!h2Drkdy4!33~mZc zqVJI^?>)}@Y!Lrad^o=-HE;GjH>dlRvm&AONkiLm-POB0L;A<6(n3Y3{F^jlJ{HaO@feJr94BO&bV6H^J zKWD`$=>78`zKpC#xY~JY+Dq^H$@{j)voZP4NM^fb(hPV+rH6Shq-iGu!fv20da3z7 z?f9p`;uzmb(#W|tBSq|TcQhb?DvpMbtx)T-TKC~~{aV6Sptuj2G5;4;i9FVXFB%PH zyG|Qid0HHsChj{!8t|dAla#VwgrCQYCTVuN!gO{X+b1tL0FQOPfjM)#B&{*MyS`|-5$8Xb{)c;d)N zCmLmm8fW(KN0fAC4!66fbpIV>BrYC{h{Pg7OT1G3#;aLTZ!E4YHbssjyUK{e#=&~z zwTnN*oa5JlYt3y8&)~U^M($*t2H%JuKM`S}!(FzLuKXk$H^q1`f2e|0vc_T0zHzQc2Ybq_*E486GH<8wvk+yANFFJFdYolw z`2zm~`q&8HkJ#`4>)H?1(KI3mA$G{<-a+ltAqcZva*VE3_AdG{R&?C~1)rb6o)#ao z3f%5>YlENisW}042~l-%q^-Wn5+17w7W}4WdDoM zgS#AcV%2HntOmmTx}5BKkao?ZDJZcUxbfG;H?@2>D@Y!weF~pvE*jmco>0kL>=JT7 zwoz0MN6I>0U_I}@tdhBZ;f3Ffg35DD6Jx<04Wxo#pE|PAwmW^IFu;+}%UEq@kR$z< z?3L+T=EYFD5Bieg%$o7W4f%=?)QI2EhN$<+t#x$iAQVnp7fqO)^2ed{2;;_^TCI8? zA;@bDCo#j8AJ;qlr*&ch7fp^(tqM02{QT0iM8F!CnM|H1K0*w2zM@S%32FPCtPDYJ z8moY0ApW=8Mkwx{UGc4by}a+>%wEaL&yds5v2Kb{K7 z-J^AMFrIk^r(OQilth1^@`fuDR;clxybqI#q~Y<~VVY?m`&2XRObk!dv19VR72>J; z9RS0rcTmX_6Mv+uhppQiA75UIAe&Px^ivF;WuN^3ps|qSKeqS#L!6Yx zMGE;GhL{o{sTrwziN{)IXqzq`i>er1K$|j9ND7=+s=91*71>lnz)i5&1Ct)=6Buj9 zc0xwa*0G0+Td)vTPUtQ?z<~(Tfh|ff+{|Ma?I-?zST3G?*}Qj}rEnmIYsJ>%7!9{E z@eyli{0;`Z&)4z%}gx9WlS%jQn@t8JYF<8NdTwnw3hb1b1 z@tBR(a|6%uoCtfMb`U}_bid_cU`S>_!4U-2%a>d&!&zNg?;$E_s*PhL8mIn_VkQWd zbX%D;`7ElNbV>ixAF6x!pC49cPF8)k_Um{W74ZA|&x+2C*2g{2bZk3^YEAD2MoeXN z8n|g$hr&oi7`C^N+{MGAw#Mc2=IO z(ZVy{(hR#0h}K!Q5`!3N=407*|FB@yz;IXjl}1%nD8&2u;lSy0hgbdTA4;WDcyNC6 zcecS`)$JrYvVoqQ^#*7TEt~}llQa`K%W~`~j-v5ZG%K-2AEv5s0AQe-XmavoUc!Efm{{mcM;=;N+8~pSlQCg6L{W zn?EA(hueoxoB7Scir$ZF0(xredP`*`lL#hR4{V7wNi-ysHfCHc_|>XzW-Kc2Bxp^w zsL5Z^(dL~YJ8i)g}wy?rIih{O}*0T>;m1cw;udFVp^_eqwTd zhhSycNb2Ahlq?CU&{iUyY;uFB^(bg_l&{I^@C3zB6kd?}^O%e#!p2HSmzsq(vD&ig zh(+(U)8%VCK7E%R{sgTKzOHDJgBTEkk$O%3H$MoWRdKA~Jiw&dw&kn*9w7JiRA(}3 zY968p0%w;j&z9gU)o-rCu^8jrM4>=pjljqj^tx8SeUXcTPdqM;Xr$hKRLe>AUb6oS zBtSI#LK61?k^2^40RsEcWWLG%yc?L){87p37sJDzpM&{Kw-89 zbpY@S_AUn)PH4EOybLNb%Y)Q9rRl z_|@bPdaz}QElGX@npj8p=SW~p$Bb?FM%VCOv{$*+7c8joGvm|3&h z2DEJ6a83JcD36s8*gkhaWqnXCOq2aw3iFd ztryu_8nCMF8J(6Iv;0yb^~2(a8;FPJRovEiT2ji}n15^2P_`+|fQ5?fKo~0zVIxFwf>*0?AWCg}DccQJ;+4^tP^&rHgP#8z9>t!^ zDwk%n93)|hU!Q=Mm^UeS43~VXCO$#sc<$C3SfpI3@r2)TNR$RM&BlAxVv&af+EjFc zNk_t+{UKi(*VLqi`qlNR^Cb{G$1#}L_F_~xERs}Y&PiI9u#dCb_lP3uM?D>VCYBMR z-f`zq{dHlRDTF07v&`eKWe;3dHar;eSeJFHCGu$i%f{|?jrwKe@7~JGsgOMt`SEKl z%bo@OTeZZvNs?adEt;dKWu@XP3kYIFUrr}i6fk5{7_cL&jTTW|bQr8L{pjJxf89Uu z9F8@LDeg>g$h&EidBfd%G=2jxLUuRE)OQn0o7K`V3M9jhe=f(VU4a%97MvBFnihns z7a|iC{EsY^h_7WdJ03!LtuRkLs-aa^*`q)w|5Pi zQ2KmWcXF02g;&!gk6G`zzyndNp7b$&q0_hr-r~f%B%ww&sJbDT$^GyK!Fx3lXBO+m zV1LWZ+}_y>D2Mg5{)V2={xVLLX8{hXF?ZmJH7nljbhj!{ojO%a`)(Ai1CO5Yr$LJ& zNo~st8Bwey!tWHuLk)Me|+l0E$bNWl=f#0hv%juP!h=azA&+o9gtk^BCJTkSkO19*O zSM1~|C0E&bP~c7@Za)l&&UjKB9%0{sf3w~0_J8n@r6F6PT_{#abD^&JcUS}hXgNGieo=N8m7}sI_ zf}p!=5+U@*eTS{C{I+TI(rnN}c^}KW%bUKv*N^!#ZK-2+d9GFs*T}>1oaWEzfDx)C_IlDrvv-Thim+A*01zAi%WY8xhQ4e*06rvJ203Uc(^@>4rm8F_y zKLPe2ysIW=5#{$Iuz;?dOgc}y8w<`*@nYx`b;Gg-?4j-_(RBCocJb~nD?&Yo2|qRb zstnmMip?}22`yeKG{sV5-}{*JB95?&%{_<^IXAG9dj>|wo4b|mzMl)64tRoIpPV2K z<*pdMct%?E^K1>AWB7c?w(4%VE!)Myc>u65CQ~37_3y-~uSo%xrXwHW`1(o(EAkCR zy%h=Gtm$erdO%JF=G|Ox&5mf}hpCdg<@2ktVOAVKkbsx+dFQvW9hQ&7Z^FIYHgo{^ zyZ#+v?xg@pyvI>Wxu57X$|<7Pg_)Zh9z2ucKmGC(#Mug?m?mMD~hYIY* zC{~IuukE9UxMpP~yFpZ^HME(4yK^!$+aq3FZ%|MbWH%SnO){h?P!Z@RyAU;E^t_2yUE3yTs;GOy$NkEFw1)^4iv9(e*HJ#OMzQOzB2n*cYFQBn zKBmO^J*w=a03=L`SKj=WI2e4J0JIB2xVrUYL^+-K14&>2ne1bN_HXbq<36ez3??dB z4@rYvLpSyptpcnNNy6#r+uKY7m-pD7%T*@^`ZBKz2AHoVGDvNs0}7a^<4LP(_djA1 zaix1{XFL~KrQobu?2&)F+KHx?@pd!XRgxJ#C0f*gap)fS2Ccm_NlKlC2}jqlC}Bv1 zM-nP(m~Cq0iS;7_1q^KL$yCeUqf`3!cVz0*HtKauaPOtkMtluz*LIxmGekyrf^W*M z%YlNVH?pLOe;B!YAYkVoQKfL{R(M-|GA`s5xY9-&z4WLW*IgUx7Wsn`L^(<<)&V%u zEddO}fstCkq%%SW6I!KM^=xR8bm^dmeb~gCY@-3+6&_{^M%%c5?CV6jS9Bf-C zh5dxS4k_FpUX$#WM|Y=`QWIC#RZLe&HwW(=a&^xe2a~6A2xi;WcsE-VTLah5z{MXW zSm)#Xn6^PyGq{&BDBvN2S!A(EpoDfj;%^NJ6f&{pQGJpaQN`>n*-!7OLdxZ%ONX5 z!N6sGQf~*|xOcZFMlRzH%=8_1m}sl5y}$nGClAHzVEKl@`=(`t<7|=x0RQkDH`J^Q zqZd#8JQ5Ff4y?F-^d<(8USQxC7;Y>zEtXfHG_Y5rNwO8;R)5>$5}wxDdH%-N8Wm>5 zlE6|4ve8D=ELQceJn*+o7bZ}0-Q}+g9v1szH@3TT zwR0BG{~Y=o{VB$ZmVi-(5I~eI&NVK|ykvc762it^Hu7;dz(m&hYDq^R2S`fx-#&qa z6@0RSK}c-MB1u2K#}1cwyXsUv2s?sQqKK!%kq6$t0lblg1Y`q->{(|D?x_^96KKmh zFS_tW1>~SFCKzQ#$ElX5u{2A2W%K`aE0d?PEFV>wE%fNO?XF#zM4s#g4p`DFcMdo; zjA3s}H`$Jifp&qwOAtUAdMZYLA^&G;Iqt`e5n%xV`OmxYzc;n0{=YJ{{I3lj|9{(B z#&MxR#Qv{rE!OtNmgfH_mX_%rYu8QLHilyDE?Ax|x`(_HuH(zXcytC~CYYV9K?nX!6t=qPyLuM|otOYkA zfSKn{>qq7f{QA@FHxELmQ#YyWeLE)&Oz&!xOn~Ff_H)3ay?|cLXSYuQ15$&d=5B!E zYRgcc;cCtGg>@^8=H(6G*sQg{?lgC1lin-8uCH!|spWKHzwRNi($R9-@n2kE{bO~- z`Kz~}zmK1x;D>fY2Jovo@YL(^pDEARYVJ$V<@$+xZ-Il>s9WeD{n0 z>+#xt=5Fmu_N=z=sO{jmTY%Nlj(DpNI4qpioVxbuS_j+h zT%RqUyGhjBq20Cs>&;Ij{B(~Uc{{WlP_mp$bZlsNm$G}@Hhua|%B@&-Y0>W!s1iJ} zez@<-`lxQ;KRm6W2y6{_`>^s`{wFk~e@oJ;-&Z)-_Ku`^dFR)J*yhL-DYD`=wEfcl z!n70pnFHC9+0b%oxzOZIRoK^ayKc&B$oYi@5N~{a{fa&vW74lTxR{-CH1p0m4z6!s64gWrFE^_hzy0i*8N7?d|gKNCgq# z*rg4Hi_^crp#q&{pP_=OnkxEn?7Ti(uy49u@AC%8V110^LqpW>^?unu)cZ& zrwiMKf*e~u$K$nI#)M9k0vTV(AObFyQv#0+0pZT^>$jdv7R5a;Qqk}^Z=5~me>N1c zD?O<#Xb!RE`xq?}8(P*|URFj(dpimp3j==2k3j!u2-pyu`_j(-A@3VD0U z?V~WT`@S#K;^o+|W+e9+uxn{6sDird(P_}r1BOk_Vm{Xftmsk_bXaXU_WaDcy2)kw zvZ3^Jc6|T$!L7fx`@Ufy<2b^P*s;();_*pa@a)HPPz3qlFI1kp9w?aUXLz3u-; zJ8D3|`^#+xdeyHBh09;ygZFU$jSnqo3B;a7UvZV-J-9P=CN1>d2j!7yW$2%G@4w|t9<;h>d;2RXmDX!k>)tlUVT&e!Ay;GZyiY&*1Q+&4D zTmkxSzk%Jtl_?;APs;iGj|BJD_P|H?MQ>w1{lG%|T)G#hTzISPciWxTRw2p%1`&nZFZ@9p+pHLiOCwz>k^cLps7T6Kk9=!)MYRox3j_sLDl=Wp!~{?Bvo zUN74{bfOhM=r()8pSP1u06VsqRlwIr;Idxf-ivQmfnnZ9oqS1!iKc)*bq)1vl3>dz zvPQw_2%xsQV9jnYqy;#Jti?4nwE(SYK{FL1_4%XR(eL$u=mTTRJ}_$ZG?#xTM=c?P zdjlN^<~X@9V}2VgbjHyaI)G&Hy`=C^1}yZ>{<>IwNhx7K0&)>)-@eCwG5LLRAiu2q zb)<)jnDa}?W`x@Ht_UF9+7W4}^qOU)(xd; zZwtyUZ*JTR^MTr&R=}P;_wm${ELN$>X(lpl4{34X+!)l%9KHPnao8aWSc32H0+t)7zO>`L z75zfg2<-`MDYvlZMen2gRLcRT^E37P{=1_qOHAs@yO2ZNMgc&^h1LLztFH}ss1J!a zB>c-h?h1@7G(Jlm@$c&|8`it;`e0CAm{3i0owGXfX49_gFE*Jl?ucZBKkOBj>p>&`g`41phd_o;Vur3egvSjxv4a z9#rfEIuGkL#kFUFISS zC9S&M{XKoXIX?Yn2bSG|H1D8WFnU8b*L_YJcDo38qGtVtxXT}8JN5bYkZI*8;uFk#t z#@QCxP&97WT;DvNqXAsBE4RG6B%MeYmLfE8mH`QKBHR{pG9!eiSDfO7G>)X0N$jw#8JsGy1s1&G%KtqdV`NxI7K9>#x^k0gXyZ zz*7t8wQN)Ta+Q}7cC}ykGF5_e8!6gm8NZWsQcmMA2O1M6(eP>IAZXQgK0o5gnB~lj zur7nvKW^>Z7)e?j5a_1{^B^VgC1seqd*1y7{9puk;)OuVlWNBJK0BYZEJd9CG4l-d zfBFT~hT3Uyl?)73BDv(dKC>bH6++~JXl9`E-Fo2GhdJ{aJ-x%ciJb}_$5mpuqo?~z z%U*%+ay&xS{cM{Ak^kgl(}WrI~+3-tj$apY^Xg z4&Gdg{PjOk`~Q&2hZ^5|)ipe{v|NSLq5ztF7ZpEXpVcb~ytyqs&Z=lX1VBSjsvj5r zSvnQnGB*w+7lPYe7gh=mHSUlt=zhJ)t7X!(SlZhfg32HcvXySa@}WCb!o;dJdl=Lj z$>>xUGo|HaEisn7NlBrkP7qTrhi37vsuOusHIg%lVL@ZciS>pg&N6ydmL;@}*PIbn zM2$~A{|!;1U}_oIZWj?FQa|dvaO}cKfF9Ze2FDr3AwNc0Km=NiNU=qRAu{{n2OJfG z4=`DJo|Z7N`c!=vL`T{T33zd4m|?UO(Mf{0g0lqMzapf>-Pu{jY>S3CmzO^6~;A*ndkRRd~ufhH6(p# zln2nHowOjL`|3CpRD$&tJtPGs_{ejjwf#`%CgknuUoYJBFcW&jrIp$mQ3PlA_FZdr zVUZ2EhEPvKcNNG(Zwo`q+fMjXUst3NKP3@x!B|RVu$qgEbhJGV@Drc3+9x%I8qG%S zSS{evh@p8mFpel?Lct1r&%PIxzNpffU@})8y=}i2r%x{>DCFq-xX_4do+II-qJkGsJhu>^n+lshlz{#Lui%Yq}Fv;S#-977ca_S(?1D3pQIy$7ua~ z&T^!1MOS=0c$v}jcRXq38jghNBV6BUr8oNsLIyR<#u55*<=|h)xGWjq1aO_ZQV-vN z3`rjsX6z>+YffdNu+v@>PNiL>gf^zuu^|0oP~j0w0LU7ZH8!ogMMn#?6o&dFb){7a zF=WHh;gIyOz2LTf;Z)pOSi=`fq?j=+CVf>`|1T8$v@#YAvUSU3gN|^xfKlW^y)~+p zJeReh95L8oL7qOeM1N^~$9{wLvYdpYLExi7;Pxx)Kiw6dIYi!bR^XZb_z;Vu1mN17qDMHl>m&G2}m0uaLzx#p$2L zoTZc6X)?(~vKw;iBaZTe`sr|Qu)0W1&<1taNfxbUA&}%uqkFWX%vGKlWMuW$h%M5;}mO%r-qtsFmVW`irv$UgAEz$Z$4RYx8Z&}33h7N1|UhwkjjI*6IfiBWXZcu?#p%Yfndh8$o`BOV@8>bUi#y%mRSq~K|SAJ>k6d# zH;M!wN~0_sbEbx&^J^p2$tK!GCE3D}K3Fm}JqR14YJGS<>I3$``iKIpC4e|X?ea-f z{f6CZaK)>ls!xh$QIvbs%2@s_e;%g)5epJ_x0Sc!SBVubZL>IHSQ<+eFFUQZElj3) z&S;gQSXQwn73eiER|-EQ88Y-`qmFogDaGxYwSqNqkbHcKeY(rK8r(_6b59Y1lE?PE zlR8BopIv{`gkIy3D0JZw`Xp?qhD+PS)YA0FKFt!AFOwhlY5iPSu~nKe#0 zVZ{+BMP^nYj|H2cK|1i}rqdvLl|(`3A`+qKf@L97SRHmgZr`CfwK1GJc6V#cn(&3q ztm1JbYYXx6czil^19;fmvV=IB-LVu{F0U7OWS~<1qdOlm8#Qe< z-D?tX6|ROCcI&X*9=j|bP6s!*?EWzcZIK#UNq7UL}f3xvBf-<86-7t z72s$N_mMAQBVS5sjWj#>yAR7m=W4PhcNOjKx4=#WN-SRrBYnxv6^cL_0`i_^$?}1u3Iu`gj$QEaE;J zM%YmXPg)NRE-$x?O5&s4Q7O z1{K*zO+VbF7v4#Mxw?*lpI^j$5GrL!&F3$De{e+imUs?$)mJV~HVL(<2rpgCb3su3 zizM81z>k`F5FBNJJA&ZT&W?1FTbfNHT4v3^qS?Rr#m?r%ar@kUpQ^jvviF)u_;NbTQ=i){i8 z3{{^(V?trFw6=dNH8J#welJXG5i1-ihUBp{V^A#S15cm|?mY4>m*IW`ZpiQaurbi zr;iC`C%pfB@^x`RY?hx~5-agCz+GduMB~B8qpSWLu{I^orFm%bfLJyg#aY^sVaGUm%wtkQu@qix@_p&%C2N@#I zcSG?Md$q7(mTKtE%k3>297kpMi!+cAp?!1x-kw%@jvI=&2n$q?N9pgt-1C)>(?@T% zBNWkYum9omsYh!b$+S2JGxaxQfEf0GE>d~6C264sD~OvXshbCQ|$>-iQY)P(L@lXhg` zY4_7irX$maEE^;!P0b`Ta&sIk>F-be~0; zblGolOT8I;^2I#I(v&*{K^LpuB#dQQ2|5-`Ng&CVf|6#iD{Cu`X362ReQ2|MydtD< zNhB0dm+`qui|Q~fM^{E@xwgxS3Fx|U2MMq}6cqUrtT00Gy9j)`2l3TbwFp0T_=uY# z7J1|&E+7KjWvNx`rAOJa!p#yAE(D2UjSku#-O|hb%>Ru@5AwU(jrh~ksf}qMLq1$- zCx#onO>5$77;8dWr-ke6WR`LMHQZn!>LPS!NH@dl_Vrq7Y^=C6XZF$m@FC)#=ETSS zNc^>D4Yc?y#J4miucq)zvr*(>m(3AFSgM?rbFN}i(~O)XYnE)-XCrgX?3b4uMFvys zfp7@MevIncZp^Msy$-d{mpl(Xjs6Oew88<>#B#F*_mu9Wyd=f_Dl-cdi;1&%6RA3c zx}vwL6BoBA=oDPLO8bl0r}XDQT}Gq2LuCuAmob*St~%ik8q*uJxN!EoLpx($k<=f* zno4ZqzR^VFr-iZ0QTS?>90#c`h2zyuvANlJ3Bjl-k(vytq%wV3bGs7T_qbHCc8ve!Q#tVg8S2fnV&LmYD$>l?j|zg7^=5cL+j4(z~sfFUVX#^h)0! zU2!3_1(2$`f&627%UUUA((IC|!i8m`LLzvO zzID3mtYTY`ELILnJze$c?fifE>JLrdI7YvieKpUeHjN_^hk8d}{6IB?5jDX}G@YWY zmDK{&sP|n?2`h(dYD)*mTpz==mxi?tlQz7n*(*)4`8E?k+|pSs`Gie+aV&Dyw-p+U zMJelfk(E&0BKu^SZ&mC2Bd3Up6vj47jAgg36qlrcYqYnK!-yeSyJWgd3;zs*A1Fzl zxJkP$F51@|&7EM0~s+ZmkVKsw~2(~6^bD^)* zdGd|c6cyP$vv0!ns!LVE>OxgG)hfWx(2SXQf4>XfElBjt*VTPW$$lDsjXzp3E}t!` zuwCYVjVx-~^6DSFvGm9(Htr>$MM7Y5LsP5u@h9`m^{_D>N3gU0w3J!>qa$L0A&PS& zdaz=s!Q5OmzUo&*6&aY1+#<=r!zn3Xp-@Xmh$WpwV?JB}8<=00d0h&Ulq2}KCY?fq zWk?p)T?uA)!^DU(zrH3{39jIscJp{@91?_HzpjP>(pTO$j+?LB&kXTWJA|@Bm@QX$ zlwQJA%Zq|N4KeL{6XC>tQ`qRbnfNj@nbH;-*s|&0w0LpM2?{tzd#v`)3souTqZX6n zQ+-Z6d;y+Fge^)-su`oct{{}|NC20oQbW<>VnF5eJPHa!!}+%Ndi>}0ND1x$xY{Gj zxR$WX2F903A@8P=IV*NuKJ@phT2p?FqH)$ODhNG$m0MD#Nmf91 zzH+5zPQ}yRmOv`CTs)O^q7lWVBcWmf!V@>r3zG%DUz0ZNBDz~mz|9751M+WINAKI1 znHybD{5*^H2Yy_JQq3t+)rYayn>KVad(f1i!p(kWW!_I9mLZU7ZCOF|m)7nzdEGZP z;g&u_0u>X79o>(b&3Q!|-fIsf5WsSOf~GJZD-oaT8>e>K#tZ;9&DVAGieh!OQj7af zl+7}441JgS-Rx=U5PpcQ6fFuOAg`G^_PhV4%`vim1OKIYPrV&}6yk+M7@R8-KJre! zDq}3>yf{o4DtArsy{!{FPt(>PEV(tjuIYifudH5L@G!f7Qk;~|l`jSs7Yak@(w7c1 zOiP2=@N{YmTgsL(!SAqJwa$F;>&CGV^EW0py$2Vo-6}wE58D%GU#N8g`Dj8C-`hAh zJ;ExaKG&&=Cu!khiDjPiHCaDSnFHJ6#HwSB_`8poPh9SwM{jQ2TeBTU6zY2s+k{T0 z1|oza9)1U$(|sk(1c8?<7kMMlmX(oFFADjAGIMV7(ye8d)RqV+>$Za7jeLJjG1}j4 zB4tB@k+FB6mN$AM@YJyXY z$(Q@-6dfYf!O_$dbPos0^Q1SDtXs7|4niGz$ZpvEth!)jGQQaX?U-CK1odl1IOp@| zp0y=Y^_H+#WuY`tS%iijNg9x*eVi%U5_Q8;8;14G@!^|tt=#8$2Yk<&og;~OW7
}K9cr`FmJHWLWjdpHKw!Hb8_7smI`p-PmYcmM32THkHk>dXER zdDYwjJxyhF=q4y1>iq+*_dTf5Z17?3f}0MujXIUuMQFtEe*T9W$iHy|nEEB7tn)by znan?7PK#}Ig~VxB?{;f6_ojUc1uCm^mkK}RptdSMBGv+nXLQk-iPkto%3`mJ(gHh% zNTYb%Kk+Op$0=YTj+osP``@WLztx0MYos~tF3!>P0uxo(nmw8BXECSbo{~y5J{Z}D zZKj;HyiqmeuTRQ}j7of0+4V>-Z7Pxx=?SX)H;zg zb;p)7Q8~IHYG%g}vU_8=WI$v>n^?aQgqF3dbP(;11O=mj^A&9B(twNgRZU=NcHcY) zMjK*Qoi1ETg0hRaik~BnC^Oc|UY^%BEYP8w^z9&en&E6oC+U)aVMr#$-6M+drH*n) z%g7hSI3(pzf$OvlT*T2UAeIe(gjvyWJTWOalnr8@y0We_|HOMzm7*p$Ex2X(aaXFI zRU(>xAfHvaqY6rL4DQw6Ul+5P_CMO-AXIGvRFD9x!+*IuzkQoFD-)7v89hxhU)mJ> zG|z2{qXHjj_I+ijcFs)hNHa1txh9X;#&#iLJu}g}2|Qq@Ju5*Bzt_AB&OYx7l#SrjW-j-4VL>-v_+k-63mD zlYZ|=EZi3@;PecLIJG*pEi!xi6}vmCDHJt;;fNX^ ziLZQlT}=2Bl>xN?<(8&$Mzj zTQwyQHx?z-h~tUcZ*l2eWz@Svo8wr}c21r^J#e0#3iox+CnE47xQmI0aok-?JLQBX zc)vQ}Rzn~GN6m0g#W?K4)|Xe-JxDiF$XcF5&h%euV9d>MZaGk^ zHH9l?nkB!z%#=MzMKS3He})N7Hqv4i&$o?v{yUDMy3l2c4ha`>$7#=R6gON zKdZ@QD3~X-Lnd!Y(V_Mor?*IxD+aa{$%y_vv;JmzvQ2glb<2&=PW9gvUA z?6jd&&<>`W7oyEVFo#R(3mJ8kFzLgt2lNMvh%>k--47Y$Y-^q?awPb)x2iF~}aAQp@x2=b`Z}&2i$4Qs0Erw+5M@X|D zQ`sn|CvjrgMF=&dtg5h=<*f;LFZ_xXn-)+M_y@_XP|ga^h$p4ABimF5}YkzSF8_Z4*?XtsA?aeSQ8k3F)M@ z!6<7ILJotiI!hhfA8A%s%bLrIi?j)>4b>a-ARixIZod05lV-`+?9j!m=8p_j)s502 zv@%2FYQuHYMf5N1Xs>dIe>Nvx&K~b<-sdJhd|HqD_Vc(F{oas}%{Y9dJ9r+VHma|L zph~Whch0dRmk1bLS0U}cInrW&8zfj|*FV$4Wqm{E2nIJXMPO^*a;54iE=WLH1@OeQ zdUkpvsk??!!t1g=+#q z8(J+YBI>m~$IsCmkr0)$`X>jf{858=EUK%FN&aTyoRCj)^}iX|Pjp$7YVyS}33kd8 zhNlL{g}hRCof8_27p*=xwuiV>GATfUM=egO3ljcfP3U$4Wo=w2Y{ZaqGL#T8*z_VJX${n+t?f@gBl&xJPnv6H~*-R#1e1t{@d2 z>kwL)CrRmK9d=ym8)n2_{t1+qYzLEoeW+NT8?bu$?ZXLJGe$d*VxVHL=(*`gp~_K1 zIz2c^0(lsk68)yE-3Vzr7mnl(UkS6f9J|MFU-Q5A%Fdw_(e>Yx2cv#9-pTM@vDafh zmk2BT3SpvBrgjtF!+?F$q(cFAF}}jXRbEo$MMN2h!BNnFs!EF(Lo1w{Xd5AY{tsE- z{8#B4{+Vs#WV@+TlkJ*pd$O&`wkI1W+qP{?c1@hgv*+{O-PiuG|G{%VH?Oy@z7@P# zCNJ47q&M8at!Yi8y>`Gd6*h6Ia&T_d6|A zQ$3byEO3g^7UwWIZnu{Im3R2OIh{dJ8ztZ`w@E%pgu?BgQq_-^=DrQv=vEw%Akjc( zZIX?x(2$*v9@f4iRc$c%F$@1C@6C~u7<&l06(At??vk}_vs|%^C4!4fEh2ZM2;D(f z>&M5aq>q0Ok$OnM$RUDgGXGxKDcBv<=F;p-NsL)WgHz9IqWz7k&B+fl&UKSx+j)?{ z2u?5>ZJoB2SnFd#UGsLf8fllmD}{SANl+=89cCHp4toM4cyuG{L`WkQZCy2OH%^?qbeAUZliz6-XvNAbWa(3QL52p(4 zNCNm99Z6NbCS>MY3&9gm(y?gnDf5Jthxn}QJP`9W{UCy4vRU<_>3^A_=ECR+TOV@r z@7gl&4}e%Qf3~OH29aKiSps?Ch!$aP_skpIdc~DB z(7es1HD94$(kH@KMgx&;(Ngk$fsDYswqtQOx_uAKv0HkTOOb(N{i`UUnH=Mr#U=WjL>JAHoiQNLr1rNB z3K=XJrHfBwG~$V@9UZ{-2bUh(b4}FVys2jP#AI_$p7a(Z{)ntLtZWi;*hGMHc2CP2 zjD3xe8X5iyM~Z4l^ZdLJi1S^@0Ns+!?`rigisfm=jMTlD>*SsCECTl5V9)KUph$2pSN(lWk5@LcPr_=vy20QuH)g-Rv@^f2A#k9sqkn_NX;!63FgM8b!I$Q zflVlJq+?p>DPv@ScC^u@wtMajZHYyXwXr{gDX%#boo`p+>@!$Gs{LXWB5cLcl3<+nSh@$pteCmT!d~&? z#!b*ww`7eON0jQ6&=#8H8PVgJQB6CFsGPQKM2&*|_vfzLn+?=So zmC2$gC&sHx_?n$fH03UQUsn!8E^EKtRddIY$W}$%vI}T;8B;l?s{Sa4NB^s+`6<*~ zf}Czr>W8U3c`gnuyRz;@%(9r^tp)D zr(x<6X*C#!xCp*|Lt{B=p^KFny|W?}`eF{FId;D~r?M}IA13|_8tLcA5;;N%pe==! z3*7j7Bs{fPeYI{7E;DK~pOyQY)%H?){cJI%<%&?wQXpw1YW<$nYQYKpFqDJGACkZR z;YwctDY!b?mXL>I&w+NjNd&{=*Kij44|@E$V!ZI1!F+$MOKQCwQC7w?|5G8fgH;Gf z>IJnf;0Nf#bDFp&E{v$Q_iGRl=EiiO&Vsi1z9_*8<*}&j;0w9MYa_q%T)$$qtX#Lk zx7-#khbqm{9SR%?NX{>N)pN1jaNEhMf24-x>7JPxJt_XKPZE4#@r>?d<(nIC!N7WW z=aQ?`6b3wPN5hGM-42>KgB^v?p|RiYj#1!a%q35%QG`}+zdQNz?*Rsa@zjH$2#3c@AEtTuw_4q8QiKyya=4?A)=>-%#m=N zZ1}bfURnTGjY#=Bh_Q9#5(cEnsL>)-x{9a|0%^g4x(H}7Tt$N# z9kf*eIaQKuHl@7p5IhR1l$1jfXdiLqF0IMosXY&G6*b(=5sFE~#P7=S=}SkkT@Oua z3X^Z@u&fg7-z{Y&sXL)mrp<#T33c>>c$svvs;;TV!*oEq9-hKdg((WFdb1#IzVnF( zKp5QLe(I>h#6E_(V)i<9C_#U}bxT70HLU?JFYgIqS1>#zJ#cBm`Rit!e~awl*mwwj z-$%FaG402xWk2MU&AdQN`k{^d4~$W+ULzLGJ{~^Z-y&qA*wv!UBold*D_}r885n_5 z(Wswxu=s2G=RgLdEcDXt#&jDkM)@eM3YC?3`N*f80_wRfIsHz~a=hs{X~E+`?e z6S3mEV|}vW@Tto{#G_BASKf!$kGu(8A!U2%z4bnKu}MzyAd`)j51#RZzvLbqN#dafDFuJ+Y$QV2Z6Ng+qG zwOmOLH;6NGLA`J%QZEblYC@3R&y-=z1x-C%TQC(u6Dmyvqc2j*KJ1U2+N8)!Tyc_V zz#s>0YZ`U++~L$R%!B2G)o*6dN}p}CCr`6cy`|iwnxVzd!DD5=-g+ zHa)eqWhw1Q%NopFR9#jzb!`nCpLH_$mCG@M9z*sNE_*ShRlxWi`y_almUAq-TR5Z7 znqA-u>~H&lc$W&0^;lF=#NZ$<8c7*XyGEYW}db&mHz-Gj;tnE>3qMOa+)b3^Jn9@GswXHXgsep}|o@#Eo}#i>kL4jJ$=Y{d5HeCY_~JQo6)o~lYxGk@K?QB4GhOkGh~6slwz5L zp>$74k1BiUTb-Doc#;o0VmQo_49p*x+Cdx)-7H1W_d>4E|BK@zIxfMVI%;Cx$>5aN zIjQ{5@(d?Wb$Ps2%rleISUl6EoF9`!&415O@M7qDhSV=LVZ=bbB}Bj}=33Dgbv^0M z$>hks`2|UZgeV|Hpv`=WNw`p-s8qB$&AC9>YyB?zoCHh-3$6b=zMPy%TN1T=hotm7xpDAp?*|O3rZSMRjNliogoW#PAl4$Y+;EGRF^nX7 zp5=FV=^+{XXJ@vIKUN;got)X;!1<_&-n~F3<5afbjzRWPA%PcprkHOW9A5))b2n^$ zAd#A11$JAfG}L?u`D;dCTNI`FORU5UJi1L9y(SUyNREez+=$ezevXKq%=E;6};Fu2b|VsP58`vTZ#(^ek$v!Ie#xm!hyONmdzY9=r`NsTX`h=BTEdI z?2hBv57!cZ{Uv^QL5L^D#Af5wt6V+LIY$k=b1FWji`4afb$@$j^+%C3$f;#DbfR{q zxT&1DV`&V8F8OOF_jxQ!I<>fHg|doQr&uI_-#{Sz!oMuiMV8>e z=0xxfuW!~BL#pa7)%-onV(^bp)DnBm>o(2txb?XKGA1=DPYUP|?ZX$nJ-!ICy&!qh zyx1JPr&2~^W<<#`G{`bblX4@%AP)k==eNH-Uxc%3WT#ucSA`hs|WZfheldu`$_j_jf`3_Poa-^ms4&S9v|2uir1b z?`)fEG}BbJrl+uctnSpT*PPDIm@Cee0*Fi9LCo&z7q=z+8?8#ZBhq25?lI9vG6N10 zY1`d;Q`)YRWCFHmgv!TRl7mQV87*U#A}Mr%7CG~oDQA9;qw{urJCo)>vI}af(?Y%t zw0`{y-^h|2pju`@k~~=fQcE5qd)-S^_%6hj zjrOu3BI`=PP>~`SLemYMzpc68nZ&ceykxwh$7D9sBH;_+)tTUDD{KZ46`!Z}5WA*O z$_`Q5BU-H%RuAzAhu0k(dC(tdB^>S#nFIc@LDX0EeMVj>_z0Lj&(qaJDNk1@Sq&B-`4yv|>YZG*qq?7bkMl+UH?c9BV3 z4v=dSA64}`|9Mz_ypXJsg%KL!n*lwS7<(4f7H%u=$2}YHZy4TmH|OUgbJt;7HE$TV zbkjfOMtPh~c&u7X1y>^FAL$2r4eJb!mr)ts!=RGydNCVc^Njco3iVgf=9sjds!lR( z=athN*=K?Uj?YBk#Q)@NsNt-9NN-wU=RhhvJf;#a+$hW<#jBAdjNvp# zXzo~9O9lnh5>O9m!kgJtke`UI_x1SqLpY1yggK$@R{_L2!jX}{UqOv-O@A$tp=hsH z7se}Dm<-coDe=sNvlMAJxJr7}SYx8`Rh)WW5fRzWQ_;{07|l#_;AGRoE%;3$&+mPa zd9&Gj7Yd>U|nP(}_QdnLlJE)T-lR>pU z2__A`Tg*^Ifa02Dz~@qZ=}#es`=p3(2_`MZ>Us2m<_?VpOS1z3Uu&r$=~Hgk5Vd_}@tu`duE;l0 z#)fn=4;I-KDCJJ2%vY-C!pm-P%`$TJs+d*u`XVt{tkvgH6R3gj?%;`RakMnp?+W_9 zSm<557_d%Q>=&~h>lhuWlYztk*au*3)FX+!IUEQVxDJ)^2}l-pF6SgN?wEdRplL*p zp70Z*G(rCO>2l0eiwtf^V@@KtlNuD_Fs&q-6mlZnMPRph^lPCDXIyh`$05UV+c+N5 z(@>HsJHD02%o=w}$`!SHL14o-hr^4NDFii|ZkiLZhSIP!JuHXkk#V zVum-gBw#)UirG7OeOP%h=OImS5O$4q0gGF^XY%2Pu02})vXMlf6XAca9>^|D3Q088 zwJfy{?qeuwLH(yav{M5{06?&_rp_#+dzrX32CyOmgqC0M1@#-B!ymj=sxaRggWMjs9$7nF_&Y z0B$Y~JHCpNjz+V~hfvNAQr{qOklgEMsVr1j5b3K;3ptPVzkOM!iZTuOKgJ_AWu6lD z2^OXq25B+yonDBv$Bemlu#dsxl0d%;e@5?VDOQGj$$ygmA(e)T8i>TdU?pcvak$&6 zb6$5*U?uZ)DOG5^_=Yb}2nI=1Hx}6@Ra49HX87usX4erz}#CIBF-f>MSj%}f^ z+Z?N5f@iKmc#;MK0b{T8l(-2=@X7W6LGEWcUnl+E9I*VWDZ*%12iMNX{N8Ia25#Tn z1T%YXM+)PKcHW_o?3tV-O9c+SOg+a7<+hk{*YYUA(S2FnIQ|tTPB8OBZL-W;fBb<( zxjnLil3@%S&^JCiteSEo4Wnz48Lx8PtBy<*a-N;6{vVsbXoJS9&XjF&u=&I2=PF{{Rv_8XHhDs!NUFM4 zoLL_Ei7C1~96eD%0B-%0JA0^@40C3F#`X7tCqwl+N??>2Z=XmBK4vJpR=%&@Byz`t zGb%#oD%r~<6eRPZafs4aydI}qfybmJby;JN#?M7vgVJki26Sr{8ph7o!-ry9ZCTAJ zRwVMm@{Ej&(Ue9W)Fwt_XF!=X83%&|o+N=aSfQYN>N4oOX7|y#Io)=EfBSp)Gm{OT zcvow6>9w@3yUGC$z+MCQjrcdTT*&_QOTmbmX8ahHDd>7D&vsqnh>^)y4NNygg6ReT zW8sVoc++u z(&jlO7e;Ra+t>a?sI|YoKFsVLZnZhOc=N3%eS=KH0&g~1XYgjbU#`YjdsQ_7Rwr&o zxKBSPFXvMYQ$~cS0WrUJu}9eS*_TE6VB|mOeu2GDyQPRdqX?63WfE2Ed0nH3sh4?2 zZQFF|X=7%*hMCS7bmscTfUz7ED=LN~95wDN6f|ADoRlc=9b*X**)F;j$qiGh`i!O~ zARqCn*mk%)k*4IO4$?G_JHzUoUEs}kii|rdg?%cxL~f8iMWf`2#C?v!2Ea`|(SR0x z0Yzwkr^&Rp1hYs)r$Zkj6QrjKCQ+GXUFpFMr>b$*@`9y9&$Y|!Q5UI^>?oM9A!U7Q z)x3KOCm7=Oyv4ZE*EnqC#l|lbA$5P`O5|Kg&YW#>#a=|K{)lievb9$RZIDwd!^^%W za-m**-TPX9!Y~Z$)Xs(a<2TJGK@qM2)a9$t~(t|)`jKs33Y=v}Ho7(rzSO-%U zxI}a6GQu<$Zy!35LmNs>3owV`ws@i}a-5|@Q|rz;(&)Utr$=Q#4L6pN&L~y5iFwPR z|Z-9|PTN8A+b3Z>=NFbiu&5NVVW&SA%D~Y<10ow{x ze4E74l{Cu%g-$P)W9v%xTs~TlfrMM0s9Jon(!(7`Nd*&nbH=pN5 zOmI_Bl`p@~DRvkVOIl%xk9FC}o%MTFHXGS2*>8hA)k?4kxzY*^R$Y%bex${#{YaPa zqBOccMiGu`4WO(5kic+W7t<&Uw+^WXXwk3$QBIZfW6=|U}uHeUz{`JA%q5xH^^%Xo@)~RL? zNHM%dvF`d7kDOqoWR3msWeNjo$UN+XLxXO|{J>R(da#pnB6K62k2)BHY8;BZg3oB`IfJQ88M#!1uNR znyP|v{iC_!BQ`MyzO_c4dBwFTC)(AR(L8?mtQE#xvouND*gw2j7n?j5pJhrRgD@7q zM_k+@FG3bCRfn`J7A~R_r)2DIW$5S*{@Xk{zFU_#+yWCSj4vZx zubPnpn~iO~`%Ct&1eeo%%DN@*S9AD^fMlnrdL}a;ktB-%sO4X~6K>l{>E7(;)Qk)y zuAI#im~mE{gR>TC)EY(V7?h=huc)5FqvYf|ke$rSnEBk-XD&Q9_(R_<2v1}aB~2Fg zQpCqk**8d-hisCQO5qH-zdNqvwTKD2TuaGcoZ1O^?H}51(iknVY##n+OUMLs2#^{c z@vh*@{_?Dx0P#?}nk`7x2~+Y`o!2^7|6*0>=VB!G2_VXB&XEfK3>P5%k!HV#O>I7N?Mu_NM-=&yn{$kX!38Jg3h>M`%5cB+6FrS+pQ z+<2gt=wU&t1dyqTngy6d@|57;-VZ^nv)#eG5=%-`ob@l29Y6L0r~vHF8=?YJ9l|=d z3jS$0ZC@gq6O>N^o{#x|xP^Q%^8e)l`{1OJ--~Pm0K))irU&5bB`o7mOg~1NBYc*& zrvJhmGgPq%nk$cUe0&m~%n}Z0&6(&pGas zv%;sV3_6b+di(=lGS8$FU$jqtB8eVYgS#Ag$U@tzUz?A-Zk_sK$%$usLaomoz#JXALE9nz=+vFNC$g`ohFfVyT0LPZdH97BGBeOPs< z@oLHu0)7AJl#&9Vk6&lyrj*D4yohhDTVuP4bnb>AH6 zzxu^JJDaWKk64*1o=UAYe8rVJY{d6sS6G?Kd!E=3%DO?-@^Z6$*sN}4?051E_o*Pv zjf+Vbqgfsoot}SxXZDiNaqjMtM_y0~yNiuSKnNxaAB^ zg!!bW6sGtQ&G)~8QH}t+-Cm))GTm8C$81Q)tN}R;JGktXwrgX(CRuK%@b}Db`S8D< zhc%3be!ZWPQjk#cB5fRlVuwH|lR(sB?Qh8o0{Q;$v?hP)hNTvr=Cvfas;S@w)WHw~ z4wxQ5Ofyr=Y{yH8h<#vIIOw59+cAG~iJE$7mRmec ze4Yl_PDaI$Lo^Xd!+v=zqCzt1@9FA^i8~HiR=>*+7Ts4;^My_$3FH&&zo7c)r%51` zbAq>C3}Kg3`$bKJ+9H{D*eLfPV;ip+B%yiN?V4EojiHKJD~c@DtzdOIh#I@HEH=5` z6mks8M59ucD-scAls6qRxi)$d_!_%fgmzx1>N>fgx&V-?pmxQIu~jlDR7BY^wt+y% zDvnKVFJ5)ZnKTy5)fFYYR*p`mpd<-g^rRb-auV&h$hKCXTRQ@MAMEZUv#hKLF?Wyj z1Hd$ojmoo+poEjbwOUES=n5{g@EMcB;LdzHFMcAK+b{JX#HDZQj_V9JcH51_$F?Ya zMaRgbsv^*;B+FFOk|z-pCBn@qnjWe~isnI-|2C5RiroQAlf%WDC5=Z zt0Qe=f|mu9{*nM_fcL)bBzTRDB&JB{UyeBj14enn3{Wng;11K%_3sWUAr_?<(qq(_ zGlxPS)tnwU_&SK8(?cwSAf2=f-9D$lQMty%(@zB~VdG>nq%KmFdkl>I`pvYtUjImu z4pPx0a+Lqlrqg_7SS2TnivxeV>~s+@9aQrQ`Z1&3{y(TW`K^rR*V@KCpC{MWPxez1 zQ^Du8t;e5#<7yy8jV@L1%<$|`YI5ZmA%pLE(3Zd&h?f_i=lKeVqHVPV%JH{@N@qJ} zMqxPD0<0az(wxplKo-2385!8FkXdenMxzeLD?8Fs9(j>tIv3;G3b!k2F8dmoW<&mt z6gnt$jGc(1i_bwtIbRDlko>Vzx*jltCuKhHLwM!q=$L1=PyA9%OMI0Esko?9f7JFt zz%$_T3br^L*L$M0f43 z?%fo#caGNe#s0UW@mHNa#uB|D~XBuo(bgozg zuPCpE`ksPFd~Ak)1$J$~Xa%)qowGR$uGYRaZfOwerzT2wl4MlXpm>30g!?@+`V`|{4b=qB*4yvG zt9R@f3X*sqQilk!8n2xdR*xC^1~BAbh-M4^-~BujBQ30x+}xgcPwHVt_Uv1DCBTAx z%S4xwTPvYBgCNIm(N~4QzTgSC)Nxq*))k52z-r|LB8gk$pI^K!5FihjQb`DA;){~F zS;OyN9*3C6S#MYzuP$yZqPJU1W9kRU#bedqGO*9=yj@vEi}OHK`&#M^Mm~+bxWD_1 zZ{w>q^wZ{@6!n(sjK=cJoeAhfb2ti*))>sSc-2Uj6oX^U{_fgET>=K>Fs^lBXL&Od zjsCCNHpPHP2W&fhrgZ=hWSfU!xMdf#B>IL9G*E8AlFI97X8mGkcR@h19R`zK*h%r{ zM&3ZVf-x3nI9NlaCCj#58mM?;9HpD0K&;Vql&gjHcn&Hm961%@v7bbv$sqK}jV^HU zHnOi2kPr$ow{nVj8`2@F6loZBz0jkl%NESF*%4 zT(X*q!3<{kAJc#lNQ{L!2s9Td?ZHK3&1O-PCT>zkJc5b)#XbwrDWREeJns(epja#{M3XY$XI){_ij_0r=jF@INST8x;&`a#w9C=A4^zp?not=C$ z$olMQAtHm?*S!kElONp_^fj&ql&zo}Wa0Ub~NM#w`nbR=8+47=uLHd!s{Cla0$ zU$2;6VrL9#o*pVOs50aXR-eNl;kno&&}oC`;sgZE^osfahK2MTS0w~{e!+*V{3d|0 zLWt9GIJ#(#*Su_)l2g4s2In0G$+&pLfwV-{1crHO8Hy$Z>yicnuXzNR~* zxxyOQyeU=Yuqh_yA2uZJGc)j+a}2)0!@)PWs7C&hjJ~`vdJ%EXuv}Zn>(}b|ghOGspTD zP$-3Iv)Yu!86L6h-bx62cJ#*XDM3UHB6mDtUzuH0~(8fAOOKCH#_Z+`a!du!aZ zwc)r~gR;}MeI?OEDqhV$9;{nvrWwnU12v(<>+)(k+SPdzmAHHjWb~pmaA3Y$?!iec z00x%4t9V<>wI=@YBp68}xsQ=B;?CS*)#bx<|JtgvKvQb5eV1?PR3NIZ2i++rmtJZp zy9zW2p)5};`k=X=IZ~@m z``rAPrI#qr&$lH?{)ym)T)jHibZX#(X((JaXaLSj60a=+4{GEDh_{wk?={_ogrFJ5 zI>;38QqwHxOr49+;76z{S3I>swu5VCV&=oQDcsKS>rV(dA%i@Vkbs7YfdGc6m@f^^$o4Upk$Po(~iJZJw&I5E|H3gDhQcO+hJq&65_W$$+N2 zA|{a)NY-oGmz-7}_M-!(qBE#+^ws~AI=uuePt_r`jArCo5(f!ODwj3DzOa{sxd`)^ z*2S#6T6AWz5sONqWOx2f9RPFr5&9Oc6$Pe?)|9oSPL(^}Z3IC)(M(dIx5E^^&jcB8 z`NLF1@;{Nnl2pfW`%1w5T77kP~%fA3p$sW$6EiIGk>7IR%P*Gx& z3rhSU_htS55fOkZQNGj<@T^32=18DYYb3H82n|>8mcFfseA%S)U3^<~0OS_ldo`l8 z+{!ze&@`X8X`Yzq!0694yh6? z->J3>;|-^y!`1EWFB_+uN>ta%R1O3$e%*~>gp``|+U`3z45*S=P`Fd*&We5V;#Qe= zt(4(><6UV%dJ@*L8|h?d7**HUA@F^66Z!#8^6h>I8cB+jHH>s1{uO`WrpW7KI#U?T zs9oOCo~{}a-tc-aD|E*lBynRXr2a0B>_sk)*lSanll}ub=-}&~f=w$b$f_g;dS0SU zKgDC&#TO@RmB!BWQr4JBnEH6Od*ed?Vuo*-$$PV0E4Gk78~d%ih%D$aa6u&VDyaA& zFTxWA=w^%ThA*k95jL3~8oFIV@dOLIVJ_*gzk!DGgR7#3sEI3AH-wImBnpm300gpM2zE14m$x@VEEY6};H7 zj*QMi{0)6_5zA?);lt2K(qiM@a|_^>+M{ru;~)n)1zOQ@Y?QL%!eZx?a-cU!;0|5H zx3ng!=4_*d#9Yp4ou=%233Pr401{^D@MGFu9*o;}X44(jFqc$E+d8)$C(>qCuj3bL z)9Zs!V)~)riM0PS4N}T^L?AF0~#gR|n@@Si_jR`-v5Q z|F*I1^QVxVvynZ8mSfyxdtI)Y0r(4%lCRcAzfV2MVN9ex`pQ2+#2)%+wSiDDwgrHL z2w5Ee7TX81JsY$}Lp3gow;pV+O~y$TBXEz&G_bEhhedbMrenaDw%9x{`YK^mnSEfj zd_YVsGe`-WKvZz9UC&e9NUn5ot02r;oI}wCnOQ8OdU`!rRO}%sK417|4g7URxs>B# zoOFYRslLTma}gtJ4eYl>XDSM@T$Jb`9&kzw3Y(9VBW6;DI^8C#3}A+D3TK2l4bVYFp%p1NNRcj@KwF zJb3xV`98->VrjLEb+MWmn?au1JKXxm@_#7`D($6oz?p-*%!Caup_=G|*rvp~6WtgT z3uejrWRsTDQR?`M^EL>%B^Npl;W%*Qfa9nicmPN%gjH;#AvpClR31U)sLbx%W3IGA z*I!eBj#03`g_;;M=kDcZ9+fAnZHSAg8^2Nt{uGk!b|&JI`2K_{AH9DqYvtWQswI7% z5`sH3T7gNSf*dR7MoFP&E~MIXPDOj6z?fG%xqa5pOv>ECRk1|>?O>d)R4PL3w=*Cs z?*e#PrTA+KD@qkWkEVlrWKBq`T6Tef3{@Lk^S)9JCjM{8QWk0gIfEsdUU>;v@-^qu zi|YBBU<)W1LoxZop5_Y@vFyP)18B|BI~2hes^6XczmVFiFs7saNTwo)WEjyja!hU; zc%$N#-+hG<;|p$#&jNQaxW#eqw_Drk;XnH$ul#Y53m5NkS6>l8IieeBPHUU0_C!l| zV?i*p6i_uthoEGNW_d1OpccJki5L~AFZQ!MW_$yBz{@YiT|ETU&Y0$|3e(5&wCofY zL-2HzuVXXmHWB_Hiy2`-WDZy@k;PwKrVL-?TRFqg#MkCTtqzmQk6MC>uXSLj1z{Oh zg4Hmf)Gl$D71!D1S5pB)NLMk1D^%sDB9q6)r7+gL7c8>HB_L5<>GOyKa_+pWe=KAF-&K#dTjZwr*<(RkBZc(0PqXS z)o|D!m{$=uX`t#~hZV+0cs*`2@AOm-n9bv%<-xD(0Bxm`pOq3>aY%w1fQTfSKcRjq zbzi0^q?Uf)+Q-!IAJargr;L65Y&O!$?kJd#>;zpWytvfwR}KDejq-wJ|NgAaJkYXg zyz8@9szuso@C~XgUUdC`n>%S#50&?^^6BSzYAeA97^pv|6nucm`!lSeU8JKH&kP2( zWU>1&tAyd+=qS{XdN{JmyV6eH*r=ug7UsX|Yz=FjmbR@ML;6dBvWtUcC z`EZsrRXpr9ZqWQLASx==?v4|s&Xr+UH3%hLF>(B|~Gxo|M0)ky~Pd8%TT3xSA_l%r*(Foh#7MO_-Th@AFKNeVCS zX}CzIFhX9}_ce6Hg?<@R4ca@WN3fd4G`25$b5>>Y&#;L;uv zV~d2c0>UkQ4gXLD!&J!vKK?eX13OUzm8y)J|4A}-!_VHaD~d$Ty3 zy0HP(wWr}~GrLFhhorOHRM^_q-ayGc35GNesJj?+&Q;a=XbibpBNfbZrFZo)1C&$5 zvygP!j*S!X>{h;EyQME-am&%NPPg3bM-3~q^Wl+!SWFSJEF}%JQZ=e(9%@87C_+%< zeJah%M&C7rV04KfUoN8Ddb=e}2UZS(JzHN{xzATTOJ%?$Jv{Z@4Th*iY*SHhCV541 zYNYZ_d}#x^KGYcv3`!SIKS+B#jjz?nG;^${^2oN#V$CiH8GWPYR(og1iY5dhHIBiI zw!zH!VXm*-=Y7pG-0CjDXoQUAm>BaS!dj!qWmc*w4oI7?-00cA5z0(zfjedXK)8#fbLrx`GK^{QebWyrga|r3Gqu zQH`EDNS#{YuK(bXIG>se4rRiA9w7mFt<%FLNlS2%4@*XXi*-!7SK97DXofA?n;hsf z)aC1yd7cBxV1!<{$n8fUqv&@H|Az8@T+QbVxpvM7DgqYH>;As*Wu2GQ&%1gUV@~!D z_cNFzW?`G@oeg-LmwJ$(9Mxv#_9L}@>BZ)*en`}-lp7~faXd6-;Yr43iO+H#<=GyG z3=D&;!&mmS2n=MYv|%x(MZg6$`<|SyuvhoeLXo9KaFx( z!*8h)ZR5XS5kzsS{dM+;$V_^$e4i)v8eKW=TmZx-ROmOCMi`L z9S5zLVk)sm^9)TX$)-+Lr4J6yj8090?Y33?CESY@C+bW(eG>N#s10eGH z5G^_b^y>n|-o?<@i=+ClcqMgkBD_hd39;Rc1(8ui&NmAg?Y@)R#H}cBGlIg;z zMdlG8I-l^k*AaNRS`JSJPC_&1W7&L#MKqY_D|eW$aWc~+i<(`_CHxV?@-6>)=;#pO3*oc4=KqcQ8-m!}n& zT94Nxu4HT6J2KSeMSX%E%OqpUN`E1sScbuQaYWbM&h?R>+nX2H=jl;E&!&sA>+CP? zU%lCC&a_ntv!><7-iNjyTrwbV+#rU=4Z3o}l|UuiC>4V{4}c2o^rFN9-R{Kz<(e}H zzLMAtvhmR1sbbP_DiKu$WqbA4*yySx#GJnh7p;%oA_|_1(WPVx1Rc;ZGOCf`=vDMB73e`_jF}(1B zk7IaYZ9Dc8m5poH3TYz90m%4$(501eGBND~XFn=up}C-P0$*3Qo5g4ox*>|3s4`r+ z@;+9)+~!B%h4ZPkf5VRjnVhv$k4*Uv#9<@?hTc)^Vzm~S#mW7NP=yq}dd{RUD{Api zAu>@&vFX`QuW4ery5n=umqPs`D-{ym=25jmTGixDnu9GzDLce02S(MN=*}gzKa#lA zh0~@^P4-A10EshBn4$d^{8~s*E2Sr)q;t*{rk2`9na%GAXMaH?;FEdtA%MW##yI7w zWAumAcq9455WT~Ja*I@86m)AFeFI+|Ns}A@B+h7}>^|O<(c2e)-9EOmEkXfs_u80m z;FGNZxJg#PvFWV|e&I{>B7}Yfc0Vi^U(_!Adr2q$Ba0~jD>D3a8{}2)OE>x8RXYmb zWG`B0JUqDnAe6j~mW&l*>`JLd=x}4&Df(B=(bPIWfz>NGS-Ea8ot0ZqO0zn5@~>|R z>$0acQG!?E^6DOI5szu5>PK=#*YZ!9d4;FEJrDi$Kn>|&Sr(c^L_17%6-=a-5CdwE zl=j6Ru&rqXo93ZXi^h{$WMA`pN?%QQ(G6UODOkRyXZIt}#^cl*{1$c*ZT5e|<=K-6 zR#b>$Ryj`yFO{iTrzJgY6vEFZ*bH9?il=75XSbJ4{*4@&jH+12i&NyQeG9xk0Er~9 z4Tv*pnwAnX++mfVVtIU&CgYN9CoWfBV1K!uKyvF79nWqF>yC+~(b;c;nL}HfbsGMi zm*uH1wlLEpicZcn30AC8It*ot7tMT@Y!1o>qoF-orM%mJfwKp-FXolQungEHJ7aar zg5SU!!{EE`ouBO@h5^>Ar!e86Z}A_jdRO6VxK*mf}DZ^--wl|uze)lLzL&s^f1 zF)>(gd0yBE7NF3lQFT}FdxHAhF_aaW-04hQ2+9nr!sl!~opvc~;59nDw)DlN`G)@4 zuv;gW#3y@y?IWJ?Yj<3{$9&O(>h|iEVikv+JlmuFaSHK{zG;EV_R>Z?Qw*ajl}x?b zrs7~$Ku)*{?)HCXSI;y@c$|_87Zx9GX~F*tiA|l{jvaafAGCA}S=$?KEEWrfPMPIY zNvUO7YP&=eHyGljZ4ZsT1nA!CGnax7*Sd!e8On{bC!kG-B~bL#f}7Bzae|5OO z8~o_o{H`1W3=EV}^_Rd{{twGe{$b^j^KKB^s5pE9TVpVi9FBzLZ zh`Y##5vE-5He2$qRXh_)$uCacJw?sct2wr1{Wa(JXN+_1(=SRQR0F5q4X~KuOc2#2 zgI&k|7iI4lBv~K43$|_Bwr$(CZFf)Gwrx+_wrz9Twr0Aw-h2PCv3Fy?Y*n17PZe?U zTV~>Iyj_~@>bRMBjhEf|uC6|w z?rwa&_&VJ|^kJ}F;+Yx4(|KBd#Gb0ZPUc7+FrqZ?4)LYq@IE>{=7*Ae8&ow1u}jI>c)kQU|?wQG%d)eW-$s>MVshpWmr zVy2cYGIM=(`P4P8(siIWQaD9c-R&n~021Va$6exZ7!%CezKtA4x(0hI1g=Zhf|6=b zY5<(>20@NOjre00cP@9bAR@+N{Fr2P7FMziJhIxyV*) z+jDND9y2t?yzHB?<@LfVA>?CR;18kG%TuPIB}`*C>uYaV{lJL7Q!Tvxl&pd&DRZo% zpW7WxF(oEzgyj(M(WaMgy8GqC6rBaXgi$jIjolYW&oVTHsN1sMjr-3g!lh~0xR`f zz-yS^C3P9|@E*+)wqcPzmwQ_4GryvUjZH)h0pfGnV6kglU@e8%TE}%;)|tE4>YIlV z*HTx4)@h(aFeFmvjtn8GoYCk{km>c?kuKH>RE!EtFF#Q3_aGbSL0?;hq)}!DlLoth zX%7)Z2dge9qSa$Or#-`83}3L^&jjbtrMIYGHp|lGfvmfk$y3QC6Rd}B>FCny7qxR0 z(ujW(#cHyoEE-2*A{MQj=KJIK!{3L}4cyUA>(mzEsE&u{zPRs}n{6R>%_I#O9~Oiq_uS0e{*7g67aU z(9k22+`#LRW1H?m90hOXtWCgC+)w~gjqv74N75@pO9tf=e}L!_fKR&#oktiur|Q|* zH6M?Hl(bJf=VD+_ddV68Ul&2F;WGS|(pD)BXta247Nq~QG zLX+Ss_-rxrF4#XPZs!v{BaOVHm~qs{k+=0R+*B_mJZe3WF<(kE+)~qD>;2tCLd;-Q zQb)7wy9(F{_aFbwv1>5%ZN44<3A=W>B#5vPQ2aw|0|?T1LQ>B-HjFq?8kNOeI{%a! z6bUySoMX`wzjUc5c_T#%^1EQK`bg=1ew_hZW}gT%p}^q|QJN<=IGUDNTlCmxV(K8~ za<$-iu12Nz++J7`%>HXQ)MWf*r#_7^kfX#?)NRQElISw#J;+Q${SNq0SWA+Phq{UH z=`?`2b@LxSg6+$5QHn}jD^B0MWPICLfq-vUw?M|d#wgbTOf?I%cKcp!xnT{Yb3|BP zF84wMFZnm-Ff(yLo1}RL?Dvj1_s{kC*VFaDEX4YYZQy@p|4h0)e3ME!H{}&fUQpJl zzeX~#gEtNMlN3Kh#p$gRu7+b5wH%IdJbS;=+48@6zbI>uv zv4<{3lAuf}RBrVHa9r%SgR}S6ZNFi!w{;dYITeU204oTD<(qiPl-SRUYZ*OW-yY5E zgmkyy39*bnx=~DqXPi}14y1>cAi2JBjxfY_$hJT1j`MuBk5M%^z${m&i=bNl7C5aS zNkxu2-`@*U@>w=S_MTCHLrcPtfN0GGy-`~P(UqPelGpypJq7P>K46y69psizrknIL zhC3nh^6d~Ripu|X#i=5tg%nb*zu&EtNg6Ru0?d~PRo=^ZV21BXCn%N;;-y;-3nj)M zE#Mc%&iz#BjJ5cW!scRT=^Z~)G<)T5yM1AaE0)H-a1uFZrd zvRD|0NxDhA$5}@}Gf9SYHrNh_KlXOq54>P}U#nlL2T^H;&>)LlRXI*?2wxWTv9QMD zx3^Cp9-B3UY=N_+_+V_D)H0g;R7!)bYLQl1_QxWt;fomt9`IhNT1>IV5r$g^)aNn1 zo@jb!hatlz*TOy3qU%^M$xf}-J&ab$Ht78mzv2G@vR}Ka8NZRKL4>F0)eO$n1I*Ep zZv#AgzjGD<5YX6wD8L|3WznXsp#?V%zCdgzd%(ycvGBiJ-bU0|oZ^5BEzM%1%#E*=)1~RQgLwd;z+6oF@mM z{-R`X|LWfy;~1i|VTdskfFB;XejkcYe;|Z z$=TK@u#s?Kw{F4va5GITPMuF6vN74Tbd2Cq!{&{VcMZH%Q{vaK!Do&Ucyk-0=Y&*J z5rCEDg=$T$_o||0-HCb4DbdVJE1q!6qwQq(RvL{jm=FS+I5UWWFO$GN>510`@rIHY z*r?|_!%^KNlL&wIy3%&G>iusrxmXBetbt8h``Fyd|44gL;V-xBh)9;+O}S9FS&(C{^dz96r_)ipbY z6q+NZkq8Ud`RIrLHM9|}=hB*^qAIy-2SNkB$Sa|)i3PQbUwm{(4q1(bPT2(=lWtuj z;A_;04{I+U5odOoBHRp83$a}knKHRpf}!nMyNvr}p?U`&rLx#HYX$R{DI&HcW%SjN z=b(|8Pm5xifUR^&T((((DUh#%+wDMcZuoH8R6@fKgMBF^v*@oHHHj)gVpiTnE6hMF zNXxI}HF4b+vPE}L1GY#QOw#a%%kG6kT6x9$#*FiM46aRmv1V^PZGjX^`;*g_iKBQI z*JId(OT0JE!4IELzt+EPUXFQ_nPrqSxfc2}OU~I!YPzG^WPA$CWO6A2oLxV9yldqW z-US%QQfMiJC4yro9tnzI&@myctDoMlJu&~dGKbCpzFr#O>w{<*GXTDxlUsOI%wI(D z&o`)fm#lLu!?0S7oB zSg^47U{`(|sC}t<1i=K7a5wg%FYB}_+P9A4qxD4oMTEc0j3o>0bBrvvIO%I{o?9(5 zs2~!03d;+2{fw5ryn|DyoLG3wQoCDL%#>sXpXM4Q7?j7Ow;XC6Z#4m-@)mgR`^~cb z?R91vSOTvztGS;<0$4pb_GksL6`5&s000mnp+t^U14J;v0>MT5b}ermg!6XrVa>7-Oa^2W*%_@1 z6_}{z8qwzV3H_hz@4)q&&r~)(J{fCSW=m=EKmYiP(LPQI$6h#t7NixOx#?GmGUH*p zRXn-P<%Cju(A=+Nt`vts?If-KXWvV7ThrzShH_D>LL``#G+;o~4a);Fo?b#9^zSSXVl9MK-zR#o&O8t#k;$=3 z$iQarJ+;A?xdh_wlZm{lb$mzy7~))WY62^tztL8)OPC`&lSlid(c*k=2leC#`$wrv zy6k!@JGpI{q`sC9PMKeAWcbRhX>lo~Q6A)56y-`zb6v?mgxUG+k6Tt;;(0I1{5r@L zT!PG_NiG4MQ|xC02#c*CCqOp7p1jGo0%5ezA{OwY2+E|vw;~!NiG+E5*z|H z7*rU4DXdR3++osGmJBcg8vGj}M(#yn)EOA20YyQ7=Lgfad67~a!Y_K}qanYg$ewO3 zYWhc^-{R}(pTqD?&Z(Ft(F%>FpiPEzo~QHgQBr&=OtH0jd*v(jHgea|vXc;9;8_1w zfI4T~WFA0Si#BO=Pg+;z+HsnD?~a~K6@=9iVvk$scXJzB4qz)}y0VJ5Tmd<7A(8S{ ziuD{x%Ej=BlOC%J&PwX3GJt_eU}>CG*{q)#w4Q8NS0c`ZsG`n{ZsB$7tg(&PYr*(` z6EJx@#Qp#xfZNgRCw@C^5IXU_~gNWQ%XYwHz}(_OpXNc=2act^2_;M2GD5baRpONk3My#`Zs<=4#OOa4)b+7zg5gY1* zGKaH3=an&25P7$RwTVEMx@&nM05$DQ#{p#>~?3ZFH`sP9K$yqfqHX$9cn7* z+w(mEq5N@2n{gm+aGLxl2W zUBNrp2n#2a&~S{EY~|KgXf-WPkilmksV(Zy)pA$285OrISaVLi^)15#4zw?YT>L-X zzrJ2CkWAxOb%F0IfE9TEs3rj9sJotVVlIhBO`S!GIls`2jMolFit96*D)DdEmZb8bHlv0FnV*@X^K_`L zZIV^BeyVFC_T|Q7iSZcaZlqh66?Ui-8qvB}rh}yf{2YkLCTJM}mi@SB1c#NESFhFr zPwM3e*xj^}Xdw&?F0;srf)yldttgO~BL`!Y0i<2HR~@s~_UX41H2C{yXmm>K`0`Ly z_#&_pNE$SBd-_f-F$oKRvQZdJ#P(?VVf$Da5P^w8jw)3@oy3(&R)TXVJ>g<2x#3Xx zp>O->Ts}5tzL_rGAYE2;w6*)=Ssx)WqnML3{W8A`v(DJ5sJMNPnBg_{#8WqARA7Ty z(f78XUAgjm)~4CTJO%v*&lWF}cf#pqPb0#Ff(y-QiDEq8!FF?UsN5_pSj-kO*CVnF zACY|RZUcRI^e@kx+t!$8IMs9C^R}5uJ$uzyp-w`frtZ*>sL6=v%20C_|2<{lf*sXc z!FeZ*`ge?&>3~xLJb2SeJZ4I^ovRqX6%r86g_@)}VG(u*s;QCml#kUrks#~+y~Futl_= zcnqo-+K|k_rDvlfJSFdmB^%m)^`dZJb(L+?D@Q|R6kcnCWSj&twcyRP5i#Wa^`)xf zxiz#(M%YMtN{^NbCu}%9qSV|9PUX5g%v1h2*558Yo{}ZT_kBp|fMxCM`_x=p+L=4f zkJ)6(oZ)v>6Mop65xUQPZhUOo^w!+w`On`B`Hsbj5uCeGKTHd#74a~|#Gte`{5--% zuyR-$ibpU!zF9g{+j{%COwV<@`Y6D$XT^G}$k8l`q&nyf)7$E4+k0Z030*pTl=Gq= zr%gGWKVEwKf7|+eFP&wpf3d$%>B^rg(Ma@%dBs-iB{?EL$9Hd*T1K0m!aTRleqMv*eEfCp~_+3k8uUBIs=# zu#Rw^@uF&+o30~Z5C}^`49cgrzXlaMIp3KI#4vG33O62_jMSQ{ddTCT?^JnSYp90H zqyvwhfI_evFXt=dDgettZ#ueytZh$8NB~ntb3vVzR$kZ{*#@iF2gA;U>-!X-h{C3C z;7{n}kaFJgdv;u6o?cPyw2AIZar2;|K)`PGDxXr15vB)1tf0D_L9Z!x_G6@;8HN^& z=sh%=C+pkS+x6@D>CF*e%ZYHjsyX}d^Tqy@@!Z9~nCl;w2$j@eX2QJ{p1IkK__+u_ z@LBGi+b1B#5^bJ>F7@L8ciJk#;sv~t6-~C`F&9eVQn8U=QB6D2>8Lgu-wZNHFFVGI1JE>3_Jut1z2K=**&g&mgrdY`C0R?ZcqEsdICH%L3(m z!mTdlWCSTMR^*o)q54CIqm~0FrEI9U6jPKn+1)+swz_Js#6j)G$)W_NHSZ#wsvm1} zXa~AJ));|ji&CpD=^QoGZJV2b3(b;PRd{MLNw|40Jm%>BBCLh%s++ZO=dg^ z!LqJ6hRLioUXM0&D+w*OD7KF)Xbvv&!kM|jS~Jcvo$rn#cfjX%XZMB{Yr)zlLQRxI zRk^63PF&JCZ9wOa~qlO&lO!E+iC2*i0TnYO$d^Z4u|Y@TqC3nxBQotgf7;auaN$Swy8i zHu!;=cY)LV`J2bIuqbSf0g({^qHOhGj_|`;oGo9Mm`rCa$E=hMHmJ(sjFT|Yg(LBf zwk$&8YquN_TttnEL*~4A6S|?$Pn*;)o(ZbOOY94r0m83{^cVAQ;bT@FfMOdy5By9E+pZJBTb zS=k({Wa3v}AfPW9Y@U8NG2<^xyebbu!&KKDnA$$xs|lTMMEW{wRjo74ilse}-Bl}% zc2klTEZA}jTneQ@oxH{NT_AoZ$_XEq1s}uKR8(z4I2MUWGFLYe@f~GCj$MTKB=Hl{ z@TIJqxgX8{iRI_X&h}y0b^xZUCdxi~j3POXFH)@M`#RYQ4!VgsT7a`$RbQm-*(#p8 z98+Y4pA$lj>+1d^QY)&*i=jqOFh-J-H%0+7PzAwtlc>f|KvSyUJUi>um?>9^YamQt zf$J=kI@5HlhKChaht*Do94sN$)F2T{ZJdRQEz80mrur2w78Zg&lL^C$x-S(ph<|{S z+9oK-Lvde42__~*4Hy`Wr;;cR1?H^wY!w;bUVvP(}#HBe#m z7PoG%ECynn2*^Ir1X-}R*BW3K>ukqGB07xQI|!JrDB@XdlTbAa&ws$UAE}J!EVQ_` zk+D1EV==%NUq2y#w-v3z*wM1s{=+hlTbcFY*rINRJJI>gm9!wQ=}wy3eMpwtFg=jWkR>0qak9ui->L7X}`1^FQb!t?IsZ8-%j6W75{;PY>#*OdR(`|rQ6it!|Q z2H65DJizf(;K8RRg=?9EIXnut+g*L!7sIup6=z05(pPNI-T&4HiHy^|m2hToi+-?m-NcQ-s#-IS3N zR9gJOw9&eTRfOr9QG8o&@WymY!Zm&aymIn-k`PfbKM!f1#kAAHK2XJMF95KLfR@=B zKxqGS&i0Dr1a?48qTa>~OpU4DB)7b{4*`Ql^y?5LD`cyFv5w3PmlQ2)^vU+& zCg_v+S>s)Q$8)JLe`H$3SnN@nG?tjL34z&peYigcu+u|2;bNOKc)YZoh&5I21uzve z9NeCc2_?+FZ`wn;*a%_xIijjHFFH5FyWS86Ws5!~{-s=AwY~nI@&(i@#!hk0`Y5Jx z*XlamNOgF!u&gaJ`R?i%3Rc)$RGn?I(fmedjL+5vp#7Lo$>JiVF>76*3VgUGz+K}g zZuej_2#AM6gqTn_CF{e9l1_>oy-(8lhwYd{X_9L|{Toy^0*Mpy&I{kxJI>-2JAeox zlq#>*A)vC3;=;vW&P(0?lA@fgmU#NS=^A^RB&-hVojj~BGvdxhN)bSl z0zRUXu~0C7pyKPHu|CgUmyzgRH$sy43H|*(zE}S7`1CwcI88LzT9A+854W0t+QKF>`Hl0mh47skZ(RPp zU~V7RIv9>tAq6^PEZARs8oioN>y|=UW+b?;pKHJO_xbenrpDTH%EEmy2sPs*ZGJf_ zHa!Y_AxEpihHf?Rt5tOR^6=!a!a?ij*EW38nZS{W;tcX=S3AIm52m>Atw^m~=5zyW zK_|YL>lZS_oTs0KRg_DF(yB==iT(LVb1qE2+rDYY2Gocd18v9pQYVV!#AY8z6!OQ3uOGF zpFw;Gt`{Ql)dj7<=c^tQjbl&d0Qm1|JSqC0hj*URGbmxW^d#7Pg?1DQ8%CW16j9Ct z)&w%4P$lgcdI+Qp^<|8#A2YK&s$D25VQg915lMe7k$z$JFu{4Kx8zEcy9uhlC78 z*=O3jp?o#Qo&G02sFIrP`Fa88{ow6VF%4_Y>-F_@h5^_9$H&tJ+l&Rj92R`Owm+}# z3JTT@yE+d}jNcapyTcBryF?wgUv9ne{>H|CHVw=5k6T;z3;5s2YBm$(5LLI@2QDL| zt{xYS`KaKs>eb>s5SNf7g9uSAXJF9h7=2uR{rUVr$-E(6Mpc<+){%3MkqlPrxyU))~^Yrk+%hyJYi;Y#SG zRBu7zmr(Wt5BYv4@F4_$4sMJ&tboZI+OJu=Hit5LSzfjiUNf^IARIxV{C3%0`33q! zCi>l+JrRdn;}^n;Ja!9cHfjRMX5AXPwtl_M_OsGy<{0xu`z+zwikpv-%F`8>EbW-I z7^KV4{qjY|R#R_qKIYmY&p`_)(~VbUqrz%A7Q^XNwRbmZ_+#v7(JZw#pu1+&%O5z; zDU5Z>LLrvz=vk#L;VzB-yF#QWZ`tp-rl)aRB?(DIg-fc|39cCK-tfr6r%McjgKTJ=PFl_7-orvl_{XpDUZ&c4lVN??yoxrR-%OgnQX%9mLSL2%}M|1#}g; zI8{+fp3Z_w&k575WPx}Qc{tToGOnRg0ezx^;2} zmg49(q0A!Mp8uG?9{gQB-keQ;U`6-1U9vNl{{eleICoQI9uBM^}REaYG!HUh_% z(*E+$ghwP=4LNQqvpzwIBB_Vu(_WjeWnr4U3?rGZbwZv80vh^; zyXGi?%RSIRXPM&#Z0kB(yU|(1!@Z7Q^Q;^kikC^ODtB_rL>Sf|hJWqhn z-BiFqZfD=gEi>P(-GUYqE1=8D{zmQgZv(6*AShsJ1RPB`d^r|?d{?3J%MCn&56+iK zN0^&s5wZNQtWt*YMtGz?w|NZSmj?(ldxa4uIUnj^30a)};5^TJRhS+oo_8vMquq-h z)=j=(nes+ay~Y_q513zydK27}i(G<;O1GVO>fEAQtP_pH0u&qTmEB3|ri+C-({m7> zm+WvoOApV_o^R`ROmb1t*O)k~zm}=KiKeX$wsb;T|6PQxksDHJEp3*sD+=3m;wk0E z6n8uP$GVpZNb$cwpe*`f!RU9fJOH9ZBPcfyJwCCY9Ikc22?l0YOs#AgxlR#*Oj^R! z%>hZhKNdW(RDCR;9-)^hMYJaJb6yU*FCF6i0UOa^|6!2sz+`krWT3bgVf7-EnOzWa z0I44RDndC2wuc0Pj|l^}Ls4dZDdJe$s)kOA^f^#l3RLZ!S;_3_2jo`7$(CZf;jxvT zZbbbpW^#M&y;D6iQx;4Aa2Ajou;hFze%YbfyUJh6s1A>sHrqaQWHdd;2(}0K8SeA@ zfBfzF-rk%ZR(*RE_{QIT1}Rhm&-I|H#6yH%OWNuCH+?!!Jo|z0XV~~KQaNt{Ml1b5fs`A}!J&*l?}ESQoK*CzBaARI7CWcf zP`l77+aF22fZ>~RJ!l?jZ>sZo6DIxJxGUW=6C*ZTMP7poax)5?}v`Q4|~6ll@c76 z4@;|}GF485T7q&mxIiv;KHWjyn##|iArAFV8c z30A56dqwm4gl;-YK=}h{vUbxVs+z-vj~Dc}L{Y$;3dlRYi;6k+t&XOsl{bC0hw%zq6!B_`3k>?iyZ4Y1YJ-Uc-6< zz8gS6#~7}xa{8dT9*PwN0JRu*e)0YrokEzdCXX=N9S_ZL5J+)nR%Ov1NFJ&+fVA!+Q2zKW%6v&GzcrR6NOGtMS)#|vW8ez5I`8a9Rf zrP_mmRi2CjgkVsWTm9)3=5U@hFrWH~qP39zmpt#g=S%pJUr!(lJwOYY762_gnc7AG z@Hq*4TajZAVys*+3iyRw85K#4Con)4v`FAd5m6bwftic^{LDqHihPELuozDzLp1~?Uc2#8w%qNO>}oS#TTBw`6vinm;os>y&;RD9C?DOi7w z4T^^9ESSdbRy&*rQe#|+<6Dg<2)Xw$H*I@j^CQ*DhL zlkzzcmhtj!K-|D7$k;ov1B_0}EBVCClL12rqF#p<_i3GAlK*f<(-6^2I%bw~TB&Q2 za+2Brmh#EM(V$Q6t7t_48i>4NmOT?LFoZiV`V`;^3hoO^O^d32HPy(OA_U!ZtBATq zmpqyCF`i)DtK>(B_6Tgt>4DMaq*<)8sasqn;v)E-QM4F&N+-$PWU>(Vz(myV3-s{) zU4x%>XG};ItH%sVK}hNVoLBm(zhH~PkBe&uPvI0HRB9p*_)-}Um8LW)dxmvo+Rz<9 ze%qyFzmkW7Kb-2S2g5ICx@ovg?xh(FN)KUx$5YG`D_S?o&>v2TYd^k9rl^TSkv;in z;x)^*DFJ^FI;-(F4*W=h)h$vR90tis%B$X4Tt&Clg#^2Yz5o956bn7+WNmlHG8U(r zbl(K6t*&eCc@(9ga-44wZ)3HS;Ft^_ZsbDyb;Fnb=)O;Vd=`Sy34rEjp8$7mpJfk# z=E+1Qv$_>fH0~ckhqJuBiuX>wW&0kHCZUhEdh4=-36RUjW+4PoV-{mdB#v?lCl#?< z(%}x+f7>Ar`N2NjWx-p;Yoczo#82XlOrVsB(MQL0sHCnvnxi?U-gDTbYQldsMz+Yl zH!m@(@K!LNbt)sf(F-v5f}LzKx5Ez*lN|3S-y$|hg@c@3eM=lo7*%XcU5tr8#Ar_@KdvX)8 z&BtB7pu=25HiW8QP}>=CMlA<}Il|IdF;qxE2CE&x$PN_q_J2rN5-0?v;6wyt9h(J0 zO^D0u+1Kn(MBT%kXX*-rD-o6N;g6@$+qEp>h?{+ci1bA4y>j6|8AD~};e78j0*Pbzb^OLp zJZ1T^q|*KF>Xt&mfK>`y*;ZANoAOEPldU42jpsG-q{xuYym*(pwRw)>UEL!`&95FM z%Q9Ub^76rhJ%dWkW^y@H(iiI5${UZbmVY(4|AO`6ffE0N)I|Z1`lyf8HULsbC{<|> zye0O`1oO&E=JLxaUklsueg8Dp!HZ0{ggT<7Mo)O<-0(SyR?T_NY! zpe~78J^MpV6E;^0eMYEIpwQ_h!!Vlo09ViCO~Zc<9XoTJO3?w6J-OZQ#3f#1QwPjuoN{p{^#k40Er>)e|q|P zToZHkRWln9(Brr1f5Ws?b4%g-{h5b#cuDWEvB741?U$qpsN~E|JuH~?{{D^2u+~a6 z(3uE!`KRbsW3D7~WYEmn`LeOK zphSTB9*z8TQ=0hqp*=6SJDHjR-m8Rc3xN!~hC+YA9YuV+w6dzQL^vA$j@(Uc&C+R_ zIxwdadLEX}nor*t{ocJ^EkEkS0$WQ2>lx#I z`9~f!)$D<}yz`!j}9Jvb}H+~ftP7l8WC*pD>4i{ok(d`#l;i^}l zlpX}lvi&6*W_7t&uqmKI>Z?qfcb|~CSt;#ub9cn$BBf{cMCcr1tuK{;64UbZ~43tawJw8$d)Akj0JR~aN**=A7 zY$_({E(?3HVrW`X0L2r)`ZJyFww+q!1C$0%m9& ziVwa4(xDH$dmuKHZRt>?TaxneR9c<<3|=Aw;-%lTvMJxikXKg|Bne47hh6Yl+pL57 z;~ToA0lBMd&#GBxw=L<1=e%$L-Qe{I8SRlO$~NDHC{Z7Nid*38#}q1-LkCP$0j|L7 zyBr&VaTTWz$g$Z`Cl0owSSl+N<2$z$n4W>Wg*PYkoA-5zuS^ra`gRRfRQc&C14c7% zMja(QQzK6|HdH`TxY25M?ybcl>uk*U?rqR1C(BT*IiZYaK?;Zm1LQ>qv^Jb0A?h_F ziZ@lyx3XxrOd$LvAVpOjZ-zM5QU}eDCA=damwdTMi%I9Tx6?vHKf4;Vb?aeNpUI1> zjF$$w5#U2i5o?*+J191GM1PsYhrWS&{acBf5dZ{zZ+8U*l3*{7z3uWOSs+07lfV`D zE;i$$F)s@Y(SVf5H#u^DQU+4uFc4(8}fENvHzrcV&2C_X7YinA=0g1tftlT=G$8p_hDt0{Uirevpof|Shp z%R2;7aSp<6WLRB2Eq`TYdP@z!x+=;n`GkodK|B)+J>)j*h7rL+)n4yGH;<;N*&6h& z)aF49!mjbdhG6P4XbL&*#A{x3ZRj=FFkm6&9ts=+o97`q921Rc?PHh%+XsOl?#b!IkX@!Hln7WCF#P;Df@&34mQn;AD53%!6{?ZS6(bv13c`4`#vf??fTa*% z&c8=(tnZ0fG%WENsza&Y_uULs-i11CLZT?T9=d$sM)j=SuqfEH!c%B}x7~762%euZ zQsSA)`{sYwxa8D)2$<&j?4drX=+47!txC5p0pW}dNo;ydJ9OH3x;*aoKcmOpzZXQM zsmvBAO^lV^fij3kh^>adCfPYW-U_AVh zXP5gW{yXpwYO31tHrdPy^b)h1RccXdxN*NIQhtR9;X$zEj$v}y3rt!+_;(hSM+1(& zYJD>%C#aBRotR*v&zr1`OsfBq+-^xjMe!Q+7+8aNe$Pg3M0`xS!F*U%*QiTA3C4$1 zyV%p<+LNP4U;yjJ??!KnZT0Qn9i6&)`u+Ytuh$L{wkGw0@yp2;H)B-v5l}JwCFV** zjmUA}3f*U>042OwGXT=+cr9u!qp?%RQYg z&Z?@mAz1DN0!2M33DuiMd~8$==412Ovo}5F=&HOiaoG3<6eMe+g&^gghh8AUF4RiK zvZEDH;yQ67-^^_+l0mx$ipdC!<#Q8ro8>B`X+VbW-?zz;GJLXT>moOKA?2Uvp?c_k zeq}8T(>KXFIsWO*U9ttX)fTaQzI&A$=TbxZnIlS|ikJ&!KnlDoCVPE4ZrlkuV#OhDf9>-j>ibr7DqsWUN)aO=ORBmHd4Udp{lLxW-rL1@oaEqqTTeu(Y zm$RwrN{;odm`|?vXfgQXkc$I|@KZUM0`G`=EMx?`;;n>u05iVF15`-TDEx^SuCJ}t zo?lnJua_y7uD*hdkkr%?1rR;kvBVm}fo92w{r4VP(kwJn%TGUroitzX2u6A_TPa2r zkT^09VM?dD6b6SKYo?v-V~)@Jlw;ruJ%djf0lI+EH6(Zeko_q1H$4#=b#X1`Aa@wOo@5(;BXTH+4VhjwWb;7rwnU1ip|9Bksh-1M z`4UMa@cvE>N*b{%k5eVmkayB@+OyuBQPxzHl^gjSvcj5FRT5CJ{9AuAib|@ho*L<| zhW=!GaHVSgabWd@A!*XlA$@Z`y>MCvUZq>nX`OvEQD>81!+^|3ZmMWE#npa0H2Hs( z$PX~z|DPptJM>zn4`_W!c}=^`XS)5S3;EW(kxdU53#*4?Z;#uD^=>K;23YH;j5qHMRKzjK3- z#~ru$I1-9@LX1yliPJa}sfeP?fZ_ln1_F=9Eq)VawWxIRSDgtDCce1*zckuqj@GP} z4G;9hgR#G_`1`Dz^!zDbE6xQYY>)zy9Lsg~8h^wsuB)lGYw6D_DIbX_l92qCQr`*yig2%*h_Hw8Wn~D6DGN5$G2#JX$vAxHI|r3JrOa(92rj*7W6~%`|GI1FO&d{ z{yo>gV~lre;v))+S^ZrQ1-|)crs^Fnbi=5yjp(2viHSmVST#kS?M3mH{AG8}AV?mK z^eInTXlY5RQxPrV#d10F)o=f|-DNFRFuyVs zI6DH@&4L^+0p8kM2VHoKVp?3;vIT~`@L?6Vq_2cD0q~|IVgEQe+2obu6*(_&)C}Ca zn^=`!^$3flb#5t67*wDX(s+=r@HVGpTq*{q2(bg4WG5!1Y|{)a^c$*ZQEc@(bV`1U zMe$lXM#AH{?s)n|ch!$e()J#+Vm366wgg9gRHgaFz)plaD9XPO47(^bIg8zDhNqd8 zr#+4HpgVUX(IHW|I=U`3ERVVW#ZVdpFqHmXwU4ik7Hs$T)!z~H`}!OF+|(+1ol8vY zFRCyRE^i!UHS(%0v*tIhO`CJ;(WM7PF+n2l-sj!Bs(Dk~+>$PNk3%F9A`i6KAoyWN z4QiwO6F>9lLM1S%udvyJ=d*Id!rWz&J=*Km(<0B4?%D>Q_RgtIfjN`AxITP1!2?eM z2G2TA7sL)Pa^XQJI-Hl;DI_hZVr*%xn;7m}&|7+H^7rrl`1r;YhPAbZ-L3G1Y!ZSz z*;qm7Vl>M%K9$C$S)#$#2ii*6c2IuLzwdSiQY`+uu`+WJWfh1)N5AgG| z;~~R7Vi~JW%%my7e~e_v?}6*>ZJ429N3H(VWKMCTcOrZK9yCmB;$G8wvfgqU+8XhMIZiN;tvsMR^xt883B`cNqLK)U}REy2|dD*XpD#cw=SBBpkunne-mWy;si zvDX)dMp>KaB$2YZG&r|%-AVJsGmmn8%|rX0QF5x;QMT?{Fo2Ip|2B($)iYz)N|QrT zBP$f{{vOJ@xjHK-V4(NLQ*PkW`fvU7=wtnck|=3eb{0l~-pP$ST?zC61vVF_8=J9{0s|E25N-~ zO^)hqAo-k>q~oh*w9NY>A1J@wB44)Ur=x=9xcOfGQz`3vJQP$4Is|OR1t9k2WyKU< zn5%VX*7xO#dLO}}4r^*=WZXfHdX<)^NN{CrX9)U~tuXh)PSZdX%0UA_>GBQy&tK7@ zEH{9v(^O=8$)P4h65Z(ZFf(Q8S7I)r_7ObXEHW!BYZ1`qdwSc-gp7|E7xMC8kvHe# zLu5PyCMaYu{h*7KI8Mn!=#y6&33;D1RqG4O&yXRN%C3>>_eoZl^@OO$r_5g@hh>#m z^lwBZSxBfm3swL5Dj=We?%IY(nNYX?h1HFJ9>J7YIf$q2RB9rLsK(XLwiS4 zTSGIzU+Ap?%a_d=++01>)!>03L#3cBbCCY`$6rK6gV zUZtgzr<0kXot%+1r&{4;YG7*NV1-PEusB_t!xsPOtXhKu2nz|7HQGjK3=r=>5&yr1 zhol7p5(5bT|3~KkQ({+Rz{B}JMNR^UoCvu7Un0lp$j9JH!}0$z{u%xoT&6~-a>138 zs5`_WJvU|s$9&Zo*DaqJP_Wk)5r@`Uh9`pctd#crDg8n*e0tKdU*|brbNE^R@Y13` z8<59w=KN;wxrH~@AO7(8x9j_avY&*3as0^#i}Tq0{VBooPEb^)!T;yN`NfTrMfVf+wY z)pF+S!E0xKSS`+aJp~_eJ0cEr#FpvjudpgE60HR(3Use1VRzJ(uu{`mC+UOEUS znNG5Rm@pyZ;cIyLmT70y-A^t*iSRXJ_sI!yq)9)~V&>SmIRO98Jh)T{2{@<&!>oNe zaW(8YQ`BkYpsk2jSpIUpbRaa)9=oqgo5}T}8 z*jk9Jn)f22RMZH9C&dJZwJRwM%)zYIVvogFwk1vv zWS3U$X1Mkj001!YILu+-(9`rOOdyJ~C{?NS;IwCwF@(R0k8A@E;>1ZM*zPTY6s6-o zY7v^!<&$ZWg&89|%|?__$9%yl#x3Px^dmE9=!43}I-1O7q%(iDqom5W1Z>zQY3q(2 zLzQ<0uN=}@_}=$)0LkHRmzNN*lfWaWKTiH)%$4{$Z^N7>B6Yoxp4|fGeg2$S_Bq2& zG}K@$Y>`k{^*JMW_vgTqis3U=S@Z_{4qkK$b+QK-bp_Y)sj1%vexL`p#>IF*D zL#_=i<&FiU(N|uT$qG{9PNY6wZ!Knun$|apmHlWz+6X9zO&i^<#p# z$QHa68~IKzf2hs_MhGE)WGm6GSA|N^!TKPEbNi;bwD@rgG1_6D8*LUSdO5uw|fIN)pfj%lW=dclux z@w4wIq`ZKOs2@3~O|{_7hnxHsWpY^^>Wdav*{6_cB+|dC01uK)m9kGN(?|uEaP>;1 z_;$Hqv^DLJthRRVzd(V%p~~e%i#}7bM4_P@+{)b@i|*6>hYv|!91lGqsiyH?8qLKC z^dxCqGs(V<+(GCZixVNmXkV@}+~)a5?T0%jPYlVwPkF=!+4E}ycuhy_PMT#G##rD4WhU)lN;{#RO1t>)V2yXM6AH!GdQOgm zq~vXR??3(nC|__TGu;p%Ape1l{~A#K12uC0U1<7WV9Wn(IGuF@0TKJ(g46#ywfKJ| z5&sKBt=5ro+7oZqITz{t%0F3@9x$((NKT$Z1|P!5$pTrctzZiVSzT(3Hz#V7`FM4! zsbiop3Fzr6qwTOxHs12OY$G5aT^i@tdbL2G>MJ2I`_eUe@#a~5nIg@$(!hRRC8qF8 zn5Fac%{W-4*7&iup;t?$!MOSvmD=^Ay!)qP=h1-QkejL|c2%lGC+z2wAFrSFOFd)M z7um&Bcm~=0wVx69zviKj%a4`14EmBvm+gAOm=E#ppYI{O_s0c!Are(_QKeN)Z=|fD zS9G-!WK9m&<9Q(&eDM4HS}zKzwPXg|8BlQV;;FAU+~r!3-vUZn*#=la%%j%}bm$EE zcmvoia7fK1I-4;ez9`+n^Yl`RKF(f7_dhYNn6l+Q$C6%*u^=q|K2sr*eOjYW^;g;I z6n65Yj)yE%u#(Pq)cPjB%~Q;1FVAT@pkuSSK{h=2B9k{z6nqq4$tJyM+C6x+8>cQk znPH_Ohea9B!R-;ssP-CXK%E+gB>imQ&UwCzkn>V+k*{o&m&#lbut|o1>%tRG;2pxM zN=2%Iw;ELJ_xLpp#^W)^wM%*Z$1Ci*BD(tj0}#ix{0{M+k3(o zSg8{>O(zOv2OX9M@oI85t-G{372A|LPLYkKHDnFcIh?hUSC;~QJpKvwlX)i`Ox=lN zN4Q(GbAfY^ghSeJO4stxP4OZuE{d6-(VOUF?~Qq3o^Yht9rX~SG zhq}>z);^T4*H=WY71Q&;)lHtmt(!J?RnYtb_fX?@+Ad0bq$|s#8dIlsT_$xRvv$vN zZXdfg+B#Rxj@Gn4Q@SoU;u&jZio!xl9}1a=9yTc!H+S}F+QCBwQ7oh9SDvi7m*$t* z`pEk|$4K9^hF(bjTk4htBD^<&Rzt8>mHy9NW0)%S(1)Snu@TA;E6-fAXxZ>Qy$}e> zrleLA>p!e$Z>a>LY*4&7giY|f2=OyFh(Dp5ru$0vf= zJ#(r*Yt&2k`F9ptp7Tz>FcmTy1Q=06Bi%6W@I|GED+NS2ARBEnt_>Y?*YNZ(qOPY7 zQp=r-_EJloKh|&>a>gzdhUWd}8h|l7+uL2W{bt z<84_cBqSXwZ+ho_4Zg|p#?p+mc$2fC~%!uMhyr(n4|Gt}RgiS~hIZ$12q?K8 z*k*f&`8%z^{WX*EihIfR1oqan2W}bNeoO;!T2YD7)OoP+RA0zcH7iwq4iT^L-?=vNYbYtTbB@$ z`xfwTyt$Fd_-w>4-LZCg>TJj7E)%=Ee-!&ZLppDGrXDg}@D6nAs{voxHL6Ko@xaJA zS>8W79>oH@V016cEs1a2xLDQiz@p(87zQP#9@Y)4?q!Fs7fEJqiy`9h_g>g$VRa!r zOu2GH?E0dd(x;Xl)<(hJ3A9*#qVGnwW*vDNgGa*|HT^UtY-aN5EQ$Rv&h1wj_IdX* zIvN?@i4~6I%4PjriS!LDYis$7&HS(dpT5=P8QO~J9L)vP3teZiE1F#lCpu!01rg?e zUI7{hCbj%cT*e@()lYV@K!j>&?+q&K`2|^D3-}#S3Ytz~)M?gRANy^P0UT+v;`ffm z+-zUCvRy;ubo1$~PD(UVfb>>FpM5RkZ_~SW*p_Sf^2!e-BMGPWwBx6S)`!|yQ$o~%~CG3&BkEWL5TcED4Ji$j`*Q1YTT6pAQGCS&H- z9VJ6esd}*_Pk^D-P3bz_ED{vWp9~%_$+P^>9QX0ueW-vQiT2R$z8asLBK zLtfu961fl;q4;=3oD&Bvx6`d~5y|wo$j2XZnYKyni*Q9}&=1r+v;al%!0Ood6aq1k zKP4K%s3ySKpj|?b{ZQl7%vQNW47mCT z5a01?IE%aTA=_WdC9PMRJ)7MS{)Q4wi6_nqoNq{K<5GR+qo2g74CusMp>AS-jGw6X zB=2kBbYa^0cJR0}WUsN`9H=s6Zvlqxez*_UpD1WcJc{{`9r2!O%yF)^0>8T4Aklz@ zBa?B#3!xt1py^S`h^{HEc$ic1Crj}8kC+MqNbV@R(^)hyJH?=*w(wm|vDjo=xw}54 zkJ|}v)D`wFrK3k6sSK|UR;}Y#1(RvLOlp_8G%8&`n2eIEwd;YR!-! zGMX98T|#v(3}9>5s_fAJB4&Te;Bw|J5?M!y;Bq> z2|FfI|FR%+`nNhpZdbI#o#;v3;5v?)?P_zhqNlJOw{r|aJGUxzt@`ZN{{aB6H);Qo z6jndBxe)`aRoD4r9Jcg1#m#Ij^O5WWCc$IcpNHO=AH>i}yM?-B%Frq8P7+dEp+CR* zgHSzC-qzF6p+1v4YvOtIYZmCG9B zEzeaWrN54-NwLY#uvREO%6X9f4oTIK$w(3~3Nj~mC!x!eLso#c7#(h+3p2ufzJ{tDD?XQLW=_QYR0o(7|9w0pPTUeF zOV1i5HISNBK0pcU#2<~`iMS>VzH}MngUlp|Y>>BL6!<$eKTRv?Si$ykQXRMa5=EYU z;Z1&}dJN&XEHr**X;UjcvM)Xd8Oh%R$O~-m*mY7C+2c)KUoJ8;Xy-u(S03@X3M`Jv zoZ*w@aY}NpRD`4ZxvZ_7%UsGohUB^-U;8h*3|Oaja3TKKj3?J0%}}b5{N-&8JqHLi z4Yu_UAYmQ)vaPeQ#9L!CgI7lfdZP=Q5w$3Z+QwREjFWg8YT=sXvi>w3HI!`4IQ>wq zwF>uZ2)r}O5qt5*s-+<$djRc@*;a}KGd=&hWh(&!qZLyXHj!g(QnaussqQw$V0&`r z>+S(50RsQxhY{%Gr*BJzMUh|bb}|&BnVu`Ciy9!D_u-*1@Ze_b*I9wRx;m|VjFGqJ zSkdAY&Y7I)l4qKWA-|xD*Ly;^WxF$gMBg^@SXmC~-3Cp6LUGro0gb%F{t4|R$wX^^ zim4Eo-g0~!S_s4g*ad|55kwwd;}9xq)_9}EXqwB}n5~XR7$cdMkpt7LJ8N9*y48~H z))0%%?z`997_8anInsZRuf(Fzf{C5ROBrAi)nZWdhME|}ApMn5p^wjA@Pk(!NP3v{ zgs|p-Y%K2kt3w@Bc_H+Bngxd9#6n#f*+*%N4h><-|8VQ`ejAF=zN%rrl=m^$6pME5 z+}nO~5^|}Un04|VHxswUo(r2Uzi?IM%90JV^=(wgLPPvf*0Q|~7A`Heae{~V0W{H~1Eq{<|kQGk*xHDs~v*{18Zb{m|zHW{zVWCNHg%#GKjmgSkza}p) zTw@DCU6^gZT)F7Tj=N*V0j3bYXMxpEc}>PsaU5) z=urii0OZ492YK7=oL$Lu9MD8Rq%!C^4}m3vHeQ}R5OlZH4*$!`Gls(ZP0P@hNSz^EH_l_1%Y%Wh$3-n3_9R z-DqvA%GNh-0#dL^>Vz%YI-8-N0(DUDI&VFw1QfT{A`ap3ef=0`jS>3YehrY^x@D$T z^}XVIL8A6z5_ez@x*4mp?WpM?!aF)np>nEROBPU-j?5jhRc6NPnY>t7d%toDYFI*Qs%X zS~AoA`gyD)(RHn~5e9&jf|Dq$O8lid=pwp>OZ#z{x6>kgd#`XCS@(iH5!*rp9HGhx zb3#Y6qJV&tfd9GUsv9kTPV&Aztao%JK{ey4@Z9z3_o)=mI(45>SbI=&yfB@vO866* zlG7%S^QhE84R}J%Lq_e99azbjQ5?)Bo_B{hZX1C1ay1vd zi{G5D53sZO_PYP!pS9p&t8Ql;S(wpItVE(v%R4*1Zp>(zLd zVS6(Qe|??X=^!pTijD&8NoH{c);H62Fuz5WctjC*ZDKK*$4HNE7Fkd#Ij7<$DO2z` zT26?7(aR$Jv3Mqa1r~4uzpXKZpE*5~W7e4knWOrub!og~Z$++`?8CzVbJDc-{8Iw% zkJ@joSo=xx8Vc5&bALL8GDONpK#o2%@LwV&T0;5EwO`daM^Jl#@yz3uWCkjALNSG6 ze0{G+pIAQ3KyyZ&D6RJ_<)Yl69bDP@YX9;K#;|fqX)^Ja>VNX5t<=V`Qd-*DZm$QI z*Wiv|RUT&Y)yw3uZnijC<*+igTVO<1}5OpMd zk;K!D)=Fz<{Ca@&73W@|E6eV)*&LHmZVi7#OtxvB4@;olp)uycj0XSe*S<{HecSOB zkP*sUini+PXK_7eA5BcJYtVrWkK9%wb6#izUZzLYZi>Se7|*^QRZ0qDL^%)fKbk1# zo8kauAO)?&9HOqCR~m>8(=5#1G4~8X)bo1g7n|SjHCA_K>FbZF{g<%fF?yPHhb|+L z7<@rNH}`Q`SCSh)Q8q|d9abI+5q*gux>R}Ba?i(^`lh$*obS?GHhK}I2%A6Ea*G0+ z!O&Gk*%*f%)tv8XdPAk_u?GDS-D2)Ts3|2e^x>^uWt^I<)~6Qz_Ln4>@{#iDT1{7({@kQ_-6drJSfl7GN3CggSt99X4KR7FP{TR5VD*8ZK%gwFN_l-5G z8Zm^2^Xn~T&WJ{gsoPKs!>d3BQS5-RPW}gSq+VcH(gRm8{2@NSc?u$ zRBaeV`_yt$|Bz%#LEU-iw31fne-APX4K(>IBIHn!!|&+&E{NV*jIFPo$42nK_y~}2 zc-JC}PA`lcfTj7BPPRNbn}XImnbHKHs0QnV_#lE!P&{s+5Qpvs(PksbX%jR&G{bFo zOo^}$_IMY6(}fc=PcvZPY`1{)zj%d~sT5)7GfRvC7)tDbp~1=F(yR`7xo5G`n||V6 zkwv>r6pFAZp9N7V?u_mM+krLJWu!E{=3@`(kv=d#B<7xdwf0**S@Zp@)NLicTquqx z_avrWt%s@9rYcXV!j+C2xqk;ag&bBtUiQh23hI|`twT8iIWPp zE<)3)QlE1sV@xL3cp|+O*=yXiJ^v9g;Dm{v>^&i+iHa4J?S~L*tYRfe7Vl>%i<#e0TfCGlkQy~Ps1lBSL0wvtz2voDBQ|7Ce<7}RLZg`m*5yz ziMOd;NoPtF#)zhEz;$cnr}}#EFqgsl$hs>Vr!^nWt_-UM$>c3l6A!PUg2HO?O+JlX z(@^h<--TxdyULD*HV_}GlQ~tn#RT~g%utQ|-ReLQ-<~driM*aO!QcF;2KVbw`v#LE6$t+LB>Tq&Q(_GH%pE zF1Qyhn=^4nw49M{`fay*8wcGiF<+6uMDXd5wR;8sMB5FGSB3{RD$+cgaTYne7Wu{$ zTG>(B(OW9++{ou@he1nxKTO(*i^hK%NUEH%GJ^_ZxNHSd8C?+Qh0mr8#0jAhT>owZbqlGBH>gJt)h z#ZZn1lipNFL#2c=Ld1(%o(E3J*6A0s@}=fvJXx1aT)*pG*%i z!|kNA*FsbNW<NtEnNM&=A#`Ghs`idae)vg_G5q+}JNEY2QE5bP3v4`=A z7eq$qN1zmqnSA7=65Nm`ICndTxb|)ig*)ro4UFKUp5Gxi3@Pk(o)nx`;<{CbC&;aK zapYrsC%4=(vHDQNUJfMF;jPVjKPh?g!n@tS8l^*pCl|zkdAI7+TDvtG*sf50Ytj?^ zpv^eD?RzC#s}kq#?WgXL_1D9u9EOwcsw$(n)RUG%Su$g(Q1&T3<=lHdhk3GKE=hb2 zG$q%q$B<{7b48)mh?&zCIR#V`zm##PwU-$23j#bf(|SBpPropC%Z_|GOQov6UUVi+ zMHVeG=7^!KoC|1WX5}*+)C%3WI-jhU*z+lFWlm?&x}m~d%8#|34PrzJCj2BLvy^4e zxTuI_F{+lG5tS=i7$xoGdKO2_#{>qNaho%kc}CJQ#L&M`L$apJ%(W2}2eJg)No9EB zS^gpJuG-@p`|alW3e%vjI2kpCi(ks}F%PaWU@`_~I|XMg z+c!$Et{q=|{8W=>uR*Udxl~E9-wyk(1dK#-M`ea9bHr>Yic`g;&r zY7oi;Wz?}^5_5I_5w0m}FTOrN54cMQ^c=+C$|tzA#}>bxr%cm2Xp41xSvZR!4joz$ z7Ev%`xs`o--orEMx3Mo#Y-l67$%3c^XDFl8Pq*eK*lK?LBGN_mJB1Im>1gm8cTOqz zIR50jFMtL9Xfx+D15&V+D5osuxn2FW`ZZjgOH}!=P`SETv}H?@)tV0+ka!>#89W6W z=m9%(9Gzz0vvd=9r;5I1s@*e;be*pU@K~VhoXYmeUSret5fAbrEupCZ&DJ+khxHVL z586>)PdPQw*nZa*;l{1WRuYQ67}$3LN2k^pL`EX)Jp3Pp9!N|meMs&qutf=)P7Qa5 zq$QAC9o6D}E>}Hb>=YkvD!m-ap(wPAt2?6Kp;wfPbDZb1#^Z(=YvoNh$2Q@5{jl?S zA7A?G&@yHDe_Fk+V&jUnkw;z34az~#EEDvdMCbYwpCt>fTuPJ#jZGu&*RX1SwKX&? zfAr=UU=Rq+#FJLc$vtD&z3za-G8TX|JEF|X>m#$c1u!m&vP4QK5${ zih8*z#D*Gy#V8rbyjT+&tnNigx~VXvu%Pkd>trYf7l56FJ}miMhwdku-f^gRZb!R_ zas{fH3y%I(SzH6Q8o*vq<|E<*>Pv$VKmGp0pq8#kB-i4Afc%Fk{9iMuivL{<>VHiq z{?8^+|AK;m2>ox7s7}r<#vcEF2virjam#-CU)**DU-??LWEOYez>?Dvi=IN7Wa8#q zPPCH{(k$%vn;u{W3v4K~J4vg=+v@Jz#(FT0K|5BDnd7hQ%L3JNb{s1lvP1ezBjy}!Bm zoyl_GwOf#%y}Q0$n^T8QE}7~+lM4D*$Wgh)mZ*!;8mSFB207$#wQbqnk+w?DllB2u zqCdInrzkuIk29{mzJm`6`WMYL)Y~^<|DPTIUkBrVTXEd~_p|)Z4#dxttw1!j z_Fr0{z&JFnIc6{Lu&5H@n#011V zKCQ?L{z>A06tJH4|sf;+@*-mdRey5G`X3a_-DU+4ILubK z7)wMLG>6QC-mfY1K2O(|Kf|UUp7_45FV0Kt{N5i=JN!I+-}wCA*nuPW@B4i3WADJP z-LLn!ulvfD?UB2d?oW6PsXV_A#BNXhWS_S?J3XJz@u$2V2WJAM+O1Ust%Z?oAGN&^ zks`;T>8Dz{*Zb+q`8a3WOfN&i6r{*g$r%gJxWxlN?hUC?I#hYNb&EmD} z)7~@8SY)wReNu4p4#r74={v9acRIG1yg5ohsR8j%2HfJTsz2B`>)~tdQYw5OSA4!7 z$$n3Vh&Kt{%bz~IYp=Y1A9`Irue@;BX#02k4E=3jZ5759*_;(m!-PTi`=qq{jqdB^>g%KZp4Br?HFYq?#KBJE z{V=tp)HKwI2ot%{NC%Pyu&VFf+{9$y?e(FC_?D~Z!-P_^DAp_2&d6jlA??L9PsgT| zw-8qCE@os!8=hb@k+CLCqKB7;(9N}l#Szx4l~Ih76kRa+wZBy(`iv85Zdqn zxiw_S+MEq|UAwnGN!%ZR;~Mp~Ciji!0bhX=IvxEJD+|CHMux{|%}`vxKF8hjbL36C zXLUd7{#gF9dq?hQ(!psiKxuCC$8n6)WFzj(jksq8Fl88f(Kl(XqlFGSJ)P1-)JSjI z!{gb*>-fWa_-i{Q*f1>)1(!i9!6C9M;L1hbJbX#UtqCBZQQy!AypNQo#+?fBPa@8H-lg z*SN|%?~8C_5TsGL25~w2b2;~Nk;`+bnGRWqOgh&~s97Qc3RY$^5tU0sc zDk4ybt#qEVIT^;AiR;KGC>9Pe1PwKcbqz^!@xRL^16DRBYL4`Mfamq2rViQs8o?us z?jFytC(x^df59{5532VdVoMNq9Y%_PtMuo?qvt2roLVQ1+i$F_yh~v zcUEEq8%T0%U~(23xB&{$1_$f7+Y7=;J!#xi;$Hk}3#-2oyu}_xkcuR+1jh{75s7Cj z#C_@Sz5#K=?y<6%NTn#X8@NGb0%d=!@eYkog!-rc_zrox9$}C5c^~0=SZ60LDh~Wp zpQ01A*{pwrok8P|A~?Q;uD44J;`}MAabQt5o`250_Ly|ee8TG%!;TbD1y8gFJq*_RTtKLwWyvH-p$H({8{Au zW~lcD=u0cy?akvTqhlTp_Y^#}1Qs-@>MFD9Hlx?nWePts5}TR`ZFet$pFiIxm>)L} z7NIQ-{Jhct2?y#guikoZD!&kN#7vhPmqXr2xO0^o+2P)9k-K(_+Mgg zyCdtEc}`R!y@H&D{yW_C(Se zY#z|8P`EUAbGPN=`SJ<<1O#?w4(iK9ME7>>4Qv#Opx;ClNlOP!Y(Mbietb1*XW_u! zLZKeeQH;pln~wR$+c zry8(rSErUs$N$GZ@SxvcVcUZPvIh>b2M1z!4S9{#TaRM{z|57;`Y}-xIUG5x9P`o@ zFEMWVYl|O&fFD7RAE9HIRT%DZs*#)E6i<|6VtuMj6<&qgG2Tfph`>&RXb1k`8uZ~B z;-N0@0z7gcGKOHy-x;%S@0Y4(P`N8AB_NkpN_96y>kuC91{Cf_CJT{oHG~>Q7%FRo ze%aPB?;gS0CCD2ycPpb>cP>)XBZ%93Zq_M)8&`J&Yc(cMPxRLoAtC`Gq8=gQICyPA z^SZe)A+aOcOwRdIqj2AvQ>6gk2ydNr+K>%&7$S5S9dsCpBOkS}uz=BBG!~W=y$U}y zy?(GVL-9*%`e9d8<@E?o=Pr2XE?j3okT|FWErgk3)`w&Us8h7VkDTck@UxnOxcU*q z=yiPr0(}HMeT4J*->3=N(s`>4J;1)vol15oEgfWs)Vm=Vjmyt#NT+8Ir)MyyKp#j@ zS#OsHrXL7l(0U4nOq!?QeExDQIR>$uq=j%o{g6(5phv-Q69Hn@e~F!rY_)SBI(tWr zdwYOAO`NW@FNn=;+@^1lyM2&ueV~`Ya2qg}r$rBI_1KotFzX4%76e%3DU-@kgp|IG zBKir5RnhA+GVJ+T_5y6Zd~J#<5T1y|;XMxAVO1R1Y>_7$g?O8}HKH)CtHPM9&L{{c zWZEFxbbqW7N!V@ot7~0 zaq7nqo%7ct{%nd@HYX|+V8^mN)$T2~jRr!zyTvIlf!={2b5f${y+et8%ApuzEJ{-Cy&r@+mZ|Mr=pSD>&uWt3h7wYvCMUc9jti%pU06t22;QLcNFC7(c<2!DU$7X2q>sH^ssjRuG$T3pRW*z7jg;=p^fyZ`59LJfvi4q;8hC;QqyEuZoIIX+*R;Ew7XeKxF z6YwTRqrGYwW0*d z&SwY*t_epN8$Br$Jt+o#a3iq>FdeUqZi@0^gJYHfFU2Y&lnSI!P17H_K4%d(76(5P ziW`;AonkI2ED5=tWpl|x)ZuYR7$;^?QD@3`Z_Wd;a6rX521hayDjAiI0?=NX!pydg zCY^Wu2*Z)oFK#dU{FE$&t*N^LNK}EuW}84oOb6)FE8WM{iQj3)YFszw&LbE(kcnmCDxkKpJ#tFQ*)SqH(bBQaKf@a=gS z@OhavOf_Kfx+*QGFfmo2l8~ryU2?iOO?#P~L1yiNvJPgUT;D|8L3bAY@DAsGGtqa( z-x{F3`=ulU2zf%>wfuH@jKSfLBp=?U0|Af~+tNbP1cz``Qsi_>2rbC-E5qRF-N8+I z<=!MzQghp40`Tb-JN1jpYKsxU?3NJm1Y zqtej>R?Q-n-18E#+Q5?namXUb=GQ<3Jc{j4-M2rB4E5LO6*={boqNS2a%V|6*nnT4 z6gSpibLsKZO$?4yU531V^12S0s{84z%E<_26gu)qzICbI1<`i$j}5z(at=i>5}Ou? z4dj`zB(P-^Rp{nx@(P^!h0X#ZqkMoi>%p&*vOr}{OmD=x_zh|UGuc~7x*KkX&d59q zA(2!6$Tkh-1k=z zE~xw0xS5ce23r+^g!qLy9kq}4Fx?@X+Y4}c@^QQJaUbM%XBwul8adhn;(d%VsbT%zm!6XOP_lF1SMUBAzh>o7oAs$wH;1q!<{HY><}s{iJvfQ(8yZVR{(JExmZ}O>jePS)fnbf(FBv?eA16mh3X!oFceu{P%SwgcrZ+K1lTiY-4hU+1 zKh(TCG2o|kf~D3@*ykf+@4Qd?)MrHZ_gKPV99ZM*hqJ32%yqBl&W@W$;LQFOYW+Ky z6Uk1V@m4gqn>Lq0H6RGl!QWu!j>r0x5}?^yg6m&I{0<5Y0VMbyE> z!H+w|@s1>0CcM+I zPDAph4ks)&XD4npE!8rTl9X6Lm?^ci5&BhGa-yGFHL(W$z4P&RIf+a>)CTO^U~}Td z!&OQQOY0u0;Sv|-vQoUsIBvcvzB8ih8B>ipcIIKYM=J}g2!wYlz^%NTiYy+in>lfx z8lvtxix6uolYgPEu?so12RWmB%_j98KS-4F5^s>~|M;5D{cXY@a^L-liBuaaJS)1L z5qqCg`y)3ZuaE~iz*X>D>TiA5a9>%#)H2n_hA{n(dabsZ#G>e0S`2nt4S8Bg5$nht zZ&M!Oj$RO5X~Q~=W=dij4X`5SsO(>WHeqw0eJVcvA~};mb{k)bzfJpZ?H}YL*{bqR z9(BT*JoYfkvWV^?xkb^HwAkyE8rZbBPr0G#lx@c=P*;9Fx%P5XIU;jd9%my=v7W$v z1O62khEor~8C1m~<X|}%UgOgG5!NQ;P`U}h{em%(0^g#3ZnH-#^ zZpvDMRL!_Xg&-gbi+OuO5ZN*Q8KD1zO!`!V#e$X?+@-%!)6zU2#mWGjuLOiTe%4H*5bSli8X{%fWvtyPJ{H-@BovHRb z(C2jON)jmNL^yn1qrcb5U}LfbStx5v?w zz{qz%9N{z?-==qldH!`Q$8a%wJ*|!k}S9N&LoCH;dT=07&Di6+; z&%rFj&JM}1KqDp6TEod1-Yb(#t>UZZ z!yqy58fj51gp~cAc^tgsEGX&1q2N@A1LC}x-@f0f+7mw)& zA!2d5M`|0-ElBWX$oIZi$A|az@Wv!APmu6o=4L8EHbqHie%3AYz^>_X1RFeaBycYx zlp%+mb0#5@(Z#<64NYOU6YWP8mG5Pm|KMD&l$zr3-7TXnCG_R^i$l#h8xO=mvJhm> zCyWq8V_)-_jDhSk#y2ExB9i9#byvAkN%g|C1}!lk5zo9yA(12(=Mj`Qce{d8k^~8y>^;V1)*w+P(a`lqghMby?iV@vsASjkWk2w z2hKScQSf9@HM+-U$7fDi39s}arD-VN;g+o-87AEeo-x+i>Q1i4EHUSp%go2DF#qwA zg#5WWCtXLM8Rhv*3aKYPA_S!7^uCtjg;`D3YMh)Ewa=9OQF zX=~g+@*h;ccS`=?XmZZx0C9FL_O6wKrTETGxP7Rh@^`CVaBcum)jPZQpNqrK?~82= zYa`P05fjXtC(hbY)gaN0AqnW$Bj8ewyDX!xKqdNSCs`|J0!m;1`%nFKr`)mnNKaX{8raZ1bpF1s3z zO2*rJVR$H4TxmXrl|{zkEcz)TS=w6X=(lk=5G$Nw)^S=l(`s1KzIW`*9G%zF=pPKt zrnyQ#9M2qQUu2!Y>)z)E#H*`g;2=~_7d*=%#>ot@HPLpU)aDK=Rip?~~elA9uCFEK>E`=otpx*-sPmP|dB3!zxa+)ZQ-e<^WX-xTJ zVDxVm@1E_1xv9Vgh)zXOIAJxqf|1T+%E^S21Nz7jjFH>`Qahm%2 zEHGUZ5G`pGVwc^L%O*jxl>vguBzsR`*w^8`H6Fp3%uD&or@7O7g`hMiLu8c261ERi4#n){Q7i}jO6&E>uUad z#2m|}xK2_rl-)ST^jmo4#D3K1WK?)&gi1T?jJYx=p&V0-QO9bzT zvJ{Q@7Nt>rJ=|31rYBgWJvLKWU(?fpuW}lk1GpG@#ga3LmCS6eL|La32usb6;~OAB zmJ6|-4BP7>>Tw8urdL*uNi(Biu^s(5$G#R(d3dV8=2-X4SoZ+@b#|G`e2g|r>Vi>F z^ZhW%s&JIiL7lF~im;6aW)SSn{!8_8r; zaB*g;n9E=BI#u0?eq%s=1mZ@zcOV-Z@**l$xy0!b(4Z3|v-CL!VDdQWP|;vkrRf&! zxK$g6FbuzwZLT~YBmU4iMCdZ5`v;kdi;r$KL#2D}Cx=WC8{Jl3l)?=5+&-keta8Pv zC@^ztpdiEh#GVTkZRm^{J%F*Luc&`C-fQ*vd6~EWP~)!=85t&DG2X?fmV^?I3aNB?jDF0X3D63+D!7xhlbD5)AUjtU2a|KQ9Qgf;lK1*& zZ7(&D`x&JxWlZJv3^Y?(GLaXn?Lv}>)RhG?IGmgc)j*t8OTj9+O{D2{rjERZR##R| zG*z8{5=!YlQ^TcbLGa@?jg6o{l+FKm837Ln)c%D}K^fgu?X8`d4fbU2X(bsp9c0J4 zb*C&Pxd%y-*DpF3X~`&2uPw(4d#W;`k>CuatI&~BZirOdDJEF@<}VzorOoV2vK{60 z%zhsxCD(+gz!``?z%HFX=|!NU7)eGbR1L~=dgbeV5Oj;GbD?pv!d0iDgPDok>1DqU zl%)~-{ATBs=;>W7b^`H}xGr~G#;9P#y%&a7P(X4l$j}(&5X4>Fq7dp zDBd_|^>oRP<{~l{LNeriOU^~sG5{X1+$$qOHj|8}JP3Zek*#22rxZtQ&&w1;=y8kA z0w7A0ReM4Quz1>jZhga!KN2lgLqU3lrjJ3H^mhD@!1??pY}9VJYKp8&(3q%_+0n&ob0UNjazqAmY;qz>+o+Y;jDS#z0vI|&y|CMV)>r8 zP4Nra_|i>mHp7z;^};02Hbd{-`CX?J)PvbGPi2-oEZCtc@%EF->^y~+F50v6j%<1; zC2xM)_|@%=@9p@LU&U{cwz0|WR~0g9_@2GjP`Cfn>$VO*7odrv)zcPM=P5ZbUe29e zKHE1`a^1NnJS+M=VkaEhQzECPS-C#0Szqv3&2UD!R(xre^7jw(@*H`* zH(cfYG3Q0nY7CyWDU3`a%p$;LIt&aQ zIf!$sKztpb?_uD8BZx)HK~CT^sz3)d!7$o^O#$8zn?WaLfozujP}Sc9v_piEfx!&f z=Ef|bC_EPQ;z@7>iW@*dj>iq4Q@bAAQ@NN6Tt63T%gEq`I&wDw zBZ@_Wfx#5XiAx%rUsx!6o@cso>b_2gVu<B` zOt%pkSjZ=Hfev(pfh~=7oQxEtFf2!Kkr7&;6Tx6$OXGQdDuosn#}OG^$jk6S2X?{0 zmd3LJlmr*{_4Z_h7;1(T)TL60VRs*qfrh+X95q7<=}{7BnCrsH2r$$PIZvNT0fy-| zA_EJ#`vO`-4g*^nXB$uwSQz~j981da6<(lD6AWx=v<{+DSYbE~XHc=Sfvgt;!b?01 K4CcX%Kpp@FB{OCK literal 0 HcmV?d00001 diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index a20b179..640829c 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -11067,7 +11067,7 @@ PropDefinitions: - Origin: caDSR Original Source: CRDC Code: "15112968" - Value:Laboratory Procedure Proteomic Profiling Analytical Fraction Type + Value: Laboratory Procedure Proteomic Profiling Analytical Fraction Type Version: '1.00' experimental_strategy: Desc: The type of systematic investigation using controlled observations and measurements to test hypotheses or develop a plan of action based on the facts discovered. @@ -11105,13 +11105,13 @@ PropDefinitions: Code: "15089939" Value: Research Activity Proteomics Study Design Description Text Version: '1.00' - # data_version + # version data_version_id: Desc: A static data version ID that is used primarily to assist in data loading. This ID will be used as a reference to update the existing data_version node instead of creating a new one with each version change. Type: string Key: true Req: true - version: + data_version: Desc: The version of the data that has been loaded. This should be similar to semantic versioning format (major.minor.patch). Type: string Req: true diff --git a/model-desc/cds-model.yml b/model-desc/cds-model.yml index f76c330..f42e487 100644 --- a/model-desc/cds-model.yml +++ b/model-desc/cds-model.yml @@ -408,7 +408,7 @@ Nodes: - instrument_model - proteomic_design_description - data_version: + version: Tags: Category: data_file Assignment: core @@ -417,7 +417,7 @@ Nodes: Desc: "version of the data being uploaded for release" Props: - data_version_id - - version + - data_version - datetime - model_version - description diff --git a/model-desc/navigator-icon.png b/model-desc/navigator-icon.png new file mode 100644 index 0000000000000000000000000000000000000000..2612ffb42538419b3f7478a2aa92fa2a63e29742 GIT binary patch literal 7798 zcmV-+9*Nqx{Y+2_P8@O|e()SiIwxT|TbVlF z2}SvEe2E6cRnL%(%VmJ0I7mOcFjl8yX@{wvsQ1T|ju$7zi6z_YHs!OWH36YHMNbf0 zp5sbW%}KTy=~&*yfns_l;>qViw0LwOx-Kx}n{tjiUgA!Rvm^tr(`x{1qBB=caB_@4 z<}{TRYkfl@1Iev4=chmYY5v6*UtCjBQBhM^SXebOGE$qLpI`2}ZW)Gxyu7^pZ25zZ z;|yRJ%49M<_}r0Br`tP_-hA`T&b#lvdl14Lk;z_D;$8!96OYG~CL5&jmS@xfKl;&+ z3a`KZ`nu`Ur#IkWFGCO(BN+2=z$*}da!fJh7!G6T z#^-Llwqe+Y_uB^s20mW9c5NHhGnB28Cy*=dGmsliI&jAlBq`FO;^~=nh;!3TH|4Eb zwQ5OGQPG(=kY^z{^$5yr9QnDB$yDKe5yk<6Fjk;z9~Ugczot?t3d2rbUVF-M+Aw1a za^fC*y|t&O=lyryd1udUx7{`bK?5SAuCC~Zt?#DynkUNiJTo+zDQG{;BI$z(k zY11p$UVCj{HcQ6PcGuEZuL=lq6;8a&>#o6#j7Zrj{Mj@_9)`ieK|m1)RJPxE0t^F{ zgXQ((wFScmSl8Qg=FE8lf_l@nT=l&+=O+Z#L_sov5tWWX@@UVVJzttOZQ4~hfY;$b z)?p~-0i*$@!Nb`NrKP1FFa!z%lNDW~g*xV{C0JB00Y+B>Y-nf*`uh63E5#FWnOH|3 z*3pg=VLj%3VcxuXufdqeivlW8JxmfeO+?X~xFpV$_R{Rwv13_DNy$wa*S#JGY!-^Q zLaAp6nDX*+C@U)qaEk`R29Ale4rAbm%liBK;n1N&-aVJ=fmKj2gl!@H^*pBeWkW;5 zCNP7f7r|10r68=&a-zx7Nl|MO%{|}1f&U(Yvvhc5q$HD_;Y0*ZRaF%f7Z-cr&_G22 zkrbpTJ;oxD06Tj0D4><@aT>*YoP`slAV2>Iwyg<4TvcCR|1xKVFkq6~OcQxrG*OUP zzpx>o%l6A(zkdDfMT-{QiUaa5s2gU|tYvVBQ|jvKJh3JRJ`RM*07<{6djhMit<4jK zL|G9CD4M(Q{+Ydd_x{&~7hXuFyfz|Cz{&e@anpD}vRQE{@jkE^-L-4i#iMPR;& ziaU?Mp+JK?bLLE_uCBHY_(Xxq1t1+yBJkkBgT8*G$%Gu0!M?nM;_t_c7cc$;CkHcN zCeuA<&YFnJL;|CAk{AE@AI6Ol8)_bEd<0;m)hgWtwZ5J2?|5OEEO zHZlxMM!{ql2}vo=n9$Fxt2#S7J?Dyb(ZXdi(1eFT-&FDp!EGZUP032hX4o zhEE0g6wxZ(f5jD7w4yJNe1%&2NK4N&j**mf(=W+F74EiXl%#H&Y-H@vWFw+JqRC#5;H_M?Y}w_nzWQn!{FgUoB)*3|A8Cv^L=e*1YkdnqFc^5^wa8Oiw(o-b5>Amn+%toLZ z5WseP{&eHUjcHkwDngFygv6Z_5g!2Qf(tIlzvY%&md}_m;|>JpB5pVVR9RW+1LPNQ z9DtfEfHp4IsPO^zO5Ec6OcinYY$+y1stt(Kek{+5tAd!Nl#!DSE5$>5v6Fk>A z;wB1Y@nwB~Dde)b=zDBMFUlvljv}!)p~bApm1CpO+UP4^`AXq;zx&-YDyyn~I5aqT zIsrtM8#_m(73XC|HtO$=8o;#w-Zp(pJ!U! z0$6~vS$Dc1E#^Efy6m#c%5YJ7Q+j0Nd}JQzBpL!3Q6_7Ok8+(V8nGkVu)5m?O(4 zRA|h4Xd>JbwV#xPk^&U<%zIH;lYDetRaiK8@uEe$4j(?e8+Ut&n|PO3y3_#17PrQZ z@R2T)oRo@=3k+}`&Ys&*7T2anS=lR#^Y+xJ?%lh;fsJ|?T_r`-D0Y~Ve3mpG4jN9ou&w1VeA3bbLnGpd zK@4Lps49gs7gTuQMNtx;UD7!Ho}94cIVV3KauSpj7x&}%{5$&hR?}97L9O3GQ|16x#6L+Gyq4kw{zrU8AW6TSjWPJyzc)EZ<81j9a?#aT%EiRe z86h#>kNsI>Ddm0NG6L0N= zV}uj={Km${Z$oe_O=E0w%;sce_*MzZ*{|a)Dd4>!(nWFmIdPqQcgI2a^S(o|mR(ZN z2xtvdTsdw6%P(#c60x;MTt#DqV^xT%;h!L=I<&e8XLO_z+g^pbsDx$+t&3;@CqdASwt+*> zG)M%{SZkw1nWF|GUhHxD-hm<5xU0hhi7ZB)pNtiv%_wdc)t14E`IWJpXS&yEXl&@X z7=wh*S6zDPrK^#n7!11VEq2*KFD`07DI_b=X*eIbX9)u2tyT#n*{Gx(BMmyVk5un47`Fp)d)9vZ9faz~&d(!@r0YOAS;RJ11wQ5y8m_?nos(q3N zNdU~2ho5%-{P|zRgr$5Gi(Ek5Fk2&S@x2JnE)+WikPaG-sR~>_an_sL4j9{>q<`|B zj|yZ@NEJ0SG+YdJ%g#hj%JPyekAU@o_Ws#e(KKoRpG7k@()6t358yzU1}LXMlO-I63K=7|{>W!Z#7Vrs#~RS@T69+Sl^$Pd?MWO$iA>~WzWnmb3lWqRt`K#$ z#cPt8N6I^pPlkj8n}|ckSr*Z@)*jD7G?A%~rhaC>+!!55*PVvR)`^SPchj1fpal^mRjw_m#Nl zomD;!=Fcn%Cbft>CjOKrOZhmK^C5gl(h1fa6nBywTR_gK#)|S)g`q~7ybna%+j?Ph zQ@00{Z2VYa)rzSm3x*_?d9h2^Z7sO;K=1k)^Jc)Qv&zE7Si~Wp*u^V-fL#mWUfNE! zT0IV-tzKl=nWJ?@pQqG~q`jf{c6RvOV*}9&m~L61GDt?_$QQ*Ov;e0*k@NPP`btPb zymO2FOkt>ops1s3MzzpywQa+N-4(va7OB{KCQ%myl%)4|9vl;I;8=mN0tTw-tW=yG+eN_8sf+svr#oc6TMWtlD`|_B?aNP0|O`7j0Y;Y$eRV0hMNX< z3yQZffW|uKd+H_v*d$SMV7%B+%mxWs6sU`0BW5i+0F%sT-ds7 zG=yF#OQ#?GU|XBJZN-4@aFR90WKk|2glsHCvEvr(C#|WX$`#{AQc0g*G<|^QgJqLj zA;SSpM>6ySAVoEblx+L}hnJH{25>xp+FS1N=NR%RIELq>vv(`s} zqD<=~%}w4tR(1qMUM49g?K)szshcS|cbV$T^}W6PD6X-umzp~JBiB>HDt6H$J|JEj zod@FCWsd_Bvtb5;XP8|AiDrRbAIU~Y;zgjOD6fPlO|=;ku5Aq;V#lOq*EZfb2rr!C^Vn&k zz?h!1k=})Mk|{m6HEV{aQFR;)7i0u#bd4$=ymC|`pZAA`hT8Fxwuw7U1-J|9EnIcS z3;<1pyQ1<%>q0w4bB$}vPP@KQBtAbK85|tkKUUc2YX}~kd+ zmOVW^ja5}uBl7U0{EZ$xXtXLnG%_XvoUw#~h|zqb)s2D03>dWvH3Md+XnjaU1dCC+ z$&D_pqNLFOT?(&t>Vs{elSXh$eGk7<#h7MWM(@n(Hu$yf*s)_DRx~W!8NB7_Yi40BDA<4U78mc4XGkmZeI=la9D88b&AT$OXxbO=Pw%Vzc*-1Sch~6!OHCLVjmw=P%LC{&)Pt zfb`*%WN}S@+S}zhR_)}d&P2Tq+BRb%F&PD$86(O1|kH>#_v{~2G=d9rjiWW<$E4*4gDOvj8(vcn^+U=xBeq-3m>zA&!>N(=KKw5JoQ zif4F$+0<((iZTIiND^dTEqf)mxJFLVtseWM{+%7+WL4^6kj4<~q^)ePx)cD!nN)tO z_wC#F0aYY^7cQJh$l`)L2fnnl7CVxk6>$-pabwl^gD63huT7xEhBz^10mZn1m`zq$ zTrB#?@%BaR z#Cp#oBO@)p{`Ifr&w~<~^pLC4gtsIhXogD@+%v-|?$b{{UAb`K!h5Iy{!r@3kt2SG zCQ3=UC26{(ZJI1@;?IFd+_9)TaNxir^XJdM4{u2~uxMkkr!5@`oTIlYq>IQJa7Mg> zz_f6K_*aG}tCQp9xXI+$i4gw)2Lps$)b`R#FFgZxBSAV6G{d+O7}IVc2lnyhXG0$9 zrXSYT)!oXSrBCDOGmojF$?<|88=?;xq&_-$@Zhs(Fx(BJT%@^&?_I;yYqZ=xmoGJi zbk(DeKKcX#<9Tzv-z-4ZHvN9Xv7)40G}&AdMR^orpz#yS9wFv=w{I|dTE$IOhD10yX zkEEXR$YwZzC`8`7van~Kd8T#e&Yds#1!UI-Qz`aN6e4h>HAl32_wEX+7 zl6xfiV6j(0k|~ok%l$O__wRRc72SCL`R5mwmzSSSalAI*e+cr|K-6dYK9)bdBx-MO zf9{@p?pgiD8*k7tB586nw=i%f(;LLq-+9%eX<9RJy1=__+qR9M0kPwfOD;JN8(HfW znl(S!UG#Y-nvk?6lGYrGxh*K-{`-Lk9-u`(1EbeN0AT%~*((~9gB1)3rTjGMB)(6- z{PN448#iuzDEqJ3Jfc~}--~`;i5IQXSU?HV_t8fmt$ysW$M!&Q>;QseEx`iuKBRKw zc?L<2xSG5X0S@cw>7lb^-OHCRPghn}o{bI8lU{Op7UJ_ltbgUNW1@H;LeIjpt5>gn z>4g_wpikZ9h8{al0fIV;$+r9%J7@yojXwv>0D{Ql=iRz>>i~k%bmp07mSMveWY3QK zdrnimUOAS;|7=SFM0-W3hhD<1@t@y+|NYGn_H^5%k_6945+q4-3qt}15C+Z%^MemQ z=wG&MS?9cY^UARkbFnki*a3Sy7M7Duyu-=>u_(tr9XWL9&^oksANj!#ey|sU+~XyI zX#bpC;7anIO(1FO&M{oAj#>0kbs$jf=uDh}9icDU3fR9#oz(v{@v}rU*+~B|2W2PS zk;8`%Z(O@}?a#jd{qNIvu$qIIQ}i!KN;0iciM%n-(-9(*1_0E(G&&^bIS5pHZEfw| z#fukLplMo5-!`%66W@-)XNB19B}Lrm8H-GRXJ_Z@XgEE3=bd+c0%22I0%Y?t=(VU{ zE#KHcaw48h_u7N*y#D&@hfX`~v=(&2mLgCK5gc!YoBaoepBeGT8=GuqGa*2I=<<0R zC*)(d-FDl@5HzthDDpWDC_R?epPV*{Kht|Bs*+b;d8MOK ze?WuiM792S89^K*&U0kY71rF^+WI1HfIhWy+Aa?!*ok;e8DPmCxc&eLfE-0Q-F9uYKyN zr(V7H-h20g{oI^M57~5&q>wco_v7t0&N1DazE<<-z4zYh{qVyNch8}=j=_GKXd!-w{J$U=t~54^_Wimn8X{$>2Wg|3xP=< z^}i}&Gm8pMq7DoVaW-t&(1RV`i(+IudM8HkIs<{3!KY#wBzc`o*OHtN3<`-fo*?p5 zQ}jt5z{&Nyb?eqW@yH{Oyz}6L50XcF1cIVWdJ}AGAqkY<6tIt7U}oCH8(88sr%AVx z-g4)|EBY{tpXSzEZ>>Ayj5BJlzWVB~*VNQphyymqG5jtO2mXJs9C*!T;yCr;mVc^A z{{LFjw^mtj+R$?QKNM+CzxCEzjks?{zdy=AuoaiKTse)+3apCX$|u5C~ug%?G@` zzP|XYU;S$B>8GDwbMCq4u0SK>tcr??6)1+PZHG=KdZdfuM@B}vdV71fp$L9|%a$#l ztY5#ram|`FtzZ^kdfUOY{?Ty`m@T|0-4yI6*hzDb6nQc(rQYeI%32iWS?*bUrWP(- zScnVZk`*gf%slVB^A;{yvSc|fiqF9{*WaMXDj)ADR(9i{*M1v1L$_|)aPrBAq`fB1TPG2DE zO`!#tj~rDnckbM27>X7xT2zjp)#LpFG&<%XX!H*cYmnP!pq?qtn)TjqPGC5ST+(y& z=+U;mzCJoM(}+Oq+q`*mBZAY7_k*~zJcwHhgJ`{JYfLXhP1ai!NKrb7IZJ9*v=QMvtBsG!)>aS||-%*}wA6XYysAY3qmB!QCU=(b3p^o({b!NeW%ecEsjU>0K< zEZ5NH#6aZ=l5PlCD&|gWBLlMca)z0#Moy>2nT`XIR<}c2QZ`PK!0`LDinDPISe`-M z=fpXhauIj7JbLDuX1PgBN%1B{qD-GMpa}r|&XiU@>o&=2MzzDVpacl(EE{MHSSF?n*#;Bk%vBQs z$rNW2fhIkq2is(3>-SP;MYTsypeV52{I z91snfY|;a1OQX~40Z&Eb0YiF8CXj60W8*%@kOmC-!I0mUXIykVIEhH>7M{H+OI|t9 zCUD}w;(IqDoz^n|!G*9*w>gHgCY6pgNU{#s5+}u7M%>$s4--j8s$)oN6H{9J*}Nns zs} Date: Tue, 15 Oct 2024 14:12:30 -0400 Subject: [PATCH 06/23] update primary_diagnosis enum values --- model-desc/cds-file-examples.zip | Bin 90143 -> 88999 bytes model-desc/cds-model-props.yml | 1543 ++++++++++++++---------------- 2 files changed, 743 insertions(+), 800 deletions(-) diff --git a/model-desc/cds-file-examples.zip b/model-desc/cds-file-examples.zip index 0008d6f510ec0716215097530ed5d616af0cb00c..1d7f482bc64beea879cdefcbdb26ad7d67f615cb 100644 GIT binary patch delta 2445 zcmb7^-AhzK7{=#~Y+bWj1&wvr<8HgI?&ncbDMP{1s34M7TR(S`TBTC@u#2c91~2>C z?SOMp5P~3eQ_zXM3G%M!D*u7%Di9*1tHg_%IqTFpo@uHF4xEdb=b868XMT^DN)`(x zxtdTV@}V>&YXekju9r7JU;<6VbNBnQ+) z#=P2Mef?IaB!n9?Me8R(k6F)HURY&XYF)!YgJt2Ou7dl#6QLB z=#6IoKB+gYi1Z9XJ=?O;3UR-6J5X5UuANWs;pPw0&ZqvCznNQrFS{!&y*#WEc0z^|z)LC2 zCZH7*c`Ia9g@EPUHFGZ!Y7~{ClH5tCGZxd|u&})uj`@|n@>Cz}Up4n6PLTppdoiS0W37o}otwleN%TlcrHOBp#hVmf8D3^}4 hgdo@o)nYVbDwmGkz0zn4Vb?O?Et@MtXq|3C=qJhVp)mje delta 3588 zcmb`IO-NKx7>3VBOf%+`Q;Wc#obfMpw3&%fyHJXz7Ebv$KRV-J(||H$I%WRjYC<)H+&3-IH_h99x}3FI>2Hb9nCieVk`$#q?yu zG+)qMiyWx6Ef8yqr{b}T1!~~h{ZZvTDt>bw<{)boN(HL%|g;S z2AK##CF|vkBWl)yiYz1XRjo%AXFLQI0#4nJRfNvV z;kd~}A5^e@o;s&aYJOFqWFJ(DK=1O+s8tpy*$*WQsCh7FS?f{-y4nwAJkWx>O%8^% zSfDJ+vNB?UpC+wa6$T%Iavp|wHz%dXMZSjNI0Kr=gY81~an0528JBkrknFg~Rs>2J z(1Tj22la7X9uUVx>K?vC=&anx+$0(WyZQdkO}Mh{0$+*NsXDaY9w_C9Hcfu@KtUIE z2FpeZeUrFf|1k(jN1%u#dchW^B4OFUBgX6h(nW6`m%Mv7QaAcssn$f9G%pdzwp zMT)%IXCPB8vgo+vk|Z)GNe-Esl10bZ0=w6T#MTkfn+9^n@7!k}*G&kSjcTbwS#*3m z2V^#yH!25Ct;(X~4|$5`fU(Nd&@4J$@JJDhzUG*zvsrX}+ONng7#v5T=)fl{LZ<>? Goc#wTu0KZr diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index 640829c..fc273fb 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -2913,851 +2913,794 @@ PropDefinitions: primary_diagnosis: Desc: Primary disease diagnosed for this diagnosis and subject Enum: - - Reactive Connective Tissue - - Acute Lymphoblastic Leukemia - - Medulloblastoma, Classic Histologic Type (CNS WHO Grade 4) - - Undifferentiated Small Round Cell Sarcoma - - Embryonal Rhabdomyosarcoma - - Undifferentiated Sarcoma - - Dermoid Cyst - - Glioma, Malignant, Low-Grade Glioma, Pilocytic Astrocytoma - - Nephroblastoma (Wilms Tumor) - - Metaplastic Carcinoma, NOS - - Hemangioblastoma, CNS WHO Grade 1 - - Rhabdoid Tumor, NOS - - Low Grade Neoplasm. Features Suggestive Of Pilocytic Astrocytoma. - - Lobular Adenocarcinoma - - Low Cumulative Sun Damage Melanoma - - Malignant Neoplasm Of Prostate - - Osteoblastoma - - Choroid Plexus Carcinoma WHO Grade 3 - - Diffuse Midline Glioma, H3K27M-Mutant, CNS WHO Grade 4 - - Lipoblastomatosis - - Melanotic Neuroectodermal Tumor - - Ependymoma, NOS, Atypical Meningioma - - Mycosis Fungoides, Langerhans Cell Histiocytosis, NOS - - Embryonal Tumor With Multi-Layered Rosettes - - Synovial Sarcoma, Spindle Cell - - Liposarcoma, NOS - - Chordoma, NOS, Chordoma (Including Poorly Differentiated Chordoma), Other - - Neoplasm, Uncertain Whether Benign Or Malignant, Meningioma, Other - - Neoplasm, Uncertain Whether Benign Or Malignant, Ependymoma, Posterior Fossa Ependymoma, Group PFA - - Schwannian Stroma Poor Peripheral Neuroblastic Tumor, Consistent With Neuroblastoma - - Adult Granulosa Cell Tumor Of Testis - - B-Lymphoblastic Leukemia/Lymphoma, NOS - - Astrocytoma, IDH-Mutant, CNS WHO Grade 4 - - Synovial Sarcoma, NOS - - Acute Myeloid Leukemia, Inv(16)(P13;Q22) - - Perineuroma - - Yolk Sac Tumor - - Paraganglioma, NOS - - Langerhans Cell Histiocytosis - - Neoplasm, Uncertain Whether Benign Or Malignant, Diffuse Midline Glioma, H3 K27-Altered, High-Grade Glioma - - Intraductal Papillary Carcinoma - - Acute Erythroid Leukemia - - Ganglioneuroblastoma - - Meningioma, Atypical, CNS WHO Grade 2 - - Ganglioneuroma, Maturing Type, Favorable Histology - - Adenocarcinoma, NOS - - Glioma, Malignant, Embryonal Tumor With Multilayered Rosettes, C19MC Altered, Other CNS Embryonal Tumors - - Medulloblastoma, SHH-Activated And TP53-Mutant - - Neoplasm, Uncertain Whether Benign Or Malignant - - Oligodendroglioma, Anaplastic, NOS - - Astrocytoma, IDH-Mutant, WHO Grade 2 - - Plexiform Fibrohistiocytic Tumor - - Oligoastrocytoma, NOS, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC - - Fibroma - - Hemangioblastoma, Other - - Diffuse Midline Glioma, H3 K27-Altered - - Multiple Myeloma - - HHV8 Positive Diffuse Large B-Cell Lymphoma - - Neoplasm, Uncertain Whether Benign Or Malignant, Adamantinomatous Craniopharyngioma, Craniopharyngioma - - Solitary Fibrous Tumor, NOS, Other - - Neoplasm, Malignant, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH - - Precursor Cell Lymphoblastic Leukemia, NOS - - Neoplasm, Uncertain Whether Benign Or Malignant, ATRT, NOS Or NEC, Atypical Teratoid/Rhabdoid Tumor - - Chronic Myelogenous Leukemia, BCR-ABL Positive - - Ganglioglioma, NOS, Glioneuronal And Neuronal Tumors - - Anaplastic Large Cell Lymphoma, T-Cell And Null-Cell Type - - Mixed Phenotype Acute Leukemia, B/Myeloid, NOS - - Ependymoma (CNS WHO Grade 3) - - Pheochromocytoma, NOS - - Astroblastoma - - Ossifying Fibroma - Papillary Intralymphatic Angioendothelioma - - Telangiectatic Osteosarcoma - - Choroid Plexus Papilloma, NOS - - Spinal Ependymoma, Histologically Low Grade (CNS WHO Grade 2) - - Embryonal Rhabdomyosarcoma With Anaplastic Features - - Lentiginous Melanocytic Nevus - - Precursor T-Cell Lymphoblastic Leukemia, Acute Myeloid Leukemia, NOS - - Residual Astrocytoma - - Ependymoma, NOS, Posterior Fossa Ependymoma, NOS Or NEC - - Dysembryoplastic Neuroepithelial Tumor, Low-Grade Glioma, Polymorphous Low-Grade Neuroepithelial Tumor Of The Young - - Medulloblastoma, NOS, Medulloblastoma, Group 3 - - Pilocytic Astrocytoma - - Neoplasm, Metastatic - - Adenocarcinoma, Pancreatobiliary Type, Pancreatobiliary-Type Carcinoma - - Angiomyofibroblastoma - - Supratentorial Ependymoma, NOS - - Pleomorphic Xanthoastrocytoma, NOS, High-Grade Glioma - - Primary Cutaneous Follicle Center Lymphoma - - Chondroblastic Osteosarcoma - - Myxopapillary Ependymoma - - Neoplasm, Uncertain Whether Benign Or Malignant, Low-Grade Glioma, Subependymal Giant Cell Astrocytoma - - Oxyphilic Adenocarcinoma - - Pleuropulmonary Blastoma - - Myoepithelial Carcinoma - - Acute Myeloid Leukemia With T(9;11)(P22;Q23); MLLT3-MLL - - Melanotic Schwannoma, Other - - Dysplasia - - Central Neurocytoma, Low-Grade Glioma, Subependymal Giant Cell Astrocytoma - - Invasive Carcinoma - - Ependymoma, Anaplastic, Supratentorial Ependymoma, NOS Or NEC - - Pilocytic Astrocytoma, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - - Astroblastoma, Other, Other CNS Tumor, NOS Or NEC - - Neurocytoma - - Ependymoma WHO Grade 2 - - Desmoplastic Melanoma, NOS - - "Neoplasm, Malignant, CNS Neuroblastoma, FOXR2-Activated, Other CNS Embryonal Tumors" - - Bland Myofibroblastic Proliferation With Associated Florid Lymphoplasmacytic Inflammation - - Carcinoid Tumor Of Uncertain Malignant Potential - - Choroid Plexus Carcinoma, Choroid Plexus Tumors - - Mixed Phenotype Acute Leukemia, T/Myeloid, NOS - - Paraganglioma, Malignant - - Glial Neoplasm - - Neoplasm, Uncertain Whether Benign Or Malignant, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - - Soft Tissue Sarcoma - - Transitional Cell Carcinoma, NOS - - Ganglioglioma - - Glioma, Malignant, Malignant Peripheral Nerve Sheath Tumor, NOS - - Neoplasm, Uncertain Whether Benign Or Malignant, Choroid Plexus Tumors, Choroid Plexus Papilloma - - Acute Myeloid Leukemia With Abnormal Marrow Eosinophils - - Glial Tumor - - Glioma, Malignant, Ganglioglioma, Glioneuronal And Neuronal Tumors - - Pilocytic Astrocytoma, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC - - Dermatofibrosarcoma Protuberans, NOS - - Pancreas-Adenocarcinoma Ductal Type - - Sarcoma - - Gliosarcoma - - Giant Cell Tumor Of Bone, NOS - - Pilocytic Astrocytoma, Low-Grade Glioma - - Embryonal Carcinoma, NOS, Embryonal Tumor With Multilayered Rosettes, C19MC Altered, Other CNS Embryonal Tumors - - "Astroblastoma, Astroblastoma, MN1-Altered, High-Grade Glioma" - - Adenoma, NOS - - Combined Small Cell-Adenocarcinoma - - Combined Small Cell-Large Carcinoma - - Soft Tissue Tumor, Benign - - Colorectal Carcinoma - - Mixed Adenocarcinoma And Squamous Cell Carcinoma, Pancreatobiliary-Type Carcinoma - - Desmoplastic Nodular Medulloblastoma - - Small Cell Sarcoma - - Hemangioendothelioma, Malignant - - Diffuse Glioma, Favor High Grade - - Squamous Cell Carcinoma, Metastatic, NOS - - Invasive Lobular Carcinoma - - Pinealoblastoma - - Endometrioid Carcinoma, NOS - - Medulloblastoma, NOS, Medulloblastoma, Non-WNT/Non-SHH - - Malignant Melanocytic Neoplasm - - Hypercellular Neuroepithelial Tumor With Some Features Of Glioma, Possibly High Grade - - Glioblastoma, IDH Wildtype - - Craniopharyngioma, Adamantinomatous - - Epithelial Tumor, Benign - - Hodgkin Lymphoma, NOS - - Medulloblastoma, Classic Variant, WHO Grade 4 - - Myofibroblastic Tumor, NOS - - Glioma, Malignant, Angiocentric Glioma, Low-Grade Glioma - - Hodgkin Lymphoma, Nodular Sclerosis, NOS - - Meningioma - - Glioma, Malignant, High-Grade Glioma, High-Grade Glioma, NOS Or NEC - - Choroid Plexus Papilloma, NOS, Choroid Plexus Tumors - - High-Grade Serous Carcinoma - - Adenocarcinoma, Metastatic NOS - - Melanoma, NOS - - Myofibroblastic Tumor - - Unknown, To Be Completed Later, Diffuse Midline Glioma, H3 K27-Altered, High-Grade Glioma - - Papillary Thyroid Carcinoma - - Choriocarcinoma Combined With Other Germ Cell Elements - - Acute Myeloid Leukemia With Myelodysplasia-Related Changes - - Pheochromocytoma - - Germ Cell Tumor, Nonseminomatous, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor - - Astrocytoma, NOS, Low-Grade Glioma, Pilocytic Astrocytoma - - Glomus Tumor, Malignant + - Atypical Smooth Muscle Neoplasm + - Medulloblastoma, WHO Grade 4 + - Acute Monoblastic And Monocytic Leukemia + - Adenocarcinoma In Situ, Non-Mucinous + - Ganglioneuroma, Maturing Type, Favorable Histology + - T-Lymphoblastic Leukemia + - Myxoid Liposarcoma + - Clear Cell Meningioma, Meningioma, Other + - Meningeal Melanomatosis + - Hepatoblastoma, NOS + - Teratocarcinoma + - Smooth Muscle Tumor Of Uncertain Malignant Potential + - Solid Pseudopapillary Neoplasm Of Pancreas + - Mast Cell Leukemia + - Medulloblastoma, NOS, Medulloblastoma, NOS Or NEC + - Glioblastoma Multiforme + - Giant Cell Glioblastoma - Juvenile Myelomonocytic Leukemia, NOS - - Mitotically Active Glial/ Glioneuronal Neoplasm - - Pancreatic Neuroendocrine Tumor, Nonfunctioning - - High Grade Glioma With Necrosis, WHO Grade 4 - - Oligodendroglioma, NOS, Other, Other CNS Tumor, NOS Or NEC - - Atypical Choroid Plexus Papilloma, Choroid Plexus Tumors - - Desmoplastic Nodular Medulloblastoma, Medulloblastoma, Medulloblastoma, Group 4 - - Supratentorial Ependymoma - - Mixed-Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified - - Therapy Related Myeloid Neoplasm - - Low Grade Fibromyxoid Sarcoma - - Favor Anaplastic Ependymoma - - Central Neuroblastoma - - Astrocytoma, NOS, High-Grade Glioma, Infant-Type Hemispheric Glioma + - Spindle Cell Sarcoma + - Chondroid Chordoma + - Chondrosarcoma, NOS - Hepatoblastoma - - Not Applicable - - Solitary Fibrous Tumor, NOS + - Sex Cord-Gonadal Stromal Tumor, Incompletely Differentiated + - Glioma, Malignant, Astrocytoma, IDH-Mutant, High-Grade Glioma + - High Grade Glioma With Necrosis, WHO Grade 4 + - Lung Adenocarcinoma, NOS + - Malignant Tumor + - Ependymoma, NOS, Supratentorial Ependymoma, ZFTA Fusion-Positive - Atypical Choroid Plexus Papilloma - - High Grade Neuroepithelial Tumor + - Small Round Blue Cell Tumor - Acute Monocytic Leukemia - - Mesenchymal Chondrosarcoma - - Embryonal Sarcoma - - Neoplasm, Uncertain Whether Benign Or Malignant, Ependymoma, Supratentorial Ependymoma, NOS Or NEC - - Inflammatory Myofibroblastic Tumor With An Associated Odontogenic Keratocyst - - Renal Cell Adenocarcinoma - - Oligodendroglioma, NOS, Low-Grade Glioma, Oligodendroglioma, IDH-Mutant, And 1p/19q-Codeleted - - Myofibroma - - Primary Cutaneous CD30 Positive T-Cell Lymphoproliferative Disorder - - Meningioma, NOS - - Embryonal Rhabdomyosarcoma, NOS, CNS Embryonal Tumor, NOS - Lactotroph Adenoma - - Malignant Melanoma, NOS, Meningeal Melanocytic Neoplasms (Includes Melanoma), Other - - Pancreatoblastoma - - Synovial Sarcoma - - Glioma, Malignant, Dysembryoplastic Neuroepithelial Tumor, Glioneuronal And Neuronal Tumors - - Residual Low Grade Neuroendocrine Tumor (Typical Carcinoid) - - Lobular Carcinoma, NOS - - Unknown, To Be Completed Later, Glioneuronal And Neuronal Tumors, Papillary Glioneuronal Tumor + - Medulloblastoma By Morphology, NON-WNT By Immunohistochemistry + - Astrocytoma, NOS, Low-Grade Glioma, Pilocytic Astrocytoma + - Hypercellular Neuroepithelial Tumor With Some Features Of Glioma, Possibly High Grade + - Sertoli-Leydig Cell Tumor, Poorly Differentiated, With Heterologous Elements + - Astrocytoma, NOS, Angiocentric Glioma, Low-Grade Glioma + - Inflammatory Myofibroblastic Tumor With An Associated Odontogenic Keratocyst + - Inflammatory Carcinoma + - Diffuse Large B-Cell Lymphoma, NOS + - Acute Myeloid Leukemia With Abnormal Marrow Eosinophils + - Signet Ring Cell Carcinoma + - Myxopapillary Ependymoma, Anaplastic + - Acute Myeloid Leukemia Without Maturation + - Lymphoepithelial Carcinoma + - Malignant Rhabdoid Tumor - Germinoma - - Langerhans Cell Histiocytosis, Disseminated - - Epithelial-Myoepithelial Carcinoma - - Ependymoma (WHO Grade 2) - - "Medulloblastoma, NOS, Medulloblastoma, SHH-Activated And TP53-Mutant" - - Neurofibroma, NOS, Other, Solitary Fibrous Tumor - - Adenoma - - Clear Cell Sarcoma, NOS - - Medulloblastoma, NOS, Medulloblastoma, NOS Or NEC - - Epithelioid Hemangioendothelioma, NOS - - Follicular Adenocarcinoma, Well Differentiated, Neuroblastoma, NOS - - Ependymoma, NOS, Choroid Plexus Tumors, Choroid Plexus Papilloma - - Hemangioblastoma - - Rhabdomyosarcoma, Most Likely An Embryonal Carcinoma - - Clear Cell Sarcoma Of Kidney - - Glioneuronal Tumor With Focal Increased Atypia - - Metastatic Neuroblastoma - - Classic Medulloblastoma, CNS WHO Grade 4 - - Adrenal Cortical Tumor, NOS - - Alveolar Rhabdomyosarcoma - - Schwannoma, NOS, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - - Bronchiolo-Alveolar Carcinoma, Non-Mucinous - - Glioma, Malignant, Astrocytoma, IDH-Mutant, High-Grade Glioma - - Glioma, Malignant, High-Grade Glioma, Pleomorphic Xanthoastrocytoma - - Infiltrating Lobular Carcinoma, NOS - - Leiomyoma, NOS - - Malignant Peripheral Nerve Sheath Tumor - - Adenocarcinoma Combined With Other Types Of Carcinoma + - Precursor T-Cell Lymphoblastic Leukemia + - Telangiectatic Osteosarcoma + - Desmoplastic Nodular Medulloblastoma - Papillary Glioneuronal Tumor - - Spindle Cell Melanoma, NOS - - Oligodendroglioma + - Diffuse Glioma, Favor High Grade - Papillary Glioneuronal Tumor, WHO Grade 1 - - Spindle Cell Rhabdomyosaroma - - Neuroendocrine Tumor, NOS - - Papillary Lesion With Atypical/High Grade Features - - Glioma, Malignant, Low-Grade Glioma, Polymorphous Low-Grade Neuroepithelial Tumor Of The Young - - Ependymoma, NOS, Posterior Fossa Ependymoma, Group PFB - - Glioma, Histologically Low Grade - - Atypical Lymphoid Infiltrate - - Mixed Germ Cell Tumor, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor - - Neuroendocrine Carcinoma, NOS - - Synovial Sarcoma, Biphasic - - Neuroblastoma - - Small Blue Cell Tumor. Favor Medulloblastoma - - Not Specified In Data - - Large Cell Medulloblastoma, Embryonal Tumor With Multilayered Rosettes, NOS, Other CNS Embryonal Tumors - - Choroid Plexus Carcinoma - - Adrenal Cortical Carcinoma - - T-Cell/Histiocyte Rich Large B-Cell Lymphoma - - Acute Myeloid Leukemia, Minimal Differentiation - - Gliomatosis Cerebri - - Medulloblastoma, Classic Morphology, CNS WHO Grade 4, NON-WNT/NON-SHH, Group 4 Subtype By Methylation - - Ewing Sarcoma - - Adenocarcinoma, Pancreatobiliary Type - - Diffuse Large B-Cell Lymphoma, NOS - - Chronic Myelogenous Leukemia, BCR/ABL Positive - - Adenocarcinoma In Situ, NOS - - Epithelioid Sarcoma, NOS - - Papillary Microcarcinoma - - Medulloblastoma - - Hepatocellular Carcinoma, NOS - - Renal Cell Carcinoma - - Germinoma, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor - - Acute Myeloid Leukemia With Mutated CEBPA - - Invasive Ductal Carcinoma - - Myxoid Liposarcoma - - Papillary Carcinoma - - Glioblastoma, NOS, Medulloblastoma, NOS - - Rhabdomyosarcoma, Favor Alveolar Type - - Neoplasm, Uncertain Whether Benign Or Malignant, ATRT-SHH, Atypical Teratoid/Rhabdoid Tumor - - Pleomorphic Sarcoma - - Poorly-Differentiated Neuroblastoma - - Ganglioneuroma, High-Grade Glioma, High-Grade Glioma, NOS Or NEC - - Medullary Carcinoma, NOS - - Atypical Teratoid-Rhabdoid Tumor, WHO Grade 4 - - Low Grade Glial/ Glioneuronal Tumor - - Medulloblastoma, Nodular/Desmoplastic With Anaplastic/Large Cell Features, Non-WNT/Non-SHH; WHO Grade 4 - - High Grade Follicular Derived Thyroid Carcinoma - - Ossifying Fibromyxoid Tumor, NOS - - Astrocytoma, NOS - - CNS Primative Neuroectodermal Tumor (PNET) + - Ganglioneuroma, Other, Schwannoma + - Medulloblastoma, NOS, Medulloblastoma, Group 4 + - Unclassified Sarcoma With Round Cell Morphology + - Papillary Serous Adenocarcinoma + - Malignant Melanocytic Neoplasm + - B Lymphoblastic Leukemia/Lymphoma With T(1;19)(Q23;P13.3); E2A-PBX1 (TCF3-PBX1) + - Oxyphilic Adenocarcinoma + - Favor Pilocytic Astrocytoma, CNS WHO Grade 1 + - High-Grade Neuroepithelial Tumor + - Precursor Cell Lymphoblastic Leukemia, NOS + - Therapy Related Myeloid Neoplasm + - Schwannoma, NOS + - Glioma, Malignant, Diffuse Midline Glioma, H3 K27-Altered, High-Grade Glioma + - Glioma, Malignant, Low-Grade Glioma, Pilocytic Astrocytoma + - Myofibromatosis - B Lymphoblastic Leukemia/Lymphoma With Hyperdiploidy - - Medulloblastoma By Morphology, NON-WNT By Immunohistochemistry - - Acute Monoblastic And Monocytic Leukemia - - Hemangioma, NOS - - Meningioma, NOS, Other - - Neoplasm, Malignant, Astrocytoma, IDH-Mutant, Low-Grade Glioma - - Mucoepidermoid Carcinoma - - Atypical Meningioma - - Yolk Sac Tumor, NOS - - Aggressive Fibromatosis - - Malignant Tumor, Spindle Cell Type, CNS Sarcoma, CNS Sarcoma, NOS Or NEC - - Langerhans Cell Histiocytosis, NOS - - Acute Myelomonocytic Leukemia - - Pleomorphic Xanthoastrocytoma, NOS - - Pleomorphic Xanthoastrocytoma, NOS, Low-Grade Glioma - - Plasmacytoma, Extramedullary - - Primary Mediastinal (Thymic) Large B-Cell Lymphoma - - Neoplasm, Malignant, ATRT-SHH, Atypical Teratoid/Rhabdoid Tumor - - Teratoma, NOS - - Astrocytoma, NOS, High-Grade Glioma, High-Grade Glioma, NOS Or NEC - - Astrocytoma, NOS, Angiocentric Glioma, Low-Grade Glioma - - Sertoli-Leydig Cell Tumor, Poorly Differentiated, With Heterologous Elements - - Diffuse Midline Glioma, H3 K27M-Mutant - - Dedifferentiated Liposarcoma - - Benign Cystic Nephroma - - Medulloblastoma; Hypercellular Lesion With Marked Atypia - - Pilocytic Astrocytoma, WHO Grade 1 - - Teratoma, Malignant, NOS - - Carcinoid Tumor - - Craniopharyngioma - - Mesothelioma, Biphasic, Malignant, B Lymphoblastic Leukemia/Lymphoma, NOS - - Neoplasm, Uncertain Whether Benign Or Malignant, Low-Grade Glioma, Oligodendroglioma, IDH-Mutant, And 1p/19q-Codeleted - - 'B Lymphoblastic Leukemia/Lymphoma With Hypodiploidy' - - Glioblastoma - - Leydig Cell Tumor, NOS - - Mixed Type Rhabdomyosarcoma - - Glioma, Malignant, Other, Other CNS Tumor, NOS Or NEC - - Spinal Ependymoma, WHO Grade 2 - - Spindle Cell Carcinoma, NOS - - Neoplasm, Malignant, Low-Grade Glioma, Pilocytic Astrocytoma - - Mast Cell Leukaemia - - Neurofibroma - - Mucinous Adenocarcinoma, Endocervical Type - - Subependymoma, Ependymoma, Supratentorial Ependymoma, NOS Or NEC - - High Grade Malignant Epithelioid Neoplasm - - Dysembryoplastic Neuroepithelial Tumor, Glioneuronal And Neuronal Tumors - - Neoplasm, Malignant, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor - - Differentiating Neuroblastoma - - Serous Cystadenocarcinoma NOS - - Medullary Carcinoma - - Blue Nevus, Malignant - - Giant Cell Glioblastoma - - Oligodendroglioma, NOS - - Retinoblastoma, NOS - - Intraductal Papillary Mucinous Neoplasm With An Associated Invasive Carcinoma - - Vascular Lesion, Consistent With Hemangioma - - Malignant Tumor, Small Cell Type + - Fibroma + - Desmoplastic Melanoma, NOS + - Epithelial Tumor, Benign - Meningioma, Malignant - - Carcinoma, Diffuse Type - - Myxopapillary Ependymoma, Anaplastic - - Desmoplastic Infantile Astrocytoma - - Giant Cell Glioblastoma, Glioblastoma, IDH-Wildtype, High-Grade Glioma - - Myeloid Leukemia With Myelodysplasia-Related Changes - - Ganglioglioma, NOS - - B Lymphoblastic Leukemia/Lymphoma, NOS - - Atypical Teratoid Rhabdoid Tumor, CNS WHO Grade 4 - - T Lymphoblastic Leukemia/Lymphoma - - Chronic Eosinophilic Leukemia - - Glial Neoplasm, Favor Pilocytic Astrocytoma - - Mixed Germ Cell Tumor, Acute Megakaryoblastic Leukemia - - Atypical Teratoid/Rhabdoid Tumor - - Favor Ganglioglioma - - Tubular Adenocarcinoma - - Precursor T-Cell Lymphoblastic Leukemia - - Astrocytoma, Anaplastic - - Osteosarcoma, NOS - - Pilocytic Astrocytoma, Diffuse Leptomeningeal Glioneuronal Tumor, Glioneuronal And Neuronal Tumors - - Diffuse Glioma + - Glioblastoma, NOS + - Endometrioid Carcinoma, NOS + - Neoplasm, Malignant + - Embryonal Tumor With Multilayered Rosettes C19MC-Altered + - Subependymal Giant Cell Astrocytoma, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC + - Neoplasm, NOS + - Hodgkin Lymphoma, Nodular Sclerosis, NOS + - Papillary Microcarcinoma + - Tumor Cells, Malignant, Medulloblastoma, Medulloblastoma, NOS Or NEC + - Hypocellular Low Grade Lesion + - Mixed Phenotype Acute Leukemia With T(V;11q23); MLL Rearranged + - Oligodendroglioma, NOS, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Acute Myeloid Leukemia, NOS, Juvenile Myelomonocytic Leukemia, NOS + - Rhabdoid Tumor, NOS - B Lymphoblastic Leukemia/Lymphoma With T(V;11q23); MLL Rearranged - - "Ependymoma, NOS, Supratentorial Ependymoma, ZFTA Fusion-Positive" - - Acinar Cell Carcinoma - - Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Juvenile Myelomonocytic Leukemia, NOS - - "Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, SHH-Activated And TP53-Wildtype" - - Anaplastic Ganglioglioma - - Squamous Cell Carcinoma, Small Cell, Nonkeratinizing - - "Ganglioglioma, NOS, Diffuse Astrocytoma, MYB- Or MYBL1-Altered, Low-Grade Glioma" - - Unclassified Sarcoma With Round Cell Morphology + - Malignant Sarcoma With DICER1 Mutation, Favor Primary Intracranial Sarcoma, DICER1 Mutant + - Kidney Clear Cell Renal Carcinoma + - Neuroblastoma, Undifferentiated Type + - Synovial Sarcoma, NOS + - Primary Cutaneous Follicle Center Lymphoma + - Embryonal Rhabdomyosarcoma, NOS + - Neoplasm, Malignant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype And IDH-Wildtype, High-Grade Glioma + - Papillary Urothelial Carcinoma, Non-Invasive + - Embryonal Tumor With Multi-Layered Rosettes + - Precursor Cell Lymphoblastic Lymphoma, NOS + - Epithelioid Hemangioendothelioma, NOS + - Metaplastic Carcinoma, NOS + - Invasive Carcinoma + - Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, SHH-Activated And TP53-Wildtype + - HHV8 Positive Diffuse Large B-Cell Lymphoma + - Mesenchymal Chondrosarcoma + - Pineoblastoma + - Neoplasm, Malignant, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Mixed Germ Cell Tumor, CNS Germ Cell Tumors, CNS Germinoma + - Lymphoproliferative Disorder, NOS + - Solid Pseudopapillary Tumor Of Ovary + - Papillary Carcinoma, NOS + - Choriocarcinoma Combined With Other Germ Cell Elements + - Secretory Carcinoma + - Mesoblastic Nephroma + - Neoplasm, Uncertain Whether Benign Or Malignant + - Rhabdomyosarcoma, Favor Alveolar Type + - Dedifferentiated Liposarcoma + - Myoepithelial Carcinoma + - Hemangioendothelioma, NOS - Pilomyxoid Astrocytoma - - Lung Squamous Cell Carcinoma, NOS + - Oligoastrocytoma, NOS, Other, Other CNS Tumor, NOS Or NEC + - Anaplastic Ependymoma - Medulloblastoma, NOS, Diffuse Hemispheric Glioma, H3 G34-Mutant, High-Grade Glioma + - Low-Grade Glioneuronal, Neuronal Tumor + - Pilocytic Astrocytoma, Low-Grade Glioma, Pleomorphic Xanthoastrocytoma + - CPNET + - Serous Surface Papillary Carcinoma + - Adenocarcinoma In Adenomatous Polyposis Coli + - Embryonal Carcinoma, NOS + - Neoplasm, Uncertain Whether Benign Or Malignant, Ependymoma, Posterior Fossa Ependymoma, Group PFA + - Neoplasm, Uncertain Whether Benign Or Malignant, Diffuse Midline Glioma, H3 K27-Altered, High-Grade Glioma + - Glial Neoplasm + - Adrenal Cortical Tumor, NOS + - Ganglioglioma, NOS, Diffuse Astrocytoma, MYB- Or MYBL1-Altered, Low-Grade Glioma + - Undifferentiated Sarcoma + - Sertoli-Leydig Cell Tumor, Intermediate Differentiation, With Heterologous Elements + - Gliomatosis Cerebri + - Spindle Cell Melanoma, Type B + - Mucinous Adenocarcinoma, Endocervical Type + - Acute Myelomonocytic Leukemia, NOS + - Follicular Adenocarcinoma, Well Differentiated, Neuroblastoma, NOS + - Renal Cell Carcinoma, NOS + - Papillary Tumor Of Pineal Region + - Sex Cord Stromal Tumor NOS + - Hemangioblastoma, CNS WHO Grade 1 + - Fibrosarcoma, NOS + - Acute Myeloid Leukemia, T(8;21)(Q22;Q22) + - Papillary Lesion With Atypical/High Grade Features + - Xanthogranuloma + - Neoplasm, Metastatic + - Pancreas-Adenocarcinoma Ductal Type + - Myeloid Sarcoma + - Yolk Sac Tumor + - Carcinoma In Situ, NOS + - Dysembryoplastic Neuroepithelial Tumor, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Anaplastic Large Cell Lymphoma, T-Cell And Null-Cell Type + - Dysembryoplastic Neuroepithelial Tumor With Adjacent Cortical Dysplasia, WHO Grade 1 + - Neoplasm, Uncertain Whether Benign Or Malignant, Ependymoma, Supratentorial Ependymoma, NOS Or NEC + - Adenocarcinoma,NOS, Glioblastoma, NOS + - Myeloid Leukemia Associated With Down Syndrome + - Lipoblastomatosis + - Metastatic Neuroblastoma - Hepatocellular Carcinoma, NOS, Nephroblastoma, NOS - - Glioma, Malignant, Diffuse Midline Glioma, H3 K27-Altered, High-Grade Glioma - - Papillary Carcinoma, Follicular Variant - - Malignant Histiocytosis - - Acute Myeloid Leukemia, NOS - - Pineoblastoma, Other, Other CNS Tumor, NOS Or NEC - - Choroid Plexus Papillary Tumor + - Combined Small Cell-Squamous Cell Carcinoma + - Tubular Adenocarcinoma + - Acute Monoblastic Leukemia + - Neurocytoma + - Astrocytoma, NOS, Low-Grade Glioma, Pleomorphic Xanthoastrocytoma + - Merkel Cell Tumor + - Astrocytoma, IDH-Mutant, WHO Grade 2 + - Craniopharyngioma, NOS + - Astrocytoma, IDH-Mutant, CNS WHO Grade 3 + - Glioma, Malignant, Malignant Peripheral Nerve Sheath Tumor, NOS + - B Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34;Q11.2); BCR-ABL1 + - Tumor Cells, Malignant, Other, Pineal Parenchymal Tumor Of Intermediate Differentiation + - Embryonal Rhabdomyosarcoma + - Pinealoma + - Ependymoma NOS + - Pigmented Dermatofibrosarcoma Protuberans + - Hemangioendothelioma, Malignant + - Adenocarcinoma, Pancreatobiliary Type + - Precursor B-Cell Lymphoblastic Leukemia + - Thymic Carcinoma, NOS + - Lobular Carcinoma, NOS + - Ganglioglioma, NOS - Atypical Teratoid/Rhabdoid Tumor, ATRT, NOS Or NEC + - Choroid Plexus Carcinoma, WHO Grade 3 + - Rhabdomyosarcoma, Most Likely An Embryonal Carcinoma + - Squamous Cell Carcinoma, Small Cell, Nonkeratinizing + - Embryonal Carcinoma, NOS, Embryonal Tumor With Multilayered Rosettes, C19MC Altered, Other CNS Embryonal Tumors + - Colorectal Carcinoma + - Liposarcoma, NOS + - Primary Mediastinal (Thymic) Large B-Cell Lymphoma + - Meningeal Melanocytoma + - Dysembryoplastic Neuroepithelial Tumor, Angiocentric Glioma, Low-Grade Glioma + - Leukemia, NOS + - Periosteal Osteosarcoma + - Myelodysplastic Syndrome, NOS + - Central Neurocytoma, Glioneuronal And Neuronal Tumors + - Medulloblastoma, NOS, Medulloblastoma, SHH-Activated And TP53-Mutant + - Meningioma + - Gastrointestinal Stromal Tumor - Pancreatobiliary-Type Carcinoma - - Cribriform Carcinoma, NOS - - Neoplasm, Malignant, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - - Neoplasm, Malignant, Medulloblastoma, Medulloblastoma, WNT-Activated + - Hepatosplenic T-Cell Lymphoma, Precursor Cell Lymphoblastic Leukemia, NOS + - Unknown + - Ganglioglioma + - Sertoli-Leydig Cell Tumor, Poorly Differentiated + - Squamous Cell Carcinoma, Keratinizing, NOS + - Invasive Mammary Carcinoma + - Infiltrating Duct Mixed With Other Types Of Carcinoma + - Chronic Myeloid Leukemia, NOS + - Acute Leukemia, NOS + - Desmoplastic Small Round Cell Tumor + - Classic Medulloblastoma, CNS WHO Grade 4 + - Well Differentiated Neuroendocrince Tumor, Grade 1 + - Neoplasm, Uncertain Whether Benign Or Malignant, High-Grade Glioma, High-Grade Glioma, NOS Or NEC + - Angiomyofibroblastoma + - Large Cell Medulloblastoma, Embryonal Tumor With Multilayered Rosettes, NOS, Other CNS Embryonal Tumors + - Craniopharyngioma, NOS, Adamantinomatous Craniopharyngioma + - Glioblastoma, NOS, High-Grade Glioma, High-Grade Glioma, NOS Or NEC + - Oligodendroglioma, NOS, Other, Other CNS Tumor, NOS Or NEC + - Oligodendroglioma + - Acute Myelomonocytic Leukemia + - Mesenchymal Chondrosarcoma, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Meningothelial Meningioma + - Ductal Carcinoma NOS + - Astroblastoma + - Merkel Cell Carcinoma + - Desmoplastic/Nodular Medulloblastoma (Histologically Defined), CNS WHO Grade 4 + - Hamartoma + - Choroid Plexus Papilloma, NOS, Other CNS Embryonal Tumors, Pineoblastoma + - Not Reported + - Reactive Connective Tissue + - Nephroblastoma (Wilms Tumor) + - Neoplasm, Uncertain Whether Benign Or Malignant, Adamantinomatous Craniopharyngioma, Craniopharyngioma + - Mixed Phenotype Acute Leukemia, T/Myeloid, NOS + - Neoplasm, Malignant, Astrocytoma, IDH-Mutant, Low-Grade Glioma + - Pancreas-Undifferentiated Carcinoma + - Epithelioid Mesothelioma, Malignant + - Multiple Myeloma + - Low Grade Glial/ Glioneuronal Tumor + - Mucous Adenocarcinoma + - Craniopharyngioma, Adamantinomatous, Adamantinomatous Craniopharyngioma + - Basal Cell Adenocarcinoma + - Ependymoma, NOS, Medulloblastoma, Medulloblastoma, NOS Or NEC + - Malignant Melanoma, NOS + - Acute Erythroid Leukemia + - Atypical Teratoid/Rhabdoid Tumor + - Olfactory Neuroblastoma + - Medullary Carcinoma + - Carcinoid Tumor + - Neoplasm, Uncertain Whether Benign Or Malignant, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Lobular And Ductal Carcinoma + - Medulloblastoma, NOS, Medulloblastoma, Non-WNT/Non-SHH + - Alveolar Soft Part Sarcoma + - Mesothelioma, Biphasic, Malignant, B Lymphoblastic Leukemia/Lymphoma, NOS + - Neoplasm, Malignant, Diffuse Midline Glioma, H3 K27-Altered, High-Grade Glioma + - Myofibroblastic Tumor, NOS + - Cavernoma + - Tenosynovial Giant Cell Tumor, NOS + - Appearances Consistent With Alveolar Soft Part Sarcoma + - Craniopharyngioma, Adamantinomatous + - Choroid Plexus Carcinoma, Choroid Plexus Tumors + - Melanotic Schwannoma, Other + - Myofibroblastic Tumor + - Diffuse Midline Glioma, H3K27M-Mutant, CNS WHO Grade 4 - Neoplasm, Uncertain Whether Benign Or Malignant, Low-Grade Glioma, Pilocytic Astrocytoma - - Cystosarcoma Phyllodes, NOS - - Rhabdomyosarcoma, NOS - - Carcinoma NOS - - Atypical Teratoid/Rhabdoid Tumor, ATRT-TYR - - Genital Rhabdomyoma - - Oligodendroglioma, NOS, High-Grade Glioma, Oligodendroglioma, IDH-Mutant, And 1p/19q-Codeleted + - Embryonal Rhabdomyosarcoma, NOS, CNS Embryonal Tumor, NOS + - Dysembryoplastic Neuroepithelial Tumor, Glioneuronal And Neuronal Tumors + - Lobular Adenocarcinoma + - Medulloblastoma, NOS, Medulloblastoma, Group 3 + - Pilocytic Astrocytoma, Diffuse Leptomeningeal Glioneuronal Tumor, Glioneuronal And Neuronal Tumors + - Histologically Low-Grade Glioma + - Anaplastic Large Cell Lymphoma, ALK Positive + - Spindled And Epithelioid Tumor With Features Of Intracranial Mesenchymal Tumor + - Central Neurocytoma, Low-Grade Glioma, Subependymal Giant Cell Astrocytoma + - Intraductal Papillary Carcinoma + - Papillary Carcinoma, Columnar Cell + - Acute Myeloid Leukemia, T(16;16)(P 13;Q 11) + - Embryonal Sarcoma + - Central Neuroblastoma + - Paratesticular Rhabdomyosarcoma With Diffuse Anaplasia + - Carcinoma, Diffuse Type - Neuroepithelioma, NOS - - Mixed Epithelioid And Spindle Cell Melanoma - - Teratoma - - Neoplasm, Malignant, Diffuse Midline Glioma, H3 K27-Altered, High-Grade Glioma - - Mucinous Adenocarcinoma - - Neoplasm, Uncertain Whether Benign Or Malignant, CNS Sarcoma, Ewing Sarcoma - - Hamartoma - - Astrocytoma - - Adamantinomatous Craniopharyngioma (CNS WHO Grade 1) - - Malignant Epithelioid And Myxoid Neoplasm - - Adamantinomatous Craniopharyngioma - - Sex Cord-Gonadal Stromal Tumor, Mixed Forms + - Leiomyosarcoma, NOS + - Malignant Neoplasm Of Prostate + - Choroid Plexus Papilloma, NOS, Choroid Plexus Tumors + - Embryonal Carcinoma, NOS, Ependymoma, Supratentorial Ependymoma, NOS Or NEC + - Glioma, Malignant, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH + - Neoplasm, Uncertain Whether Benign Or Malignant, Low-Grade Glioma, Subependymal Giant Cell Astrocytoma + - Not Applicable + - Precursor B-Cell Acute Lymphoblastic Leukemia With Hyperdiploidy + - Neoplasm + - B Lymphoblastic Leukemia/Lymphoma With Hypodiploidy + - Adenocarcinoma + - Ganglioneuroblastoma, Nodular Type + - Subependymoma + - Astroblastoma, Other, Other CNS Tumor, NOS Or NEC + - Low Grade Neoplasm. Features Suggestive Of Pilocytic Astrocytoma. + - Transitional Cell Carcinoma, NOS + - Ganglioneuroma + - Angiomatoid Fibrous Histiocytoma + - Squamous Cell Carcinoma, Metastatic, NOS + - Astrocytoma, NOS, Other, Other CNS Tumor, NOS Or NEC + - Papillary Thyroid Carcinoma + - Diffuse Midline Glioma, H3 K27 Altered, WHO Grade 4 + - Chronic Eosinophilic Leukemia + - Myxoid Spindle Cell Tumor + - Tumor Cells, Malignant, Diffuse Leptomeningeal Glioneuronal Tumor, Glioneuronal And Neuronal Tumors + - Neoplasm, Malignant, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC + - Neoplasm, Malignant, Uncertain Whether Primary Or Metastatic + - Melanoma In Situ + - Acinar Cell Carcinoma + - Squamous Cell Carcinoma, Large Cell, Nonkeratinizing, NOS + - Medulloblastoma, NOS, Medulloblastoma, WNT-Activated + - Bland Myofibroblastic Proliferation With Associated Florid Lymphoplasmacytic Inflammation + - Ependymoma, NOS, Choroid Plexus Tumors, Choroid Plexus Papilloma + - Neuroma, NOS + - Acral Lentiginous Melanoma, Malignant + - Melanotic Neuroectodermal Tumor + - Adenocarcinoma With Neuroendocrine Differentiation + - Combined Small Cell-Large Carcinoma + - Glioma, Malignant, Diffuse Hemispheric Glioma, H3 G34-Mutant, High-Grade Glioma + - Myxopapillary Ependymoma + - Prostate Cancer + - Cholangiocarcinoma + - Medulloblastoma, Classic Variant, WHO Grade 4 + - Malignant Melanoma, NOS, Meningeal Melanocytic Neoplasms (Includes Melanoma), Other + - Osteoblastoma, NOS + - Acute Myeloid Leukemia (Megakaryoblastic) With T(1;22)(P13;Q13); RBM15-MKL1 - Hepatocellular Carcinoma, Fibrolamellar - - Pilocytic Astrocytoma, WHO Grade 1, KIAA1549-BRAF Fusion - - Ganglioglioma, Anaplastic - - Head & Neck Squamous Cell Carcinoma - - Mixed Glioma - - Renal Cell Carcinoma, NOS - - Tumor Cells, Malignant - - Low Grade Glioneuronal Tumor - - Myxofibrosarcoma - - Chordoma - - Infiltrating Duct Carcinoma NOS - - Squamous Cell Carcinoma NOS - - Posterior Fossa Ependymoma, CNS WHO Grade 2 - - "Desmoplastic Nodular Medulloblastoma, Medulloblastoma, Medulloblastoma, SHH-Activated And TP53-Wildtype" - - Choroid Plexus Neoplasm - - Chordoma, NOS, Ganglioneuroblastoma + - Adenocarcinoma, NOS + - Myeloid Leukemia, NOS + - CNS Embryonal Tumor, NOS + - Adenocarcinoma In Situ, NOS + - Dermatofibrosarcoma Protuberans, NOS + - Neoplasm, Uncertain Whether Benign Or Malignant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype And IDH-Wildtype, High-Grade Glioma + - Metastatic Secondary Tumors + - Myelodysplastic Syndrome With Multilineage Dysplasia + - Neoplasm, Malignant, Medulloblastoma, Medulloblastoma, NOS Or NEC + - Serous Cystadenocarcinoma, NOS + - Angiocentric Glioma + - Pancreatoblastoma + - Diffuse Glioma + - Papillary Carcinoma, Follicular Variant + - Astrocytoma, NOS, Low-Grade Glioma, Subependymal Giant Cell Astrocytoma + - Low Grade Fibromyxoid Sarcoma + - Thymoma, NOS + - Ependymoma, NOS, Atypical Meningioma + - Diffuse Midline Glioma, H3 K27-Altered + - Teratoma, NOS + - Adenosquamous Carcinoma + - Nuclear Protein In Testis (NUT)-Associated Carcinoma + - Mitotically Active Glial/ Glioneuronal Neoplasm + - Atypical Lymphoid Infiltrate + - Bronchiolo-Alveolar Carcinoma, Non-Mucinous + - Acute Myeloid Leukemia, NOS + - Glial Neoplasm Showing High-Grade Features + - Astroblastoma, Astroblastoma, MN1-Altered, High-Grade Glioma + - Ependymoma, NOS + - High Grade Malignant Peripheral Nerve Sheath Tumor With Heterologous Rhabdomyoblastic Differentiation (Malignant Triton Tumor) + - Serous Adenocarcinoma, NOS + - Acute Myeloid Leukemia With Myelodysplasia-Related Changes + - Embryonal Neoplasm With INI-1 Loss By Immunohistochemistry + - Glioma, Malignant, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC + - Endometrioid Adenocarcinoma, NOS + - Sertoli-Leydig Cell Tumor Of Intermediate Differentiation, NOS + - Giant Cell Tumor Of Bone, Malignant + - Low Cumulative Sun Damage Melanoma + - Neoplasm, Uncertain Whether Benign Or Malignant, Meningioma, Other + - Dysembryoplastic Neuroepithelial Tumor, Low-Grade Glioma, Polymorphous Low-Grade Neuroepithelial Tumor Of The Young + - Atypical Teratoid/Rhabdoid Tumor, ATRT-MYC + - Paraganglioma, NOS + - Malignant Neoplasm With Rhabdomyoblastic Differentiation, High Grade + - Epithelial-Myoepithelial Carcinoma + - Malignant Lymphoma, Non-Hodgkin, NOS + - Undiagnosed Spindle Cell Tumor + - Meningothelial Meningioma, Meningioma, Other + - Oligodendroglioma, Anaplastic, NOS + - Large Cell Medulloblastoma, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH + - Neuroblastoma, NOS + - Ependymoma, NOS, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH + - Tumor Cells, Uncertain Whether Benign Or Malignant + - High Grade Spindle Cell Sarcoma + - Diffuse Midline Glioma, H3 K27M-Mutant + - Meningioma, NOS, Embryonal Tumor With Multilayered Rosettes, NOS, Other CNS Embryonal Tumors + - Malignant Peripheral Nerve Sheath Tumor (Mpnst) + - Ganglioglioma, NOS, Malignant Peripheral Nerve Sheath Tumor, NOS + - Transient Abnormal Myelopoiesis + - Supratentorial Ependymoma, NOS + - Retinoblastoma, Grade 3 + - Medulloblastoma WHO Grade 4 + - Follicular Adenocarcinoma, NOS + - Sertoli Cell Tumor, NOS + - Ganglioglioma, NOS, Glioneuronal And Neuronal Tumors + - Medulloblastoma + - Combined Small Cell-Adenocarcinoma + - Ependymoma, NOS, Posterior Fossa Ependymoma, Group PFA + - Pleuropulmonary Blastoma + - Mucinous Carcinoma + - Epithelioid Sarcoma, NOS + - Pilocytic Astrocytoma, Low-Grade Glioma + - Spinal Ependymoma, WHO Grade 2 + - Embryonal Rhabdomyosarcoma With Anaplastic Features + - Astrocytoma, NOS, High-Grade Glioma, High-Grade Glioma, NOS Or NEC + - Lymphoma, NOS + - Spindle Cell Melanoma, NOS + - Adenocarcinoma, Endocervical Type - Colon Adenocarcinoma - - Hypocellular Low Grade Lesion - - Mucous Adenocarcinoma - - Glioma, Malignant, High-Grade Glioma, Infant-Type Hemispheric Glioma - - Myeloid Sarcoma - - Smooth Muscle Tumor Of Uncertain Malignant Potential - - Serous Surface Papillary Carcinoma - - Desmoplastic Fibroma - - Astrocytoma, NOS, Low-Grade Glioma, Pleomorphic Xanthoastrocytoma - - Ependymoma NOS + - High Grade Follicular Derived Thyroid Carcinoma + - Medulloblastoma, Nodular/Desmoplastic With Anaplastic/Large Cell Features, Non-WNT/Non-SHH; WHO Grade 4 + - Neoplasm, Malignant, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor - Morphologically Consistent With Pilocytic Astrocytoma, WHO Grade 1 - - Sclerosing Stromal Tumor - - Astrocytoma, NOS, Other, Other CNS Tumor, NOS Or NEC - - Embryonal Rhabdomyosarcoma, High-Grade - - Lymphoid Leukemia, NOS - Nephroblastoma, NOS - - Tumor Cells, Uncertain Whether Benign Or Malignant + - Nodular Melanoma + - Residual Astrocytoma + - Astroblastoma, MN1-Altered. Histologically High-Grade + - Mixed Type Rhabdomyosarcoma + - Craniopharyngioma + - Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, Group 4 + - Granulosa Cell Tumor, Malignant + - Adrenal Cortical Adenoma, NOS + - Alveolar Rhabdomyosarcoma + - Adenocarcinoma, Pancreatobiliary Type, Pancreatobiliary-Type Carcinoma + - CNS Embryonal Tumor With Rhabdoid Features + - Invasive Lobular Carcinoma + - Pinealoblastoma + - Glial Tumor + - Gliosarcoma + - Medulloblastoma, Classic (Biphasic) Histologic Type, Non-SHH/Non-WNT Molecular Group, CNS WHO Grade 4 + - Ductal Carcinoma In Situ, NOS + - Solitary Fibrous Tumor, NOS + - Ependymoma, NOS, Posterior Fossa Ependymoma, NOS Or NEC + - Malignant Peripheral Nerve Sheath Tumor, NOS, CNS Sarcoma, CNS Sarcoma, NOS Or NEC + - Neoplasm, Uncertain Whether Benign Or Malignant, Astrocytoma, IDH-Mutant, Low-Grade Glioma + - Choroid Plexus Papillary Tumor + - Ependymoma, Anaplastic + - Leydig Cell Tumor, NOS + - Synovial Sarcoma, Biphasic + - Medulloblastoma, SHH-Activated And TP53-Wildtype + - Glioma, Malignant, Angiocentric Glioma, Low-Grade Glioma + - Neoplasm, Malignant, ATRT-SHH, Atypical Teratoid/Rhabdoid Tumor + - Micropapillary Carcinoma, NOS + - Desmoplastic Nodular Medulloblastoma, Medulloblastoma, Medulloblastoma, SHH-Activated And TP53-Wildtype - Astrocytic Glioma, Histologically Low-Grade, Most Compatible With Pilocytic Astrocytoma - - Adenocarcinoma With Mixed Subtypes - - Neoplasm, Malignant, Uncertain Whether Primary Or Metastatic - - Stroma Poor, Poorly Differentiated Neuroblastoma With Low MKI, Favorable Histology - - Meningiomatosis, NOS - - Meningothelial Meningioma, Grade 1 - - Ganglioglioma, NOS, Ependymoma, Supratentorial Ependymoma, NOS Or NEC - - Spindle Cell Melanoma, Type B - - Dysembryoplastic Neuroepithelial Tumor With Adjacent Cortical Dysplasia, WHO Grade 1 - - Atypical Teratoid/Rhabdoid Tumor, ATRT-MYC - - Clear Cell Meningioma, Meningioma, Other - - Atypical Teratoid/Rhabdoid Tumor, INI1/SMARCB1-Altered, WHO Grade 4 - - Favor Pilocytic Astrocytoma With Increased Proliferation Indices - - Medulloblastoma, NOS - - Neuroblastoma, Schwannian Stroma Poor, Poorly Differentiated, Low MKI, Favorable Histology - - Cholangiocarcinoma - - Rhabdomyosarcoma, Embryonal Subtype - - Dermatofibrosarcoma Protuberans, Fibrosarcomatous - - Olfactory Neuroblastoma - - Familial Adenomatous Polyposis - - Glioma, Malignant, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Meningioma, Atypical, CNS WHO Grade 2 + - High Grade Malignant Epithelioid Neoplasm + - Astrocytoma, NOS, High-Grade Glioma, Infant-Type Hemispheric Glioma + - Meningioma, NOS + - Gangliocytoma, NOS + - Low Grade Glial Neoplasm + - Mucinous Adenocarcinoma + - Malignant Glioma + - Lung Squamous Cell Carcinoma, NOS + - Soft Tissue Sarcoma + - Meningioangiomatosis + - Adenocarcinoma In Villous Adenoma + - Squamous Cell Carcinoma In Situ, NOS + - Malignant Peripheral Nerve Sheath Tumor, NOS + - Desmoplastic Infantile Astrocytoma + - Medulloblastoma, SHH-Activated And TP53-Mutant + - Subependymal Giant Cell Astrocytoma + - Glioma, Malignant, Astrocytoma, IDH-Mutant, Low-Grade Glioma + - Glioma, Malignant, Ganglioglioma, Glioneuronal And Neuronal Tumors + - Hepatocellular Carcinoma, NOS - Ameloblastic Carcinosarcoma - - Amelanotic Melanoma - - Myelodysplastic Syndrome With Single Lineage Dysplasia - - Neoplasm, Malignant + - Squamous Cell Carcinoma, NOS + - Glioma, Malignant, Other, Other Low-Grade B-Cell Lymphomas Of The CNS + - Atypical Meningioma + - Ependymoma, NOS, Posterior Fossa Ependymoma, Group PFB + - Sclerosing Stromal Tumor + - Gastrointestinal Stromal Tumor, Benign + - Large Cell Medulloblastoma + - Acute Myeloid Leukemia, NOS, Myeloproliferative Neoplasm, Unclassifiable + - Synovial Sarcoma, Spindle Cell + - Pituitary Adenoma, NOS + - Astrocytoma, NOS, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Familial Adenomatous Polyposis + - Not Specified In Data + - Medulloblastoma; Hypercellular Lesion With Marked Atypia + - Seminoma, NOS - Malignant Lymphoma, NOS - - Astrocytoma, IDH-Mutant, CNS WHO Grade 3 - - Favor Teratoma - - Pineoblastoma - - Thymoma, NOS - - Hemangiosarcoma - - Myeloid Leukemia, NOS - - Meningeal Melanomatosis - - Anaplastic Astrocytoma, IDH-Wildtype, Glioblastoma, IDH Wildtype - - CNS Embryonal Tumor With Rhabdoid Features + - High Grade Carcinosarcoma + - Plasmacytoma, Extramedullary - Abdominal Fibromatosis - - Embryonal Neoplasm With INI-1 Loss By Immunohistochemistry - - Granulosa Cell Tumor, Malignant - - Leukemia, NOS - - Medulloblastoma WHO Grade 4 - - Adenocarcinoma In Situ In Adenomatous Polyp - - Medulloblastoma, SHH-Activated And TP53-Wildtype - - Neurofibroma, NOS - - Malignant Lymphoma, Non-Hodgkin, NOS - - Glial Neoplasm, Astrocytoma - - Acute Promyelocytic Leukaemia, T(15;17)(Q22;Q11-12) - - Embryonal Tumor With Multilayered Rosettes C19MC-Altered - - Hepatosplenic T-Cell Lymphoma, Precursor Cell Lymphoblastic Leukemia, NOS - Brain Tumor - - Neoplasm, NOS - - Acute Myeloid Leukemia (Megakaryoblastic) With T(1;22)(P13;Q13); RBM15-MKL1 - - Leydig Cell Tumor, Benign - - Oligodendroglioma, NOS, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - - Osteoblastoma, NOS - - Bronchio-Alveolar Carcinoma, Mucinous - - Neoplasm, Uncertain Whether Benign Or Malignant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype And IDH-Wildtype, High-Grade Glioma - - Arteriovenous Malformation - - Meningeal Melanocytoma - - Precursor B-Cell Acute Lymphoblastic Leukemia With Hyperdiploidy - - Myxoid Spindle Cell Tumor - - Adenocarcinoma In Villous Adenoma - - Papillary Adenocarcinoma, NOS - - Poorly Differentiated Chordoma - - Adenoid Cystic Carcinoma - - Pigmented Dermatofibrosarcoma Protuberans - - Oligoastrocytoma, NOS - - Myelodysplastic Syndrome With Multilineage Dysplasia - - Astrocytoma, Anaplastic, NOS - - Medulloblastoma, Classic (Biphasic) Histologic Type, Non-SHH/Non-WNT Molecular Group, CNS WHO Grade 4 - - Signet Ring Cell Carcinoma - - B Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34;Q11.2); BCR-ABL1 - - Control - - Adenocarcinoma,NOS, Glioblastoma, NOS - - Adenocarcinoma With Neuroendocrine Differentiation - - Retinoblastoma - - Acute Promyelocytic Leukemia, T(15;17)(Q22;Q11-12) - - Germ Cell Tumor, Nonseminomatous - - Adenocarcinoma + - Giant Cell Tumor Of Soft Parts, NOS + - Oligodendroglioma, NOS + - Tumor Cells, Malignant + - Glioneuronal Tumor With Focal Increased Atypia + - Adenosarcoma + - Atypical Teratoid/Rhabdoid Tumor, ATRT-TYR + - Carcinoma, Metastatic, NOS + - Glioma, Malignant + - Neurofibroma, NOS + - Neoplasm, Uncertain Whether Benign Or Malignant, Dysembryoplastic Neuroepithelial Tumor, Glioneuronal And Neuronal Tumors + - Sarcoma, NOS + - Neoplasm, Malignant, High-Grade Glioma, High-Grade Glioma, NOS Or NEC + - Blue Nevus, Malignant + - Neoplasm, Malignant, Low-Grade Glioma, Pilocytic Astrocytoma + - Clear Cell Sarcoma Of Kidney - Malignant Tumor, Spindle Cell Type - - Medulloblastoma, Classic Histology - - Pilocytic Astrocytoma, CNS WHO Grade 1 - - Squamous Cell Carcinoma In Situ, NOS - - Neoplasm - - Composite Hodgkin And Non-Hodgkin Lymphoma - - Adenocarcinoma, Intestinal Type - - Astroblastoma, MN1-Altered. Histologically High-Grade - - Nasopharyngeal Carcinoma - - Glioma, Malignant, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC - - Neoplasm, Uncertain Whether Benign Or Malignant, High-Grade Glioma, High-Grade Glioma, NOS Or NEC - - Central Osteosarcoma, NOS - - Merkel Cell Tumor - - Merkel Cell Carcinoma - - Adenocarcinoma, Endocervical Type - - Serous Cystadenocarcinoma, NOS - - Xanthogranuloma - - Oligodendroglioma, Anaplastic - - Atypical Smooth Muscle Neoplasm - - High Grade Spindle Cell Sarcoma - - Neoplasm, Malignant, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC - - Ductal Carcinoma In Situ, NOS - - Epithelioid Mesothelioma, Malignant + - Epithelioid Cell Melanoma + - Small Cell Sarcoma + - Subependymoma, Ependymoma, Supratentorial Ependymoma, NOS Or NEC + - Glioma, Malignant, Embryonal Tumor With Multilayered Rosettes, C19MC Altered, Other CNS Embryonal Tumors - Brain Tumor, Low Grade Glioma - - Combined Small Cell-Squamous Cell Carcinoma - - Myofibromatosis - - Adamantinomatous Craniopharyngioma, WHO Grade 1 - - Chronic Myeloid Leukemia, BCR-ABL1-Positive - - Basal Cell Adenocarcinoma - - Undifferentiated Nasopharyngeal Carcinoma - - Chronic Myelogenous Leukemia - - Medulloblastoma, WHO Grade 4 - - Fibrosarcoma, NOS + - Glial Neoplasm, Astrocytoma + - Vascular Lesion, Consistent With Hemangioma + - Juvenile Granulosa Cell Tumor + - Malignant Peripheral Nerve Sheath Tumor With Rhabdomyoblastic Differentiation + - Carcinoma, NOS, Medulloblastoma, Medulloblastoma, NOS Or NEC + - Neoplasm, Uncertain Whether Benign Or Malignant, ATRT, NOS Or NEC, Atypical Teratoid/Rhabdoid Tumor + - Favor Anaplastic Ependymoma + - Schwannoma, NOS, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Oligodendroglioma, NOS, Low-Grade Glioma, Oligodendroglioma, IDH-Mutant, And 1p/19q-Codeleted + - Atypical Teratoid/Rhabdoid Tumor, INI1/SMARCB1-Altered, WHO Grade 4 + - Yolk Sac Tumor, NOS + - Small Cell Carcinoma, NOS + - Carcinosarcoma NOS + - Mixed Germ Cell Tumor, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor - Juvenile Myelomonocytic Leukemia - - Tenosynovial Giant Cell Tumor, NOS - - Acute Myeloid Leukemia With Mutated NPM1 - - Pancreas-Undifferentiated Carcinoma - - Precursor Cell Lymphoblastic Lymphoma, NOS - - Squamous Cell Carcinoma, Large Cell, Nonkeratinizing, NOS - - Large Cell Medulloblastoma, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH - - Ductal Carcinoma NOS - - High Grade Malignant Peripheral Nerve Sheath Tumor With Heterologous Rhabdomyoblastic Differentiation (Malignant Triton Tumor) - - Myxopapillary Ependymoma, Ependymoma - - Retinoblastoma, Grade 3 - - Sarcoma, NOS - - Malignant Peripheral Nerve Sheath Tumor, NOS - - Spindle Cell Rhabdomyosarcoma - - Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH - - Serous Adenocarcinoma, NOS - - Neurofibromatosis, NOS - - T-Lymphoblastic Lymphoma - - Neoplasm, Malignant, CNS Embryonal Tumor, NOS Or NEC, Other CNS Embryonal Tumors - - Medulloepithelioma, NOS - - Glioma - - Pineoblastoma, Other CNS Embryonal Tumors - - Ependymoma, NOS - - Adrenal Cortical Adenoma, NOS - - Appearances Consistent With Alveolar Soft Part Sarcoma + - Myofibroma + - Posterior Fossa Ependymoma, CNS WHO Grade 2 + - Renal Cell Adenocarcinoma + - Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Juvenile Myelomonocytic Leukemia, NOS + - High Grade Neuroepithelial Tumor + - Neoplasm, Malignant, Medulloblastoma, Medulloblastoma, WNT-Activated + - Pleomorphic Xanthoastrocytoma, NOS, High-Grade Glioma + - Pilocytic Astrocytoma, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC + - Lymphoid Leukemia, NOS + - Atypical Choroid Plexus Papilloma, Choroid Plexus Tumors + - Benign Cystic Nephroma + - Sex Cord-Gonadal Stromal Tumor, NOS + - Neoplasm, Benign + - Glioblastoma + - Pilocytic Astrocytoma, WHO Grade 1, KIAA1549-BRAF Fusion + - Acute Myeloid Leukemia With T(9;11)(P22;Q23); MLLT3-MLL + - Glioma, Malignant, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - Hypercellular Lesion With Atypia - - Tumor Cells, Uncertain Whether Benign Or Malignant, Other CNS Embryonal Tumors, Pineoblastoma - - Myeloid Leukemia Associated With Down Syndrome - - Rhabdoid Tumor, Malignant - - Carcinoma, NOS, Medulloblastoma, Medulloblastoma, NOS Or NEC - - Astrocytoma, NOS, Astrocytoma, IDH-Mutant, Low-Grade Glioma - - Lymphoproliferative Disorder, NOS - - Malignant Tumor - - Embryonal Carcinoma, NOS, Ependymoma, Supratentorial Ependymoma, NOS Or NEC - - Acute Myeloid Leukemia Without Maturation - - Neoplasm, Malignant, ATRT, NOS Or NEC, Atypical Teratoid/Rhabdoid Tumor - - Dysembryoplastic Neuroepithelial Tumor - - Craniopharyngioma, NOS + - Myxopapillary Ependymoma, Ependymoma + - Neoplasm, Malignant, CNS Neuroblastoma, FOXR2-Activated, Other CNS Embryonal Tumors + - Head & Neck Squamous Cell Carcinoma + - Giant Cell Tumor Of Bone, NOS + - Neuroepithelial Tumor With Glioneuronal-Like Features + - Neuroepithelial Tumor + - Leydig Cell Tumor, Benign + - Adenocarcinoma With Mixed Subtypes - Parosteal Osteosarcoma - - Schwannoma, NOS - - Squamous Cell Carcinoma, Keratinizing, NOS - - Craniopharyngioma, Adamantinomatous, Adamantinomatous Craniopharyngioma - - Neuroblastoma, NOS - - Angiocentric Glioma - - Gastrointestinal Stromal Tumor - - Meningothelial Meningioma - - Astrocytoma, NOS, Low-Grade Glioma, Subependymal Giant Cell Astrocytoma - - Metastatic Secondary Tumors - - Mesoblastic Nephroma - - Not Reported + - Acute Lymphoblastic Leukemia + - Infantile Fibrosarcoma + - Langerhans Cell Histiocytosis, Disseminated + - Adenoid Cystic Carcinoma + - Neuroendocrine Tumor, NOS + - Glioma, Histologically Low Grade - Rhabdomyoma, NOS - - Favor Posterior Fossa Ependymoma, WHO GRADE 3 - - Clear Cell Meningioma - - Marginal Zone B-Cell Lymphoma, NOS - - Gangliocytoma, NOS - - Acute Monoblastic Leukemia - - Ganglioneuroma - - Glioma, Malignant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype And IDH-Wildtype, High-Grade Glioma - - Malignant Peripheral Nerve Sheath Tumor (Mpnst) - - Anaplastic Ependymoma - - Malignant Sarcoma With DICER1 Mutation, Favor Primary Intracranial Sarcoma, DICER1 Mutant - - Pleomorphic Liposarcoma - - Lymphoepithelial Carcinoma - - Embryonal Tumor With Multilayered Rosettes With C19MC Alteration - - Ganglioglioma, NOS, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - - Mixed-Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified - - Oligoastrocytoma, NOS, Glioneuronal And Neuronal Tumors, Papillary Glioneuronal Tumor - - Supratentorial Ependymoma CNS WHO Grade 3 - - Follicular Adenocarcinoma, NOS - - Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, NOS Or NEC - - Central Neurocytoma - - Carcinoma, Undifferentiated, NOS - - Papillary Thyroid Carcinoma, Classic Type - - Invasive Mammary Carcinoma + - Rhabdomyosarcoma, Embryonal Subtype + - Glioma, Malignant, Low-Grade Glioma, Polymorphous Low-Grade Neuroepithelial Tumor Of The Young - Ganglioglioma, NOS, Other, Other CNS Tumor, NOS Or NEC - - T-Lymphoblastic Leukemia - - Burkitt Lymphoma, NOS + - Pancreas-Adenosquamous Carcinoma + - Germinoma, CNS Germ Cell Tumors, CNS Germinoma + - Control + - Undifferentiated Small Round Cell Sarcoma + - Medulloepithelioma, NOS + - Glioma, Malignant, Other, Other CNS Tumor, NOS Or NEC + - Choroid Plexus Papilloma, NOS + - Glioma, Malignant, Dysembryoplastic Neuroepithelial Tumor, Glioneuronal And Neuronal Tumors + - Acute Myeloid Leukemia With Mutated CEBPA - Intraductal Carcinoma NOS - - Poorly Differentiated Sertoli-Leydig Cell Tumor With Heterologous Rhabdomyosarcomatous Differentiation - - Glioma, Malignant, Other, Other Low-Grade B-Cell Lymphomas Of The CNS - - "Medulloblastoma, NOS, Medulloblastoma, SHH-Activated And TP53-Wildtype" - - Gastrointestinal Stromal Tumor, Benign + - Hemangioma, NOS + - Perineuroma + - Pilocytic Astrocytoma + - Poorly Differentiated, Intermediate Mitotic-Karyorrhectic Index + - Astrocytoma, IDH-Mutant, CNS WHO Grade 4 + - Follicular Carcinoma, Minimally Invasive + - Glioma, Malignant, High-Grade Glioma, High-Grade Glioma, NOS Or NEC + - Burkitt Lymphoma, NOS - Ependymoma, NOS, Supratentorial Ependymoma, NOS Or NEC - - Prostate Cancer + - Neoplasm, Uncertain Whether Benign Or Malignant, CNS Germ Cell Tumors, CNS Germinoma + - Mixed Germ Cell Tumor + - Medulloblastoma, Classic Histologic Type, CNS WHO Grade 4 + - Central Neurocytoma + - Medullary Carcinoma, NOS + - Proliferative Dermal Lesion In Congenital Nevus + - Glioma, Malignant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype And IDH-Wildtype, High-Grade Glioma + - Neuroendocrine Carcinoma, NOS + - Glioblastoma, NOS, Medulloblastoma, NOS + - Astrocytoma, Benign + - Ganglioneuroblastoma + - Astrocytoma, NOS, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype And IDH-Wildtype, High-Grade Glioma + - Medulloblastoma, NOS + - Favor Ganglioglioma + - Chronic Myeloid Leukemia, BCR-ABL1-Positive + - Schwannian Stroma Poor Peripheral Neuroblastic Tumor, Consistent With Neuroblastoma + - Adrenal Cortical Carcinoma + - Astrocytoma + - Neoplasm, Uncertain Whether Benign Or Malignant, Choroid Plexus Tumors, Choroid Plexus Papilloma + - Favor Posterior Fossa Ependymoma, WHO GRADE 3 + - Leiomyoma, NOS + - Sex Cord-Gonadal Stromal Tumor, Mixed Forms + - Neuroblastoma, Schwannian Stroma Poor, Poorly Differentiated, Low MKI, Favorable Histology - Poorly Differentiated Neuroblastoma - - Undiagnosed Spindle Cell Tumor - - Neuroblastoma, Undifferentiated Type - - Schwannoma - - Well Differentiated Neuroendocrince Tumor, Grade 1 - - Seminoma, NOS - - Hepatoblastoma, NOS - - Mesenchymal Chondrosarcoma, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - - Embryonal Rhabdomyosarcoma, NOS - - Low-Grade Glioneuronal, Neuronal Tumor - - Angiomyosarcoma - - CNS Embryonal Tumor, NOS - - Sertoli-Leydig Cell Tumor, Intermediate Differentiation, With Heterologous Elements - - Subependymal Giant Cell Astrocytoma - - Infiltrating Duct Mixed With Other Types Of Carcinoma - - Ganglioneuroblastoma, Nodular Type - - Pancreas-Adenosquamous Carcinoma - - Papillary Serous Adenocarcinoma - - Cavernoma - - Fibrillary Astrocytoma - - Pilocytic Astrocytoma, Low-Grade Glioma, Pleomorphic Xanthoastrocytoma - - Malignant Glioma - - Malignant Peripheral Nerve Sheath Tumor, NOS, CNS Sarcoma, CNS Sarcoma, NOS Or NEC - - Small Round Blue Cell Tumor - - Adenocarcinoma In Adenomatous Polyposis Coli - - CPNET - - Pilocytic Astrocytoma WHO Grade 1 - - Low Grade Glioma - - Tumor Cells, Malignant, Diffuse Leptomeningeal Glioneuronal Tumor, Glioneuronal And Neuronal Tumors - - Endometrioid Adenocarcinoma, NOS - - Carcinoma, Metastatic, NOS - - Alveolar Soft Part Sarcoma - - Papillary Tumor Of Pineal Region - - Favor Pilocytic Astrocytoma, CNS WHO Grade 1 - - Acute Leukemia, NOS - - Hemangioendothelioma, NOS - - Mucinous Carcinoma - - Myelodysplastic Syndrome, NOS - - Desmoplastic/Nodular Medulloblastoma - - Angiomatoid Fibrous Histiocytoma - - Gastrointestinal Stromal Tumor, NOS - - Neoplasm, Malignant, Medulloblastoma, Medulloblastoma, NOS Or NEC - - Small Cell Carcinoma, NOS - - Small Cell Neuroendocrine Carcinoma - - Secretory Carcinoma - - Neuroma, NOS - - Ependymoma, Anaplastic - - Myxopapillary Ependymoma (CNS WHO Grade II) - - Nodular Melanoma - - Transient Abnormal Myelopoiesis - - Choriocarcinoma, NOS - - Choroid Plexus Papilloma, NOS, Other CNS Embryonal Tumors, Pineoblastoma - - Desmoplastic/Nodular Medulloblastoma (Histologically Defined), CNS WHO Grade 4 - - Histologically Low-Grade Glioma - - Infiltrating Duct And Lobular Carcinoma - - Juvenile Granulosa Cell Tumor - - Astrocytoma, NOS, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - - Central Neurocytoma, Glioneuronal And Neuronal Tumors - - Giant Cell Tumor Of Bone, Malignant - - High Grade Carcinosarcoma - - Malignant Neoplasm With Rhabdomyoblastic Differentiation, High Grade - - Glioma, Malignant, Diffuse Hemispheric Glioma, H3 G34-Mutant, High-Grade Glioma - - Glioblastoma Multiforme - - Acute Myeloid Leukemia, NOS, Juvenile Myelomonocytic Leukemia, NOS - - Glial Neoplasm Showing High-Grade Features - - Sertoli-Leydig Cell Tumor Of Intermediate Differentiation, NOS - - Glioma, Malignant, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH - - Chronic Myeloid Leukemia, NOS - - Lung Adenocarcinoma, NOS - - Acute Myeloid Leukemia, T(16;16)(P 13;Q 11) - - Ependymoma, NOS, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH - - Subcutaneous Panniculitis-Like T-Cell Lymphoma - - Chondrosarcoma, NOS - - Non-Germinomatous Germ Cell Tumor - - Dysembryoplastic Neuroepithelial Tumor, Angiocentric Glioma, Low-Grade Glioma - - Neuroepithelial Tumor - - Serous Carcinoma, NOS + - T-Lymphoblastic Lymphoma + - Stroma Poor, Poorly Differentiated Neuroblastoma With Low MKI, Favorable Histology + - Low Grade Glioneuronal Tumor + - Adenocarcinoma Combined With Other Types Of Carcinoma + - Germ Cell Tumor, Nonseminomatous + - Tumor Cells, Benign + - Dysembryoplastic Neuroepithelial Tumor + - Soft Tissue Tumor, Benign + - Malignant Histiocytosis + - Chronic Myelogenous Leukemia + - Yolk Sac Tumor, NOS, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor + - Carcinoma NOS + - Meningiomatosis, NOS + - Spindle Cell Rhabdomyosaroma + - Pleomorphic Sarcoma + - Cutaneous T-Cell Lymphoma, NOS + - Chordoma, NOS, Ganglioneuroblastoma + - Clear Cell Sarcoma, NOS + - Langerhans Cell Histiocytosis + - Supratentorial Ependymoma + - B Lymphoblastic Leukemia/Lymphoma, NOS + - Ganglioglioma, Anaplastic + - Giant Cell Glioblastoma, Glioblastoma, IDH-Wildtype, High-Grade Glioma + - Supratentorial Ependymoma CNS WHO Grade 3 + - Adamantinomatous Craniopharyngioma (CNS WHO Grade 1) + - Chordoma, NOS, Chordoma (Including Poorly Differentiated Chordoma), Other + - Hemangiosarcoma + - Adenoma, NOS + - Oligoastrocytoma, NOS, Glioneuronal And Neuronal Tumors, Papillary Glioneuronal Tumor + - Germinoma, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor + - Mycosis Fungoides, Langerhans Cell Histiocytosis, NOS + - Malignant Tumor, Small Cell Type + - Neoplasm, Malignant, ATRT, NOS Or NEC, Atypical Teratoid/Rhabdoid Tumor + - Ganglioglioma, NOS, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Embryonal Rhabdomyosarcoma, High-Grade + - Differentiating Neuroblastoma + - Malignant Tumor, Spindle Cell Type, CNS Sarcoma, CNS Sarcoma, NOS Or NEC + - Ganglioglioma, NOS, Ependymoma, Supratentorial Ependymoma, NOS Or NEC + - CNS Primative Neuroectodermal Tumor (PNET) + - Ossifying Fibroma + - B Lymphoblastic Leukemia/Lymphoma With T(12;21)(P13;Q22); TEL-AML1 (ETV6-RUNX1) + - Hodgkin Lymphoma, NOS + - Desmoplastic/Nodular Medulloblastoma + - Malignant Peripheral Nerve Sheath Tumor + - Glomus Tumor, Malignant + - Pleomorphic Xanthoastrocytoma, NOS + - Glioma, Malignant, High-Grade Glioma, Infant-Type Hemispheric Glioma + - Papillary Transitional Cell Carcinoma + - Chordoma, NOS + - Rhabdoid Tumor, Malignant + - Ossifying Fibromyxoid Tumor, NOS - CNS Embryonal Tumor, NOS, CNS Embryonal Tumor, NOS Or NEC, Other CNS Embryonal Tumors - - Sertoli-Leydig Cell Tumor, Poorly Differentiated - - Solid Pseudopapillary Tumor Of Ovary - - Rhabdomyosarcoma - - Astrocytoma, NOS, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype And IDH-Wildtype, High-Grade Glioma + - Invasive Ductal Carcinoma + - High-Grade Serous Carcinoma + - Pleomorphic Liposarcoma + - Aggressive Fibromatosis + - Spindle Cell Carcinoma, NOS + - Medulloblastoma, NOS, Medulloblastoma, SHH-Activated And TP53-Wildtype + - Neoplasm, Uncertain Whether Benign Or Malignant, Low-Grade Glioma, Oligodendroglioma, IDH-Mutant, And 1p/19q-Codeleted + - Chronic Myelogenous Leukemia, BCR/ABL Positive + - Ewing Sarcoma + - Dermatofibrosarcoma Protuberans, Fibrosarcomatous + - Malignant Epithelioid And Myxoid Neoplasm + - Poorly Differentiated Chordoma + - Oligoastrocytoma, NOS + - Chondroblastic Osteosarcoma + - Favor Teratoma + - Metastatic Signet Ring Cell Carcinoma + - Rhabdomyosarcoma, NOS + - Granulosa Cell Tumor, Juvenile + - Pheochromocytoma, NOS + - Adenocarcinoma In Situ In Adenomatous Polyp + - Anaplastic Ganglioglioma - Extra Adrenal Paraganglioma - - Melanoma In Situ - - Tumor Cells, Malignant, Other, Pineal Parenchymal Tumor Of Intermediate Differentiation - - Glioma, Malignant, Astrocytoma, IDH-Mutant, Low-Grade Glioma - - Pituitary Adenoma, NOS - - Neoplasm, Uncertain Whether Benign Or Malignant, CNS Germ Cell Tumors, CNS Germinoma - - Basaloid Squamous Cell Carcinoma - - Embryonal Carcinoma, NOS - - Mixed Germ Cell Tumor - - Sertoli Cell Tumor, NOS - - Tumor Cells, Benign - - Pineoblastoma, CNS Germ Cell Tumors, CNS Germinoma - - Periosteal Osteosarcoma - - Lobular And Ductal Carcinoma - - Carcinosarcoma NOS - - Unknown - - Thymic Carcinoma, NOS - - Pleomorphic Rhabdomyosarcoma, Adult Type - - Papillary Transitional Cell Carcinoma - - Ependymoma, NOS, Posterior Fossa Ependymoma, Group PFA - - Ependymoma, NOS, Medulloblastoma, Medulloblastoma, NOS Or NEC - - Malignant Rhabdoid Tumor - - Medulloblastoma, NOS, Medulloblastoma, WNT-Activated - - Tumor Cells, Malignant, Medulloblastoma, Medulloblastoma, NOS Or NEC - - Ganglioneuroma, Other, Schwannoma - - Lymphangioma, NOS - - Neoplasm, Malignant, High-Grade Glioma, High-Grade Glioma, NOS Or NEC - - Malignant Peripheral Nerve Sheath Tumor With Rhabdomyoblastic Differentiation - - Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, Group 4 - - Glioblastoma, NOS, High-Grade Glioma, High-Grade Glioma, NOS Or NEC - - Lymphoma, NOS - - Precursor B-Cell Lymphoblastic Leukemia - - Inflammatory Carcinoma - - Neoplasm, Malignant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype And IDH-Wildtype, High-Grade Glioma - - Solid Pseudopapillary Neoplasm Of Pancreas - - Squamous Cell Carcinoma, NOS - - Teratocarcinoma - - Papillary Urothelial Carcinoma, Non-Invasive - - Meningioangiomatosis - - High-Grade Neuroepithelial Tumor - - Mixed Germ Cell Tumor, CNS Germ Cell Tumors, CNS Germinoma - - Neoplasm, Benign - - Atypical Teratoid-Rhabdoid Tumor, CNS WHO Grade 4 - - Acute Myelomonocytic Leukemia, NOS - - Subependymoma - - Rhabdomyosarcoma, Embryonal Subtype Is Favored - - Schawannoma - - Therapy-Related Myeloid Neoplasms - - Papillary Carcinoma, NOS - - Infantile Fibrosarcoma - - Sertoli Leydig Cell Tumor - - Central Primitive Neuroectodermal Tumor - - Medulloblastoma, Group 3 Subtype (WHO Grade 4) - - Choroid Plexus Carcinoma, WHO Grade 3 - - Papillary Carcinoma, Columnar Cell - - Yolk Sac Tumor, NOS, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor - - Ependymoma WHO Grade 3 - - Neuroepithelial Tumor With Glioneuronal-Like Features - - Sex Cord Stromal Tumor NOS - - Sex Cord-Gonadal Stromal Tumor, NOS - - Spindle Cell Sarcoma - - Acral Lentiginous Melanoma, Malignant - - Chondroid Chordoma - - Unknown, To Be Completed Later, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH - - Glioblastoma, NOS - - Embryonal Tumor - - Paratesticular Rhabdomyosarcoma With Diffuse Anaplasia - - Olfactory Neurocytoma - - Astrocytoma, Benign - - Mixed Germ Cell Tumor, Myelodysplastic Syndrome With Excess Blasts - - Large Cell Medulloblastoma - - Adenocarcinoma In Situ, Non-Mucinous + - Lentiginous Melanocytic Nevus + - B-Lymphoblastic Leukemia/Lymphoma, NOS + - Osteosarcoma, NOS + - Angiomyosarcoma + - Neoplasm, Uncertain Whether Benign Or Malignant, CNS Sarcoma, Ewing Sarcoma + - Pancreatic Neuroendocrine Tumor, Nonfunctioning + - Mesenchymal Lesion + - Ganglioneuroma, High-Grade Glioma, High-Grade Glioma, NOS Or NEC + - Papillary Adenocarcinoma, NOS + - Adult Granulosa Cell Tumor Of Testis + - Intraductal Papillary Mucinous Neoplasm With An Associated Invasive Carcinoma + - Infiltrating Lobular Carcinoma, NOS + - Undifferentiated Leukemia + - Hemangioblastoma, Other + - Serous Carcinoma, NOS + - Neoplasm, Malignant, CNS Embryonal Tumor, NOS Or NEC, Other CNS Embryonal Tumors + - Pilocytic Astrocytoma, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Atypical Teratoid Rhabdoid Tumor, CNS WHO Grade 4 + - Small Blue Cell Tumor. Favor Medulloblastoma + - Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, NOS Or NEC - Rasmussen Encephalitis - - Acute Myeloid Leukemia, NOS, Myeloproliferative Neoplasm, Unclassifiable - - Epithelioid Cell Melanoma - - Craniopharyngioma, NOS, Adamantinomatous Craniopharyngioma - - Giant Cell Tumor Of Soft Parts, NOS - - Undifferentiated Leukaemia - - Neoplasm, Uncertain Whether Benign Or Malignant, Dysembryoplastic Neuroepithelial Tumor, Glioneuronal And Neuronal Tumors - - Follicular Carcinoma, Minimally Invasive - - Spindled And Epithelioid Tumor With Features Of Intracranial Mesenchymal Tumor + - Adenocarcinoma, Metastatic NOS + - Primary Cutaneous CD30 Positive T-Cell Lymphoproliferative Disorder + - Astrocytoma, NOS, Astrocytoma, IDH-Mutant, Low-Grade Glioma + - Small Cell Neuroendocrine Carcinoma - Infiltrating Duct And Mucinous Carcinoma - - Cutaneous T-Cell Lymphoma, NOS + - Acute Myeloid Leukemia With Mutated NPM1 + - Subcutaneous Panniculitis-Like T-Cell Lymphoma + - Retinoblastoma, NOS - Clear Cell Adenocarcinoma, NOS - - Diffuse Midline Glioma, H3 K27 Altered, WHO Grade 4 - - Metastatic Signet Ring Cell Carcinoma - - Micropapillary Carcinoma, NOS - - Subependymal Giant Cell Astrocytoma, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC - - Desmoplastic Small Round Cell Tumor - - Mixed Phenotype Acute Leukemia With T(V;11q23); MLL Rearranged - - B Lymphoblastic Leukemia/Lymphoma With T(1;19)(Q23;P13.3); E2A-PBX1 (TCF3-PBX1) - - Dysembryoplastic Neuroepithelial Tumor, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - - Glioma, Malignant - - Proliferative Dermal Lesion In Congenital Nevus - - Pinealoma - - Transitional Cell Carcinoma - - Adenosarcoma - - Medulloblastoma, NOS, Medulloblastoma, Group 4 - - B Lymphoblastic Leukemia/Lymphoma With T(12;21)(P13;Q22); TEL-AML1 (ETV6-RUNX1) - - Meningothelial Meningioma, Meningioma, Other - - Germinoma, CNS Germ Cell Tumors, CNS Germinoma - - Leiomyosarcoma, NOS - - Low Grade Glial Neoplasm - - Adamantinomatous Craniopharyngioma, CNS WHO Grade 1 + - Mixed Germ Cell Tumor, Myelodysplastic Syndrome With Excess Blasts + - Chordoma + - Cribriform Carcinoma, NOS + - Mixed Germ Cell Tumor, Acute Megakaryoblastic Leukemia + - Desmoplastic Fibroma + - Genital Rhabdomyoma + - Infiltrating Duct And Lobular Carcinoma + - Residual Low Grade Neuroendocrine Tumor (Typical Carcinoid) + - Plexiform Fibrohistiocytic Tumor + - Neoplasm, Uncertain Whether Benign Or Malignant, ATRT-SHH, Atypical Teratoid/Rhabdoid Tumor + - Oligoastrocytoma, NOS, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC + - Pilocytic Astrocytoma, WHO Grade 1 + - Choriocarcinoma, NOS + - Myxofibrosarcoma + - Myelodysplastic Syndrome With Single Lineage Dysplasia + - Bronchio-Alveolar Carcinoma, Mucinous + - Medulloblastoma, Classic Histology + - Non-Germinomatous Germ Cell Tumor + - Poorly Differentiated Sertoli-Leydig Cell Tumor With Heterologous Rhabdomyosarcomatous Differentiation + - Pleomorphic Rhabdomyosarcoma, Adult Type - Infiltrating Ductal Carcinoma - - Acute Myeloid Leukemia, T(8;21)(Q22;Q22) - - Adenosquamous Carcinoma - - Anaplastic Large Cell Lymphoma, ALK Positive - - Ganglioglioma, NOS, Malignant Peripheral Nerve Sheath Tumor, NOS - - Schwannoma, NOS, Other - - Mesenchymal Lesion - - Granulosa Cell Tumor, Juvenile - - Poorly Differentiated, Intermediate Mitotic-Karyorrhectic Index - - Nuclear Protein In Testis (NUT)-Associated Carcinoma - - Neoplasm, Uncertain Whether Benign Or Malignant, Astrocytoma, IDH-Mutant, Low-Grade Glioma - - Sex Cord-Gonadal Stromal Tumor, Incompletely Differentiated - - Meningioma, NOS, Embryonal Tumor With Multilayered Rosettes, NOS, Other CNS Embryonal Tumors - - Chordoma, NOS - - Carcinoma In Situ, NOS - Acute Megakaryoblastic Leukemia - - Oligoastrocytoma, NOS, Other, Other CNS Tumor, NOS Or NEC - - Kidney Clear Cell Renal Carcinoma - - Medulloblastoma, Classic Histologic Type, CNS WHO Grade 4 - - Malignant Melanoma, NOS + - Myxopapillary Ependymoma (CNS WHO Grade II) + - Mucoepidermoid Carcinoma + - Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH + - Carcinoma, Undifferentiated, NOS + - Marginal Zone B-Cell Lymphoma, NOS + - Central Osteosarcoma, NOS + - Olfactory Neurocytoma + - T Lymphoblastic Leukemia/Lymphoma + - Mixed Glioma + - Medulloblastoma, Group 3 Subtype (WHO Grade 4) + - Cystosarcoma Phyllodes, NOS + - Amelanotic Melanoma + - Pleomorphic Xanthoastrocytoma, NOS, Low-Grade Glioma + - Meningothelial Meningioma, Grade 1 + - Low Grade Glioma + - Clear Cell Meningioma + - Nasopharyngeal Carcinoma + - Spinal Ependymoma, Histologically Low Grade (CNS WHO Grade 2) + - Infiltrating Duct Carcinoma NOS + - Lymphangioma, NOS + - Mixed Adenocarcinoma And Squamous Cell Carcinoma, Pancreatobiliary-Type Carcinoma + - Glioma + - T-Cell/Histiocyte Rich Large B-Cell Lymphoma + - Desmoplastic Nodular Medulloblastoma, Medulloblastoma, Medulloblastoma, Group 4 + - Mixed Phenotype Acute Leukemia, B/Myeloid, NOS + - Acute Myeloid Leukemia, Minimal Differentiation + - Favor Pilocytic Astrocytoma With Increased Proliferation Indices + - Acute Promyelocytic Leukemia, T(15;17)(Q22;Q11-12) + - Oligodendroglioma, NOS, High-Grade Glioma, Oligodendroglioma, IDH-Mutant, And 1p/19q-Codeleted + - Ependymoma, Anaplastic, Supratentorial Ependymoma, NOS Or NEC + - Dermoid Cyst + - Arteriovenous Malformation + - Glioma, Malignant, High-Grade Glioma, Pleomorphic Xanthoastrocytoma + - Mixed Epithelioid And Spindle Cell Melanoma + - Anaplastic Astrocytoma, IDH-Wildtype, Glioblastoma, IDH Wildtype + - Germ Cell Tumor, Nonseminomatous, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor + - Melanoma, NOS + - Glioblastoma, IDH Wildtype + - Medulloblastoma, Classic Morphology, CNS WHO Grade 4, NON-WNT/NON-SHH, Group 4 Subtype By Methylation + - Paraganglioma, Malignant + - Fibrillary Astrocytoma + - Ependymoma WHO Grade 3 + - Dysplasia + - Sertoli Leydig Cell Tumor + - Embryonal Tumor + - Undifferentiated Nasopharyngeal Carcinoma + - Adamantinomatous Craniopharyngioma + - Central Primitive Neuroectodermal Tumor + - Ependymoma WHO Grade 2 + - Neoplasm, Malignant, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH + - Adenocarcinoma, Intestinal Type + - Choroid Plexus Neoplasm + - Glial Neoplasm, Favor Pilocytic Astrocytoma + - Gastrointestinal Stromal Tumor, NOS + - Acute Myeloid Leukemia, Inv(16)(P13;Q22) + - Composite Hodgkin And Non-Hodgkin Lymphoma + - Myeloid Leukemia With Myelodysplasia-Related Changes + - Hemangioblastoma + - Choroid Plexus Carcinoma + - Basaloid Squamous Cell Carcinoma Req: true Term: - Origin: caDSR From 07624771c46fb530f925a445d8b25cff8fe84328 Mon Sep 17 00:00:00 2001 From: wfy1997 <60631776+wfy1997@users.noreply.github.com> Date: Tue, 15 Oct 2024 15:08:07 -0400 Subject: [PATCH 07/23] rename the instrument_model to proteomic_instrument_model and delete the experimental_strategy because experimental_strategy is already in file node --- model-desc/cds-model-props.yml | 11 +---------- model-desc/cds-model.yml | 3 +-- 2 files changed, 2 insertions(+), 12 deletions(-) diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index fc273fb..35a2cdf 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -11012,15 +11012,6 @@ PropDefinitions: Code: "15112968" Value: Laboratory Procedure Proteomic Profiling Analytical Fraction Type Version: '1.00' - experimental_strategy: - Desc: The type of systematic investigation using controlled observations and measurements to test hypotheses or develop a plan of action based on the facts discovered. - Type: string - Term: - - Origin: caDSR - Original Source: CRDC - Code: "12373576" - Value: Research Activity Experimental Method Experimental Method Type - Version: '1.00' instrument_make: Desc: The words that describe an entity that produces finished goods used to perform a diagnostic, therapeutic or research activity. Type: string @@ -11030,7 +11021,7 @@ PropDefinitions: Code: "2866141" Value: Equipment Manufacturer Name Text Version: '1.00' - instrument_model: + proteomic_instrument_model: Desc: The words that describe the style or design of an entity"s finished goods used to perform a diagnostic, therapeutic or research activity. Type: string Term: diff --git a/model-desc/cds-model.yml b/model-desc/cds-model.yml index f42e487..7236b59 100644 --- a/model-desc/cds-model.yml +++ b/model-desc/cds-model.yml @@ -403,9 +403,8 @@ Nodes: Props: - aliquot_id - analytical_fractions - - experimental_strategy - instrument_make - - instrument_model + - proteomic_instrument_model - proteomic_design_description version: From b017546f9fe1352fe49fdc9de218c2a4c48545df Mon Sep 17 00:00:00 2001 From: wfy1997 <60631776+wfy1997@users.noreply.github.com> Date: Mon, 21 Oct 2024 13:14:17 -0400 Subject: [PATCH 08/23] Update cds-file-examples.zip --- model-desc/cds-file-examples.zip | Bin 88999 -> 116084 bytes 1 file changed, 0 insertions(+), 0 deletions(-) diff --git a/model-desc/cds-file-examples.zip b/model-desc/cds-file-examples.zip index 1d7f482bc64beea879cdefcbdb26ad7d67f615cb..662777cb41c44dfb98e26a337d6db06b2126c217 100644 GIT binary patch delta 84984 zcmd42V~{6px8_^bW!vtuZC7>Kc6Hgd|K;kkZQHhO+qSLK&pUgccg~L45obQlWJYF0 z=DH)}T6cb0SNyKxX0V4a2sn8u5KvU0e-29-g;+QW7*A9r)2eWE)249rSOILfzi&1E zRsMTpk2U>wy(b(!ITiw#62Qp7Q1`=}Fncz`k75TC85vaH&)Eui&xD0kTHYQ39Q^Cx zL%Vap-#jcgm4Y_Lfi`cP6;Tat||dJ*^$cyMr45-gCs6a-|)%~VnEKdk@*{eAwYb;!Tx z59xn5326lkBowa?Obn2EGOfjZ)9$3Wozm#Xk{g1You>w?qqK4Nay6}qM{53 z1hIhhKQ`>2O>=gG0RjdsD7=OPJww1#=+s$vz-5o~KJpp&0C^tISAFt8mzz9Y=aJ!J^&mZjP5VDZw`K$yt_XWAPf(e zSErwU?q;WdE)G^VhY)OcdVi09K3M=fz29HY)6dU;+f+9#zwi4zGkEXWxPA{`eokIl zFna?4FCFe}eT!GScRm2ujcxpqX{&0Rr(wgl_ud~_G z`-;zJ_4n6(j0=L>qHBoLD1Yu&8 zj-Tv2LDefe%Mq}`^ZEX?w{L5^_4VBT8_@OQ#;^0_;rjC6_Wio&@qYT`Q{OEW{d9c! zxW8%tZg*SL>Eo5sm7YLlzH@(f!Is=!{%IfI;O1Jp>9r>F?AF=2L10T?)x;hGa1u)g z@NVg5Cb?$g)1NLJ5BJ|103ILSHXpCPZjT-kl9S(^D76<9Q!#mdS{P=+hk5<6g{hMh zeP;3|l;EMYTAK<9Cm-c6(Ap%|a!zmH;av^NVUw|m?Y44FPG3L&oIEmdWtL!}J^#9$ zzASdiC7&%==i=L3Uc5SLcx?^=l&^EAp6)%9ESDD$VVKu8M2cXy*Wb-;@#0JKmi3#KrS|%R4vZO)=fp@2 z#P_uM(Q5g2`k@W@k3qFIY6*Nizu!Z$w|u;wqqEgr^k|1M4kf1Dnt8VX#QeGj8d_p|D;bCD-)>Q9@3(JJw zR~y37XMp#&CGyt3j%L-wl{RK)Fv0;rX6@4{p%OUPU0w$K@G^HYI=UpPDyyeIV*3t> z-*fidaaPh56Q$tW!u}_qxBv-oQAMsIAt{q#N($rE+?gReb~(;}=b^qH(ps!9&LFx^ z{8NxJ5QPtlwDmoG`h9v-voPr8&Mp4wr9c+py*$1q%l2fOeSPzjB)fqm|9a{@XmgIyPNvWY>jzpHq zJXjryKQcDHdHS^NmO=LXJ|FK@ok#BTOWm})YM={s@{!TTkEc`yjupFEf*R+MbBunn zG6eOg+V|j7J8l& zvt9Juu*>E(3-ApnaDE|5O0>N!(#7Y#jxy0T`n5ZS0~TZ=$W3pwnulQ@_5}{w_C)BaxN{YgZ@i8a+I@`!GBRAp3lKX(sr3`nu-tS`oAH`ZMIXpdm+TajbCU zl>n^RoFh9+ps!VPA5L7;*0`%pYb$a*c7NgM!<^r`A5IAn^$=5ov(@;<3dz3(=Eki| z;%cp$E`s4(!9-WxBMWoYUu)NZxD)}&*xvq?!T%h=smp43&t%n@p-uE_NjA-BdAupD z@e2lou!RWxtR~~2!;a4s+yj4un26E=zxsl)1a~_z)G#)a8QH}8LQA!xAQ5Z3|xD%!(P(r5kOLu0R zb%c6XLb}0g%3#>5p?gZR!PpqRiOrRRxrvXQFjmz=xpAyPa=VepDm!AV6Kumr1{z9B3BtUnb% zLu=%?Q@G+YFCun0b#f!Y!wAI7pakhufQT_8nL;Np1A{zJx$T5BOCrM1mm!2K9=W7) z$IsU|Y^K}M)G>Dv zG{rh-Q|Dt+i91-a^TqkoEi$JN2~!-f4Ry_03$c9OsxF+mEViana=E(3$dQbO0>4NW z^(K2Yn0$s>EF#{T(1^mIS1T|$VnZe`@j4A@2kWB1LDk2&*?3H1P%C>;!v0enlKU($ zK~donZ&j13lp-;XC+rvJD6Eq~dKjFMM_MT9*tHs0gFex5qp#vDnOpXQoiQsw?~fi) zcpuj#y6a74cp*6QCp{dK6j0#CStIp1D0qeH&>sGc<1b&mahxBQV2rBntg3##L>MGjx$+eUwp?&88RQ%6033Ey1 zscm7lv>9{-iwm8W+IsE>ILKO!>{6{AUWdB-u&XpQ1A`fSV^@KUHI`EV!%8A zMtwgliShvf)>@NxvaF_u69t1x{29^5Qa$~}^Cg}*SdL0;X!K$*(n z!=EY1G2&iHe!hZe{BhdJE^fuC1hSn z$SIqWT8COSYIz2D;|=T&)aT5PQWu#HJeY&tTL`YTIez%*cK#YSrxzMYX9R9>`zyOO z$JMBiweF{@wy!9u8W1E_<(A0TbMr-O#ZyIL64-N4K zj3r4`>&~7CdDY=1z|f*l`ATcA75pqzEQ|P=^Im63CTq-hUIUb7F2liv!HDh-G1X!* zGvW`7DG<1+PS~7Yv&*;>1IZXwDd0Hyvl848uDBP9+0<~x0UBUt(y7!oB1$(-mS=Ia zsc$OUR>jcLTf8vz{=oVjBx5vHe}fz&mb}Tv2q9?r2*_m$fH03nFF)A42RA|xJfk=s zOAT}Ov$N$!vkP`8p0{pa4*fHn-XsX5%ghH{O|g#4Ytb`kE^c0QIOO3_&h2!z&dEH5kOBay3?RZ4G@09`&IL@inPKQF+mB5^cku!88ri z6!+^Am7X-bie`msA*Y#-;|z2vJKSI3c0LJACqCndzV}OQOi~z;YF=p3Eb5^@xEmPL zVDYg15Jbkv(9^=##a^hSrxu2+iU??F<&rH65}CmR0Z?xFKd!=%DY*>xyOEn(YOFNK zTY{2+ExF95n9-iFh{bT^Oey?p?|*Uxf|Mm(YPCp#l;$o;1YB^BS9s1AVoRDNseQ)P zx+Om85nKO}pZ8@{gp{(~m{nhc<{pVFwm?@v(+5A+*nEq0!uVJUj#*Zl8bLR&q){ab zXKP8Z2T&-CjHTV?SwM_v(?}4oAn3pGEFONk)SEC^Ot7UYQ}oj1FONQ2pCFcB8y1Y` z1VFqLC_nnIvTL}6EJa=!67M4t-y#+&t0OEaPoYz%$dKvFvtSs-rg2DGPKiLh&Tgha zUlmpfy9FgqSAYx`K%>-0n|VCs!r9Y7j4VKrYEU~tE!lhcB$K;)p=Kr5O!=#*HuW8hXN7zp6{`2f{xOF(k5E>q&rGW;^zYC&8FuHAOgga z0H9Y|;8Xl|ABSVkr`<`QMD_(|bUZ`h%7?_ukT zrGHxMbj7ts9vYgWWu2OIFqhH_y%eY00E=4fd@{Vf!lDqas%3jUj#Om2ycbY`LP z(5zZHyVGZCdn>8u_>NSj-o>;7A#5FXX)p=BkQxanqcGMFJmS2x`v?{l^z`%eqe0Vd z#lJKW8;QcJg;VFAw$$?TQC1+8_B#u?QYl$9@qyBTpO`b!k6YeHmliM3C-0X)0exrd zISc{(;YTvyka&CfVOuopoR}5M_CI-L-OLB&f@_kv$aAzV%|agWMg0A3@bPVf&{rb( zh)5%)$n-lnFDLcAR{Cjy;*y+&-4Rg9EmtXf&NsjaR_5}Z9^lJ3z>X7@^-jx;$Q|Uw zA3dC1f)8@z%gYb3e_DE-L&~>O1M0az;db)G?}B!YiM*4>d|Z>|p(GbJ%$2Rfe{q1+ znV?zPx$|XPiVacwC8{gYH}pnW+p$44w-kpHGpe@QC?=nkCI(?jR`O(u>4qF{#y#ya zIEl}kGAiH{zhgdUlS;Ae7|RXhWwg{hayg&%71RYo9^<{lW>(Ka&Kr_! z&q$J7Se&SRO75Pkd4Fp6TzYu~xg_^W2T`RF=0v0`PQA*Te^r!9&+;LFOjWhkK`*&8 z=IZk(=U5LMK|e2K3C+xLL$r$Xy@Xoix!86dY(D9|=@vLcV{$VGCqD#XfSam0TKneksW8yT%?W z_Xi4AnaTfYhiZSDkmEO}fyyKHks2C;b)w7K<%#Dlo3v^H+eBXJxX@5{1q(ki)`vN!x)&I;OxDNaV<4LLxr{A3+tvaB`@% zw3L_B{6TAL)NH2J`Di51dDBNeiMPhSF@yWZWJS0Cvq?0~7w}ks&5rdfIE$z#4bJT_ zUN0c4uv{;T!f-=JUz!7g`$@MYOz%JronK>67cY74kszXX<`CSGt%Mw7r*keb<5pWT zh;`QcKsOEqhOSjmiz&&pVveB~3sQ38F54f(JdX4f&$E8)%I4bUx=fxXe}-$3J!(FL z4O;LFp1|xR3lKKj`2nGnYnjS0`Z5t_RaItbH+}|Wuz;fkR8Bm!2^a@*1cXi+KAju7{tAiqc z2s0zT&oi@DJp%th@)fKqzB^^_=NiNXh5qHV{)9z6hL$^M2P5H3zuE2&;9n4)-lml< z;X&l&d|9sK%c9}PRr2qkS&#S!$ZgEh6;5LUW^G2HgBrz#eolv0)^|mXFr4kWndJOv zyO)#YO8_f1MoodWj4ZV@cKw1T`7d^8q{A6T2KqQeIMvwu@CpiMHJ{00@(eAr(?X+J z4u>0uJ`eGuC5yzpbp2JFDgWCPh%j0)M`2&rETcFQy+(Rl&*bn@INc&7I8;KqHi5lzt1$0I1Ud(V1?e!tyhe#Nf(mfFVDXvPod>zCei8)t zwc!0FKIhor8LG~Q<>{)ye4;;+9kxhb-g zKx$4Y225-`s$mWtMJI)w-u|#yfepkfX4cc3HFZNn^7(VjN`f^_f$z#9+Q+?8Jp&x5 zg*{)VHP@;)Jma6cI8f|f)Xd8J-K`S_*C*Roy8KTgyYUh5{m%e|_v?x4KOZ=j|=9{cOM{ht%di zfSrV-$TdJ^8!SdEyR=$@NdYLwPY3TMwJ*;g(1G9zhAR7pP3w1R^I}D19CHM@j5ptt>5BYCe;HwG#AN^UsE&^n2SKR-^Eht{K#Isoy^(;{$I9maG7^Cv57pWdU~VFg2G&S_9cugQ%0Uf;L+ zahCL zeYQBi3{elHbspR!5=$%CPeC|S85&mO>lDmH*I>YrOkbo@4#ttc_;_{GE#y=%Nrdkd zBBR1Vs%0IkC(zZZYG#Jkyaxe0LrDDiaxyP?*}OedIZM^sQP4oneXoakKQ(EqNwHj3 zf!Rhx3L89e&;A+yyqcfbbK!U1!9)u%Xt zFgc(PQY>>xeU8rzuVb2j&%hSrbG_GFy78qBQgpls{m&HY(g9S;PIvB9UIMfpaS;1d zV4;)6wBN)dR$(z`{8VKiMkU?piU8$1U)W)AsJ4R0#6=N^%h?h6hTTgAup8HD8CGgo z#T503jc!j&`>`=re-14kB_1YwgZ6ggmj1XA<}?wMiXP@7aLc`~n|Tq|s=ZvZ48 zSoYnB&=$@lIPr;10>!U~7?J9SlDbD9SE~BvNxV~=NFffy{Ra%W#!8OA|F83oB+7=% za?(X55$mFImrZi~!w+8L8@Lbq*-tvZ?bb}WKtJ@j!0f2 z>US-JW3apu_4V^kO`vu`@4IiFHDHe7^I8Q=9?81}Al-11CJKY6+LQT(3hKPv)R^2= zO>3#ir?I}NabmY+aCdGYMX+Q<>IyH$pprnAj?cNXaTxdQEwv%_6fLi8q|yQ?pKqxG zj>U#|*SJ_&u*r!2 z=E2@VK6$rgQh%flTW+!T^1_DRlQxvqDb8k%xQC3)tr|fQ!+-8kx;Ps3QR2KozS8pjHOt zwI4l3E5s66dDj1MzArJbWF;vWlt`i(z@jU^{X{vNF$bTyh!XM96KNFZL+RFBJjZfY zElU7DZkF7YW)U_sSCh%SVDg+SSzJMtGV?tX-(-`%IcI*tLE;gOJ!wotF1>cxP?kOK zO$EahTa;ycIxLX+6QBe@nBtf7CcgpJoRTCZ%EyU#PSihsHPtvdDC3(bD_e%3Llrw@ znYim!%N&_|o@SS{39rYTq8f~wtyF7C7Isk?6uN5)#~)L&`VCnzjfd_AYI=Wwug7E# zWBkVsnZzhwu^i}Ufd$yE^I8>HlJG0V`O?y&FR{S27^2#vD3B&#_@p;hK^GLBT_0vH zdbKj^9$w)0Re@F@=+b9g{}5>n%rQ$&uG#~W2U0B~))s|++6e@de)$g1w;e z7xXYrFgH!_y{&c4`wjSHkCzE{9MLysk3z?254ny_F+^UlTB7|s>TORdO?Y7PLQ%e` z$U*PO>Qr8DT#6fQZ!Po^&To1!2N)($YI8YnOZ+?frH%vu!pW6}D59q+@>M~~{=*#! zKa{W!B#!bR+gCN&)XGO{HoYn3>!jd?$?J*oYjRofnGoiu1XA>PkKCL4DOi zW^xn#??*qtwU)vu90*QiJ(J!F5K_Ty&b(m2EOX;ZMt%P%RN^Y=jFY_M&Flo!7LO{A zJ1eH5EVOy%9`ZSHZGv_iMTbsW@k)ptzPy*9lGsE7c4`1a-V2g{th$y%%;|SqL%q^^}cR+D>eh9MkCFA*jYpp9%%#M$7y0DQhqryMlClR4U27d*5-#rukKsw!BmPI?X!i+@CaBG7zq! zzD6>oMhED85hWsQHHo_JH5vj5EuN>9S=$L<4OW1i`vaanVKVB2ANR}mo&dJ`; zgI5=T^PKXFLH!qfWw;$z(~IDm8U1H-TguWO`LM$#%U@@p98v13o1=(A#Ax=d0o8^q zlOvQvhE%T*HC=rVpG%ztY>C z7`3Kzx1;*>iMKM+aF38~U2M>h6ut1xy^W&)AFWm;Pk6fHp0oar0RQ=EL(rvDo4(NT zm=-kMmC0~U&&+6SW~*SsxJETiQRRRN2-xK%%}NH6!dpgV15{CFmLH`1zF%Fgl5~{6 zVLB#3afp1|2>dN~Z>E?c%HyVld3pI(C}43hx>Xm1L@Mwm6)#%RVcKT%{Elb_I8*u5 zv@K8We2pK#g+3*uh(tt}mXTeatS%oDU#6y>rk;?Z7MGelCSPK!r>AdZZDM0)5}ROVhL;hal3{&m zWO8bzcX3p7Znbk%V7X^xR%EGfby{Y5dSs+;p=YCKc49I552OSE$pm%`6#Q5EKl1-J zmYhTfj1sR6EC}%ra`gAAF96QR0sE)Q{h!T||EuG+50krD>(b#|GsU~%#9EqEe_?T5*QTR;pShhIUL#ZK>l|rwTh#g#b z(YmDJo5#NScojS1W`MwZ^p;vLB!7~!`HBKQKTO^(xi0vkhIiLrvu$`T-u7S4_nCMB z?pJ{5Zkhcqeis7UPakah<98dL?c())mW<-7g>Tap9ouB{mW(0q=cmMReU2{oQ-+OU zx#QRFPwS2;z{xb=?e6UA=2YwTbG!S!JkiP)y!l%X&ye5%7@iJobm=9YBBk&D)Pw&#g{{!Jjf%Ug!k`x?Da;pb_|piQ;!67m&D!0z1g7;@#sxnC^Zf6L+Jkx{%kbNN2pc@40G zp;zjrQ8N;=7(mNv(dHa|y(%u=W!N)~^lm2LkER&he+p#s!j0PZ$#C`H>8LpLz?CP@ zVt4B%Kp@tTd5C1)la$jw_O;Y?xybTDx?KCknNW?}XF=}r?z25jz;r%nm)&;WGHmO* ze;Sq@$}hI6+toF&^|r8`byH&F_6-<PE`PBR>^haNYwt_Y-tGa9fAs9^{Vc0>!<&$xuzSwUC0cc_cB(!!^etC?`kWMrb?1)d zc(@%QR1;&|_jYG^0=Rd+hEQ{_vw~Nva6NgRq%0U!`d;lyu*yKGTZ6kTry0tp8?$X* z4Pgi0zP_?D|(ddE5rTmshj`SKX%4bNudZ<=q$Q@h#cRG408$XJpiuDf1!O1hms z?a~!?*)pd0_rGKoUEHZl;ugeMiEr0Z4i4QcF|Ixz57Se!f*bQCl?i$iSoEBOQmOne zmIGGvPc!l6wKB8bMutdD^tNPrG$sQ z5m7XMyxkCGj5q}g<*I-PdJDwopr)NJnA86laj01kup`)#w===BNAc$~8fmaXaewnQ zr8P`~uyRCJ_gW^`0|S&7+zZNz&qNi&^Ix%n%Q$i;?DLJ8JK_2sgB@MFT#vIN?1?5? zf%ehlghsmiikPs^a}Ds8l!3jDK%{X;uzgla53!D7tY7l>vPDFshI?%5r;JQyC`+6W zC)LGiy_bcIhh`$9t`jC8@})^I$lk4(9Eq4%&lCIaq@azZ762&6r|GQx;rhfF26tcM zX!k6CHA`tv6k!PnG9{UPGW-~YN($R+qjgFL^#HfVo1PH&snpYrp()%II!W*#pQP{Y zX{-voA(9VRkUskLWY7DZW*>Az6b*9}LD{BU3)=Is=)DvGf7tfhlnBQ|v`&>g-;TA1$@8p55*y&u>s~_+qnnWDN?KhEFZh&~(ho_%# z8S(~%=3v3#qS4x*-cl(ak$U3~MOY)%{2_XS1dL~T+gG+i59AO@vdE~-NmNARtX1%; zj=S6CTylgeSaU_2N5z7=D(!r64F$@8TSfP#;;M~>1xI-j-tf1AyurZ6tvfb&|DOUd znmNMBrF($cUm7Dz;1eo|BYYzU6@@eGkT!Ng%fxlfGQm_oI_DrEVl@j)DN*{WU7-`A z3q%Lt9nj3~TGMcc>Z7Thppe|*w3eiM6RJ48`@tNTZ$F{W@v#YkG=RR38Fx{*M01nmebtvdpK*MGQ;*X*UeVg;!Pxy&;(je8nvnb zmPs_EZd@wmH}*)A^(;)p()s(=IFu35F4+B$DoK3QB|*(>$e=*8EYw;nm*=VBtY7u_ zxiXwr84-kcPa0j$I$lvuv(Te%PM+};&E|*wuQSIDy@=h$fm%l+U7hVJFhApCCxAWY zNwQX^e#)2|pJpJ0j9HLXTszUNpCX?EaI{dw$jE22hbW5ZtXBx1N;N?x=9wr{B}Jlw zWNu~dbEBNT?VQxrO}={wxEzkWPFQk+f*Vf4m3C~4wbFHD3CO_ef82SU{$$$^<&fP}1da)|=&soU7_7Lt zQ(Oxc>w%n%0%lc<4^Thcjt(5$_V@6QH6Y6&SnZ>(s%dnlCOp+JWg!O}VzF=!nfYj& z`$?g0^K&I`zH-5rJz!QA-;!`{O-0~%W=cP;9D=XJ%+g@3)yBV61PYXbbZX<%8m2sT z+;NUbs*Y$DfoOgglM4oed72Xf5G&=ZNM4N)4P=mIFNL{$_VgZH6cKaf8>9NCr>N6< z!Oawdt@QcF?uvq@v$+UD|yKTFCjxzFHn#yVYCivfwNKuBG znkZZIgKY6=?m1ki-UV^kAWZw@+=hHE;y7zh3_!WVz?7Bf<(@&`2*FOiGv^c_LnY3U z`r~B_6B#iKkyyEtKbRMB0C0B=R+bsW5nQTvHk`GH#>OGRFJe&6m<)g54wPX9ZIO5o z;qj^>l}8gU;-H)H)PRI?^E2dg3~t?MJ;lm3NfEzr>F{zuGG>2wWH{SeXH$wq9o7G& zf4AbqtcN>8vcSE>Tp8h&x_DESS#}Q3vntgyGoWu7qQ|K66O)E?1ej2wHr83gl)%kH zCon(=u7Znh*RAwm%TNLl_1n)e<{Fyc%}^E(4W)-lD8;~{>B(^GhGJU*+Xa4$Y8q#S zG7EA4=38iwj3l<=z!Wn-tm6!-lThChlm)Rdkn|u%`qu8ie?X%r%B?_hbcBos!<6B4 z!`^4puN8d8gwvU|23Wc=r-P9O9)b4`r`7?N?vWk4z`+Z=*nxt;xe$S?&+^UDc?!SS z_Sg>(V%waM;EC7MlFwK~&c`}^riCn4K*K`~M(#`*m?_Qu^ZJ?!yM2;P=q!^1F%$nGYO?@}}E7sP#xB%@W+O z6KSuFhgm#%ox1f6NMcf##|#&nI$#RtL&Zs<3wx_J?fSZ@M0(_m{S)a&u}Od{Vrjtj)%1 ztrNq3O0#TG(&@}tB(Mpyx?Do?!ZGCEhO{F10;1oxoORtdvAqf!%q9%4PTz+Al1mCB zK*6(^6az2vUGSY;h@yXg7>{$tEO^#^&ZS9nl>BtgIE`LVBvt*vtR?M8G>4T3*CBeFfzxjmkPOzmSOGF+5WIs6x#tikR=s6yy|Z zy*}!6=EGWtR;v6|j;#7$m#mdd{w^VzOX5^MIH9d6N-Hn|4u4kK%_PH4ku+fA#`+$f zEQjSA?4NNSn(JY@5FQBVp9%QyIFI(f7>;3plWnPi8S(5KZ2z0-_}`6301;2#PcQOVJtSrfy zrNlrC+1YhWLDJynRQ?crPOq!*vVm(Kpa7Yh1I0M|7BYw%$HqN|1~9Gfa9_7 z#Xz{2n7CL2{L1UrwJefOBT`yNc-7;$H)5S z2J!|v;wCzjga7}D`|q{g`hk>1{M9y}976|;75_*e0P!E5Lp=|n8pOZM6t4d?Q{a;U z%D|ZaTJT?F{~z{%yeN47Q+9keMa#cbv;AAOuL>~g|5d90(+B#W^LFufKtL@2pS+#0 zvbnXs>3>Ps{Wp%#ppHf~j#!+})hq3};MQ=y>K*jZTHNmJ1P?N5dQ#{q**Z_eWB0c7 z*qMon@h?%MA}d&inlv>PWuuJWUiM#~=AO--+JLpMPp2-x#&?&;%H?w@v8>zYxsA9=#YDTN4J+J{r8s5Y_;OeulfF`$K73`PX6xQ z?e_P3`V+CKkoz~k$56TR&)1jt^h@`4PJ$=`7X;Ifv@Dn5$NuQ{`=jJ#dAy z*KaN!u&nX`fKM}xBGRNef#s~?6P@V zogmL~nSWyYQ6^z&JVp7`+;c+*U#>faHb+rtLekZA0tWNI#v;c_HUreuugj^Pn ze|a@)*e)GEe0@A$o_2VwSZ;-exR3cu6Nqd##(-OZBZ(HkVt!?LNMyeBEDdzPoO3S*xW#k^*+-`6y2} z``-ZjyDe+HnN8(1O~vUr_Fdt>+4zD?&_N7KKq9ru$F0)*omz8vuPR>tx4zqQ63#$QRYA(;8@2E!z+nt_|-hf-fYc&Fw zF;D8k4~=dEc`vb?w1Sf< z(<)8K8L^3O7?ce7HAw;f%sVRV4+=XHd3N&@M-xu8wudAOg+&0%mos1XX>tv>Y6djg9S@$9kW=KaP<9A;vQFch4ST4!Mj;KEjAZONlpatUIS=J%jH) zZFupk#+`Glcdc-TI2gad6c!XNV|-l^2Z@bX7OTk+uof%#zzVx|J-~Jcz6%l`ZZt3s zIwqP?NMjOZK-&E**x<>p?$+;1Ghs`GB!JipPtl@e+yGj$;2U@gQXyiF)F2w0Rk1K6m56u`&X@_bT!nRluX7k9r4Gdw@00c^SWO;t`e-Q1 z?e<9V!z8YZs7&I0?~hyo`8jMIW#6{Ktj)KJ?1}(LG2TL{^uVl!Kwz{OwNbr9Fr$E2 zuBf(DO-$k0F2zDig8?e=aKtBG0tjgfB8zh%V){swVBFAY9snOLkh&X%%Xl6Io{wGd z7)2%>!wRb6c@-07E-IMCp7aPQ$mrawWyBz(kJtM3-*i<8CwFcKQ(%FMkNTNC@!~l1Dvd3pOqsCrKV3K!Li0j@o zk}Wo2dtkUqJXt1HvvGNZBp6vN0iBG-HOZvQULlVtsIpS@RyXAd^={1aHXp_+EETSF zf0L5sf_&LlyhnyuD)~QP5D7SuS!ZLCr=?DqjXN?6@(z}IAI8LlSH8@{k=@jr68>fNwhEQc_FA^a- zcAu^M#(M-1?Ku~iq)~p9ydO;pVj}RG<|i}yiv7O0-%HP##QOl$^0q8ewZbSfkP30~ zMt#yaVG^v&wJ+4HqVuQ&9}lQI;e4L zL?T6!G!+pjP|*S%xT0w{v{Uv$EiprvBaS=Dw4!KTN>KJr{=Gm;tRmgHfrd9^CZHbJ zkQ;KxAEP<0Ez7%;BDXhZ;2rh7t~O4pl7Q2G$Q?i9Sr!y7BLrWtoiN8C0Y#N`U41z# z4HtM?YIJvuRePXe(x7x`tzfQCtY@ipC-D|c{Jv*5t#|l+bs|pAsox0)f3F0HNYrVp zw_{hU=Q!P9VYkOV54p-`%^RN?3xHMu8os57lZ#id0lCn_F*hig^<;yQ?|2weMg@j=@xoQTLg%nf1R=X7w1Th|VK5Yu!UM$vwk0`ti z7ddB59OoyfC!#1Bb;xSIi4f`l4T^h%eKe3UA#i-v$%^O=p4KR)1Bx3yBL~h{`FnxcHyCBxE}ns)P`L+dkqb|u+0Dip z$kEFLk59y{))zi?ccJ?xpHdpA&eyCFxwe(^bJaryoGq=#Pkg&(O4Pwowzc2LjSyK- zlAJaZ#iPpo;s0UooSr-H0wy2Zwr$(yFSc!SGD*JiOgyn|+qR8~t%)XfGW+aSZPnhq z_xnGbI(1I>r@PHri4*mqp^JdhKU3(?iORM1(wO-N)^{bdBi?N*!l)WLB{=H5{xUwQ z<5>{A#QE3x$O0@}$g%|>uTp_kj&I+$Eroy3-FGhhwA?N`BZXiwICMI>sM?ud3{y8C zNuKWW^HdYA@+7F-jhl0zN25B>IJcB$_P5Dy>m&lpVdm6eLj5h(!>0@+O(wTR1^Fbi zShJa=IR6U&E)H#c>d2(%#BmxsT>oO)7K1U_RD?TlS7`Gvqhv1uM=4L?a}-|WKb^;c zrfKX)DGe3lah2;}b)DuyzhP8GDji0=UGFO(B(Ox!&x-m?$A40$ zhGGlpQ;8*p3c-h7hy8n&NQq&fn^Dc$G8P9c-49++*>p=Vd{JT)6U!HW)}T$fGX~xp zlO5rb50|*uh@4eOO%eqUCAKb~Aj;TBUVnFCiO>8-$X?A|Vc$7O0>ksyar0fhkO@wt z5WCzVI8o*8s`P(6DDGp*7(G~x04xc#j6B2}H6tqTc}Q$Qz)3s0gGr}R_OHs27*fq} zW!hPLx+WF*s@O-vd=kPrxYKh^($6L*MPle*Mb$C?Wf{rX{N-ThG{=3}g7Bj0Lu45x znTqDS&Stl zP98Pr)66LWGd!+SVaexg*a!0woCikX?`$z#;8CF^GlB-T z20s~!*$^1!zLljIpz*pQZW)GA`~Gk=J&(r0=+8_E=C%l~rjWyx?1+#Dbw<%N+69=Y zRj~zj(p2TCLqaR((p#A~nwvPCG=!goaK&|c%1g}v(74p~4b$JqlqEyUGB%7QQ3H`) z9SoEkg+=pST@Ql{;UQvUo)^HWNI$(M3YAaM(UQq^Eh4sZW+3rQ8;>A723u+3N^{vy zxsws;j>CxC>WfC3q|0gwECwSjLSDAY!4NQ*9tlyT^)7LX0lcFwjhTMf{AdMGy-D@)#xO5|NHDs-@BM?mhQBs;qmW7`O81SC zTl0~cKJK@S9$Eucp+U?#N1J`KTiGM5WXpeL8MXLzEnzRiiTJ1l3n;&GDj+3gSp@b& z*@q&2guvqZ2a2352hfc+1-7S*>R_#xXKkqgiJ)=T5)k{Gxr^L3GOyFd2>clyJv7_A^opK;t7wo0 z@4B6y^e+%=Obp6iw$Ca7rOdT8Y&UG0ygt}&?lWk#;5$ot5`>{Q1Ie@IdN!MQu7cbz z1iE8SHNHKc7kU@MK<{M|IjrfS>_(o^6H~&F>hgTuG+{8%^vRy_Dl|Nh+{z_}6bJIe zw^wiV9ZjzaW4+ z(2vTmF%4g1dc*RndNO)bdIyIm`g@?EWw&eHTwe}PzQ*NGKeYL3IhN1kZ+|#Y;wFe< zCQS*X^>>HQ-_0*K6E+OM(@H$77aoFU19ysZf5i=xOkET|s-@wUpd-^))o&+6W9;Hs z96k}xSqrwsW+ZI6W%e8to@Spz#QTjmedf6PGDwxVFz_@&3)UKi@iC^1>8m0=NX zh)H*!cgMFuqfX1_l^8?0@;-%j$3&oNe!Hpz=0OcRTYJV{4=n`577DR&J%LU^kk%XY ztoD+HnwrQD%Rex#(O_TCYqTGRGrCQ&=+ut)@xbyp-&f284K4tG7J0+JUv+zS8u(mb z4SN~Cw=B$TN9Ec5?>y~9WAAn3Ai2W=TX8d`f~NzH1TdkRtQV*=dVWVCfzO^&*kt0U=a&`&=Dz7>*H6SHT- zWOfM$%I?(t(wqfJ7X%=+1N9P`=RQUE^}mpS!Z%Mg{^@`ES##tV0aDkJuLikR?;#Q7 z-1V*^j;HzNaksxyCM~tkOYIR;HB$T?g85p_Ht=JgdyoJe`wIQCmc6#=%-YT7b@Epz{kpf&2FG2(-Wc_c;1jA7DU!%+@{FU z??V&<$?LEzP#OQQPtqLJ66eTSz?_dtvXKXZ0VEzlGozWD+;!sfFdJ zvqIYN5OHVV*a+6W%Ws+p7&@oA4fe5fLtO4mxpp(NsZ` zBX~eE^z%B)HOdmpWy?u*9OhTR$(sw2^Jvcx-uatfX#%W;ltZdPx;-|BcuDuwokY0? zCt5syKVyW4i~SNME1@t=Ri)V+0YCOsOP6HRu07lAnE7NiSMfCK6}*wL)=3*RJf-uB z^UU#4ey^gOu!#5UCi*;cbXtz25c<`Wcb2b5m?gLq_pOr7t<(4uZNmCXbAaA%C> zrSyBOIC$-Fb%Qo?8$k;poD_&`fAK@1%Clz#b##a5jjY6*r#VxIjva7D6ZKZ?B|3m% zAyUNVv7R)B5#^@oCW{{Eg5}p1zuSJ8tXeMp)0~i?{bd0~31eAo?P=DvpJ|$NSTbZ57 zC>0r@wiP783ClDl2Y-BfMzsmeR3-=Vy9sKvxfQ&(^=v(Q;&-Ca;r7+@@)U5SB@4-f zqg$0`;AjiP$>~#;sG7FpCZKH=?2qdv>k-o=GMxun;uat~YEZO~%*EEtZ%QluXhn5n zi}h_f;rpZ8DtdmRt%S)3{_0pibSOv>SjBHE9F(z1kI&DLetM*|^#n8xU5zIW*ED`EvfGClc=K?CPAYLN`-0DiCurw3PQjBT9uT#AjcmE0XFu@;S~6 z@?DVs!*SdJaaQ}Vx6sBs##<#R3Ha7{TD{QuVxbrh;n-(g22nW^EywRa&yzCqOQYby z|ER|UPh3MxP>ixb#~U#qYwP}|TjvgYAj8~6N_(#3B+!Po5YG#!-<2ciFQ@Fhgy81? zQk5VMGd@FC*@tarmh;QvHICn4MT#zu#)eDTVFGmv?23zxDV$D<)f~B&a1qjCV_23@ zZ#a{zItzX2jz0eT-##aFs;r+CJ{Z{lc6k109$OTQ49vttSzIznj}-6!aM@J&|_# z*SsSPn?i;z(MBXzZLeOf9{)hin{|^jk5@DXM~`*4zi)n=Oqm-^-_}*X^>ttWyJH!| z{rh*)>f1XS_Qkh`@!$7v8rv?Do65c0ILB`UfJf5Ya~5)dpuQ#Q=7rJva|vM8x@`n7 zrcK?=eFj(p&tsh*9s%1-?Z#F&r&Xd0dO+97zgN+%yT5;18$Nd*N1_#R#+U|yITL?j z6{JHu45w4+-W_cG)O6OUZSJoUA-_DAscoZPrpDt-N#mVEo7&ceCaYWF_}Xg{9_m?2 zEw_g^hlgBgQe7OQ$ZwXG(?IU%0*wi_H)s+Uk@K5~*iaDGY$FB9$4-$afL@FlwtfgPyxe)dC5=hhP5CSlaZewKa zGVjU;MfKi!^A_BWqt~_gyZRT7?~R6=W11t2R95Vylx#nWuO_caSl%wR+?odFNDWGD zQ|U4BXFkK>(#FM!bTr_ZvSYxh> z?Y-4GM{f$98)uZgg~xv69HP%Py?#5`2xo4ArMe^uvb<-6Q zF7z|;KkbGMm)gDoqD|Vo?fzw)wsyqd&#!(7e=FyFfxfVgUcHkQ36tY0$Bd<`_2lSJ ze^^PLF8{UbyOm2!5_QW1E_=~}Z7>@c%QzR#2*ef^fUroY8C|^s?s?b=N=02aERo48 zjyF`X1>eATkpRrPJqDI!T(Xx57j<*A-cY0(mv6uOUSg-V&#Cd1x~c5%3{plEE3O49S#RqSY08MsI3n>DuDotnASXka=;eW=KF z@*#W!jvJbIW)d@0^=Z@^I>(lF>c+>l`dEs5Mn3zI15KE4_}0?aX%6&%5bnh#q|)Oi zs8x@hJZ3x0e5982Pt9bZ=c!q8uELoW&K_MB~UD zByCx}esmh*R9#?SV_yr4i8uVq-QIJ{Yk5}#_!mayPZ=F0?rS?v798|Ccu`DdPSqG< z`Xfnq5sI{u<^HR)d?TvezYOSIJ4Ef`HrdlLAbKZs%z&1)P_%UGlCr`R()5`7lgZkY z_G+-ruz*oNS5l`TZj0Q&kf_P z1?U!Eq;YvRzB|W`-Non`9z>>-8-18f;L|Y<)vpQGzF*jKWhLx>mcbwyAy$?ke;i6% z^H8Oi@$~qWW^Byx&>pE<&J5|=<}lypFNt>0MRT=9*>WLk5*>AHS8@tILoM!0ut8^G z*C&g?@x__F#=&lH#nnwGX~lBT`i>=EmZJ`&EsC#IuwsOcT`*$DrY4C1!H-EKAX=SL zKPH1gch21_)FD_00=KOh_PdCy(-_XK1m~8D|4+DEu~yphNYTEjLY3zF>bK|2Ca2wv zG^8)yXecIJ7VDeHnzRN}0@^8P!r*KS?{LU?Vb;l4Vi4)VDpLRIs7}+}X7x_Odfv!& z?bcuG`i`6b-b(KG7|*8gxQHqC7~|EY zEmZu-l9JI|T>0&Gdj2khP`hb+2#v?|*8UNpq6ZNVj6cVA5gS-WS1;Ijf*u!9|YxSY|KDOhij36k{?iP}zRX@5W4^}~R zD*PyCz&GNS&-SB?=#RrN>3%?6%}o{ZECK0((Kkp7B#XnE9*<|nQ%WVTN~bf?J$o++ zHb0DWIk2qR+?i*v6ddG1pu2nO8Q44MpY1UM{)PXc?ejN3`1^0gyycy-!V{8v0j#gQN8IO`jgY-MA zt(k?3s0&#z0g4-Ji~xV#td5DxSN!{1W#Z8Tekr3_FSc$rlOAXWUq1q50(+!ffblfetjkr^uNrHOR8z)P63 z!q1CTZ*li-?IzU)(XOjHuDpJQ%?G!&EA0mkbV8(EF_^ZF>l|kyZThKEgnYOiK?CEh zuHbxmkElZ3%caou>W!y5Bi>I_(a~*bDsaFJ+2L=Q*!CVE5@j%gN?Y_##y7-i^$F@) z$z9^BiD0dQUws&ZFDzo|n@Nyt^4}z;;8b;r-Qw{>1m8z(c6q*$*h!^t>(kRy?pE?Lk3W(a^(DmODnuwpfsBNC*Yrh%J zsxSe!t^)+XY&0r9s2(b-ro^8JZV27zM0D>rk64MIJ5EbQv4c=6G&2;Yg!jvlQ0{(;X>5g98>XJw@TD+#JkcBaV-EDp-mKP{ zh28;=oog<0h36%t0%IZlTqx}3?P~+PS>FxxbbK+4Bq2o&f;X8cBP5?0>EWP zUuh3~cOSY#D%K832@Fi4!;3*shFUH=ZiCXu_aOKWwWLg+$o9IhfML1h=y@nIvfJI_ zez)%~iBG=D;Bx{F@h{K3q!&<}gn|nD>MDRh>N%U&f;?&4kEDInS(f|n`R2Y-te$fW zLz$CDWS+3v!2IN>SsG%U!2t;u?GL$ zF=X0Y;xV?DX=^P}ABk!&H`qZ%VCH$P6LekbSJ&s{xM(h0udUgVmnDE{(;!ieqV5)A z?!9hJ4kc~HO49mzZhb$$D&WKeVG4B8Q|PF?`g{bgUbF5E%pOGJYSD+1^e@X^B18r` z8&N9Y#_RF|iH)g1h?Zp|QX~3piIx=-t2(>y{c8Y2kigi*AP1h_D}Eol z%TbgP+?w6(l)`l%lEQHWc8!_M{05C_Jpr%qlga|KmQ!)#y{9wjFZ z;({4U6C*8GTvLJ<+lt2}(rDSu>CdrDxpd)A_j~94hSkDmW`M$8wc5*lR+LKj>KO#P zeHxiGVFW?1BHIX|X(IS@-U1d1Bu!_RhmGyb;Cnc_?~Sen)DWv6?#@#cb@8{)K%1!z z&3x-;6}`8*d&G|ht2ju)?Ft-<5*Qee%rpLi`O`WX6jJS=B4P3N0Xj`oTX!M?vN{IY zLQcSo4G5pSQF>z+3UT(!;~#NdfZlgqv8zrhe7=o^kzy9y>5e1eF<_^^o8TF27FSUU z6veT}Y)vKtp|!9NaY)bd>oB-9@@~i)zUxwp^XHRmJghyb7B7ZSCkuYpgG*+yU9!>c z(Gg85K19{Nl#1`S+l+dpRe8K$IhMSx1aMxtjr1+<=_uXw{~oY{o&+~+`B>lZw3tkY zNgzHx@gh=~chr;!hk#Kwzj)E+*2l_rdX5)ICkJ)oBPGyRj@O;c8Q#>zmXwqjx?+Hd zDV@%|i|b804*vA@>?ko0qQ?!atV%;TuX^d$&5pmEXn2+0eAa;o###f(;S&GKIsE96 zrXPbwfSzMJcBJc#8a@Z(dapMXAN&%q3E!%y zw#OC@Vs{kUJV4X1sHmCQD)A==gE3RJg#zYj7V$ypz0d1VVLLJhSl*<2XbOfw^ksjX z^T)w&`_P^K4yT{ZVtH@J9I(b)PO?6QBd#!X3^-+KTnt|Yv9zpcd{-oeP$vj5EgcFb zjySTT6K3nkln^zsGPBl!}(HTqAEtC6z?HVoN<0wZYjZBSyLZz%i-13w1wh?eySJjRXLM zvZ)M|?l=l_&$3I$8XPBE)pAl{ma*Q0>~#8^`C>$vcQlz_Mbt45`a~QYAO1Nwlyb}? z0+{Kxq{~ACxmYn;+z|rU^RF|*znO9}0M4!F>ClSWrf67>Lf4}AZ`iVWjIcisUDh)I zq9+=14<{G&KkhQ{%TZsxO{e$rhGsFn>T zTI{xj;w*-!a!uY2k7!M2G^b)N0+ct@5oruq;eSTs4I^K!;C#6WOjsxRz37$9fxQZx z5I1M2X=-z+PAfLe;{!h<2y+X{Ai(AMVjE3z`4m?jQ5Ls80Ig*r%Ib3AZL={TGf@y# z(p_q?Z)py`z@vTm+m7KI{JOz$qCI=`lCOVB(l~A1T`m2fG!xd%0!#LuOVE(xl6`B5k)KLdpqL5dF5sQQ*ZxB zgx;!CwJN4PhI6T9+IUAP1+pZJkZyhfgt4oZ7u`1cO-)0|c31N=J<`WyVoaoFwFWv1s5rLdD;pAZ%{uK{djprU`tqsA-X^0qN6gK=hSxG z&GDd-o#u^Iqe(b}T6sQ(Z_~G*aEXpZX(|xpBtEW;6JLe?tmIS!D1ZvF@A(i0;GKqX z2a%8+@l9H%e&P@9xd@6sYEt1O+A!-ld5b{iW5qecJyJN& z74Ja`*3V{k))W!N)pSbRDMcom#|5@|KQ)#?to=s4^A6~0>y3r;4z=n>%g*9^Ja3pW zp#XKuYa&X}L%W>-YnaTQqyc}K(J=cr8_twHctq=?e%(7cJAHIJH)3j~&*Z@O`tPlJg_o=18Dw5MU7;6yz^gDT{ij3pujR?LVO$GD&lf}; zMr;5*Z4Y1K0h`!DT2(_{Lz-Nhz(_mAJ^tB&l|j{mfRoe(SVYPGmff|x8V#C!k|V1y zDnwjh5Zz%EX$Ue%0jCS-3CSq5G)Y?pUDnhMvkNOdQom?ojNiHG0jV-IW52^&GYs~;H*Z4KfMFeHP3!#$nt!uBED1 z(K#IaywCTnTe^PxGH1$iWgP_lXl5E~_<< znsQ@{*dBs$EmVOn|Hv8QYZ5Yqk~HE*2p^7k^joKx7j2L01L{Wdd9 zej+^vWa^!xr)G>M{#a&JsPwqkbpQ#_<>16GaCdE`FD7qYhEo5qD+tOP#A-V3sM9iw zf~ZPRmDSTZ(%lS=A)hOJQofRTZ#y0$s}PfR}9wVnmB z09>w9j(7o>8YuZHIKWbaSu0A^x1~;G-m`cgES)1UZ&V?JKwSU($xE_Oi_@d{h7N=^ z+zNTa=;&es>F;aE&2LW=&g-q!F79R7f+@Z>h8QRfWZYJ{^*TfRp&+yI&2;BFzfViK zA7lxBdlSX#WMIg)elio~H3r(zV^iO{fG=&P3V)GQY93~)Lpz1p?_}8`%~wt*Sike@ zV;54e$(}Tc{kQ|xs4x;Hor5kq(@w)?64D zs3}i*o2YcRr>QQY>x*N_uVIeB>ha9K$r)Vx!N}~re9>VDCsTU^hw97# zOzJ98s2Nbv7S|z~X62EqxAXGYlef1+WjX15pg{;-9c6Z4FF`#2jw69LRFdjcQ2NU4 zp{KrH6!ncy&enx1?1&Z5n0DIz>k#v!2jjVa1-JS z;>U|_Gnr#bF;&a#dX~GJgN0+~;ZKyzU6nl`W0`S^PAZHzRA~IPrYQv!Dpy%qsGzh= zm{m!|yCtucn3-rQzcxMsB;_$8mBkfO+jad@xYjrMq1^Dw`TeJ+qd_-{I@j<<-DAIy zE#2N>44nRpl|-U$5e4*rp*}A$S;ZuzaZ!-c7|awA+l<1pUxZ%%sq6|QPQ-(Vc-F5F zKTFu|0Tr64lkHaYZLNwb^e!Z~iGbEEz?{92kQ5rJT*|v2 z#>ng7A4bpSU#`^2_%DExc!;<{@GCIQAf@Z{mB2eK(KX4Qslt_AjlxPGc*T>*)XR+R z5gnByv+{|-S+{I?xi+t(wS2Qj zp_?kvqGd;SpQmLPKqO}&wD3t?VWu};dSJ+nf+5{yVCuEq8KD>Ovp#m64Qj$sU0RD$ z%K5BD99F+5iGXkT`JaEFGwY0KUf+EfCurZN48%o&K0Sa zd(OUw(Q#MKMzC7gS?#5}K6w)P{z1OEb&v|2%S%vRt#-WoLwYx4aFq7Jz#^&u;Ou#k zJuDqEm-Hmkb*R3S=1TtD%Dc1R$XV9MKqvS+0R;%8&K9k4K;9z$@Af<_k&7~d|a+xSH-l=yd zimqT#f#|*h%WPj%#$c44Mnzlt75|&nWFRT+Sz3nXlcw$R-K-)plivXiTI6^PaRF|1 z(T;UPor0C8UlTjpw^4}HgW*XDj&cm;?X{5!z|ArDA|8Ks)o8x_*}Ar7V;o)WzB)&Z z{bEqeb-CbxZD(Y%<)i??hhw^X(u#1%KrqKDA{y}YVdO9;gL}Eb)I!1FokqhiZysrz zseRnOaPHz|t1qYZe1wc(ticn9q*p~fbqF|U5O_>J!IY!u9^o-MB-#%{Q{M(k$&76S z5trV}(2vFl0rj{E>RSk$APYLM+0OpI%0s_cWxqG2C$-A*sSL5wlrKZcD{lI){`OW_ z`}oLMnakj>(Lz|l6qRxN`_CcgI1+PbK#yxRlwjji+up1ETC`>=ng8mIiw8l?!r&~I zXQe1kEfV?=nb|Jdy%_>WC0#anOnj9Qz|$9#AP|n-*E%tGR0GxII*=!YF3uHKotL%P zCuhJN3Kq6$$rLiiuIkc;i^YX2e9(_2(oKG|8%YylZ{}e*e+PXUeu6{ii1KKgnu2DG z%a`}?iPMmB)0Z4l&xcK=R)%e|oQU`7uFfqtgBJQ}U|tDQ(i6m?|8BB_RzMwqdq#2m zeSvxPUSFEaPIJg0+?dPdN9rl67)Mvvj}qnQ7-ya6OQfac6hHqint4+FTPN(SAy1T& z2KuBrhjsiu&MdxFP5JxX2$V|$Mw*w~&FTa$5`+AyW9m^fT+?<@bG*8i=?yH@YF;nZ z5z>OJq;5(D^_B@+MiIe@W=s`;grpZLEPcA(0>o_Mz6Qk!VfglTZq&eq*C*-r<*=?{ z($s98h?ZH{CsCVidx+UpW3UKu1+Hgp4;%W|4l=62$@Vs@xV!kAU^G?4&}f}HNSdds z^LxI%2fBx7$f5IhH%J^~W8vXMkp5HCZVLWx zt1aE9~tlIteH+Za4b@s4f=a` zeO$Qvuv=vI65+|6dD9>ulm{(oH1y6nY~28`_7qs1wM2{$Tq130*ZXX(mP{itN}#=~ zq+9*--zH}1&AD!-K(nifO`j0!tvi~+p}(e~Pm%UF%yZWYmOWJt4a(f#9JcH@T=F-p zzZ$GS(>rum@z@B|k+RaWLefg=Ol2)2#(dzA!{5e4THsKNgGCV{BW;F}5qXS+83}E1ah8$M}DVWgfTqSHUO{ znW#h;bH(HDc#dsnuZ~M@u&BTL-S7^yv-uWEje|3xyi1%o9|#o|CrQF_0eL3=B7n?F z9X&kMb(JMv#TYC=fW%=cMC_Isg(i1k5Du1EB|Nu z&fi%#WH*+JJTLLT8r_h}x@O4)kUln?dugkI%73TSO%q&93r6U!y(T|>y#kz9%gXdG zfEDfa#n#G-0{lsqtGIW}RZ|jwHCLzsTSq^9w54ZVRxbxmH-Cw^d{Gt_Yi)C)&9don zP0r>_Bb;)u=Kg1tg>Fxq}^SZ$8MG0 zl*FOhf5iTGLaZ$%^+oyI9ZRv zf@;V6qFM$3oqHBVGvJLtBo5ELj#sRTOL(3F@u5A7p2UeELUX+4CiR&93;sJ+!egZ5$ zPNvA1I*F?J-tZ4!TCJeRz`iYP#msDvEWwh$3E})e@E4aF)zv)2-vM-17n18ubXM>5 z;d|??U(M>g)ueR^Y@%+eMi@ec&KB<-ccAt2pBM-p_U{TDHDi^HqAPcpLXmT^YLCnr zG}}ikf@yO@Zo;Xy=<@{F_zwGaezA&SAVY_2RK|qh%{>v=eg}$}@3A6#10ZJv2A@ znqk|Y+6bP;Ufh}jR*r zyL9n%p+2~q@%i3ViQfFP2S$jE7`Mb4O;7p!f-Oo0t-*AUkbSj2HrkEtxcK#3lx!{t zusuze$g4f1%tDM!21y`CTZ__+n~q6QqWBGS5lyR=%H^a|{RjEDsWcquLhWfjyH#%a zq{`Y2{`|sumF#_uzq<5j=xssnRi=zCKTRM}s&(|z4*DCOxyDs-iG`cEZ@*G083*>o z+Sj+K1p8}{krRPnaG__WOj;=K?)cdpcu#(lKx4j*x;aXqWoY1|6bMm_Ln^8#Uut%4 zursa{2*Q&MH%L$V%ey=~9FMc`gA;6L{?a-%!Kttb@v1cvrZ9b48}|cm{3fYmKPAjT zH&%$|UBH_>`vs6tFARVjQR%`+fy2CJA*A_S^d4AtThd5(%Z1O?8Vx1}Gj+KDd`^j9 zD+CB-!H3t}i4BzK;fXlWUY;4^x`*Ed^Lj$JX^{4GIkm+0<^mjHV&{Y#X(o`*+kMW8 zayCmK%SvKM7MS3tYRw;lj1tiQZa*j=!Br{GF)Wy$zgG_hTaP#LR2RLj{a4Ael;LNY zt9X#av%h~qNpU&-=Ym!Nv9|0EK-%CjH83@pHC~)+>am4?cBxA$s(kN$o21oLH#f^G ztcH=^+bw4)t0HJo{^NA;UouyJPUy3}?c#4c;x27PK1W$~-e^o%Fle!qz&i3ZW_8(D zpVY)DTh4;;l5WYkNH%FBcwi{;+lPj>%Nc$4{B3`>Zr@2}g}B~=o4yAd5EQh9E1Xo9 z^2WK1g6UK0jY`2MA1T&{ngKOBXzzY6KdOCvlU=&t4~ca@K=VQpqMSL5(;M)}ZK7=d z$J8toQEPe7t)9m>SYPGHV1LnFuW8|2=3J(9G)qO& zf-+*tC1ld2p^TNv3r#BwSnml%S;?ExmaluVB?K?~%?u;&8W2EhNJ2;bw(;FjOj=V7 zCk*=7%^o01U(%&*?QYgd$N^em0QRo-rbFex9AR%bY!87iA?@Yh1sy|Dn&k)dS#`um zebM=1MSO0lC(rx`WV_*YHF|b9B}#KCjL4Aeqr3h7^jPLbXyy)A};)xO^oT|ljM?|CBeN(t-z$Y}t$2_#;q z)~zLdY}i|kKyr|@5jmt_f!IZbZT;IR1?9za-=TWpHa3>+Y#HRO`QgEt?P79TAj_(2 ze2w>hIM%qv-UkBlE=jH$5L_kY>-pM~XtG05nkRhJ+na<050CR$2enT+Yz&)g^g^?@ z==FRx;*tE{fDDDmcYvw*qV$fHZrBBmRukKIri*`%&;TvrAV1m8hAksqCCX4f($mT) zKMzD`kU4ivtK1d1KT#lisaaIDz$vbgxNJtKt(s9>?E+AY$aSic(@~OM>9NC9&;OEE zN#`HUcI@Lytb})hv9>kij_t#F<`!~Zq4js!i7Ee?RPZjVP(gol7dE7r@;ZToT(&Y- zQqaDKrS&kNv!(@7Qsyk*MrT8alEw(sH33mI3D}5Fsy?E`zfCn$W+dIIXflPJWx>7P zt2>kOh5_Ht5kP|4Kgbj-lSs&Y-H*6Fw}u#(e|Xbb1w=v?{99G7#L)<3NJD+LQ1sGO z){im)QZ`7-H$fhAK|ZeHywu@QSocOEjy|uGEF0dU23rDkS#Eds7<{C&p-Ge4laM=T z^yXjxqGYy}f;5YXT+G6J-O-%1vhKqBnQGfBcYuxyj_!&?dWeN_vz*RtuyiLvKfj$+ z>z!O~`S9nFkf}L zvnFji@HeO7NB?(XbKU%fxuxVd8R@q93qq1Rn_7-D=^wsYb&@s-BYsvpq({N!$MQ*6 zga+{AHt=4yVNg zRN0ivkCOX=)xCnLPwJtLK~_7G`p^^a5Uki5?jKD%A4vlg1uy1v^ z0KC?N4nt_XKKm)faV%!}vWtWxwO{g6_A&Lulc_U|B7IxWE2RnOFpMuJpqrig)o#>M zZn8~bZHdu8yiHrWMd-hIPn|8)Y-X}B6!?z)3IeQGfoa!o1;Cf_8!1%SYufMde${>YZ5BZl%4P*BZ6VLWg$mR*m*&s4S_dM-u;^0D817 zrNeo!A>Iq@Us80;@zL`gC>+%-hRH#@7OU->5mwl12m+{bY zc6Y0{UF>nFs5114u~&_E<*C4|JS8o>6lDNvm~Yy+Q6QmlqBeb$)5Q_Z@SZb;SS3>I z;CTeCaI-0Idne5gl-pbTQG(-63wqQA)4UVL!&LjTIi@IT;b)rE^fj}y2netOJHAr2 zi98a}$H0RZhWRsrZZF123NcjxGW||f(4eGIs#8zpU*dS?p?0fcE+)XGuy>12{Nec8 zd1ckHInk-AzB+3<@m3X@MMQZB%Zw4(l+uIfzoEcG8`Xa+Qm?RN$OsW8`;5`aWZ9?Bv3{pPqcp|D1&t-+Dr4=%s)a~X{PWMS}H@`20 zT4rH18j{WIIcVg6L<2#Lk)W0fH52#}>-q zgX-G6Jc3Vsd3W-cT%5sTHfsqx(NfOO#~?esB~0P^ETms-(%Zl(E%}S2Tc@|R2RB+0 zSNivzpP`LrSBwr^aTaVZMZ;T=38#K}sUhGBZ!T*2z|EBY-9@iXzjljW(nCy?=8ACfd0z2*rtTn@Mof)ez~Qzn z&K@TzwRqcHvAbC85r%I3Ntie;2TMES_h+bYH&4c+$T<5w)mw9M>C!BeE?;x{>=j)zSfY+RYH19v?@^1D-P=ExN?uo0!7(UIj;wH0ccqGUtRuBbMAe;#M}I72as_( ze@;hQf)J#K3u;aexr=TVfqUT<7QA3!Pwp4>CLB5saB<{bm7yK_Gh^-@z{|Jo`GB@1>fAsp*3WVg z0!!JC##^M=!;Ai_$t5rV|1qjilvcG1SV?a3wKCyHS8oX_eBL=lSE4@}=s5fY|Bq9q z>CGU&j0pt9vFCp}W&WqD5rTk?O~VE*4^0B#ZooDhnBd~VSM{y$^@ z3jUutdjZMxL;uYH{GTJ^kx|tAg75v;lYTXe5bnRU}IUr)KT}-4?U?MGPz($3%@8&_fAi z34s?-SD+RKx9^sV>r(_~m9NIk-PVg4=NpeB{odF77v(=6J6DVVmhPM_IgZ-{qZ`h( zx7v;jn{|eVkJAkspZ0YAR(mpEi_VU%H>b9AHsss26(e42yQ7TvFL-|9nEYkN{oI)= zpEk$s&`I;k{x1&>pEUcf%dSj@E?G0c?nplNDj{*`#K?=kbHhfxUiDv2s#|?%|KpCW z+vUsK{hU>+<|aKrkbdxQ&G~UNwM<;f`#}kZ5&K}=v0y?hWhFN!< zAT?3nEON!FHCr~jseZwPw>zt+SW~vhE%C&&KAqhfg`r~DnY}e@V=TEVHpPP8(h+NCr9s;;Kc1@ao zR}{;?GNc11`%ru%`zMBQ(j7K@x@-iS-9Dd(r^Pu_o0IHw^|!?b{r$}EvhG6}TyM-a znXmV_ViHb|3{TaauS?#KRM@o>3(h-y+b?H(#S9ZhZ5mY+TZc7i8RvWZvFCd>Z2Izt zk@t3=y}n>X&1&qKr)s~>;A$q}6v!)P2ygznz9;}!gE@8r<6h6}lb`AR$hPVnS0s-t zabz|h_j*r1NBV)_zE7g(lYX<)O+>k@S1OIIzZ-QPX`4MU+5BJkSnKB+A4hvfA4NLA z%9a$^8|yv_WJD5Dk0vit#i4QDL~Sb)o3>b+BG_r+4)1%t`0VmtiF&mk-vQs~qX?{Q zT>JX}xFWiG6(abNIY!odFqz94gC*E`7ajjNfN-uGqO%~ai92;1Cb5!PXn7q-bmFnCx;AA z&Vhh22Httrz{dma=x3UYIn9&LlW}dD{StutQe53l$niU3fYgU+Lq?q=*I3N}5Ukvi z`=S(%7(I#>u-g8%ML!lOs{vEi_1C0nu+40#Bxuk88XX0O)e zR1L!9i1(RyT>-!OcsL=up@wczn`ZWr-jKf>*UO_c&138}WH@r}(whCjmWZnmUlB_V z{bU_+)p!ZG%*$?0)JOV7}ZgZ4`@HAz;F06#;A^mk7## zwK#FtEs+`?B_**yk}zdLUHQ;OM#1q8_JDNnEc?uU2*5jd3&elDhrnUK$d7mXoa?(S z!QtryUL%~kMzU-HB;f~GA-*o$$(us2Ce5^Vrt7n`rL?TNDYSO$)%ba`OShZrPe?r| z(;e2|UUUu~+tSdAoR-1c`+$yzycQs1-kf;Q|Auanra`W!pdaHxNW#t}H zNrq^Li|=}1-WY>2wK7O{Ot$=bQPu+=FFBXqTU6I#Hld^eOG^M0`*ZsRk7@wr1g{X? znE4611}^hPZ5MKd4EQ+)f+noqV*dOBUdQIi9_QlO&3)Aq&PK``N+4V~)UyLQ!ZN4y z_KQt#Kel(!m#@k+59(4=TtvM-FLFC?OE18x0*d<^SXKd|{9syOf3JF6MQ!H%*_Uh3 zyYSE5UsDOHq0B8c@VTL@wHl;)*yl-5aqN=^i81WCfGjNfJ|IMn#<@3!#&*A#1@~rb z&OfICgi-r&gTh2+Hi+@i&sc(n(p0;KAt`M!cLD6w5qk+i<*dHpqL|}KM6S51Ial1! z{-SB*-LY|nz6SwO@)n}BIc({B4kvAov|Nd}6 zqO|>mNYTYOG0AM&Cgc|Xoo`EgdmKXrdLfG)EZy4U4~Lg{CabwA(4rp~lNGZ(9%K`e zD_$1F5~5U^lFLF;A#E9?12 zE^X?4X(*iRA;rWF^M(iJ+qKMN+HtK$ZEWatHT0ALG=hZ)kSUW~#>|hcM*AODB(#I2 zFng>FeeiT9@T5lHOHuQ$qq?V~(EmV20s)_F;#}P$ucE#_e0|QM&c)zuKP@oGD`~vz zN9P$uQ;%4g5Lm|@c2FiCqu{6?e7(v@_ckCGdm~U}%+Wm3N7ep?w80Uw(!=bwDu;+d zdv6;Ys_roHtYx(aB^pBLa>MIpvZ(J&^vLaz^z@Bgp-NkDs3p>4%lJ4kG^9)a0vM2Q zP`^v4qkgB-KHJb3)Ls6&LD{o4g)&}0IJ$g{qrm6j)rMf{$pK}Df|F|kp+F5%(j)4( zu?}WTRi)i=E_U! zDYtstJuCHiwnMfm)pL{)F)L#$4tP-$^D9*Ob)HUI2#G8i0SD+gKTBxY*`^Ii*tPUU zGb;I@lk!$q#RtSJOOAj&m?Lyh8UPAJ?&ea?za<$N?LzaL_7;yWq6rS!gmt4fnoy;w zOwi;k-53gXR-2CFa<4||5uKL$m{X07jPGLKfHAZ|KoLYG93L(b zzF>L~E<9=Hr_Zo6?y`%X22WvF(%A=DaJ8+=qA^&&G2e^ldC^0D5B_n|!lpal$59|ebA(@eAF9#$#iNw`q6808b z3UWy(ygZo{oA}CxYT%pg33G!^8K~ng?_~Bc~aQW!aGTi;+rXq zFnZI$nN{b*LsmY1a0sSjP%LxL5Rnn{;0eO0h^T7DU0a?*zO8$_B_NOlv!GZ|srXf9 z*ZfPqCNhwqgb{qK8-nZT;Q?$MZe1)~H7@!JziA*E`3AtIuks}4Q_3=bDKx}BfLrT)m9N**sANHO z?hWO%(x}i6$7NyDPHL+p$B0uetFUf#TN8Z69Lgd-sCj7q%HBiChVG)4V)QUZLj-V5 zbbXS^uC}J_EFgygFKL(sj0bg5wx}^3FSN;)YCsjzu_eEQ9Z40^@DC( zFlm@QfL(DOPMK*>H@6V1scmAUBAtHk6Ae=nuU-ScKAyf>F(8UD zb}f?-10`$`vA6`B5FG7pRB6a9 zmz9lEc598rJ*aAVY>ND$Fu-J!5lV-L$2>pZQnOZRlep~UsrN8Om;8xRYp>SOH*iAjTU1>I_-u`SuB>tFL>fHZIP zfW0h~9Vn&tf;06+sUB-K+{YEf&J`5z>ZP`_)hhM#QXQLl7Eke=!`7T|o?mXJN1q$eW(_L&N6p~Vr)Ml}OP0G^8Y zlm95JZ{+`C{`&}U=uR7j!2OuufnnhjhTT?g62qdTlP0MHEB+*qukp1{*`BYS{8*Q} z+_q#lAA7CO$Xb5QR^vt_!mW`-|DnvG_Z4@N5T$kTs21>Nmx1l&!8AdqrmY>f8T+@` zGK5ZC{K?KlD=9s+Nq7}%!H}esBw#m2qoT;pHyvL(_n8?rAVI%NarNfZ&Qv}nC_)E$ zqkj@vmubgEy)tp;IqleVL_j8|N0z37 z@a@YvR*%Jm?QYOb_sK>2(4`ic-mVdtUq-xW@Fpcilz-Rnu=|0&RFIfJ;D^`X5!HjF zKuYpDP1;`Pdga_&h#|`-lX`_v5b%Rl+A`+(Dfog49tT^qFpZ?k7=H_6Ua9SZ50R}> zK-{Z><6jKgq)Qd}a4AmuBXFkyGe)A&h{_tkBL=tEvHpitg@m?pdZ9_$OHE5Jy%O(9 z;K}Q-lZCsh>osgtbT;g~L{_Yi8an*rFE98*-luZLwB@Kod%4-gxH!Qo zb`6Kz=UO@~ad1c$i__#?5sX!6r$OS0*l_|K z(63pNZhnFFjlj)M0eETe-hseJCB_hLmA^<3&X4a?nQziUh9bjIe7)YJT%o*1JTCmI zV{k5@f)d;(+Ku$rUglQ|B;i$;cA`n0(37bB3(G@VD$ugXoAMR0o0lHB-)r@YHchK& zp||GMsGoO?VRJ9;!opg9?1vTfME&9-YsDQqEHM>Y7FK*O0|dkQ?F3p>hCC+zrjY3O z!Dwslj21}-nI|QkD|ZqkSGL$f`UZoFWSLwzIJGVE@p$m*}*A*u@P|~&54)Bm#JK*hq{z% zLi_RCd9*775+G9&=Pmcl{y1JTtapM;h>cb1W;fzYm{|EE4g~3mC}?%&G)m@lxVEMLYfS>}Z5{f>U98HiYp&wZNF=p^ncM zthKiiEJLPj18Ng0@)}Y(!-QSS9}~87y^UGdP;>2PB_PHzYICW8{fQBmVhcH^uL-ph zHFlBN)-iX4(&&zTCsw>g|cRYk-$;f23J_H9=n&3c;{7)-zWc| zPaj5#2=8|>Rf?2AfgvMl%sUaiNC>fnSeEc6Q5w44V7gX{ldw4OcCQG#_VX2D6a1T` zzZ{3=@4+0IaObx1!)aAQD^bcNuRLaQaZwft4p1wop>k&Z+&9&IAwet&p#8>7v@IoO z&>QNUDDd4rEf<6CyKcpN2CI#XB7aYkJ=5@nFb>FN5K*}1-`x>X)T!8wPhNNQ zYFmh~lD#7eJ`X6yQIlhxJPLKEj74@6K?=~`@u;@0xrHk$B$YH;_^o&<&6`2LOPrQw z{sH>>_AR!%o10w&#P*LeVO~9CY&eS(pYctKQ9IILI*v`>bPfYX>>OIFZf|p6j-MYw zr^wLYdnZg+Qwb}yo2$%E&nM0?WwvZub#r>lv*|XVxwIKBIm~gVmDg5QM{Z(Q?k>*o z@h&!|dKf;DM^6{&2P|p4>({jEk@IBOOqE2nL&bA$Wr;>}k1>q#G8WkwNK}|x*Gyl<`at~IE`(Rri`+r2V^)Y&giY_CL9lPl`1OU8-7~CoQ+ZPw^86e>{1n! z1vy!QzPJXcQ?krCBP;Q1uk_C`Dw2ERQmYO3kR_1kuwbO zYo#x;&abA^Qr{NuQ;C|$1NYLSCWyg1b6cIXBZMa?CF2UI=&5a3(Zs6XVJ|R@t%x`; z3AWgd4=E&X7;Ve9^Mv=A^xjRR<}@^%7@IHHD+Y4dFI43Mw(yZ9crH9RCoteulusG- z)AhSAA1-#!c*Cr_o?IUeUOid7&fa}%q=*bGGup)?pZzj_ElmY#1A0tgn{3wqLe$a2 zwK~o1*t;P*;YZj$WZkH|Gs9GewO98=GPjD?H8=nb2S1n&lAd-1vzA>3`sJNv^J@3# z-yce=9F}hF28B<;jB{-_DP85}iA{O*@rrrbZR6ySM6{zA#@^#L=5YnVy#Zt%uU)O& zpD(8wx8-g*TLAYbFxtleejN%^yugGJ<@`gFl99lcjL&zhGbx9Ny6u;i9C}6LiWu)1R)Q)aDz>F3qy22;a78RjI-!U~fD|4XCQoANO@dV?B4SY4Zda^Xl@KGrOuH<{EM}&bxH+|;(rtLI?CBz( zA52nViCjBeZ5!kFReG#rmB;boAk;xp%MtI&HWViT{2FtRZF1)mr-N2$N|j{OVZM<< zR!052E|ir13mJtWiq!H=|`__^(ODo(w45o zNPakUAr1%6z~cB}uZ|v3E5i)orMhmmu;i@NMm3wcFwX5d_uSTKKUxP)V1!AtwpLLn z9+HFIGAPM1V4rN8qBZRud%B^xUD+p`dqr(usw9GZFDEM+^RL-uN0UGUgQEzl5roLK z+y+?{Kqs~Ay5t`EP7CYH#6!F^FTu{4dGOSF?RN!_b&NA~$-M6d(jNhTr!$vQ_l}3x zQ4)>yt<dmOR*NwrsK?0@jF8qalvSxjX?rRq7I~YH`ac@y9XE z(@@&w6lZU!ccleA%Ren4KXPdPq+Q#>GiFvofK}aaXet0kW%ClW9o_N!ApGy8f>|r0;4Et|~rU zxtX;abOfrZ#k9OersE}b9-2OEQ50tdOivzhYg$1K)UtwzX-=my{binj(uwRy%{X;9 zV58&nPtBs1;~SFi02cnA3a(z_{OI(N^-+E;k|sEq{oK-wB_m%5bn{q-J=VmA)4HvuuC zr8+{K3u!5;q0Ok>%VGF;Uc564UH;miWSO*D zeIyB4_i*^8e;FbOCLFDVVoPy42j$Gpc1^eWXJj{2K?xRIo*2?N)YM>cB19&6;}JO} z$pMy7{xBvIGBxdi*}zqZlkyxJpw2Y)&k~j6=3lHRf{c{RL_S^CuTWB~3@wa;`3B zgODQbhVA8f5-(5AY0Dgx6vrc)Vxt<4OK0kK@v5@~tPy!YpK#);#gOQVpisU!&NIV%j5XX=P-Q{D~@Qtt;p>DYCXqwD61A zUQTq8zLTifvUYc4TTKcjrMV%^xO*pcZ&~#-v&P`NDCrz*m~SJV2ZYr_Q4uYz8?gqp zM}QuEh9P>TurVHOtff1A9qTDUbh~G&P4W+Wy91)FbWe2@Z0sQCP7xkp=}`W!OaSupLE%g&@nbGccUw% zP8YMNK2}!}D+tjC0`25Ae<`Vg$CBtew02>)GZU4A3;2TYgQu8vE%PCvhcJT6VcGX6 zs3VLNu1b%CC5#DQ?%ff2H`=isBtCYOOdi}XC&P^VSZ3A=XH>G)fTy-il`qi%Kd>Y} zz$6P8T0+oGZe-#TN(u^IMw&FEJl*bR9CXDXQEP7KYriK4Y82 zst%8>f6|IL`t_8bSiyyQf==<}K0(5)F8GwFsXy`JhiJ>55mmhdyeP~(N~JwZ_s<%& zp(ThqOQ>GV->8GE%T};8S;7;oPJ=amlWt^8zteA&b8+&H?!!b&Xbg{o*!?i1z$La^ zUaV7$T9j!9m^L>w|LBCiMzk{pk9J7SA$ZC`X01<&|9m0hXp zM-|Iw*r+XIlXJ*IMIhddA-j37Sb*tCX5ED6A_&4 zMgWlspwQrm+R8Hg+}l!K7(cC?Gv+AEhhPKE?7P+<#^q++SK2Q29eHiemw=Cx?6p%n zv$E%mN|1Z-B_uTEh2!?kBu|V|Qd|a;$3dg1QR#pPO}xNilUk(IH5H1^@tjvAGrur- zOm6*b$&R~Wg;r9N_>2ijf+ar4}-78>VBs`cG%04wNOOh3x5Kg zo$`ITx@iURvmbt$2DK=?d%oZR>FspE(HypPZy6AyjzK{HHQ+WH!u|zWcu`c<_Thj5 z{Op8}$fPQ=i7|A1Pm0lQ`n`3X$~hBS2!lNz?=1)z5$m*GSLqY;A=vSnp(_PY@G)L9 zfBq6f$S;@fjDbv#;|6u$z7fx|8wqFmJ*XC?-=O<8uY-cSgjkdry3{_D&f^W;derI?l!mTyg5f(CtCST6ut5CS09ol&JZJTGrKkVvg+xR+U8o9NhGMa%^i`Tgds@j?z*c5r5Phpp^dxC5R|}4=4O$hLY=zLn zE_yQ^CG?>dOD-Z2$-vYMyd+$R+I@M-SyJgm<<`u`y08O8p(MmVPct9Mox1L*x&MxW zokrk#4Iu>q`Hu+dzYxioATVF=|I|mpgZ?KUQ;~o$)lMB05B`7aqyE3qekBI|C;v6c zggZ#UIj_s#KRCYecWd5nQKkGm7Y8{b$EL=_-+v1HYcn#c>ishktHKjW^L|$a*ZwK5 z`je3uTDphP5l0h_ zx&!V__5H)n3wCQ&-Eo1-x;oP2aVcs|N!y|ybO{KiVpt=?LxM_+OB{Y_*pGdnZV2PS zgmIG07a*ZO*JE>T@1B7U0qu=e}R=*jj$Z6`f zRm*69%*e<%e~13`;#fOsU)Y=T^y>cPe#=_8c>i3}86xQ1+5l`Xmzvc->MokQ?W&h{ z_TE%CZSnE@&s?28-CaJu`1uF7eAhp`obHFtPN(XtKRY8n+c!TiEnS}e^iSdY?!WB4eE2%y zUYPsT`)a*~4qdAE@|F%eR)gZQmLJ_m|_X3?Tj%xXc1>-d{crAI~So2zUUR_3G}@ zp^dqVxx>-Vhpg`W^843EEi9b4SnF{U;E{j@9Vw#s7A5No7gUNcY>1E zh}tPo{+RJPu~59$*!{loZwR`(3!ksLYlU~cvU8*2d}aZP5f|frLdznihy6omGsSB8)wqv(T%B$DxDA z=A5mMr@aMaptWt|$!)Znukt;@_(6Utw!0Gl@8|Pv&U^Y7f$Lw*2cgKuM! ze0{3;el9Sl>f!O;{opaWT>it~cl9MS^<(Bd3;6464Wm|@bE(F0+V0ie^j`g1c?fJ) zSDnAl9X`0;?mT~3x^(*@RJ-50AGqb5Z`=lQRJ@+=0k1yh?;oSUn07aypYfV8@$IT6 zcI$mh{d7Y3X(e>x{r%yY=}Q4fqruN#Roz5z;U<5&Fm!+TGFm=6e(;-Wo=0(lrDpl5 z*d4A7n+w;+*FW7}*DBTT`p9Pc=e+M~O8l@o)OTTU?0;LF7yZ~xlZ@7NI+9zi2y(terng@h(_8*6z6$&IVEd1ye;4iDK&PsOSf0YOU?WCRu_OxP>=&V^}=LVf;){3 z$#^hZk>=Ek^lW&gkH|c@UM6WvOZsheRb+MA+>5+sz|a23&g>!7T;I35%lF33p}TWU z*XQ)JS3mZ1=xCd~X-QohAfVT&wD;E8MuawuILMK(r!NeZZZ#R5I(+Qx7i+)A9ckQB ze4FCo<$p%m#doKGEZ`XbDYYDLMITighRkmV<~sr0EnPdfR%uvIy=L9If@8Bl7wK5p zcd;)s{Y3aEXD}FV1#WxwSrtF;2(mAC9oxG$H+7yifNw9GDXU`ipOK)c?$*vrzpLpzM0Y%5+)%Y)rq7BTo0$ZdF(DpdWTL8a;`D77hoIqrLu=< zY1BjmLY<4G@adIO)SYQ9ITBXc5AAJG@p6_1YXZ%0+AIvwPF5+aTggzUxs9-pfVgNa z(@F&aY@lH-M<~X<-t&l~c;oVv9|yT^p=&9_)N|BSLT1FE^^ozYI;2&+TCzu!MYC z{igfwb(AyV!}*;cQ3-ghuC|2C*;PDXCe_xe1ufDEiBh3_Vf4X%QxB}*%t4mh7_m_` zsVFRKQl_O4^uQ~;OxOLO4JestAol$NsuqT_$Tv-VsCm3oWcv2r1i6LM?lC-@R8RsJ zdE)I}k5?X#bILFtouD88F7IToa*ie39#YKoyIzO%yFX0Lba2ufzu(B_h4s&WZMEnK zhsaCFo5<&J4x>}agOC|(mLv2yMd?4)P`0=pewU57$y<0G{U%jJ?Q3WOPiUAzxFb7l zl_rZnCvSK5ObSm!UpJ0Eub&Q!H$VZuTK=?;y9WmS&u^y14L^W~I%Ts8ztY&l&Yh4O z#Kf=3x=)uh8I3P*kWP_Ldv>QcJc~@LvFc2rk3y?dI~t?4<3MagE)6%xDzJ>N#hx~Z%Ut7CR%B5qNO>a z&MM`(4h$GN^v5Y;6uC|A_-(%5j3f#wKYOB-s)aLP>TlB21|+xrl?ng(JncoEAlFs> z)F1_|Vrg^eN6nT)p0Z|?${7B8<9x$N+!?)w`jOmSbHEfV&CyV8d=LkjAHfxyu*~Y4 zt_@R5AVJz6E?nuA9-P_PdVN5a%-Zr^ayV@i)Na?q*fx^&fImxp9*VL+o)orrr#jcFheP_-msG6C(%Awx-G&Hz#a?gEMm434CJxyW)~48&1e~jjYiq#i#?Z#O=_ri0 zV`*$o!o#2+71pS>25pl}XfF~t%l&mA`nJb|AX_Hx9C^|WXHsxt=PGk z(K;D9MYadqy+qMSs7Fm6y!G!`=UUhu0#|wa#T>q8@djU@U9Eh4g^hCy!iWO-;f+EPME{ z=(?lq3~tv*%6aa&%Rfnfc2==DNvMNVjHvy96d&5BafAa0ztClQ%&#SL!<5I!{QGMH zcKqsIEm~Dt-9JI>=uM-BJBxcsifX(6fEzQ%(S?K`=YIDtvald1Qczk+^$J)_Ra*bc z&f1-_GeG^#$OtGI_{YEb?hQlDfSfQ4Q$O9Qvt+^j-C$I7csZzUun_s{%e+%%LSUt= z6llUDj+fG6<$wChc0qk3B>keF!Lvl01ziQ~tBe-w8;$D+4bTj2&*dk`;D9nTLfVBP z#mIBtDoZpC?8$!ZVAMM9ym6+|uPzIQ9MX`%7FdF40)FzDcj`{l%f7xByAu=mGS9}2 z;(~-llQ^ss=aa4(ixBesHgVH~WioUkGQJDKJXG*Pp_-Kmi)O28)iN42U|+Z3d0EOZ znH$FCUlw_H%%i4sWzs0pSh5=CCXvK<(vzRA$SPhxjluG&k zd-~)iAUuchx_xbfz?Vc@g9ZQ5&9U5FJGm$6HtrPmZ;~V))K7$sKxF1q9%0NFt-5DD z{O`jUrYsWhd;RP*i2rzggpstY6T>CRE=&(J5i1)y)yPpI7B{0S3q_XUoN=9CSdvc9 zxLH#%)EdGVjJ9ereS>FxV@zY{n_!Iy1C2I41;oCAvi+Ub${y_w38a~3FH=*HJX&S2 zW1(K*P-YISjZ1ejO=O3D>=gAXn)gx2GKyS^2f3HWOM8JCTC=No{Mvyb{;8wo-xNW) zuAq{^w`osCg29D68SaXv(F2^hOpRgS!nvZ=+!=RfrLHKd{scbj(tcaF5(@kWtAKr8 z4^o5QYfdGi5JG-n_jr*AzNXX)Gi;pvCV3remKi#MxmlE?!Sh$Bs~l3XpSy zwAA;oCivriuNcFFVnMK82v2}V_R-D1RQm9{+o75YhI#UbTmI{LF8w|GWOfAq-N~nN zB5gL}qIsH?*EET#0flcs*f1`XGPB?pBgu>sR?&3C zNyVi?nH7PwXD`_zyY^8!(_U)RB`_YJF4pecHsy_cd8S|A`eLTjwTSfK;5{27AC7x0 zTBoqEod`wZSnO}Pf5^_Gk@BDExq{X3B3)wEMiz(?NBT<*D?kGmCH*-&wBuGlLy!CJ zC-jSk#>*Dldf()`%xQT;tP|Va!%;0w&$8^F9~}-Ue}Z9`+rf(BtJi7_fPXiPX*-2d z!y&2ZGElN8)JvG}#Ke>A_s%S_I0uwq;kb=fb0PCI7_(NI&6Thd^bSX@ztKrDnIDVC zzO`PW(2`h^K#i+|%}FfT78$heGNu_0mvT4o;i$UR)nTTOgUVbxx6Sj(zW&MbrDTGy z*+Iv7JEr4bwW4QXec>xh0lvLO)exHURMgt<@fl2lrHQ@R{fK0IV>~u&Az!Dlqo>#x zmJZ0v-9bJIi4}`@TiHz5fbsOh!-#hp2YI3&xdyh}3NITC8Iq=wbWLYl(jJzJJ& zOV4&elH890pBrAOH2xd>1L|EA{V;c2Rv8s&sMDc4LBNx3xT(ez0azH`^>oJ^o++r4 zewIT(eWhiPWcewgYDrikIPglVTn9tW5ntS`(szyqVXzqBjP$zD{*wt6L=NPMR$!B& zS@%;@5?$9?8W%q%rN$N0Rk`V73Akvx8~KxAuZCnT>^!}}vNy<#jhC0iKB>xvhF9oB zJ-1Q64S%tFK+hEk0qk(khk=<};@vrrQ@|ztVRlNWkWrFi_3?yvG$7^d7I)|IL7L$` z?u}2kMif#V)i!`q9Pj`B-RzRDUUxiR3cUgdPJ5h1uLLiOuhR}qP%@y74#W?UDsvYk zIZ>P(ToK%@5qltu#S@VZay}8TlcsqzoGGEbAX-uUYeMnI05CRNqzv~#x=olBy^6BK zpgd}b7_(a8?5Tt-ipSLn^;F80{7-|i)U(rp(nZw>R*hH4Vyt!S{{G@Tx}=FxmU>zw zP+h2S+$0JE?UAtNmYm)x7%7qjh({fIi=?&RON;J=M==o@qrJDe(L*cv5InK<%KTj_ zFYqMHR4V=f(zfQ7r&T{Ta>HXVdqph-*_|*{;|63?aF;u^*fk*&R%mfu%91(CG9*)F zx$<-wd85yEx#t5axDh<@@ZiITPybk`Np9+EZ6mVEDAaHMd9^NyYjmhXji=rCXGhxM zREvpjdTgMiMxIHx5MUsv&Z;iDQooJi)S}wMIvaWlC?M6{d@Z)^G90cVldGk`b-p#* zI7Lz45p}KLIPpq;zs8a3E8t+k(L z4&&M0ajsUYa0Ddxu+}A=Dp1$$ezp5VgA@C`~lf0;P=tDLk4>Bj=RAuB5N&t1g z>RwvMQUT76nLqg((z#|+EAMb@Pl$y~TK)}AQIiG$q2?G#4bboX9Z=3QzDlLy5rG9n z1a5uY^j7X31w)g+33SfdU;DeIai+e^>F_0YlJ- zfcPk?;4!%tna?U_BeWD0dInD&sY}IqU1;0iWTy-5u zx_*7lOm4Zt9qd`jFNOYvt4TdZAhflb*<}4BzG6=2W83N04l7i|o3UpHm0@VDQPk=I zO$yF4#X6fw;DDS$KxJ3vys;K5yXUr6gbW8>hQz4_uJN~k6Am<+94qocfk2~5g^1Id zVSL?6vKlVpb`;4?T6Gh?c)*Q(L)j+sF*?Ia)wEP!EBRg_3VmlA2)JDW@Gj}A05xlm zz!;6NLp`rWY-ou+&&a84B`n@GYHHNYj1@l866dTPpNVxB9qOk^%a6{ShtoxsatQH$ zW27ANbDq-{Z#QI{7=HWv43BjXt6twUD`T|t7PX2hajFIOd^urk$(dQ|a zSL~SEyF^VbBb8x`UHLB_BAB8*DPwffDs_@HG2(y5I4=LMbXU1fIGK}k25I{Wm>3}hh0^djhKjVHQg^o1ev&B&$Ny8gcXjBM}6xF0$gcbes zr)9ibG!PxOoYf8FO@Nyex!=?y#Zt^{7;!R2pKUOwa4Z|f?G0>Ai>Ik!ffPDO*99Lu zl~-c7k$!Z!<1edm->5#$PT36M>gjo+R&soYCLn4=oh4|oa#!5s_1=8HYw+s*84*&m zH@v1SOC16_H+)TJ{A|pP;K&JKQCoJUdb#eHf1BUw*)9sOIH7h@u}_%^2;ma9D$v|> z9Z%%SIb6k*nH5 zGg}O@dwzkY^H1V+Dro9VG;|dvHmgiQXr=rRp&}~ONFfky&8<$7%nbzT(8^=?yc8Za zX#DzPq-X;n)KdGd%ty7Z$D9yD|M}Y6&tNW2)gI+fmfM z`8LhJj5H?I{AMXgu7hNKuhYQ!)?*>_enVG?sfqKun2s^JVVxOWmsrsPd!O;kcgQ0* z`)5IwglJ+wNVaaBI2AQKK%Y>Hq7B{;f5t=o8CweQ)1Yt;c^1JfEiP?=le-gbUTTkR z*LM6>FG+yU$ObM$65WKLnj*3P9f}L#TzLt6-Sdzr*UZrmhv%^CJtCAh66&R7-`w2O z$AGs(jl^`6TVuM<3U}Gn+KL%8_OYgQlXu<54l|D)hc3w#Y$5?u>+496M<=XHUI&B- zBJ~5PrnC@3Ix4i@R#4#(Q{|n65|!wugAqQz=#t3(NZpCTmZSYle2YSpk$|b%zKhRp zVUCenIGG2!o?lK1x?|UTTDV12;hv5C8mSF%EbB}u2Sr{c8HaZq9hR#sq!OhhPk$a* zr3;`W&sq;JX%Ll5?V0r*L_r^q%%@eVt(pK~=s`6?!`!@Zv`r;NCfy>BmasA;f=vkb zX%ZX%8MCp9b`Z^TaM$cQ%nm1rYZ6R=KZgplqi2S8If5+owTmYSF4JLlC??r_pmCHr zsamkYC>e)E#VT%FrWS=^T8%NN49R0-STc?;_5f!9u~0QncvKrwWX_B7-#es#!$8Vq z4!O_<4OQKUk3fBN-j0qof)$0Op-TL&6ir|G+qyq8Va%L@zjjj>#$Qi)K=JVCU zP}Qd1QatYMS~RjrGsJEl_jOwk2Jm&JvMd*^Nd7ugbTt)lZQC6u9a}r@use3g?#cVj$sEkV zoXj7ntJYIhPhr)%Z$(%`iG~Yu<-WrdeUBw8zLN5%?43W$doRowt*n1S=f=3S&oOy? z^7AAgZP9CJlUdlm)O3lu#j3S!q1~~xq6wXCOtYtY?zRGulpN`mH|hlnuh%#L;UjDF zo3bqu7gyi#1RS;XWbueMAzam_qNyF!c})naOC_t4BpPM_QKopsQ$eh|)*CvCjK>Z# zr<6l58kGX-$h;+*@=69f)soyu-?tE3cGq{t+AXrx&PJ#QSc~8W!N^pl`@V*bN^Rq` zUm2sY9nLdrVgVn9H6g#M!AS%d%2!qmqqdvRnfVrr=@RgG{@Og#jZbzqxJMN7WX4ozNsRjucXdXM3EoC&o z)zOWGWNd3fuu(5bJ1n6$`*mWOG8kHYmV#o8SQUJTOcOXi^h1!kl?kLjq6r3ryo~MV zPk?5TAer|}a~!M(J%?BFj;|V4bl!8lLOON4(${Z~lS%9^^^!w`XfH$&?Qmc6>03qX zdz)vkNqIMVq+G~awl0uAo%p1Ujsvl6F=(V3R^17PR!+!;Zl9vU)qqX65hf1jq@hls zaxp*-0yOcBNer2q%_c$=NgP|#68l_06_)hHadP3#<&9k*HEm>X$qE@^QERHrDW9b0dLFz`*p;mzzZ7Ks2 zkLW8fjYP{8o{Jj;;unO_KWmEVcY=Dr^o+nAccA~ia1)7yD1nK(4&e$Bg&Fa8>4_O)JKuG=z^M!2092G_P221Iz|*4Fqb;E zai*0}jku8Vxuu*Qnhxy#BF&$oKd7EI$03PJ!EZkDl%$nM z6bhzjyn|memV3nK_BQ{->z9SO>UP(|Kc=qsU%HFTLyExVq9*<-SeAZnJ!)i`?hO|S z!}as0ToL|^f-|Ir6FWEWiz}-##88-kXE51wXv|^ z-3Cp$y|3E0WOUR^;u6jW8iBvgZ2BT1lW%u=%#;2<9zX-W8RUyd(SVCSiIvinr0bAVb zlO;9WD^X3KQR}C%snVmL(pCka^HW}?ogQk5F~ln|hoikQklwue9g{u=+{}2uyaEq! zgb+*BD(Zr4%bJdgYcT0Jzf2Au7IhmGzJ%BnK9J&CFRctuIkv>?`1SD9G07;z+{}b@ ztccl8e-VmZZ}^mEtk1hZCDJG;pelGBC)RSHP3|j$$a12tOH%wFv~1@!dM zU~X2R4@Nsut{{Db25hH_k9WfhqYMMYmfhm6qYUEAYFa0lL&z zko{S{lgDM9HSh_eL^fU^v6sq79SZB#$@*S4FIZ3_SEL0I0b=8VAN_eIH6&_;L0VKT zw}4QW+sfK3Kp4YUbN4!rSTnrLl{)?T-^n0Dwo|+pvg)0-| z4=yzc+GOq&%I&Py_rN~0VQ9_N@6ZN2i%`LN zjId2V1P&4m_qb_EmSsm7zLE5#`sjwRB&;RP=I*nw+~C}eRkaRW0SX~#O$D#ysU|5ft5%SYCztm z3OAagjHECbR;Yquh6I%|6(-gP;a{^$thhj`sriD#VG(3qomPkL#!KY6e%A~slJI0D zo?L0KYM&B0U?|ZEL`hqBJFC!7@y7nRVi#VqQ;$&`@_aTxZ4b%~v1Ls@X>BIU|w|pI76Ai9i6ooIBx_s+ok{ zw}*XE;drT>{|)n0&ylmSA)n+<+Fg~Rju)5L10#d+%h}@jI!7n$@gq%nicqu=Ti7tQ z+=YqvP_}J>&pGf_7i=-yJ<{}elJat+5m>QoGo%vxzBOJs_(b*h!UaP8HlT`Ae=A{= z0z)Icy07#>?Hl8X8;Do2A7gGIBd!_PGVp3-jO7$7VRI{+@SBmGWCZt7`lre2ea{ow z0IkoB?5)DT8q}5Y#O~O_KEv*7`pIoL*(=(m{y2sSnKFhi3QBumhKVFK8=qqzi3+W z4`~Gs&k#5g$FM(%@m!ur*s6NK&RCVONKslR_xU2U7fgKMN1V35B$>!NSO(8>w+!xX zH~K-`$@*pO{z)@dob}R;F5=qZJRLwI7!60FECM(U0j}l;=_<;~{k99;nhjPBW1_3I z2(N-{DO(E6+Q&#DZ1D!G_XD)p>v0Ksc46MRW5i*|`P8xDya zC;kysV{&WwZcy+5Vf4g7|{TwIvH@rH=v{fR2?i-~9?)(gS`? zrYL`@S3OCt9mO{(p)dLsN@4UT{qE0`;<}*Iu=@sSgI8giMWLauxyI-ZyE=v8 zZ9+F0)_rOx;P}9T0=ja%pt4(pWdd@x$Yq=RHen)C=Hg#2Z;^X~AJf43&ikdRPs26Y zLn~0|KVsRjCbMuLfq1rCAw;$5xg5l1`k09dTV7r5@B=g92g-78usQR$3s+*T zu+379V98)Rdf-1e*d64H+DtY?f2R^kL&F96mC)bjo=X3C<0-o&{DB zjQMNyH{33&6VD?YlO4=qYm0@K<)0z(L(>U+WP%!h%XEx~)_~4zQy+3_I9jX{qNwdvc>0DN-JD3(Sx8g(9!he3m9 z-`VM}xx4UqKC4oZANbSyM{3oVe6jw<&`80A!^ClW>eMCv)6R%jXaiNb3nuVoPr-sP zO!0Z(puwn1vt-N7F9qLeFQuy&SuAI*Rq9T$b=NwLjYI{5ZUXjtfPxKSw+OTcPeuCT z?6f#{V|mAESoz3?HUQ`8>{M^#%AcX|H51Zli@&||yp@c9DB@=&BTp&-} z88kQDA6?i3qa$(!d%F4bVqbzw3R?(Y&@FA_SRK8}DHy!zhy9q!(^FV9U@&FEs$j(F zJhYP5nd1|_x{L4iKttLd2?Q14&i!7Q@61W}_$}iog??4UHlI_|opgG$>XDBnw%Nd$ zrix5PRt@v{uA~`-rfmXN_)#`5zu@_8{!yu;2)3#MT@wP@Hp2@_?zf-Fkf`m=@FFBF zx`S|qwnI!$ZpqjQI5iBV(}2>H=%!2!vsCa^T=DI)_TW-Y;AuX6qbM&Wbl4&%9@`kT z9An(yI7<*Qf*PbLp_+l=}lM)V(F`z-cE>`hDr^^gEK za#OdCLEz^Nmkp>l$~{_fKRrCC3>v|NfTzo`Ztdp7WL!L7#vm;HAouVa)VJofOdZ=I z3|_t+AY)_o(H{Bn5xLx>QuR^Ffai=AEhsO+BDl>%WN3>etokPVs71$^V03~9fE>2N zl@Ycc*fh+lR=x)oo+bLt-Hu(a-sO=9YOnmBTK6_n1=IkaS?imnf|M*7)}I0)b)tVt znHojR{|m}{23=ij6QzzJNS4inV7=3k@m=8!_!C8(16!Rn{fwSx=ohu+RST&9-kXJT z*^Ug2mW*7JtqZu#=y)gD?^KW~eVB@+b$o(5NBNBY5LB)_8DhoK53i%*hQrh8Sk*0I zr6Rm;3P%x_w_nr(jz!rH_?^;+u2f8C3*m`=5KEi4B__!OOu>3s$R?to)OJy>I#S>T zs-8vo{LlJF>Oc#=B^PmB5cz=IukC{%Te8`XVg!s+-Vc+=;JD3+y%tuL0vU{wCyGVm zW2%sWiD--!9__Ezie=Q}Jgn%QTn$HtfEb6^i4txj=2)Fl|O>DBuurWX~el zb`R819EPzW_+etKm=`W|j`WKafUbjX_lhsrbEIvc} zpE7B$wh{MTT$Kx&R(dSU9*l~rAlstsj$$PAZ1yj4uYRO}8D zsYdB(UV>Vr*do@w$D@tF&|k)rFSc|#5t)g)N5~v^dxRF-cJ_CZ^;qfxS`5rZnGB}t8S2BFHYKX!3<%%rj{+ZP)y#LR9d zF~h@TAjv+F=nQ<>Yy3AmAE^De0}T=VyM>*73ZrE>L>3I64W>O1(_c8t)g}jgV+!Mr zo{CxY=Gx=;?l5;6@&dF3+TLn3&`j5bF3%9Nm2Y@-?!CC0mDgv)aVAYoRN;M2QlMBW0UMhPk41X=HUq|dA z<1oAzEb6DjTcm*ex}I4EN7}jeDeSTvIsHk|;2;qmM>9I}O;jtqx(dC}M2U%Yrtn0_ z^gffuItTG{`3ykKB!;4oa`)yJLuJ5k7kkfylM$VC*bk!io?rzGyP zA94igbVbjjr$Ld3J?rYZ6T6@1=P;eheZj29|5=wybeY`6DdHzmC7u|82r9au8-aDd zXN8xWLRa!uv|x~3V6aMwSGQ(uNe6s-!KxIijMb18K~I{dkjaR+FPW*Rp0l>07kTuC z`5Xjj5NO~SVj)hph!lzsb9Y)c7^=}sR;tTBbII-~hIQ3W=(qbhOn0P56_EiRpS(OU zopds!oVND`B6x|lpp~ySv!u056z!dyTXPDW!<2`>u?w;l5z8*x+q)0^x@{19==$ZZ z1zilgjLn7GF4vyYMe$>|dxohbHQK~;1s+yI5{R>6n|kU-QCAak$zJ{dHNO01teUtJ zV`y45vlTdEU2aP1U?ver(4f6zNLiKo+fO7&I?Yw{9^1|*S%S3+eS%g2PlxCzU$hdR zaHK4UYw}7=OneGUshb4^(=4SOM;xYIIZ-GU%0U%u0CLPd{Y?n~pQ3f*@ECLOw1|m=>*8Os^G85>^)_4Pn^}tkbLEmavaH$Gf$g z3W!2!q4f3foE<~ft1#bw`iuT$H=&we^=t36+7-bVh{83hQ?9hlDCxjlyFaZ`+y0id z1vX(ar!{9keLu2?k?;d*Qk8bpGUsIo*i$0U+jO%oUtL;GjA%ko)#zEbar03WNnQ@; zAo?u4^3PUDF`zA}QN&^lRxWy)iL)SL3>|d6|h`_lLT*;hJ zqqtpywKx#g_jRoo)!@na+4NClT&Pf`|IcNPcUg$OzNYgn-+7#cIvX`JV?4-qFMqW;i2V{)5NS)IZlz7kK_4Bv zPlXTf6-}ee7^Rsmu@Vwh9JNHkOf5b`Z%oTIJ>R3EeNgAJkDW_Hw_|2@A^rrCrAw#Z zf!c(b7x7}14=Wsk*Bb90V1n5Rbk~GQleiaUE~9Qy^LG2%6phriK@{=~vtqi!Bs-RI zm+PV(ZI9S)0Z=EcR2EJnj=x{l@A5&syWIV~o6XKA*>;ttrJzPy<})FHtM#nfgvyxx zx^}Iq!Ve18i)KWZR)a6>K^ytQ&RC5bPIVwpApb&UTwMzXrpR1}Vaq=Q)T7!LaB_*# zniY02lC#zLJI9U3?C0{%2?-Kmsu$m++y`n5i)y5eQI)qC;DKT9I1Bsy5i))Ua zeH0BuHQ^(TPOG1nFExb$8+veN9A3(k)A^?z_B^yOIZWmH$0J=FKx$!e&^Ag#fPuLh zuz>$P^|j__u+d1e3}Inv#jjYn`vN@_xvvw?9oVLm3S7~jR6%LW z>+vN8#7CahZ0J6p%nunD3qo*JgU_Uu+ZHq<{6YlJU4`#iz!<7^E?q`y+XaLym@`}A zGcv8KFGC}QLAH5wjR-w_wn$H1DtJ;_-FIBZE(~x|Y}bovu8}U)3>%0&+fuVz+$!ia z*!WsPTPGmrxK6%u?99u36+LL4v|T#Qr1yX_^cNT1@ce?L>vsr%w1SjKifC-y!ja!ym8Dz7|vihk+8y%49>b4&Xvqg2UL`iH0_JM87f+KY=!&D$fCxa z2YHyWcu0?N;da$~R5~e6i|g97jyN1qJML2pQijYQaqbLV$RgJXxdAj)2Fqxp4r^0o z!;I#u&SSNVNc*piqSX^HIMXlkiJQ2bv@I)^oy#+rOuCNuC=5&*UXWiNMx$;P-P?AW zQ!1e(JQF=zc@t+E39k77^{@<(Z!xW^bR9NrAk3ww`xIs~mU6KXfbS~l*Ln>uN2eo6 zW=}kw!tx@GX-pSr0_~8iows4c&-9EGyi zX1-NUHiE>OaV8#!_y;FbMl}_5<@X9#2bUEY@ZXeI{`+K-od%M~lN#Yz&M3FJbJ&`d zVxrd2ZYKS}=V!Au$#j-}n^1d88Wz9RF>d4c=oH+1r1|2qe+@&TDK+$f6rEf zF~%hL%y*CcLFRP4PRJ^!uoJd+990D*{7KWLmLmE(hu4h(z-X%mRJMP=T(h8Q4n&q- zD@Jq6&{HTLZQ1Hvn9?af1;i0SH+6KlG)EcQZ9rIw8g=NV6<9h@Eg)aE$ugDJ@?#8F}e>Aq5&*b z2u1Kdh0^3erM@-|d%_zzCV(0{Y-*0JBX;2we8^qI-<0H=PGggN_gGB1%dgq2UOPs! z+gJI-isYAu#8XR`&Zd=iYr1i;T?B(<23$s*LfmVWsjAZtM}V)<2aMYpv*~i%X|L-Er#6h`tDXbCX{g zn5eF%FV!Tc>C9Neld^PTEo|Y<+BjKy{TRj6n6{E1WMi(h*r)MxPw9SZqXO97>al5- z(8Mxlf2`JI4);e6>h)^NZGb9p-~ZGvIR?Ji!i&50`LKrXE6EbzHA6wtFk3fL+Zw=R z>2+Wfe`0ire2_(eN2~SIoRj|I@m8}hI5V6SWT{sR<<;Ht--%vNGTbVjnm54;sm^&P zo1nFd)5N=qqjw3J%V`Qm`%y_obhub18X^a&&R;JTA!s(8b1IhH+^Tn&S)czll-;zzhr?vKrxOn(m~qVCFUx z&7Bo|_)wVVGNj|1+5Wb=hv8QSAj7|%7yVw;o6QMrF-H?R7!-M^!rz0-C)kPUs2!xw zJVQk&X`t#{#|1VKb}OqhB*l0FXx8z5suhcJ)U0G8fQ1yjZa(68`e9)joQe9L*%2tixs-KD$?ciXSHNoF8Hph+eH zp}r%6``eVTG~uz3kf^K;OJSc&`PEU27FxV(PEV}?<>e|)yKpItiBCYHUP9LG8C|jb zIlIsepDOe3{kU=&P*(Y!?`{X{?a%(q}vNc>r5lKK%vGP0jyF*a?$ zVjJ?p-<#*OMLZ$12iS1|g9R!V>aE{E)8FD;6;ho%ZRf!9aP3z)EmY_L{b_?5zpzmc zi)1dp?4UGR#~h!txJsWIj27M%L#|%lo@R)t8y=%H8!`9OQ=UdUSu4$9Rky(eD%?YT zVVarj3U@s^wklU4BYw_=no0euCrbtr+Y7t{kRYkrSD4>8^cIv04rx1<^nS(v)^r)t ztc+)Vxn;&kC}+%S@A}gY+FXa&xL(}Cbtr0f(=TpY9gAk+{hG>dHUmabhVB1U(5sJ^ z4vtz5kI8udF-2f;dd1@5X!XTt%OtS(qE+nJx{6_vz@{qd%wcO|Tt%QsnLh*CREfsD`)&J6CodU(9Dkji zKg5u$YiGyjxmyv~<9*>z`gOKUH&enPD}v|vu`0d+ZSf-ZYhRDp*oDgEB-&@pP#^rv zpQzo$V$vvRIDfHlH&UBf`x25=8!)z;aeOE66sOp#y zbasoo(z=C2nBx7e5o}DB#!{JA*i)mrE4m*ER}GhorPm)ZO6!m?EAXs%kC3HhU`U^= zp3^yH483U9EJ8+Z6@;>skL4KTNb-)9Q#t@c9tL<|6NK`_0C0_RTYs!BtYo4H_=)~? z=d3FCGQ)n&hM}k6>gfR5{7sty$z?2J9*?>Fsd>FK3aNjLrf%Etni{8^(fyh`wGvMW zCu?ya4V!2m$~0Y8MGIxMH=a!4w5y&v9OTb))pzLN%+44DYMK9C;#JmJs{5U~2T;nf zJ;yrv`Huh|-TSi~N-Kt9kvrSFO<^n*;03J!Y3WT1E_t*FKpF<>KWN%gJmX>f0ijK3 zXo{P`b`vt%bQAP$B`Ke!V>q)~SxF>-jM*9_DCC!$#o-+fC1Ro^aKn-Yzqr<6*>T7B z)0@(1S9pK(wuG>B%E{my9vRVuOt8YWRb0uu8NHIv6lj=vGjSri&2nBCK(qU*X^f4= zu5R;9Xj+0Sr#OJn08J}wdoh1uBymGe#iRRbNNjWvPnypnKJ#aB%yE5FYrFcGX)7eI z-`6AGM)aSiYSnRg-JWhOL?GpVUt1!~WtsD;fE-W=2IZWQR>_l$iwS{EcqmiL2LOp! z6aQu34-F&UzIv8^dSW~6H&t?1GV4r0jjm0W8-pTpwGVIyj+d9mugJ|sKx%I^t3YDxD228)pkjA_QZ0W_iw5N_s~ooS6n3W zo7D7T!<@Iinc}(7vQ$M%c5K$~U7HE})$@*1igl%Z09dAFH9`F$JN&kAwUFVhd@Vruv>#Zfr!O?xUV^}NPLLwL zNzFR_GUT_(O411M??H}HX;@jncvJ1lCEg^-t=nA5+Pr78+NxIuT;;NLh{7Wo$q)~j zP9WiMHdoV9iksR-HG(%gWHRZz**Y^z8!T9z;@5a7lo(0zGLl8nUc#xeayX;82CWDN zs>Tm~+j>)$)XWNHVmyCWdZAFOcs5sO-qJ`U+qAyJ4WVwOYhFPvq~JS$YeM1&MwTd< zxWt37`_p{12$h|6sa6{2!cG|6#g_{ST%~f*Lpq&HoFi$p0U_ zmqW4txW3r#w1Q_WXqUMGO@J0Ic5aSV899zNlsQ?2xehP3Ru2w-OH+_+M{dc_o`@v5oz`ww3zR13SO3qFa zvf|2$ifXowrq-73|1T&ieTKT~gwrX3tM3Q}G)GFy{Q_=|4pB`%!Si|q=qzl0#ehfG z9&Y^|D735Z)6lZi;=Xemf=ybksoNTOce{J5&zUi{7OwqgyYwrQWHQ_g3p!&bJ+f(CTFTVZREV#Q`)3dj>FK!QNeOj@zZN9JV?;QcU z+Ndi79V@@9Uje@~gfnY*Ni*iLe?QFMkqUR5-^31lIzF~g_5J?iuPL|!WcAB-ZYsnL z?5pCst5m)_JA5&11=ipQa}S_3>T90gh{n!dKAx6uHY68v@&7v;c5Bw1T_rqVIF1#r z)%;+(uC26uKEBQ!y?eLq&}~3t3A9Hz@Oq5l%etJl`g~Lq?48Bc7X4xce&f{F9%qs9 z*|+-C+x~dIXZ!bJuYUWwVW(by)SCHPJTTL*z0drQlH}f39XMM66m}SDcic7Kn)ZJB zXW5Zeuh&@NAN}CaYB$$>3&iJ z`}}$fwiHQ^fw^|w8xj8mBAf{hJ_X-tsz46iFMT;oI1enwN9VKtZg(zE-+@n;N5d8$ z9H{evLQPQRnU7KJRZR|@k00;L_q$UNDJr-3kII2;tq0!z%YW9lo;Y)+eEKuSnV|WV z5vz+o$RA z+Bew%;12hX%%^_}(V>Wk`SG!#@{^qf{`~{*-`zdmcwU6`0}2%jhXj2Pq~AFFemPad zZvP7d^$on<;3+-bPE+Q6IP?@K9t-16&pLc-Y@|-~f1P0YG+g1+7c>?iUUs~-*Ai6B zWVu^AwSUkn6yvFSd7R&Py2+>%zv|sJvN(Tj0#-VU$~oV?f(u3dGKl4fGJ7G|q0M?1 zK7NSB0sYYXvj#HxvBtD<9md|(*V7kcoa?gpc2`he5Nbk$%56OKcgx7X|CQ~fuc}A*W26u+2io` zIIuPmq|7o6G&W!=2sz@M>+p71JQweJH1CzXC?d=hs8l&#i@fvAbqpbIq+K)QnPw!z z8Ev;Z^4~U}^6TJW{emX(WDUSdt|j?6BE}b-4S_~=?$TlQvPNt0dfuJ9yJ$zDc;qhm z+!n}6%*;GH_G%{254^}Gb?!GZ+%mpQ0RH=9!S!LZvU+TZlV%5hvROGj9y|Rj5jV{} za|s?>*xNa5)vghxnf>4S+VuEaE^q;<@?ck_7Lv&QqP0{_eqB^V(rwMR@{Z1Yy^Q9*UFQL0WhqJ&VSoQpR;`tIvqUlYD6`iIGpZWFR^Xyjs)yj`f;@!XePJm}&`-M8a^G_Io^xy~0 zLRk`4N$E!QwAQyD|8nMPG(Swq`SoUg*pIB(>KC~1Oh4Qozgs_N-HZ=(H2xG=F*BGi z^fqRrsEUw8aO>*xdH-X+B%K5Q4?;80 zuKjT+gfpP?*}49n!@@jA{yzHTBEE(zS~nfLjcHPveUKmWTN2O`1jJO&ResXe#@!WL z_I_xJt&z>7E-s-hrOsa_QsKKQYi+(ybxx$E&wL7u90$+ zR%Rw9YX1O+`Du+C{(89^J+xA1>S)ztPfZx8B!3}PR&&wue^D=jYpm~3Elua2-)ty3 zsEgNxm{Rg+s<%GI?okPVzJxc;Bn<5NLcQt95A5v@==6C%_Q*VDW)_0kW!rrp8*}q< zRa4?M_3CETyD;@yd%d7F2Li?9tm7WGz!8qSmZh$slfPe><4N;|=VL?n8DI5c5-h@d z(au9jBrdXlx_Q5KJxXwU8f|?nuPb3_qr!hAZ{dR;n*YQ%K9ItTn;6fd1w5y zNhzO>#7Qfob+x2(20cVZ|0v(;$p2=29dzW$gE;`H#Y4SfB&e>sD+Gjzk63>1ULA@Y zpMEQf`G+5S--XZ2o;fI#YlpRfZjTJK`8p##VMj+7pdivoU^G1~ zkr((!3oFg33^6$a3Ik|hTkrK&YpB9pYtP|bIONl>h3hTM{3w_|0v-7w{jZ>4uJ~W# zTs7BJVsx$Ct;z}58lpLqj-ZOzdEecYfLpE6Lac2o428YKpC?AoToAXQUS;(5yw@NW zX9hezry|!>jt;X}2V9opsRAg6%>6b6;GG#pCie>Gx6MkQ4*;S>8QxvoPB2R=v)N2j2KyKb6a>zTD7d*P?#xcE}co>&lq?6xkihRiMb{Gv;_({{t= zKaz%Um3$>XOdgSmGX_cBC)f$DxiJ&=0k?%(GY3D<8 zL-FuYc;EG6LR2dX4b(7#+$KOYA*WEm3 zfoRq_OJxZ`N#II5DP+4<^-0+pbY4j|o*YB8s2+v&97aG{z9ZV;?;Af5Zx?tXQXegquf8*ghkcZa1t#UU@yD)L*n_nShicl9i6xY)WmUAuv1Uc!F}R zu38ciE@oA{X`oLTg|flUNaN-e>5FO*+gHbH9S55xYHOLcUMUx3$Z}TlQb{9r zU3nCVZCvn$=B2j7r#ftp-> zH9cF-8NB{(jxwsBZCPe?-Ngf9Jm?zvc z!eyn$GnlXS{M2x2A=ws35i3+XZitKIGfHg^KF3?jco@4grN2 zg82MXtjfuWDRK-8-Q8!|F-cztq%z&%eLUhhPm-%0L)!UJu9E7~GzT5X-K{(1bSc_Z-dzTYE42%0!6UUFa3f2o7Pp( zH^MjkA>H8c6D5yiHJW7sS*|=dRZP(TLT7cU zG#S=lHJyd-G93fhwWVW|Pp`hY{Q*O^>iTw=Uh_BA8A-MZLNuraM88Y9`AI<&kux9< z8oc`ugq;QFodRdP(S_aMAK~_1l|i%+CV4KHF}o|We{p77n~N}_mbv(@LcQJ)Ezt?^ zAR;uXc$oIe?gqlU6JqPk@7fMfA=QOr&Suly53Y>$KkBie_RR%CkBYGGrbxh?ST(O< zTt13F#iZS)Ug*{uV@Klzm-p->D8BMfxK9*;q-^RS51c?l`r<0rrVBdjWu3OS(Vp+^ zmbHNadc+niJs8c<~!X#rR+X2mMr%XrHEk@j7CgK7GK{gdVJ5a z-#Up>lh_Mkg^8Qt#lN3#<3Fo+w|%9bg1qumR5|ZJI@cG&S(>LWF>VD~o&dZADt;;! z7j0#>?&wspSG7AIcEe5BHbiB`FqEv!I-OFJNXC!VL1B~1K|IUMg{DMnis}Xp=F2nJ zPakU2fgzxj@?5z%AwtRf<&6P2qe zK}c(bAvRu7tdXLI8u|&;rEDc}(Uj}-?QqDn@qCBnX!2f_<+w*jqi~B#x&Jfg*I}R{ z%_XB)DgkYT02|z#zmmhrQGCadjSuUKUhQf-X|5M4^0e5q)TDiaBh5%ONG>OahuqQE zg)}x*c$kDxI4?F?h))u**~$?Vhz8ShJDM|xcyfEv3vQPtfmaR$W0j!@6V@qs2mOds zr3so+uFFU&ire2azoO2@Y@flN)Ge;%pOS}cZ&8c_m0eRaBa1I#L1INe=yomws#mS| zUAaCu%FO*rJiG)kzL|U`1vzLN@S~Fdif@yyNqpDlCoH(yBcIVzcblI4;LiDQUNFSv z>QF^T$yBqU?Nb4gpV}|?L?q97LlgxF6|@Nwza&e+#x7U~?IHAliMwIZ-y6aXL&e|F z)8%STzZ(jN?wXrQJgKS=K@z5IC;hx%>d{6;bSRGZCQ1 zINFoZsTLpuvx8*6(T+N&73a9f<$~|kU#>1az&6u63_=1L$WarcEJ=i_Q;68_am)Yp z8oTElT}=sCUk)?#Pbkx0b_k<7*kGU&=%f}~T|v(t^yPwVSgt1=lO#qwbm{f5y^zkW zMXL~*)Ds~}q<12W(MCCo*Cic-%O~bKNg%%J$$ZA!vzVVIdM|qC4HY7cvd0;dhb3yz z+GH!RG*AX6J1tYHR?*8$E|KhQj?F>BHM<4q+lhU#$2!Qg7Z>YM#c7ZTb3X_6B`z); zO1A61K3mITRL$3VuHArM5c^Mia21u#yLk8 z=0;iPy38C8Q5%8nm$I2U&o6!K*n6p*&W0kLIJci7o68hly}FRB((t8;;tu)JqkuEB zZYYbIm0lmewZ)o=j(8rK(%wjCfx86~WdNZvl{N?t z3(7R1Rtza!vcG@`-3oUFowh4BY$PwfFrIF5dTN8onulRHr>G#;lH!>7g(1=S{UYIn zC;ixD67ae)NEsH|MPsEc$hAxyO-I`JwU7szDF)~Vye@C@gmQ(kd`{Sxk@fP>;fbT* zYW1SCo`Gzg-{s(`RXvG{Xxlx^goNZaB`mR4vlwlbVkK@Mv* zhzr;;IG?#`7}nbbNS!^QknloBFnNm2pj z^(y92WY6W5IiW?s`n(o#di%i%hMI^BKz$phjpZ+P^=8H2i?=NlI8Gk3K(HtpouMl` zsh|*+Q>>evN`N-4IlW+Z8S|xtysiuQcEJetkJMa0cwW5X0Cyx{O3Ck8IHcgrP7)wU zAqJJ@mHTUNp+yyzW@lD$m^B_Fc>Ck1SU~2 zN!XZHtyn@A%hoD;v!nHtu*|nS4{x}C7B$C`=8B3T{b;dRRZR^_@8K7TyJ7BNt{jXkKh3>vs1UZy@R>2A;_gO}27JU{c9PotUi zzW*%y?z9<=@N8Qio{p3b!AxL2rZboouA)H1id%`vTkv@b>ljh}E=l>~zIhbc+jgSV z7nR?=e+$AX&eV zD`s}EnU$nR;{~5cN@(`JwQLM}6p5{$B}zfOX+e>~$8HX$VRb8qJa9)B@~F>uZO|nb zcC#S*mPniq5?TZtst+-`lAuL{?AiK=tDF5ZY zIkE-vd9Lepv9G#cHt|7oApr)&Y`SzX3l!Y$OLg@9@}!>&O;hp}rspb3Qwd5bcU9cG zcq8R-=z8+H4?*!&6E;W4u%maW@qoz>SKqE2-^#<#t4+~CNIFKVc|B#t6LnMDH%h84 zw}DJJzQ33Q4G7@y@#kvEJ)s@k-@6pZKmyFFQC)I^+d(6$d_1$0L@7wSsTwrb9fOQF zw45w{I_`M6uwjTw{0K=R9~VXH=BSWXXWARnh(9JM61|Nxy-V9D`gS_D;0`nr7UsH| ztDqia5{i@`GTd!YX6yooo zg{I1HHu>=4kU9EzckG<$bC*Q4T4_1H{o4mvf`%@>yLxHwhmph!b+c1z$9_=ueBlV5Px ze5+T}9PH{VhMz^zpv>FLSL?Uph_SvX`&?$CP;E@XsxfnA(F0_Z*iaAD9yDf2tYA%N za=dA^KBzW4nz3JRl+rDaS7#68U4lGetb=7~7|`Pbxel7blYe+0Z4nh)u3V{}(q~oP z`3YGox@CjDRf};CaM=Z}kxrm*jyimR4+@RXsJrk#?&rm(XLE%Ump}Idh*y#PV5iKe zyMBlAr7$3+ExKR3IKLOR7bl5wex%6j&c&Z^Jr;xvJ>i&Zk(u|%CB%Di6a-P%5EE4t zvL`i!!&M7c3URd=-Nnw5{DxH>Q+|Du-9#ZlJ1KJDtQO;l@8&=~4(ZllTAVzm+mqypZ2Ek zbIWyv4EB#!gXtiFMi+tA&cj~JwEkh$gqbyAb?|Yz3$*kQ7E#@T@nKU0%_fkvJg_H4 ze3B%okM~iRF-)C65ku6*IQJ|wiuP*2IKLI#`>#sIU_0Ms-+MaBODcajJ#PBp=jgk@ z0ADJA9f0-CG&25jQNKDc5m5Xxl`{_uUEA6yYeR2l*&Xq@u!+{`c+h7>S75KNW5m;CGOBvpma<#7tCluK6%i)Q=AJ9 zC{2?oAzX7QxZFw}8Rx~;u48RBKswGxLI}|CzWahQp>f3qCXBRf{*koJp;)p}sFzh_ zoz%EW*bN|OTQBZnZbT7N9ILL7pqvH7Jb|#ym#2Zu>wQ>CN&n9e9hc@?HwH{h&#AL` zgfJuzic)Ypz|^YiY=Qx-QAJ)#Z-Yvy<=L_O3i!-P>LqXGZA0`mSeZEpnbwz)fG*6)`UR&_KEx_J%-$HOrtbD$%W9xL=Bn49tNHJni(H|*neA0+E% z$d)<5I>eeFQZp)R)~igg8O-^qQQm=X;5si)L&t|7v2kdWMcc@Xih`w!S9vatb!6ld zlutHK^f*4Yrby$f;JKC{w1RNC&5QRWpt;z3Z~~cRN$|tx%w*XDASk}k*rB@G-|S1d zls@$2cVrK>IWJJlL&GW&Ah8gb{)}FjdOHtRgmnk6InxduADNgY&(NBoAodZ>+zB4L zgt?jE%7@trNq$j`kgO%06tJJf4cT6frGfJ##@#}&mx7aT*Y4Gq2ue&U_%@4V(i~Wo znFiG7#IiZ~Y@uRBJ#PKADgrii+;9yIv%wUo9bFdmjljr?te01w3ji(ct(T@4XWPd@ zv4>Zi&;k}>&5X>c>xFmf5LTeXD4pR=rO79F@9H;` z35|gfqqWobNIJlsYo^FbEmA{Kb`P`Ym-++&t|e%~MEORjx0p9Dx8lE&1rS7N0WchL znqtS-_5080ZxOAc!Ap&?O9L_oy&Xvl%p;hi7~*+LPa}Eqh1InvHtMCb=D!qTDgo7N z=D62yC_=wHk<5Xpy1x@p7yVF(EFF-o1(9${eb9NUWqHc&cPYQNryjWbbghCbeGPW9h$K{yKgkoh+p-6R7GV0m4E5y>%zA|fMtBI#2k z7fN3vYDA@}hzNC+z00{1!1y1t4WNkK` zIQZy}5qzc+%dfRM%1=0@9c_n&s&mSN!%j(0lfr@7{*dpefKEd-SC_yc z<}^)mmV6*=lai6mJ1o`nuvQG*dZO&{=18Dv#@rr$%t*w~4DTe5go9xu+7-w3rq0|q z6l=>82reb=T?o(uaA9UxU(mU^W1;YK93n()SPy2097jc~341w&gL5Wn$IgGO+9h{h z2CVq;(Z||KP=v~p zLexN8adWG>GnLdIBx43>w*Uiq!Eh_swq?WMO;#dD7iu=$VHbZCz@n3}LR9FUu^cdW zo}{@%wy*5)k>p&b#bsMlV^?UrgRu~t9(e@|#)K<)q@IH~%&47J z@4Y~B5({+s8TkmY=7QA2=!;r)K79FXL^c*L?U@ZH*oPmf($rDFp1K{krjModUI(6? zO4HRu$K+f}L0rU8AuWoBW3!vQ4$sN%n_e8I&#DAG53kZD(pWk#jsy*ixzXLx@1g+EO5=qA3zp$5%c+vZ+pMnja}2&n3^cK@W0e5AW!G4!mdSsC{PW>Dof7g^}%24o?QpX zK`GVpaG4gahW;8P0f*BM#ksnr}k}M&`;}!R?qQH+`3Ml=7T0 z;vJebAv5zdWlxE~nRc&cMW0($rXCY9hn<{UM1Ge?p+b*o!s|A?pMvgh$ZA%oJD=3v zgkDMQE-pU;LkSVyeK5Di?pBAv^esIFh2p%SYms84tCK&umOy4bhI)!zK)9zmm^o+6 znKAxLZ%H2r@Fhq|F;u{W!@qA}4th^%kKr^$F#{wsXb{Sz1i|kpnv^kM7fBjy#WF^4yhhXUx;*zEcOz&#{3`+4EEnL=@+{q9NNsAY_W; zWnV)=j+C7(y^3!Hqw;`OW3wY4cRp0$AX{i?7W4U49%bOI;Zm5#tU@+mfWfhYjnu$^ zCThz7fC)R6J2?G_%cMv1)&x9oupD>Fx*Ci%%^&9z5@0RV9ZWu^Fbh8&PT+V>ueYVE zv*KdQh)a-3kcjo|Bj{AO!lipz(l8mN6t}>NqDq(N2oETB#F16i;fuM=YI4R}#hvW- z5Kt$CU{NolUB>?)`jwt^2lrZiO9le+D+vkjzs^sZf6HDH_$x7s{C`bS`d3z#Ffrsc z6B{xFzKC#OzHEFfj-YK!NiYftV`g?cx zVq!zu$^(8CyVdlq{^rf!dtLV31ySqPqK-!UezN)mo zd#+#M3^VW0;$ONt4Lcz5nb>)3-C#hP^n2@5Wx)OVQ|7jshaI>O_5Hfr&%^Sa!OkUN z=HA|0Yk+)!9b~@x{ z$~>;NO*N6B;=s47d?z2nXUpwcwR&4SZgH2&BaI?&!z$kO@)u-TJP8QrT5_UC(D3eC~TTc%75(-QAeKUwhCHSoY3e26nCh z)oiviz6)T*5&iIzXg%|7=EoO$c{d*R-LV4(e4WqMUK9Nb9HBSV&q2ayL9`wEM$b&k z%I15x_?WM)wW*WKllO`Y^7!3ITWvmp<3QNB&yVA751Q3Mk_)GIn89YZwAB9AC{z4+ zc(xUjZl7OPeX8H(N2Y#m9wUjj-QsH^0g(Gbeoj^Ef}3uws7-NplN{v>z}wO4RicPW<paIjS#;L2Kdj3F5+?DP)RO?<31fF5Bp2t}~Vt2)5bPmjX5?eNY zddg?Dyy^my>`l#SyIWe#qVW)5N zNgIQabLmK6h8bAO2|`v8=W_FYoLuS5lri|$yaR^Vu@u}07vc>b83so2F|Z%WW^zfO*_wF2$eTXw?CE_Z zT1m{WwK+0_J>eQC_bj;*_gVu+%Yyu@5>SzsfOc@6m4->$#$sV=>ttR!l#892<4ygD zWDW~_k*e1KK6l&S*ZOh!J%QS~7?&*RMDh6Ilj3RYa&SD1O2Zb#9PNYM37Af;m4X)N|#6W)y9&aoL_<|Qe@Hsvj7flB+l z;`j66wQ@TDb*;%v;2bz>joM(6vEScRG!zmh3`-}dv_B}yqgc6;@8!Vu9?ctVVW>&? zyDkOpr{F>8WPs2NWvyVbg}QV_9J)nr?&G)hl~nUq_jIL7idZu1LTb}JZIbRR(}@6E zInp&nh@T#jKWbp1$X2nDEWCtgp$mQZKOP6WA*1X1%oZi*?D7L=_&1>I7T>`*XDU_` zIA&|b3wlBi-q4D38=1aXF*kc6zDxslxUZ(g>cx~3Fc~BL?$#eW{SK;pWtN~MZAN5v znT6!K0eEP^`rANk5gfB)QU8A|V zsJLp`i+asjGqef(6z~I6el_gVFLu zlO0_mVk5?Y8yC;_w?-YOv=P~YhOjQi2{6%+^E~#V#m)LyIN!hx5O1?LJSyefQ)&ogGd=ksxKg*o)vx_#E zD9b^nnep@7CXOrprnO&e-W?RY=rj_^`IL-(+fc!Zs&yOsNMS;e9t$TIQF9786<~rk z7f+#`&9%o&DhxX#=h?O>%blV4DMDsc)n@g%*i=#<(iJ9kCB3sDHNO%;!8$Ae_oO)K zIV4;Kn9@;(ofLr+#ZOi4L~XoNJgf|*?Mw#OD_d_f>0hO6XYWh?7cPUK)U7`Bo4jF}2r@0%IW!u&T(J@ZAxn$X9;{1VoRgbX(-@uP zMKQ>cT}j{!H%Gi^n9D^&)jl&s_;~X^J<&Bc&?cSDN-V?aRomvvo$L4LWC!RHEk8zV z6HkvQb41}+$>f~-!_WkoBU)!J6E6TmhI9L!oTMkb!}#stj5dyOTHr3BaygM(lPuhR zT}=#Wpe6);K<0ZRnqJ*#tFZM1LE#W`Xo|89M===&KnVU23;8FGT&M*Vme7{83*HnY zpmgU+-%`EP1`~NBe=Sj`OXQPH6WXn*%3^>+e_=(Ts(Xg%X0V8K=p6LgA&UvCm*)@p zsL48Z!es=lh8Qti?#X)g6c%~Mup&4fw|f_p4>^_eYFqV++=uvBpQVhFg>M*<>nmlO z3r1G(A>F30`ll$UP6=6J(kaK9tXn~sfe2DkICKPid!Xr+gdIgkXq!H&3KTvcQ8^T| zyOeZ!^O!!sl=d75rEm|{Dlm^R$T!n@ki#F*GjO19DN27t*)DMc9nmswaH=<~WpYd= ziN5oa8~G|+XOnOi4})Ok_I=My(y^bGE!e+5cv5#!@su0OGoV2l&b|zCPa7l3AIQyC zbAx@ehuw*S-%p{!c*(?bl&;~cM9nP(O{_0c^)St#XoMy?Ki`@0bw<$_%f&YdzG0YW zqx#e4=qRDVRcl2lm167SE6>(vUn{T2;!*IIy?(J~bqbx*(9~uZe8Z zG)3Q&-7L^ZVaYf4J2_zRGL^zaqJZnwd9KQ`Md20hKXhjU3uJp!#F(}7KV-sRwHkd~8O5$!ozGgY^Sbk5zLr z;px=KI3bQ|ASYjo03 zxZ&pO7p~GsMEHtc?X<^c943UWkhWEV)md$xNFrA*u5EH$!xA_Nn+v|A#WUQQ+;%vw znG|=6ppkuIDt8XM*}b~q#{}Hv^rGM$V!buih_N8V;iEu6vig}gKGNW7>@?trJNApeQtj5W3Lzg+hYQ*OwjjOP;EC(o&!(3G~sk0Bs>|0(v z!-r@D;{vmayc6_ty@o*3A)la{4M7n*#z+1ed-r6y0LtbGmQ! zaKSy(%b!od`Q3H(v|tKtH#xVrG4Vuh44`u0Ug^4FUz(=&@$>zYQ|J3gthnP54lG!7 zuzu!y-|ks}bs?K-dltuor(CVW>gXS|GXwh&-Mk|^2;Ub51r@y+pbUr5^+aI4%e0#8F?sisC&(3^Hx=AKj|bLaF)6G_xY zCgm~**=1X@F(5x!;tOdU%x|F0(P=v#AafNrO<*DgK72PY=mNW5`DWor85$qkOh@hk z8={tuDp}F1NhS(}EEBU%h}xC{P3v4xEG2E9LYSRZwjw`aC_bvPoFZ7Vz;?o5`?gwo zLoh$tJTFdM=7zzeJ}$^B7ILsQv~UyYtBWUhVwNZkTDyPOgkZU4>6638+9u^AbRjK( zM28qXZizivKiBRmA6URB+oGqk*+x5}$wXs~I=0s6+A{(?WXj_`a%xQ2qarqWs@;+M z;b(G0QIV8Tn8^2lS{bWVL*8}rEpzT<+qMCUsP}F!q?b0ttSvcVs1koq0-*KOph;RB zETWB4q_I3AIaB$CSA zg_fy7nB)jk9vmXto=JJVpb&jc&%$z+j5n|aY?vO1o2MffT!7xAdD+Ki5|4AWZh0v> z+jB|i<%(<`eJYm2UlLKISS6ZDLp{}beGtWJ=Pa0(tm#!I4NETVTw78MB;LN4q>9I{D8zd|BqFsUiXp7ajSul@NznX>b+iw2EkH>42e z)j^le^lKrwd(UuPGD`Bj+=Kj2H>#@J=i4I^rvMVN;Kex#JkEk>Y%6GbIa34ES8dE( zWHKF?f~b!s>5lYHPb}tgh+Z`5Sp1%!A&OssHpTnU>e0@OVK)2H7m-Vop&&u1s$;S9 znS_*@7WJ-5kh=I7CefnCC^#j|X1cI;q(}J?dq(yao8bPR_g2avH#@;xV6&pkHIBk` z;#cA6MG_;YJf_vM9nm5kk!i4oB}UP<0!!gu@hy@?KLyh4h=^EZpz+9tH^u6O$CR1^ zhYksdMnZ(gTDMPd(eiR~zlumldBcBy2l|Z}k@x}!szfYZo0l$e75ii$W`N;3D-iF(CJFeKm14~Bi6*)oV2G0?x#O-TR7bpct1$AD%S&&FfCPPSX6>2= z4TI{YQaolS46mc6hx>xVs9(fvwfB5A-CIl7&JinUj;8#ej@pA`eBqDuCfF)Lx3Eeh z;H0jeOz;n|jW9}JuBUd{k6;oin6gqC%$R_6I@6&taNd3PL6T_Biy^w1llKt|K+FSA z$Cg+;+o^UeT`2)KtEpnVN)0FYr!XZpm{F0p_Jp0$qV%;5vQ~Pr#UA>68@wE>Hc5&W zIW^Bs#7E_-lboxcAvj?_pI0fJXc4BR>0*vD;GtY`N22v&nPo%AB2|EfWUbl#&p<9mMpGq%R28Pnv`j=`f zQRG*bvuzk7G8&m%yWsl%xFoM6ArFoY?^;;p6`*xpPxyX&xJ5_@f6BUmq6c(Smyn#Q zry!Efs@tsh_%@G$01UE;8Hj8ozdAzTf)7?3k>{;+RpflMY^r=jWb00FF&y3Y*sa@6 z&<}MTB4cbdTi52Enka<~1cIcQ#@v^E+PZ0oJs2YHZ9$%M;5I0}re($o^AUA45vGaK zxnNhGnq6l}Q8vJ4t(*r7D4h{689GvoUUdwE&|8;0V5Q|Z2g@Uyg5KufuG)12dxS#> zTYhKjKa5M*DTZb{pw%cfFh>o)G;zW9m@u~=1P5JRL@WD#0OLVW6!@L3R~VxRy&Rju zL<(U>G9p+*IjRoQf?2)mNX4Men&qf&;V0o^Tw!KsFfwBKWv>nwxMCYbeF6!`hb4c0 z1}qKW?RWNdxVXCJgKaEtAN3y;%oFsdI7h>#48YL|*e&7do5>kc7w*Josl*R59wJ*@ z?-Ndt36Ew%&LN@YzxyT{ih=Z` zSig3VJ;}b)k;5y$$CrgI1qZ%ni7fQ$ctt-`44brMAo?6_MGf2+028Xpz|c${3@G&p zG*R5miS#;J=;PMP+R#YNIMiXsW(1FihN7kr?NnX#4qvzavPKG?vJ$m3L;k@MV`<6^ zpOf@QQ}9elBgPfZW%eK;I%0e}MO0ar7$v#&{5!?8ZAw(Og=sK=M5`(oQJgk2#m*l5 z!;@@<+a`1t@*wbxZ$v1B72&JA99UObmuHW^5jtzZNv{fanlX{?yel(ds6sCUZO2CN z0>lPs%}oT!WEUgP_ohVKC-uSvp`qxGz8*C}+@St4jBzrW(0#VN{yCkVz2j?PZVjh) zaL4m#;SyT!p(;uygEsRx?@u>HbceN~R6a8qGOvupq6xrqFhQ!T+9-&M}R5gS6#=KKC zi&D~&$(9o@sDrixPHqt~xy(jPiTIa<`lz~TU+2T|H{M$FDNbmCQ%~tZS2@hS$2zxP zW*DeJU8VwBp|MzfPYxBt&1x@f9_&B~p`lpS$VG~fLP*VBCMrf$=C7ocUyd(^yCYMxC~g4yIrY4E$FUT1U1+k~CeYGn&j!haA(b3!G1~ z^|Koafn-7ct`gwuPW`&1{gDD%#yC2|KjnTneu8M-ua!K|QFI+KL|D2g8Cl&5mJ^o# zPK6N;IXkM17ByrGAA(Qc#NZZC#(bV+Pu2os*0 z#kQ1C;RL70TEF{$Utc`dWb& zqQKGZ%_6IU6h!p+m`OZ5qDZ=G6p(0etjQIAtZ#ng2v)?bAinGa>HY)KgYhsstlQ;c zM$wY1G=BFZkOAsAJx0cH4Q#ktMCVPeXC*QvmM1S1k~WPu0DifPNyhqArcXCxkkpKc zlWt=Up-#|#3Fr^L%!Dqv<-E?a-b(NRsK5{e1=41pB8}IMD>YEmk8r<8VXW(L1jy`2oS6wPW;{f)B=QvR}~GiIY;y(s|4%t1?bZ`$F%o%YCz9 zwn-Q^s^dxH>y2<_c_Mo*8cn=&XOpWfgucpC6BfS$e_eHLW*#>Az%N zu7`fz9EtyR)kXKutFHg;j_Cj98!v8M5D<>P-FPXAss1077tmdc-5Wyj&GnJNcTu}5 z{ytlW(2o=wWV!_tJD`V_P*yLB^X2oj)rSWC={o9ng9w<|(M4Ju9UY8E*%cSpdom9T zL~BSJTa0@^*Pr#=-}*mi`ThL%Fn{%`u=RR#E8yqh{`{!CIS`e1RY1h=)A4-1YVf^Y z0O2QB-q8Go%j3=rL5Gnoe^bB5k4Illw~lKUzh$DKQsAfOAKz|ly!k(MT=3j?+|Oi> zd-uD#A3tokm-;@Wagy=-KD>VJemXg_2fplN#j_840KNAn^Lz{C)9=c+I6vztJRcs+ z>`k-ggeGOvj3zHBvg0$3bP_ocKPk=VV>5zDu)N<1mXE z8@^OHy5?!Rb(Ss4o!}PF8#SS1^5xVW!{TH*nm;JsGFlLM_Tk}t9WS==6CkKzGT{}F zSlUnI1}ev+ug}Mw@65EclxN3^0Ilv{FJFrpDj(-^CBF1~45cwXH$Ii3DBTauOGeXP zpDce`<0usY+Qx3w4|Ank17Ev*ht9&>xb!lSeCs<->!0qt&Zc}ac z;ReIdPM^Pl%GeFrcw1QGlvw$+#YN=M>m48617FtP@xDY7*t?yNyV{1XMXgYcB$N5{ zYwD`y8LIMrS@_Zd{IGhl&cXD^0{?nH9gNTe6;bP7B$G@VfCkgLhDIfy6qO{vt5|LvAFH=7t-*_SZo!_ zW?%_!gR_3FpXbH>PXd#$^I$Fg>FFS-}lO&P%6U);xIaQf9ihMn~z&|p1;VtXU#n-tQ4n{_?WCZXKPonc}so8X(6`?W!q0)@};@s(?l)3cRgf2Z)Y}V ztt?B{iNc~;Ti%6rHY+iHmVCrIvQw+gv^jGgCk4r+Y?y1$@aV+1+K-btGXy4|KDYwWF+hndJgphJPwUmC$^ZeMThzkXxj=Gcvv%^No~vloqP`E*QnCl1GX#7< zYINc~&G%zW@GwrPD|w%MQ%Id?oVUKDp4P`7xP)5O_!dc&&(tb;it_JPFcu9W#!_+}bJz}z2Z ze*?TnHw_Pk-=s-a(V6yMAcTvu8ff7++F;7Y9f%vWvOp0hW^;m5VuXsIAly#uVi!`_ z*uYQ`Z*9boH2SsvMG3zr>*HeOyrm5{269|rJR6G{=FbqkZXAnQH`Jgmt$l19a^gc( z93_t9xnz?De8^lRNp%xOn|xk}Jhbtoa6!ME>*gdO2S0j49yT#Erp#v365zFp^{V^u zykZH*nL-vfLX^zPs&mX>|5o3_s6_i7dDSP&crJ;G9zL~BK*S~_iI@|T6~JB-vJpIc zNymf&DmU*dpXCQwh@u!u@g3RraQ~VwmI^|RgV=$f34-jD;>4(3?8RB%RJC{Khhl0?Nror)Sbixp4WCqMcr3?kV`|vejX>WD4?GMVn?d zEn*bsPxKEZ+DzA9yoxdE-z7-}fZ@|J&@b>PY9_6+T?KW5hp>_aQSR_?`VtTge@Y4_jdC1uhKn8;?H(3XL< zkBohlb(8~CZV>IRVmne6UGo9T>jEu1z2ENu{5TO6%S3~iIbivFkwZRdX%ngwcYB%7CLU|2$j zj)agPx2TFyf~T)=!$Qua&#a+SBF3t#3T*(r`PSD9-Ub}&9%F9f#x6#&iCu-|8^0{? zI8O{Ry_{?(=92=DVrBaJ;3FZ!eM0 zf|(!PD(b}b(VV>XttYX8;Np>B`{4$LuoAQfYp6Mj-~NOq~t;ah$G)bF*;3AjZIjqebaXQMn{ zKt%f@%0)C}>IOFV_4z@ChIuinFx31ca3|-AjwIXVn3!+MGWFnyb?XwOoD`#|3Mv?Q zjoE^3RoeT5khwh?UGgZXY7M?I)abl#kcnX-m0K+L0O}klIPl!3a#9WyaxFf0D19Oa z(Xe3f7PUr7A#iC%%o2ooJD}U^upJDwZWMQ5))`H-huh_P`cHU^asP_+!idRD5`1eY;OpjS=OscCifust=9b2SFZG&(-s}HR$5A13dj&Ahn|bPWcril=^7>yHj2hd zupYoPs}$iowz_T9td)G*_J_lay}`f_)HK7H6t=CZQY}$nyLiHu0-v zQzTT4R8j!#FKQ{I>iZZ(G+DHyFj5pfo4^9(1By&2J1!6}CT@@h(s)x!)(>1Mjg3Qq z_&a}8eVe8A@WyZ;T{^=97Ofe(%E-vqQ6?jrsAq+D-y~q2+vI^&WW2~U}-PxwAsGJT0m+TqJC3SQNfd)t2?cuT?^np)< zUkmn57=x`*P*5n-8G6WBHZBdd+{V6$v2wh>6z2ZXeCG=zc+9=>6h&6>r8Bnmo2Z)n z6dzOC_{zldd%U#(_GfU8E^ZXhQT*8V$^%5RUUcXgT7$AELTIG34T0zF z7*jkdjG-Of?ekyZuItrP851koGDv`Rl)15>p+8~l8uMSAenRvVwc~IM<-wwiEX9b&Zzav>iOvu#G^n*?$e(ditB{IMm{dDnTg}jx_5~Bi{{!mRR+FE5 zR~{Py1mxG|>z_%LXwV?Pm%ID5)fD_|t4Z%BfIs3n5lbM#v2tZ2{K?3kY)ka}j z)I?#ngd+hC@Ic`JY4&sgi9i1OFS2sPkT*DOIN_kNBqTz}n3}@?;(KwGK5z^yL&JFK zsp&--dg>9W#c?TmMj8frIVmZ6DK$js(26dQfhBnO0%+He;s~(_Pl^oBa(JW=@Oh!g z+_e)Y|6^faFfceW8#ZSVwx}Xek<;z$fqh#WDmEDjFcVHrJqs{SDm^qRauGH?I1?ES zJsD0aI2ABwFp;-a9rBODeDFt3#kFrvc%z-b2*6HLr3di*HKG)H01E)(myg*0@=@BQ z76A3%M)&`3hU+g^$o|Fogb^T4^2-Y>iU8q%t@1OZ2>fSy>^lPGBrVkR3y=68-+X6s@L5P2W{_#^3;GK4*1R!Jm=ah3Y zGPU|616at`R?gnk$kxim>fdTF{vz=9`v(EyU*Nx|8q56+oRK2UNCiNY_N$2H|EY?9 z@Fz}NR080FDp00fD*{3cfvASLok4Jmyx{bk}XTWPK90I-VaH;?_Agp_|%)Ta7N5eL{` z=4w-UGgq71ALB>^ssgb8IVXP6{=3b1enV;s(9ruA<$nqOh1;$AhHIw(C+>?X0R6wm zefKw9LxbON{nh><_|K955kU~C5?*F+r;$lFZ)?nN!bJhrhJPshE74x$e>krDuOm|6 zZ+J>x|046hgZ@QQ@6Fkt-VV$wSU^CWdj1|YO#!Cf|FE_?02R*U-vi~BY+wrG@P8F3 zO#u+gX%EcPeI{~hpe1b;ur|9uH83Ro5YgW!LB zZvQu1{?1eUZ|>PM{FCQ@jQcmbzdsB99y3J&uSS2+{STh~{#&Ageqo|RyzNV`THXT+i&)03V>_)2j*Ww azbFRi0I(6sLC8VKP~Tn#Y6QG}zx+RIHT{AB delta 59066 zcmce-RZyNm(=Cd-I|O(4;7)K4?(Po3UwE+K4#6b>f@^Sh_u%gCytwXs-}(1GcjxZx zshYW%sp++PrmA~ts@H84d~p*js;UAs3=YJ9T7-jqA}T#{0tSNhe|j1fVxkxk>c3gt z|1SR+xw4pgFAVO3iOH7AdTf3^bCN{sXUpNX}N5h5iSce5if| z>76{SApre9cnr0l{^8+@jYFt!lXnL~^M!@Nh-cuk8y-RY*9LM#H{a)fHoPJJ>%f$z z*#B_=PfHvAp94;Y^8Xhc_|NJ2843Mw@Z?UTX4sm4ym->CV<1`6&RQUG{_n7WdT38J zm84C3ZiB=ELS+%G|K~ofJ-m@2AYlrBU!uaCpp&Ro`s=%|H76Z#(V2Znem5G7tBs3f z3gT1w1InQ?9{lQM{~#rW>5$>}EKVZF~)eV*6LqmyyvBg_~^wB8_X)eW)Bi|c*= z{4ot35#;J+Tv^^0Ubx0Ordey)nCGso?d4IsnKpk9_ikm#9PbgksjT(X_kN%n>u(F> zT%z-Cmff{JgPRq`^E#c&MVoln@#;^}0y>`}4+K9>McXTzH;WHGoFHQ?!qY?T+Q*Ad zH|;|BE)QE07a#Vc!HZO=#A4E-RHwW$>o&Awn`KUSu>f-?o*?iDJHSYh zLUTz_vBUF}!kX(?c6SWki#p(*(VI;h7qtfSPF-C^&F_@yW%r5WjY&#Ss}#y7v&A~n zhK?*D={8B^UUP>4BF25L=`>ndEC!L9PX%j-y!#6Vg;30pB4RhCk7}7x0n7_6UF{bH z#>^rIr#DW>O&8QpdK*aX}|2S{f>hrIa z-u-ro@Dz|y@F%JGW^dRB_U%#!Wt@vOEc9e*c{RASs=H|QQw>7qAKo&VBixNd%azg$ z6sADqQvjkhQX>M8SGGocn&rGjHK8=_-1G6n%Y}fq&8&?PZNhr#d~5h-)ni7lv|+-^ zk_|7d&8t2yL)7aOit|Jn!@N_HP^R`&??K%-Ww%vvUjf2l~&-Qk9xg@5HJ(ai@mY94+ozK=mp40LP}F3_EW z;`FPI%ooaOhC?4{)e}Cuo~DrQh2N~|CWzV)=9>a=J`({qrZ1I~X{WC;evl%XOpm56 zmq!g%>jQA`MbtEGawhj(j!L(()5%CttfT%avn5$y*WD1XldR=hmV15(I!&{E{xGD$ z-*@UwSQiF5>936SU)4x2@U1ZfIR12kj5pSK;p@Hi#Y`mOA8HML3Ac}&hRPFOgbPX; zFd5UxCt#BCc=o}{!RYkId}8GyTE%eOWl|>&IQ2JTb}sX1X<0T2grs6{8r_Y5#j9%e z7=7V6s>i&af7a>NdgHr*cJ|kFF!{C4Qk+D4>5UB}(}!xcDsro%#NA)-GcqK_^m$c! zsAEMpQ8$!hMTvDERp7;X=4=L|3+OvW=Upwc-x~z5HF-B}=Rbmoer!# zJf^+3F*b#Nk+qK<1l9u{NmQY;srT!x8+vA}DMKQppk^(ZJ+ULDB)(cjMappW3!*So zQb_=Zb1aAX-a0?LHh7Jgjd1n(>XTtQv>_8o*)bfIPlzPZVYJ0z5NU%A?9Pa58$r3oQWf? zuvoPr_Wmf+VFlde>uD8xxN2w8e|Aky|5^*o>%tUrQZ&2qEI$6Yv4ZXLjK}llBfU|o zRjN8ca(Q$--MH(KNM?x9NX9=L3Uv`nx$ zYV4xdQ_vNwI|_}lDXpK_Ca5v!7mgEK4;QKzA_?md6Zz~0?v+1QzcI~^@JBg^N<5|G z6opb~vbJzB+jsVY5^Re`Ka-EiqCE!tu_h6#kX_%NpweUl)(Ais(@sgDsiPjl-sLJFx0` z8_t%4hXL8j5v&fxDTP!o`TA{IR`?jFci#0kyX8{bP+5g&3G5>(=gsi$+xz{Y=g*wK>suy8eb8CEr|v7nBYm z2=#yh3qL*&EdiTD}@b<~k(89I8>A_2z2mKpIUUV^PMe=<&Pw#c)PH>q~(3TSInjRINU}9h!@tW10AJ$!!CWOX#p|X-S&c|~a=T(he4#;l)blxGT?6Wr+ z^&BEP8v{(7b|;BsN5Nkdep7`hZO1U6?j$AYI;f#JLVks3;y>29+o28bYk`c{a%iFn zsPH=d`}hZg&TI@iSaXr#dh*e55i_Vxw4?jn1(rFc1!7}c2OFx1>hVX;HLnqIaEgOz zr13pO-60|**VQTwqi+CSxN8Onf@6W^5Fy-K?JIzoI(H^rP5MI|=Zx{J3c)LOI7;fq zSk@Cl+2Z}qLLe2JQ#(3|0l%+Irn+X$@mMDhi3$$%K4u1gMHF0;)^QliJ1_Lf;xdq) zsQa=C{jp_9hSq2Xzr0X|H6;t@K;;o8dd#qvx$B2bKoB;9YqBI_+LDIOA={LaE5UsT z!UCZAz1mQjPN$23_k@p=k73~T$Jh~xIUb=J0$gUyCnNkpc-@Lx#29oxZFNEYw@qSR z=j)cRdirf$qW8-Ep~j_kJal3DLfHj29q|oBCv{klKIT}`qVM7;JM@98bR-8d?CnNA zRuz@LNv~R2e+M8TneA8jn;efPV4gHk?3@7?rNAri3W9Jc^J!B48WwlS+ zl(}cxomG%jDLFF0G4n zSs}}+dL9~-U|=!6F?V%1$s*JkL;yk9Eo33iRskn6vpVx}x){H3A5nA9-1Y*9!E)Sl z8WWO6z-Fm5i>EA7 zJ=TUKf}yjp-g@@=PuJR^y?T>;vyH6GVr=r3LPVWzU!PBkJGDlt$#u`zwFOR^TQq=U z5}P6%>oZ-!R8r{~*anOwPEz>u2~iVzlU)U_C%!w4q6tle#bRlTz?=W13|(?*GFNcz zr(}ts#ICHl7;THftgu1%>MV6%Wp*y)78;HU#ZrnVbr+>p61S4q$Xf{)L7mNGb{7(n zJvLLg_BAl*Ru` zwFqT|Anb6u)p?sGAPNq@_?GFr)P&T|>TB#!r2V=7#FEk?+Qli$NdV-jl#bAc0;Q=m z;gK-|6mY{GG=CR{$rcP8&L|uM+tumgi{hiEbCui$8n#e$22!K@OCASBm;1To2M*oR zTPP`IZo4ft(gB-H2y%~m3Hm+R9QrBCFbHGV1pozA%a=zQUS%nG}=wL;2ObwfA4j1lLCC`fE#@8}f@2TWMgu z-_qljz;;dS_}e?_PqMN%4*Z#6djd(d|3Ma$I{-uvJOINt#3xQk>r*VA-3%veny>Ry z3(Z@I@WkxJOk{1d!L2t$G=X1bn0T;1H&zdH8jvW(cc8xi!mXFC@%Ef&e-$9mtIF-0 zr;oba0@4>7ZP`Rv`3vf&h!!zO84|@!FxB2GU9u_V6U}E7(1N2bG_Jf9Pc}`gPbH0< z@PRdaZ-93tJu>{{niX!_<_b1&y%+$s`bK{EJ-xrl>7@1NuL|<)(LerR8KI1j@1wQc zTJt9+MePn2lqo483#5ydq&q~9Xfkz`5t=d2>cID?`A)~`6 z8}m$(EtxnZsy(Y?bCJLa!T0hgwZUAS(vIFiKfuQZiH3H<4x!5PW@`#|m0 ztSJ*j-UdliID^REsaaQP>)EM#11D%NcYsdB7L5+^S@i^8bC7Alq&BsWl42EK2E!^O)G45JvIs~K)44CRs9Z1VJ4}T@c6=1L8Q8O<`!ZD zHDvWzvEeb#tOdr1`_4ikH?2-GmUsY)pqsipMd~S%%ZK#ZA#K*1D+gDzO&J+7cWT(| ziIN}M>-oMIBEq4w>aEQE{GDi_F~M*n27C*{Jzgl+#bJ?XIPJkQhRW=zGkLNj`B*sQAvJnL#i)G1H+@BcCq$brPDF6OaUd%xy6TP+W z2`Vk~eRC0jJ2<-&maJp#;bZISYcOi(wB+Z}TH|G)ykXt?dxvGL$WLEHoFM%;0X*4Q zer?qvQlU7GP?}cMG&%1vUKe%fUg^-&N&cc#<9995RwhjlSId!XPH(pBVOdI#_tYK+ zG0UON%z|RhI6+P-BOd^sjZc1nC2vMT-)!D@*}wXTTK6Y0(-kZFOrD*FA1GB8JHlK0 zC-KJincDv6NZM-^-|OK!zgcT%2M~`xN+2hDz^lYbTD~JIBm4KOoWK!`=wy>G82h4c z#{t$aqk6)0^RuJbS#Dq~83j|=nq6Qg)HAuS03&4(!67qj-avY+XJjFhK7$mw!~M;9 z3jy=DXG5MH3az}(8ot%W#myU?d-s4|6(?2{I(yevh|v0WHn-#pxV_!AJ)i}JV!~t^ zngq6$&!Tc%-Z|gT29p$1(L8{Qlu2bHrhY|wh+fZ3T$_hW^xD+Vi(6bxo`2mNS-e%g zVG;8D9qaFuCM|OSE~76EbFewYsydI}(pf-5kbT=xp;Ht3Q)%|?S znCM}Mwx{t+97#!-wSq%h7WZs~;SM5YVc~0bJx%ghP?o;lFOz4{vOCxC@6U@{qAOHgB~DqkS4ObzI>jf&VjnAbQVK=laMDxgM1L_V z^op~?3R%u*RDrv43W~C~#1^ca1RWxh5Wc<@jVuUMza?idnF*owDVfxFzxf!nhBI8s zh+`xp-dHZhD{jJ4847vIqS$S?GR@m(y=+?8UqYXRM~o8vm65!XKpPpYpFB6PP?fPu zb4xD+2*%pExJV{YKpeY4;O*KSNvoMmv&_O$D&Zd7Wq^ll%+bG~1T33 zijFiLv|}aZjhZ8+(wG#TxBu2|i8RvSDT+TS(h#{6T2#sWWj^^yB7z+?Ta2l4P*jd8 zO-QxshXTlyO@Mq=#SS2Z(vN23)xX1R8fOD?=5pz74g9hnE+^NBS)7K}>FGc16nGED zD7-{%Gzjhbo3MmOes=6R>H~P~9qN1+d9M7f#oX2jop98`G-jyUmOaGtLDCzj=(*=BYT0%F->I`rQuOU_kch7FMx~n_?g$P!%^p`c!T>5M+&XO~n9<7dNfhdLh`>p6`*Tk27 z&Z}`#dyIC5r}^YFh;ytTO#Z15hbEQp%Pe2FXSIHWDwVqf)rDfn+YXC6tKpXs^ikAH zOJbmOM5QIyN#oZ`_Dsv*?yu5ZAPD1*kP`pkmklulJN^_a62f<9(x}5Qb&K19S23k# zqY8sWy!M%6tA|Y>>DKW|derPFa%1K^JhGOFpJBYL{^ZdCgRvDUw zgcbOiKDfBN37PD;CiJ+K9t`2X>bGWpwA%nUXlKpBqjrMySxYmvksXha&`WL-wpp;T zT-!GC+XAO9dpy3MbM#Wk3BNQO_3&~|m^2u!m{yJvPtX6+V{w z7{1os5#Q3FAVemP!I}wiBZ%SnODU5wcdq>2-mP+t1nNBY+UjTxT-E%b2_69S z&&=l%;@~(jj!aNpbbhreIjb(wehcl+dC`QyJUwJQ{|vxb_zTAijVw8G>~B$ezWq!M zo>%BRjyZHZNEWrmZN1&dt&_dUiR<}Ce!{n6K5ZHaRj(ay; zmpo|ltGOX0q4f|AfF%F9_Kg|9r8ZLJy#{N+BY9GBcB1Bz#PQX?AC*Kkmat$mm^EjJ zQyfk3lHRPhuAn?I0j>~7SQ2Po^ET3|+Cw$A7~t@GLlgEB)Oc(X8M^T!@IelwO=!jS z2|dOO1^7FzpLfw$$!f~ThN(9kdW{xonon{vpuB`u*BC-MnRD+#U3-B+*6tR?*B$RT z6ON_wAB!^*`@d(p`O8LJ+=2>t@BBL*m;Ej|9JwZZ9>WLCN>dBRL>#5^J|*ED&&wr- z6<9)S`e>Ai338~)ac5!p`G5J%QSuEXDnH@i=Zb3ss{)rcLXc2;gJPmkLYUY>Ola>! za@A7efChYR?<%HasD%l@zh6e7+?!Jx|7kYGm{lQS1T3Ij@EU27Q06FXNMuC;@!l#< zOe^DbBYVbg3CWKmcV&<{ZZ-Kuj9H3SnbuI<)WVkzC#R^0<*+=Zp+FY#MB))v(c-Zv zf*G#Pt!OOR?Kq%~;y_dOWQ1L{W{mIcj)B`sf550INwEikFbM&O_uKm_a6|Aq87MRt z`&~$aULa$dkH_Q8RhiWGpg9GpRihD8jC$*#`}3@hfMhncU^)SksN!a@TKmGtc-9S1 zYA3kc-Rmvum{Bc!RyWe>~E?L zu`<`Oac}+e2cIjT!>cB-Z6K}5I$;7jti;o@6V|+i1!WV^!!ESkW*mMu`a2}JkT7uU z!%7o9-yS&|Ko`S6%9W>mTBdjRynHTYFPz_n&YJU!u0RoQ#1D&swn?`UsVF6eON;Q8 zB?Wv}(n3kwEiT0G&5$s;UTi)&jqjTs6hOo|UCo}hUXTLR{Ah0~W5dgAP!CDonbAp; z1nj=+ng0fMsMm1C1dB*%+$X*UBlvh9>Xf`>&}ZBqmYidw^7W7GndnAh%+V7}?tY4p zP0Qr-@RIGmh7Bhq;t-emi&7V>Qnm7I@v}3U&>o*A)0tasz-eV?IsDwsA7;w=W5>Px zDvH1NSXUFs8m-h68~_P{u}Kb5t5)??GG|B^pxdpAmfo&UORn`xiq&bzwd+}~GgR~x zN4fZDhJ%Dclxz|;cRRLCvpk!*lP0|%A*;{@TErejY3szZDTRK-SceqN2;E^14G4aU z{vKdk@%D8vg$zcN8#c1DSLd(~#v+Rvr*)CLm3au@#MbLk@-+zZvU;0T;`69n>U~#C z&J3uGi>QpDZ17VZM(nJyLYa<%5gbgsP*BaPR}Ydw8D*!8h6EK;S4Z@_E)As#hp%p> zNQHebd75K39`Fe!G?l89DhvBTQekT@W!#v=^?t^8Q&;PApx+rIAXTiO!u6Y+;0rAm zC7%nBe%Ibzy1Ws3b;Tr7xq;>N*`RwyLMoZ*dr!h_u9F;B1XV22Sw%^Y`8x6r_X$7j z;ZI62Yen*I<-o$(1L6sgvk;#>z<2#H2Q-!abZzAA0q&ZInRoC4zV$ z)n16u=evPzd@e6Trf7v49~<)Y+_+T060e0^wihu<6n&1eT@?jo)3v-DNmdG{urxr- z&O<8`LFd58ZcezX7Ke}Ysf@CMw^?(;UC@y>&fLUgBHFr|(dBDGL?1;|J&A|oC^sMK zEWw_}jK)_eTOIbAaWixIe#8MLiZ^_~OJZQXBt0WB<;yrC>ki#(LgkJSks8JIy=`O= zk!326L(bfoR5zfy;?9N_V%nDdW>%cgKYZ2CFb?J(`-3#k*kdxsOFy6Mv7_ zH++o%-Q{O}Kn%QE2Yb|dhLMB5S>`4CN`o$Mr8jne58DD8dIan|pF|M2mcfcQYEe|jIDaCijbbWXQz|$gvR39g+}288S_H*H0>6sT@bOG zYGeV&L@uNqa2qHgIC|(7D^O?_V37foucuF0+QyT5j6QvIvUDr^Xbdjh&G~FF96#*k zQWVqaE`Lb-7k>J>MGU;Z*;u&PblE#D6KNJBZyP=;yVlt5cfd1oZS1PozUG>+{btf6 zOiAArLnFhnzk=nJ$HLoG>FVTEusnL}o9xUp%Qf+y??CL2#X%>O z@uvSCZ;o39B7M119!te$Fz?vw;#R~t&vVnHARBtyRMrN6rSl9`n5TwnZM z?Ql5tTFCb7;72EYX0`fej)KG}{*bxKf8J6a#1bt2qrw@vo2>SE76IPHC7R;Lalk_S z8ia?yUz8$2*k*u3h@H-})d7x;=ywC6b=CGXkbz6+Wu@FiHb2@g22DL$_^yXSCxWf6 zvid2ExWB0n^N)~4=+D>v@_>$t%FaT0=>(Ed&K-MlEecI3m6Zv1D!}#lPz^+*k^ZdDXHOty=Wq|?;>i+EUu?2?T$A3^%1iy^KRCGnt>^T@Zh7-t=Y#%% z&Gi+AlVv5LSx7{>Ah=jZg>tm^8%%{~Zlkked3v)KB#yG!j7-~oB9=H8Cn-~MI@ZWy z-J&xdv-d`;pXu=Ub;kDxcn#=fWwT7wfMA^Db86rsClIAUc_{Zdz^u%^?xW~tR^j8J z(rnP&GFTY`$stjZE6!D>+fwcG-ze8w8YK!_6jrXl=cQb}lPnBk^5HM2CK~N~6+CpW z1>3(M0wgj{qzQLW`L1TIAQ0bbEmyf8H-XGrzc;_*YX!AWYDEQ?oSE>o78p)n6p<46 zt^oiEUnf?0Vdj)psUyK}0fBQD!4~NO;FGe{9^)XKMa0Q>iDq1Sf)Z)>q{2Pg8!%PbX_sQ!;a0 zY8I)PeV;0yADw+@=2<2cnK3a!CGk*r90vG*Zq-F^0;rMHPtsHenPTK6{C;Xa>HuEwiWMx7N27tiRb%V(Bo*;Tez&`~t9i zL6@#E0e@oD^eW)wTgNWHm-T)IfCfGj3-^G&PpKRDN!2{Sx-+- zB4SeQA&e=w))>D~t5!-k5c+~sDGw-m5sVJIN-GXm6>fGI=&JuK-hPdBR7A8Plsac! zXpI4hu-2MVQemgsNoP?j=O-VAu&St>?D0b#vY4Eg03ZsUpPkScm2=euq@|F;%y#QG1GhdvV zeYbDyoav1{+IBCQIz6jnqwQh4`O$HW+&L(si`gM9qN#Pa(TmcpP4@GqD=W31YiQr& z?(H+1io~Xte>z$laem!0IV?2g_@zP#!V^O3iA5GrUe|n>Q^{VLereQHwaZIIgo|!Q z87c~9CDG#Mnxvd(g(O6j{t8TmCo;Ff;-R_@)H*qhA*+`=ktH`i{oV{x5s)*KQZGN+ zf}g(l9>JZ(sgPnfA1Gx_Tos2EpFJwFkCb?&{$+&D`S@D{@Kd!!^MSZ|mn;QgoJ-)W z&MKP#vi9czE)xY`#+zbcOl_?;=11$h?uT&D)aTy##wU}!e({8#mOKFE@3?J(&8~Y4 z2@w5wXW7SzeVQnq=)^p~zqTWIUe$P~&vRM+TLqbKHB<(Er+dUN6Mv5e z0Uo7{vGBKFOX-dr*#GLESXU{26t*eVJv2ZLgNAYA2Vqs9<0fPDC7jpN~;L zgUrp#J<2^a&;72EhfbE;CWEGD7n1tRH|htQTLX$P{Xx1P9es{&$9R6Uml(Vv4BkgS zjFr50_hU|CQ){mot?!#{3s1q^_cDgWA=@oCWH5%!gCVXTd(adqt|tQy+UP!B(%^I@8-$N}zEXKyBw{G)um(cYj$cj!_) z?zi%D8NByEJPw&3RtRZpX=|k2%d0nkRr&ej)`Vs$9(f}#DlC9bgpHf-*;Nc5IOR^~ z>WhJNW2`RYw)(LEGh-o9r`#g&=76 z&+q(iF-76Yg{ATZpS+_-4{3RS9|r;(HH6&=5W2$&F+`+5*N*hZI2Qy7b}zN^eJ*m? zl&p-j<<8O~?>A6dgFSj@3Aa@8&Ku za_GfuQ(Qp+n}EvWRuhRYNhw0(jgR@C&bLuPJe60xU)V{;zp5xsKb82%>mRA6$9yrB zJh&c!JrRFrnWAZ8-#}~Rv2Chm`~77Fx2RTps)qLyPf(1bL|nzunp%a8*J5dZxgrw( zVa}8;6sdZArx#-+cXRai%a4*@l+Wq(nCa1PJD--ffM#>Q?J_A1(?7S5Mv9zr{$3U` zsdkG&VmO=o?1rpPaE%l8MN~Kfs3V-XrZ=flDhp6lzhT@2^04%a$2wJL#&dS4cPHa4hq|jY zARBLgT+iS9Wkag(Gy+m5E=`pWrCCh@Q!o-G!_&;wbiEF_{v{A|v%7&1rRD>d@J%4- z`tUVy-E{LpGl37Vs}kd6;XIVT|2?AoX>hazK!5H(?z1nwo^Q->vvTd3of(qL6^Xb# zaOtX5LS$&pLD@e)Q^N~?!O&N5+Z|Z>O>r_v=mDPwn3;k+%O`3HoOcCq3msA9j7{@q7^**uq_KgUcP5IWa=m2#R zC^m_z6*JG7O@{rJD}QlUj9(MMN%P^ozIPY%M^(k47t>`4Ya-zKmgHQ zo16KnfHx+JA6?6g@4McP-w#aN{sUV`arjz?V0Cir?2!gN`&xLqh#S)T?UHV+yD&AH z?isn~K|!b*$@A8q58W@tR6w+)ksC z4e7N|) z@z$rSS$40k{3{d~C-J$!YI&9bkgW?~=?B8K!3jsCEM|-<(Hg&?O0d-l(r^jX>KyEd zBNgi~kKy-FRoNxFPBtLVlVdQm_`Z*=>y?KvvTkl;T(#njSotLtmC0y>jepaY_ zT-g~tR6wy^w`K5Z6kFQdXp>0u?$jTceo8frRksjAw8#ZLt z5KYhgDadg*O5l?y-^)4{SX(eC6+>AYwykGova4@AV=in@()9dA4REQJ76g^j|-KMHG3kK|qPGO{e&=e}n&B@!MI8>Q3k$tO`vm z6M-W5=4I9gT~t^;pwE$WBKL+)89$D(i07o0SVC9<{$zwzNp5hMZhjn3tFTi(=eAvy zI+BKDjU<>H6W>#(Kaj71{Uze@59~gpcg+P`ffiw0}j{HFXk3wg^ zn=ne80|MfotmB`?1nQqw=2xX8^8Xfg{Qs-U`3DF)Ob8FbkQ``4mHb+T_Wva)8Sk)l zUzKlUc_bv6`3SnEyzrN-SCbt-dWcM=*Hz1u$X96*;joEpTn?wyr1o%FH{Q&EfG1Dv z+Yn5y(#8#fRwqZKb<=5iSh089G`8+(dNRX{>a%z!c4%~-x=bDbJrzGL0(IVwjcb!# z6M03ePj>u18IC|jE}j1M;J~YG$SMpt?f7AN&+<;laJ=dAPV{i>GI_ac zxqsJx3Wakd_JzKsE@?#qggpM6C9eL=<|Z#vbf;Eyuk(EI+@ zod07n>#5^(`M{$y*Gc>IAq)4_(O7%x@}YdfpuM2erB*K>4=g&7HalP;=;vct`80CI zHbbwZ@QGE&|D`d*F{JJ~f!6~3>!GcPh{ejIZ!(~xil=?XS!)V#jy`y}R>_&$^as1p ztk^yl0uQtC^KYwWTz-4;c8#FS9HpkZ%U53L%@3iE`*X*>kE`qW;~mtyIPjD2J#|%y zAI{awqx!b9j+66dE?!*|>XqT_Zr-HU*tu`(GSp_v@?_D}WxW0d% zmdyo>c|P!FztlWGe?%S*u^CnwolK57Tll0aJuU@gR06ycx?B=PSrfM%PmPNYcemeF zB&tO>cwbSYN37nB>qgj)H!uHoeK0K1^i?z=T&@bdWQIu&DcY_k-z)g1&E zABgJTc_cU8nQzYVV18#UkphPp@T6OV!(CvORqg@y!~Bif>-yuyfL)!B=(j4v%XU4H=*=cQ z`^`olKc9@M%?1E4oEq2+S9oV&0~ZfHEeLruN|$k_dXn}Q#T}fpaQTy zQNaY9%qIbR#z)<{ zC_9_;obv(<6bIlxRR^qyOnvBNe3CS9pR&fwhud6FIVT++c!SLrOnqBBRS^* zA=KuXrUB1)#@t5`|ISa?JAcultmT01p>|h6AY-zS1pFeX6@%Ab_)TDU z`b7{ca1O$e!%%sVuM5Z!neZmVQaIOZZ`^~3W^=zY zY@|K7APu_2pdI7w9ACW5x*?S5{@6OSdn-wP^;i3jTv0MS(}4Y^fmOQ+U{JoIhgbz!wF5xq3l2CC zP5hWXHoNoxD6KON*L*&_Ws4gY}ox_Ts(G|cZcHHeD#fu=S}GS*r(ImehZsy0R-RZNNR93T085& z^|Uzq@dnK6=WRXtrRN%FzX6qs1;u7s!v6H-^v?+*b%*GhxrYO@6=k_g4!yy3;30Hv z-oCLJcr7c2v0$0^Pesn4=N+;)oHa)vV(>6aXd_cSE|qTu8w}+LK|0Sg+KmrUpCHTr`M^!^$BY2m_|87XWE1SDm!!fpB#2av99 z2*btihR^JpyL`Ajc#H0+Z;%yion35;XK$>-nFl=8c~cv2E^LNSD)dnz?}Wm7p{Mn& zqLYQk7l5~JOuYj>x01krIDSaJ=Z$=8%vE|+noJ#gT0Q83ZSra=2-L*ii5~Q7N(RrI z@6JEwCHpor!ymSD0bu{(E$fbysa$xKwjiPyvaqIjAcmAwre}BlZhm?Fe9P?{Nd!+v zD~ZS}SMxUVm;ew8S7fmOka^Xyo>{;j7w|L$`+!Q1G+AW7k$32h z7Hr+KuXwhW+B08Vx8?ax*OgTlT^{tWkb3*n&PCY&=~;*bs9_TyUv-|884Ry`s4I`& zGV`8rW<;9(6Qh7C@GUmU^>AEpy(<)p%|5gAxw;dhYTaE6nNL~(`ngY|kPnifj zjec_e7h`V#*Cr&^r$$?mN;aJi=EF}SIj^5L6=AgiTVV@Odn3qS?j`P_f4z66O? z1RowpFKsEm-whV)&Pce&P4i8^y${mi_MO{{T*LvFJD$9+{mvmx&#TW&UB%8I4y@T# zY2n-RuD|+%SC=`Rk!eq?)`Fiu`WIVt+#c5BDF7R%{%KbHU+X`p4fNPr?dmM z9QpRg=Jc3(U*nNG@g|gJp|6}cHt)^<1>UQX_wUu2pzv{gv`!Dui~Te1=Bib`sd2IX zzXzQjdU%&sJllGoHZQ@YQTfE)ivfhw23f!yaCM@bDd$xut7U+)LtX$5Y80%BE3(jlX0BEwOzz|)9NEXy z_Ps+w*v!_D=SwT5{eiDm_%t65mU%6lNSn*^fwS?ZD0ANXAlpaQPVold+OJ<5)07V7 zES&BCS|BcoUf_!SO}O*gagGsG1RV=2xm_D#xYuXyCzR`2KK=!-TLeG}Mb^T*G* z(-eDV2{%8dn2vFOM?dl}EkYm9wgj?rx!G}NiNg`IA6AQ2l^3U8{bKBY+R@akm!DtW zA7jnB>6EPbv`V{Bu*`*N63oxWO^JUmZbzk`6P7Dj>2y$VEHH3W^9np3DQak)P46z^ z>;cgnXsWyxxmrADwc6*?=}j0ClK;6WH67e|Z6V~Zj$VE~{~b`Hq5?j&f(Mo|%!!NC zo(j0tf8EHHicGB}=~$%JC+H>}#^CnU#E)VTGb+F^s&Bl%#Zs{=SeW3Q1}?u{IecTK zsB=PL9_!79l_HjwV{h+x1qp)?L^fhYA&U~qhXmhS9<;5+UHx&hjSUSz0Tm$*+Pnol zeI;maIqr{KXcwZW{4jr5m;k@EJ3d2%Bk#e(YuwA|v7li>6_#serVB>yVq&-b2@1#^ z*1_ujUDgMiAUg)$Dxhqmm=J`y<)eU|d0oEG;hfoDQcF8`Q-7 z!O49ISxL}^j~kY-(*M}=wYc`I3q4EQ`C45G;58Fp6%z~dt}tz)0<5OjSjwVDKNcuE z?m6wdA>$A!g>O(?c!l|DeSu>Badwm6O^EfHSN=$txhkzFFYZfyt=;l$AW<|n ze!^iSKyL%(bPR2x8geKwny12~wto^unR*ZK@FNtu8Iffl4sIUrE7=)y!J+*j;97j? zNah^28(z-ladHu%1F(`x7xcXK9mN1`j}M|@yEBqZbacW+!m9jv(J=RdWIDtUb1l4t zb!!Ix?QW1PzYkJ&f8_HQicMpInQ}s;MiYck)+HZQCT_`mVmp@JtDbe8e0cu~RT*G* zw^1sFnBI6-R^QdtoqcD-n635utNe!es8K@V!)NVzRLb}!3_u2Bl-tJ$EM(ffE&R8M25vv#yMhLl6?uXrZ|5KEy}G)q>bmc)p62*mS(ex~T75!M z5j{Ho^gC3Yp0l}svt3Gt60CF3dG@J`BoTRV{VpWlJRbW`v>gK2VOW7TDjbt501$Lg z0N>AP|M|FtlgFfg}3Y_l(^MANqdZqa&xnYn-q%a2~mH!goD=>dp zSy`Piw_JZorDYr88zUF5G#8UA9BHuWu)lnbgwd@e13e0HJTGyqfaRv1Ub6tQ+_x)O zrpP!Cu*qBL!IZax?K{k{zW2(|h1KnuylUtXr zmD=#AdQx+w$HAKl?7_dYgNvJPfQf$>G?6Cq7^HCAr68iFLJLC!pFKd*qkj9io$(eiEL;~2?ctc~)1Rwo~mbxm$exgtuCdr(F5k#k0iEH9cpM`XxAP_JeN zhrJ(-Qq8o;d6%zH+*h#HjUMD;79H@6-8Tr}aBW%ZrF8E7pUT20+ zF{Zct9*5IQu#4T&VW$=P@HWpxZnUK2xf)Rk(kBXuA>=Qfk0=R zsnVf@3bFoRe^7DAMSRn=U?P4cy#60|l#C?{AzM{fUl9%S;NL;8FFDXzF@Tt#iwJdmmON?tXU0TJ87K;pyj$qcU2xe5?>yV>9b(%YQ3_k9dRHLU& zY)TNE{`W0n+&2X1!C`91l3%QSI9YP1JVQ7 z=3#o$tK_7K3bS!8V&G_eysWG~8o;kb&VQ={=mIn0)pC9I^GMsqo7ITu1C73Qd!rO_j=ddY+g_V=n6 z#Nz7WjQ3*x(s6@yPzt5en(`_gw%`hQ_>;4tG468u~|M7G*d_P+KaTu}zB1?zB;IhSpTdK2bHh`V8#;T%1} zI^|pzFQ6giFk!z^;h?Gn^fH-I8Lw7NH8I%aL`XtDQS6;=8Dh>+clFLqx{21}Cf;dK z6NDwNOwEi5$N8eGYG~>;Y8(QVQX#iHv&vTS9N$&$5`iI%ZB{ag9pSSL1odeE$;*J&ajHGWJB9z_4g7%*`prLo>zh6I+OUT1GH2LDlNeO!OP-p5p;M zUULvtruO-xw9XaKcVNl4qN-Pcc}`mJr-P-+-@F-=zCT2WsN1c=9YrNz2Vs^bSY~(Fx#Wmm>t; zP4n}P8Ullm^Jynjswn_yx^Bg$`-d`Y_7Cz^wtxC@sQQ1U8pG;u7@e0XT6boOfw9$pfv2@~tfKUe* zTH@SB8rzg6o_NW`rB8PXv^M!FM5u|nH2r_Q4C|#YlIdAJq$0s;9z=Ga0!aAjs7r_5 z#M)5W$j!ASPvSpfE=`{UC1-@^KZnPISMv`$J3{B-duUV4$ZpTSVHPl_zjiEu%TRouhU2}@Q6T!>TV z>?h0FrudlC6^4Q1YqTDDUy3~sXZl(ols$^Rhh&iv;0s1It(oaB>ZNYf05@oP&opOY z0LBHDJ2?{`g9d19TgCXABK%ZJc!A=h4*f<2Q+pyKV`0qftS)A<)u zjp7umFsF)$(z#p@46WZ-l8t+!xLJE4(RQT67=G!XdZ@cHNj%7;qCP;5f4L(s8JN2C@lTS({t2r-kfpo617Ansj{Kiksfi(~NwLLvte) zrE^&#*~xMFIh9XTXTCe?VuSg~i9?4L)6zJ$JZ+`^=jRYs%+}(4vosxXM=mY_gl^8L zbxF7A<|pO~iFXIQG2BimYJ>YCWm6sUS1>^Y)4yZfyOeL*Kr`oatqPDHLCVD$sGM>Y z=3BE0ZQ3Gae*j|zQP=#1i~xC1M-&pvan+tXaC%`H^pI+z!ZPAQwUmPtt=d^15j6UIYi}f z=f(2$-4c=ttd0tno~Nfa=tcQmP8IH|>U(sJKBe+`G3v2m%I2z0ePt6NCvI3Uel*`? zd1t8`0AlWmVv?R0C+A=zAggiw-#2Uh{-Do(R9gr%5jCz|nra!PJ8NrYTFZac+&foRYU zlsVki-3 zW87IyZvCUAJXfB?b<~YHEBL)Ii}mZ@_=O*tJ1WIOhl&haXKfs#E;Qn;l`3mKdd+)>iKavkd0M)L>C+J;ldy(!s73w9zfSp5799_!f-3AjQ_X!8aHJZg*SVK z4OzFp??OXE#knn)pXr+)rRXF-fb=b?Xvgu+?!5qDZ%GHC4@h@X69Ovb$Y3l~PAj`t zacb*Djng*C*YEPudV;h1ROEkR!>RQkxP}n_iSF8L_*$8E8Rn8Fe;RTe^Dk81f#i-k zPLMaGr*tdzIXS+l%myqI8*lels%jtUg3X~;R@N@RQ+(wj{WoT>`u9B@kS?S{bA#vy zM;u)(B=H8B@C$5l!Src|LFSAaO&|cmC^L53U?pW@XX$Yeu?)^u=A$v9|8%icY-=-G zLjKd5QX51gufbN<)UM78&7PW$p3xyjt6%6jhOL?B64QU0=+!y8BFs{RDdvwTGV=hd zQdKU)nT4wAdCrgp$x?QrH7Ho<@;>H!4Ir#hT4wiyb|t-J54W}6Z106;MP*J|xY&_# zIpKxnsJ`QOhk`K@lV6>E{b7Cu#VqxHH5~eLv**&dL4%|dv=?wa|RvtT8iyyDb>R_TAfr$;nJFdD|ft_@sRh0Ch zWxXGY^y`18f~cB1A@YyJG-roWC%qeCAw&#HpU<)rAz3{H#*Iq+J8NhE*alF4r{$ zd@A#7@!-3{$tSQ*>CGTf6a27vYqEg={z~mu5i86e>}TkSg42RMDrH zN36a;mqU015kKo?d6z-Hk6BdryMC<4d$Sg5m+fy0yXv;wx`!`B#&q;+w{pl*p(x+N z(jcaQ@jP2&VuC-z#M$4Q%N*`mDY;Q7uBqjOW z^xBDuaWvz2T>GkI$P1yxSY;NY;=pKg9xO?bZ?E+OrQ*Z#vjsxRrWM)1$7KzQB4nvh4}9w_Y~&u`oN z%K>O4g8y1oV=by%ILfoZh+yoZc}>F!9_N|=nx|2zms9b0vmutoq@2L$m}EhJ{)s{@ z5#v!1>zUII5YTAAGKcR~9dxyJw}$w;tK-Mt5gRYo;Di}&gEv5Yrh4@;R@IxO?_UGt zCSdS{xa!qzR%Ncq9g+DR=gOk0bdmn{C0#9)U3g_oQ6t616UTI<>)b{iH1zR+wXwj%EN*af<>34iu;v~IYr~f z1$};1KPbKQcEAxDvWSj(NtUUD5je*M<0CM9aP8!J;nY_@*x9wfii~m+%+3K91sRVi zutJvI_`MTn)}7P$W~{R_b5eRzNjc1H-miPMvak}1`ZY+%Q;xk!xJ_}u@od@XhOj5y z#w61+1K~?f_-nIsy!LS$*Zf`MOl`*xX`-%HCfUHTvT3fhL1@6=OdppH0z#b?Sa2}s zbDNmrpht1~FAg4PL$Cmz`E0x;ibFMt6=uAYK(Pr2Fkj)6YzXU=ilfq}Mk7b)WDGh4)o3WAQi(dK?w#DNm2* z?U)PP7B2&dvk>h*;5zcSefoKI<=y)A)39pY56m`+qlx}ViO7eRpi|a=iBrMwC5we$ zFj&gUXqo0D0${oL*M(VEvPx=7#59ar;mC%en<~}-dR(Ng$#HO$3C1NWWyUXJh@o_xQu6EjBa()6Q%p(@Mcu`Lh99&kpA}9#FVA{(4Bz|zlq*+mTv`v9GyIv^h*#(5p zq^m|oUltlHLVoc9e_Yy!%nM`DdGBA*ev|aCy9=F&2tGG6U8newB3)8a2eo(~L}WFA z1Lt#11<$F+x;8*n!3viHJcLSCAclCwSRndDOBz;nNGjNpZn2M5%{58~9#3105ns_t_d`$U4UGP!||< zx$DD(=LA5x32EHhwCGfCmtvM7Gx@KOpo10?a60E4O75r3w4i%Qe!EQ_)uc(!FYS(a z-i^ETs*Db&9u)!D!EIFmlsx%%Px#VPW3BO+48^`@rTHJ(qbw3gzb9}n9j3yCej@A! z)9*s3-?V5;;#Mp2e>^+IGX^JV@-}_uyqzYTP<~7<(S73p4mnM@>wm%3Rk=JWr?e>X zUj`b}oI6#dV6u@z`qmCg`NxEntCQ>R4GE7xcTr)ihVU0Y{ibCJfQ!$ujOOBpH%>4q4nzqpI;doIEF8$g&!$;7DnO$pymYS&HA*&hi ziA0)$%0|>IXU|vDAn61n&P>ZVNl<~AICB@bzfEBxD8(F zlW$NQFJPEU&3rT|IV6l1VTP%)wlnYO%eWSO^|$np=IuY*3UxekF>L*LJQ^L~DkS+4 zw3om@Bf=(@|G2_lnD!W~I5|;A;9_@P`zA|v79!;$e!6^~qBZ<+uGa)#1>nvGDoa4z zvr;ie^&b}bhQ7bi<8EdWynOBwQ=$nY(ERQ)m@ z_@2aCw9L(EM=Qm(dl{04GPHSZPJD5xba4we6rO#zL9aJA*!q(+(C&#_@T?i0ja^u? zor_(4ya6p%6jcc4%(s@AvA}1j0&4s^^ZSODY&pCIokJEhcJ@Ua4BpNA$oUW6i%|2+ znq90F!|Uf0mrTub5Vm!pTPtE>cXvbD~TOQM059Bm6-s zf-1)ccK?0+Q(y6?4}4pA(*3`h<4cOuaa%VdKWh@w(Re0b3LL?cTGSTmO3W$zp$#2_H^=-<25upW10R~ferJE?9q%0MRvu<%>YB%A7huJ7#Xhk4Xn>@Nw>Qx= z8)FknI8;(sz+tFP$QFLtZ#qy&l_|jBz0a=fT>Vr5&XE%_*mQ8>R7}dut)NDrGi6(& z%9|8}DRZKRd;2vKE$FyWQ7d99M;d2kzv(zAc)gREGD@@HXg3IQ8K(LACyke3a-1X% zC`F;G;7~=psNzU2d=^lw);No!DmqYF5^7D3{UY=hvGWgDSy`f)&iYG`1Oh$62uhDg zgo{wXTJQ&dE!1QiT5#@a=R)#l-t;O{bgVDQr;XcSbdS*&%n+o?eJ=jVKFGEpXIf!CzL=VdrpqZNuM9*xQd97m zZPeNuI)6xaxLDL%RGVW-x ziK7SJUHu@J^o(Tn1w!X7(Atb31Nivr7NYz*=CST*8K&lcq-AV# zON*@aYW$xtL8;3y-&J1AQq2`ZF9wE@F~3lTwV2g;(|ss{)u@E^9#SVSSP=_e({I+4 z(y0+Te2U?VLa3ZJJ=)U}jUFK5)>`IB4z!WwM|@PSYhec-8F8yu=gAO~Z}m z_@-^UC)QieIlS?04hm>y(ZhuNv^#Fs&o9KJrlf96bD_W3pI#lDd|Um#U;riwGyJ0# z(fO=x8mIW+*F3B>B53Nt;xM{QM5JCVYAY7OD7=rp<{c#ma zo2+1%z29+eYMvQ){vE6$-wr2-`cSd>tKZ?d#gBh}#S(8%ft?Xp(R0<2%9x{#b-Z_! z4D&EJAr0l*UKA{yvj@uiFJOwV8=tyIuV3>1?UbD&so|TxrVKu5W=DTnTCyo+Phtn{)$B+J`}+3+g14_7UrNKIX_nPfcv(^+f4D)88a*+0 zIewK``?+Pc94_5Q03-ORb4){`Ycufre!Hl<(3M;0jS&TsjPPup(Y2CN6JD~j7P+oC2xQzq zb(LBXPf`8s9Ube#Sk9&)VB?L?nDePNW@pAq@7vgTOK!fxIxO)p$N&+Pf*vszOv z^)DE~rB+;>e&kWJCflMO6$mhEkH3 zf75lw!#5=a$U2PHG@9<`#qD;Kb%p2D8wKPK&!3Grx$Bri_QkP$E1?PmlMXP709@H` zIt(SKC($KS2$@hjy zASu`SNh#xi@Y!aK&A^_D))fN+I1;!CYuuGFzPD+J7N&?9*J;|d-A7AAZ%JWe%R=&N zWYTcz^AfNbBY|Q>A3JS?63~J5bH2TQF?Cx#kQlog^z`hXgfx^gXW{EFo}9sgX{{;s zi;VlS9RxPD z>^XL>O7L$lF;An?Wi|pS+GA2@c=9JypC=Y=gBY?3hW24?YOc5A;u|gF6_IKK0)^>; zEohH11x!WkZjQ%Oo9hDaFu3D2369PwqWEu%nP7dg-AW1cb6)IcwCB?Du2!p2Ya|`7 zPbxg!_36lVwLdo%dwnr|W$k!IToBM2ESLWBb60B-8k!xSGh&t1cO#wm>~;tl7M~<@ zkbs^1yqHE+sZtn67E7$edR@)*6&}I@i~C{cb*eWt{0Zcs>L~Cvm#D#a3))ZVTHp#~ z>_;`dckz}|^i0dL09=jnQyF;B;)?GFkx%F1-dZJU;yDansF%Cd$b`R$Fr8x)>#&vQ zAR|#ozbSu539itvn%F-lQi&bA5o&I3!EqqVYiJ(8)#w=F*$q>Z>nZqOXe}FLP?%;T zBNzzVoEqa^!PIHCCF=Mve2XWV7NCOQRcU-;I{Zb`ZN`` zl{f|ooA72pfh;U9_fE~Pcz&dfRINYqL&}U#Y%HItA6LdnxY<9) zc5w**8g0eFyL;tRs?w7HJZ!`wNxN9u>k$le7Qu(dtKJ-9AjjFr9o1lnFJ0Ta`9H33 z-kl-&B|eyea5Dk8L)7L6Nj4M~jmt%N`J2er{9saE=dZ+g#~awa0mpC7Tt{&O>ourn z!4o}XOmwihvYz9OsvFSw0(k01E8oD3te}@NBSm}AUGKTZ4+UfpvvOm`N>&@GVcv;m zga#X-V8!tj59oF>R0ri&%W*oD3BAGys%X*B49a4?B~*B{rADUr-2JVr7M&e-ogRx9DT*eKpUqxp=KtQ`Gtz?<{x6o+<7WQF4MGpPH=)+4e=46f#p}h z8ZUX{9M`pRTRu2(=#{`q`%ew2W<$pw{ZaRRUB3BmzTo^ZBXJEEnFxQU6lkfTsPs(+ zN#`RG*)qYf-K!Z|_oYwK;B(v&*g+}7Ylw(x6+t%PX4wDs^wr7W)S*a(GMDsoOW4Mc zGX=5WVFZ_8ShV_DUBgd+sHKI! z;+w+#-m#=Ak0SUXCG23jjxXizH|ms9$Pc6=`RCbNZE@J{Cz=Sh!sZ^nb%aXsG0kR@ zpU?6deq8sw1{CP?dX3SF-IfJEmiunl;$@*kjsvz*w^nU6UB#ugJ+>$au~ z{4Nh;j)3%9L^8Bl8F`C^`=O~R2)$eu7u1MEEWdAZ9a`&{Ec5Ytli{i$+~81>l|^!^ zZm!-7{KZ0|gGmJc6eRCF5oL++@}S(-Kmqj$9irFOu%%^`+zr{Ww6U_zmu~xLxHN=laPDRka_mDcT+S4)BI-2SJ5aT|dLtgFcT6il0W3CNtUd(2u^im>r4 z&^lMv)^ju%Z;nlAsMXg3K@L0L&K_A|P?7k_oipo?gU>=2@3$|&nV7L3JHf0L>71dR z16*a|qR+~#ajHB#0zrg%t4?4v3Y&}IZpXC7TJW2Apk5TdZE;4R>|$L1z1O(;OA48w z+-QX4Z^`Tvd5N(Lc`4CfMKtnVrQ$TfaAKHF~6BFb~2)3?;6J1?)HT# z1aN0VpzIOTKI=8%#e2#>pbto?-UOffkXjQjxf6$G#RcOmomO9bD|GVRbG4!Sr}AyG z7_4LBZ*=t~r!R)QQAs+%}evh8&9`Cd_GVY2iCo>3NpqWE0RB6g=0zMkkmMc z@Jmz4S?}?_)EoHbyN10B-C6KuER8LEMk@O}uQn3$V$ zz*r)xS1T4JZX}U-7Fm$|PMPG&=|-YT1n!;o#F4MQNw;~;u^sp$9y8BX`?5iQIO=$6 zijGT%DVPS?$9nU}?no?#?I=uLvnjEG-ipZ3gs#E(BHQ>-YsIip{$zW93dW8Jj@0N3 zMA-p|*rS7*?WIE7OLH9&=K?v4JpFEycaOHl49Bb}W3^@BnZPo-0h ztC%yL;d;h#fj>FgTJg-TO#|y1VxRWOSUX* zaM`T&$%Vs&497$`i&`LLC8y~O?yS;!Msu z^0EvLt%#K1I}y*de3=D{su%ESc%5Z`r~oK6%ly;|IQ_a`b2yu-n}ZV`=AQ-sD>?oo zq&?DEIe>pU=-&{s)mHA;d$#ZU88t!?{0hzgG@6tN){yb)a8*3XG{BjA#*Hh?pUz{l zz6?Q1?TzDB1@g^>_liuGuzs-`xK$rzJI`ojHgQdbiXNUwBFX##=dWrLEzAB82Go!X z?%PMEEULr!I9&nuO{$|F>oGbq8P(xo41JWAQ0Bb3f-CS6ZjBPA%cy$-a z9x!G@>MS6NT2Bfd9uD3PY4U1*v`vL$xLleYtzu_2%K*_3Sxe-oF|6{H{?O)#izU`{ z>v=&%*W+_-r_Hpn+hus8+q80(Yi#J?wgax;w zZMtza8A&}Pxa#QmD@CxsS>kA}N3_+K@}i<)c8emZUl~k6O8A@dtO>^s#I1v}E4e}y z97XzB3LlT>i@6OH!bM{ZH}-3_??+U{cAy?XuvQ>F^hI(9I7(d+fGqOK@yr3p$Ak$*;jGq+mtBP zB+FI{oqVQX8`mb&`RV>3fjT-^rnKv2RD&PmFsYYvsehAtTgs<~Rg%tCssNra#AFWV z-6x#}v*HHHW?|)eJ`?;e{2yB0Jx--cXq1xI$iaj_X?vV_@VyP@p^hM?11b>DsX9I@ zp3rt_Vt@C9{1Mz?cWdK#LsK4+FMLu_wW!=o6Cc*iHcwHm4}XflflYBv{y0l$HV@54#WvGJ z!dxfSrBcF<6uy&uoIBW_{Z25d_iNKN%WlIW5%#m09PPKnHbHAg!U=g#%YhkRr)d z!ZY3j>Y44HDnK5*^l1zDh9(K0jC{4U2bv!jmu;?Zo$naf#Zl9T`_IkzQ5zTqfFMp= zxwBL3WE0k!B1(#q+Hn($8Gmvn;s3W!A6K6biiXS~ND~ri3T9QFD{_{~l~p(?g0*Al z@b3#<`P~M1E0c=}`8}AG(u{tI>XKNd29ge?zIhK>D|rXQDQlknjo&Uj^ZhY2Ku#Ci z@9s+9pH}xbMqbQ?@47~j<>#v+UM1zj$=R+c%)qtzp-(ST6hC9Rl*4GI2k3sI z@Q~k{-T+LD=QPl~&b^!?>tp#{fS1^wR@Cr%B)Qm!#})+uHMX=siwLfc`(UEbTp z5%fr6+Cn~I`fMj%j(#q3l=&u~fr%N6CNk@wWI?^Z)n<5Fe^%(AC@`NcK3eiyIA0tA zO-l08ntfPe%2U9=)9};~Mhmrb36-hO6&~L8mXd|d29R*uZL5^9Uk$EImvZges=E2j zMHw%T>*8|R!30q`7gMf^mw3V7Op*{6K8~~LyrhxAw^i9{iPyCxve6_x%0PfYa4~#H zUV|lh=lg$z{v=mmJm9Y@USJJ%1jEw6@(E?YYi(Bl^EOk=#wh!>bmGFKtRmL^HNpvm0I`Nq_sFs3qpW(4u> ziZe$PoEqeM$gwQ-LJ_sTvC{X-@k+=7_>{#l^q+5pvi4ZlvK$uUve&JS$jvz&HZ4)9 z5PGv~4dThL9@xN?9Q?We@9e}!w?`MZMx4sgNme2pPz#ZQ74|=!D+D9U>_pAWA3Eq{ zVW;0xb^endSe&qgbXdRH?yZ5%zb>IBtOrvLZcrr^Nv7-QCs^lG9a&*3BQcSI3xfz7 z9=y52r4`w-3$iZl3m?pMZfJlp(n7tGrNp@5T>1t6AIH%<@7ys_x|S%P$Khbv_ASEH z1&Dgw@qKd4nv!7{Af|$)L z7Vdy@M@k-MSt2}2(1<5ay{R9MfQM&)j}JpPeeoY2>?sclm~S0@k^b!U3W3! zFv={>rTFDhyUK6s9PP9kLg&rTQ8iqN? zSCtb-6D4=3o#_kDF{(zx&X90Ol9M_ty>w4bQg$~)tT2GbUw9s!u=8xlXD*x5gks+D zjdK4tVd})~oZM;Uzj;I{kYNOftQ16g`}4$p@ggmx%V$>CjdXySR+>K862t0jUMaHJi;6q zqajnAVu-O8RDWdyc``wtm#QIH&JR@xKQ$fG>}2B$$Xd>0y_c?N6bTr zZXJA>;4Aufk{D)Q&#^k`kPY-=T!QnHD>}o>XRWZ`>Tm^=VRsMrf1RFPZnlKeG?Hsx zP2~GW$SyHluPFY0EQH@UMe>C}(C$Q|<75}CK$QyM>UM4Wu6S1~cBEt*x^mJCk1u|V zlKW0HdbUv6#cS?JL-H`kkiO2FW4OtEWyhG-ln!YmE0aaOXbtz8$I$IP$Dw>*`Hi$i zS)RaqU)P|Noi{Y)w_1p|K1m3#Us2IF?M(@t4;G*x#7FAfU2YXA6KQGGBhSiiU?_?K|ZK;wcJl_}45=W;xs|g8@<;cJi z3MJCI*EaiNZ9GhSUoK*-Mt6IA&q^X^7~q4C=qG&?8Pg(BJe~z&MN{t5Jt6(QDTw{- z__Q}klc+nj`|8#-YVO$2rh7%xjSNQgf;^%2k|;3TKI>)^1d(Efjp25`=6@$T$j%dq zOnbb8KlKw$_I14M|Ne*}CDMfBLE1h$o#;~Y;P23+ju<6IAH}9iqU*#Ckl7ZpqDTXS ztA=+>^JNZ#RkSC51evR}H^WD|_lZEA2r_xyLIfIoHt%wXa+s@Gh;2Z%zvBc(a@M(k zJP(>SSgT)3`mO+EeRJK(r-;VN*(&sJZtSgslQx*i>IJ6FU+yv=FMSW{f(1yn)1qYN2?0zZmx2`Lew!9N*r$W?Km(ZJu3sp_Qk0o z(Jmu=C;GS6yPWnDXp{;6K*BaH3CRqzN7M9+t5Cu+%q6TLHOL|h)L-g&fjuFaF06i& zPj{d({NdGQc{}P*Yv9aHs2b$0MPexpW2K(;fJvX z<;|yb8TS!1QF6kxSL5|Ej?zo2o1hERb0i2Y52!Q!y>X3rhHV4n%3E`4=;AXIH3vzf z2CS&03`#<;>hS=~)?w-do!?6atE`Cf%xsTKGb}sfNVVBha#z&UV!=j*{@0E0w3RF? zZ!MK?@yWT!ZMDj5i=M@~v7QzzHi<(gZ3y0aWhn+0fsrLf_*C)4>=P}LU?_BBk?;sr)$%AN$~@k zh}H(x5D6o5y77I7LjVuQ;uGCk7;Z!$Z@1XP(MBJK$ zsOe7)Q^ey05SFEc+qOc4m3`*zGdC+gLx(yXoP*bnB2pgB==AvVP(*^{>x%OnV1O`5Cn zbm-q%8JXt%jbBUKTTZ^#%mG;|3Xtilq(?q(`7+Im_9d zG?~$3u2pijL8sJ|G9)v8`%jDctc`19bk2R z5s&Pc5e;rkE{tB

s6l1W`_Gk(pWW zq|5x-J~&-lr;d!nthVoncY^?;T#{zYq}CbrM{2vU9rm~)dW!z|pl0ODK?iM6ochW^ z1YsgjUuwUwO%}-7OvesPA%92;?C68}V7SrAwir)AUy}1Lor^gB45$L^&L5L zLv7!g4Q{wvF+5*B@95|_GNm07(2+OUn|??X;r-eKa#)%);3pAcqRL*@tG2Ycvw)ZL z`6#)``$o@wL}iVx6&~3zEM3u=hf3=L1e1|D>D|ucxq;ZZR=vVc-obPXeYkO=?b;JO zkSe$+Y@`7>O&GlYg9PiXWH{eh6Pg5|#qh+H$`Ol;-hy%N>f^&u|2@OyNB_DCAM;g+Ld0%)l3B2uX z?HR9NqjL?vR^UFNVOY4E_@69%bi<~68@Ei}1SBL=X+Yjrc}CDA3geUjX8fu#-Mf9r#G1I_Lg^a1haGs!!Ykne=Nc+` zV}h(_ufKX+*i>#UW>CVCSg2LYYnzcy!$HZfu;!hp#RomD%!RNdbhYy^nqugqILc#O zLt2AP7ZaagFc@{<^Fx1Q?OLLf+rU*7UR}GrsCjm)W z5>tMXXB&LzXO(}VhrHm5zDXZB7Pr2!QO(I3h9KAH{%J$$6gf`jpZ!T8?by^FvLMDJ zDHV1a4`A_#hcWKhqx%ihS^*TL7xl}On>58V2^cd<#pNx{nM!#K|0xV&)JY=-Q2Wm5 zXCf_R@uJM6JfyKE4ukbxAH`xm0X}a15Wgumn%4XD4faz`zY@+zq;HGumlnp&Abz;W z*KE}SsDpP|JK#Oy1NegoZyX=HJH!dO1NSSR zl$DQOh3&)G`*D!-cuX7>Of#7RBKLhUEt+Lt&-b3Vgu}1}otuJCsaYN+xEn^Gr=TtV%xTD+qR8~&57ro@80{~`v<+dcUP^dT5DBB zX>?+}DJWnJ%tW(7mNOg{Vw5)(G_f{vlH)ykwGipNPR(s{L2ZFRuAIUREy_;Wq(BK_ z$JiDGCbK9yvAt;3IeXGrEJsfi_gW<~m6VLof6j zB0zc}HA;gaeJJ=z-T9G?uLB=EHOMjm)LGlm{d)>%d25V6{hZGjGEOW*4TjeiRDkV4VDhX~(4DjJ)rwch!D{I~>0W&)7|I=hAxs%c2u5H}+ zd3J04W;rD^6?|RWddm14Qv)Jubg2foH^Z_=sL7F|0}XuOL0SURDBj+DUgyg}3b)nc z$i_boD_rau=!Bu%^3itaO0qi}2{NJ8&4_`5i1adBBuWh^UfGeBvha&+)43?OR;XQ3 zbJ=(Q6kC!{xZpvdWAu0oJ#02|viVw|O6A2~`Fg+%nuy`h7v`Oxtz(|SAs)b5O@)7z z0;;sATmPr+3x{XG^&P09IIj0Zx|REDDI%%W!A94Ek0`%sJ6v74*zMd_r-n6FNY`tz zb4b@ln&DS!Tjt#qwSSc^;DSpftAZKg+^|`c+Q}flgRZx1neM~7DAWU~^iFZ&7t_`h z<1-BuN4k_R0&kU9Lw!$vH~<@+_Fukz8%Lyqdb94?oCRlV-x`;+DsN(+JRNviKPk2l zC`R)AI)p`5L9fS<^t{1zzYCsC4doa^al;|T<`c;kl<}6AZ`L-wj3$~tMC=1>VlM*Z zq5Ez@>W8W+j(Kkk!DEwvEJv)39ZH!+wq=JhE52FGTl=>bLU)2>1fXhAJl`_RffG>47+v zz5N9a;dTf_RzWA}%ZW$u&@=93Mj+H!{rmv|L6qiilYdokt>H^ zA~O`W#m@qHeRuc8OPs^StH~$~K$gH$3P%_mT|qVs@f>=X5&g^t(*do+EObH5(?i7uRfg<=8gnRwJQw>ox^2*$>;wTby(T3oc%8vi52@`lr>d@iud2_k9ZA+rZBbhzUk#FarBEOl4BuY!r*3D7`&1_XnK+#IcIAdW7S3?$N5q1kmM@m0@R zH;|@L=AC=TS*^Y!DZ-vU*1v#2CQK^#sdCeYK5DVP zymQ4cY|I12`kUkM^|){VKyRy1_@|e!Vca{%M(>_!&}6*V{qh8xu46fb6xakHkMHKy zP-!?$j2S>hWqh z+1GjF6}xi#(|M5@I5ONX_h7{5bNCm3s(RbVwZ^}A;*6vaK14|XjJVQwnDqEiJ-AzS z7br_Cw(s*So%2OCet>t%$)%PU%C3Ttt$n>79TDTuP+p3{tKVWJR|bi4ZrTh`%g%K~ zihqkQkwwRnT&T!Xi9Tu_q>t2UP`x%kW&Vhl=jYoJCHaQ&g0EhkYdSUXK{XUE9W(%1 zIEmL50#7w^!hr=?%dPjCZi0i+3SkN9{Mg< zO;`vCDBgjWF0&ye6Taq2@zMpu`KwFD9$6u-}*xWlQ}8o)w5LY;ol3jd=D0 z!J!J?(s$+IZ=2M=7C#mp333V^yc!W&?&O_JD4S2*wN6ZQA#}4tZJ3r?SdrlvFV~IR z|9`THW~?P*B+-Iekqd_bv!@9ik4qPDp_1t_uC%Ns@Ei|IHgvUuk{cP8>tLs(gA6gc zs2N!`0;pgc5St(zHlIScXuSR@B^ij+F-nlbjrIb%BbDXyEpj6jMn2?B3)@%I9t+YX zly*c*3W)5Va-MW33WyUn@r8`qHr3GBTSyKlm=nfqmWa=MH&2VNt@-X5$A!Is4SAZe zO{d;$6OqVj7Dk0>;l78s@A|{Iv2s~+a*|_J%!d}vs>XPan86F6Hs+2nQ1FC8k2;W| z!;D5dIfz(C*{<{GXJitUnlXAQuLVPFrZ{9umJ&O#9L^QFNG}*J9Kr}!*C}31dEcw@ z8j<}q>i10whf;XDHAGIP?&Jb^Q)URlTi@sUi8iXPe~Dw#BIKe|Bf28+JGfA=tT`w0 zy;@jdjgd8D75$ml2I@1$NBsK_Rg2;gdA#K(`F269;dErEhJ(Xp<8)K8+FGgVq2R^d z{TND6i8-&`furMq8leTL2dUny*f%d`m3h}nDTX5NN(_>3IGo{yDs^_T4lGoW*3WK$eUX~I5`0&@I) zTL%h)QiejA-(_QM?95D)m)h10oe4!OCB?i zd%%Nan`3O|Tyf_M$>b9!Gth~HkiWgRF8|G*X=HR3+Gtznw$nt)%<6UQLTze&076th7&M;Fe=0>Xxu0P$bon`{ z&m(0T^EU|Wz7-Lj)iMo4Y|_<%*%vkt<{rLcMOKO%fNh_b0v7g0mLw{+ag*(JxoTRD zJy*G@IR{!xPs9w1Q@WOMX?{zeU)}+gEmNr#-*_~gUz*x z7|CKd9#QEA4mHS-$gVonwAj)Xn}{NKx^0>j%m9Ej_sHP9TP%HouBr0sbwEvm~{<#2`ux&iuvs zUA=QfjtTz!SY~K(cs0T`qD&np$w8_1p5gg;%eopy(b7!0CwO*~#02%0?n*5s0#>>?1HC`STWIo2wd#_LnQvRRdN5q2I(8tRcPdiqv#v3b z*RIlrdQEperanoje)Yp*z3@Afn@ZcJAqZ+#APU3KifV>rIqD!B9kehi@ znXIu zsr8(bQ(Y*~<0-m}>^GWG~QTaoj=kw#y z9Dqg#NX?Nuq=6S|RxW<5L=FH|x>Q6!A~{Yt?TD6RP4|D`tsjoBYNTHRCdYg&s4-W7C19YzpDnRVU$ggEYIch z)gzZIVI%zY#WKpG#y7wRynK^9G=eJI=~6t@Ao|#zmz`sxaGw9<>DmG&-6ujHWl_T{ z@XQHTi)FD_m&rmG`Bu&_w6Jy95vxO_@**1T_i55@cS2eO2pNr%0uiZtonT>JN@7 z!=#hOxWAi?w6i+$=fgWIujAfa>kq01|Cjx|VA+2#Ydg;Yu&f&I`tFr#k@gw<04t3Z zUH@N2DW%$x$^lv)%^Xi{1u&FV_Ggy>Lz%oE?HbZWDq_*hpnppyiw}cp200nOxq4o!B0N!#LfBp}Kn%*^kFBA=T`LQH9Mh`DO%=0SYoA{I?K}ws{D*H=( zn&*2H4g$dY-TBSCFEe%yMuG|t!y`p>RL*fQ3>>Z&iL!4Y`Oe1f!ZTSo^bPy=nwUvn zCeT6AOtzU{Lgo34p^EuM*-t9fQEVT>Im3Js5VA;`@KbKa+CHVm^6@NTs%Y42+@SeW zKvYz!-2=ma*_IQ`Iib--LrT?r24hAZBmKeOP9`2gkI?}D?%bXbEo1DJUA^G!Woi6f zV0(JpTril_>MVo$I#oW)34_N+#MZJ>ki-^~q#=!1NJ90YEQJ;GJY1+-5GJqp>pge` zV3Gk%`%f8liokx_o>Vi6@N)aFFNs_H`S1TM01Vvy!dW^B@`0s4D9RQgSviP%>KgWu zDvGJH1$69PN(XwpCL(z$7yq+l^vFlBX^Om`WS7J77|brZn)hZ=7DZzNqFYbH)n-_R@$aD4M>T8BWP6^9G(s?^NM#QsQ z<%ao=rkK$^TiYhpa=MMxFP$BsU9r*ARrx zHH>7rkZkMYjwqF*Vi2eg<7VPIU-2xF0nYfLDeiAjL@lD53VYK@%8Qc2Rc-*WB@M{> zU}uyN2wgn=l{(`oe62>N>0><=f9y&v*6ah|kvDqobar;EDT82=V`$B&8qAEp7V_u^ zC;YOTh5TuL!mT`x#!@CcfB%kIzOseTsWY+oFb!=X-puPminMWttv21g=u(PqDM>q` zQRGE<94XR@3+ei}KYIZK@7Dn++h%CefvjqT5z5_q?p8|TQZdL>azxYf-k7;)N%Hr# z)eJCT{vG-s^%N>XpYmGJ27DffZMKdXE!mkIkf-KE`2ns$&P#t8b)OH<{PU{eqif=q zjb>1}i*xoHx511W&rB7ZIMLorw7EJ?* zuvU0l00aHi_yOf|RKQ*f#$4L2-QdU5FR~(7hfh7hxGsLba$;U0_m+};b*zX+PhGf9 z?NGOW&~WU}&G|<%AsK(*ICyPRLnVodG2xGjM>rPi=yR@gJOYpmTXZ(rkY^~$)+=&7 z2ULI!ec?iPfIpq66+qLkp{yTM>vcn}ojr^khmrldzb|xI_bvJRz8=Duo#o5p3?hL+ z*minn0~+J4zEV(*d^3IfiNc}eVslqNDB@kpogJzd% znU+$N%SNGCFp`}G)q}=K8mb+*i6F}Atwl+QHIk?P*eyESw;HVSS4r9hVN1Z z(#C%lC$Qq=2kR_h;psF$c>quHHL^;~xj-eeP=PPGmr+so;?)?AE;WPI7jYvQ8v{8w zdm<@16rA2M6-Ty!_c)G3m>}P|KM(Q-)xOJsju{vlj5x+0|Q2BVx6i#fuL9PC?67#6YJoaI3lCj6*kIC;u>JSQ% zc^HsRz%v%tIt(vo%hAceNpSjnH1jWE5lx2qiXDb)jPw-A!e+NJ3BRYFliR?@Xn!-o z^K+htfd)Q04RMwvR$YAx6HN%-DaoFV1m|T~B*N3e_eZp!$}NuC-U*;q%Yt<3?MV~g zmGjY=P>KI}9MwdAfzrw5j6IJ$Rpar^IwmIr_%&^R&_}qlnUL5xENZ5Kmjrb=oJk0k z%{F8j8S8x+Odb%jsfDIsh`+b)7Am{AnEDUGhJa<^5Fokl>gX`sy5~}qyF|ouds?}E zj9l>`(hPb%Yn;k(X_A+Bc$Vo3wA;cPm075|R4>eysEQk$EG~cGW3*pX7>(K7y*;l0 zAZmZUCvYa(VBQlWE-&ii^jIbslU4W$afqcEoEL?4-S1rg@pb?3;`~1S^Sfu$RmE*~ zk87_tOWlR4DsI-a%-H+L?u%2V5@?8sqIrX?(r_hE!8}S%>%l`nj&yoaY=Lb5W`J)c zc;O2h!|=k!ZY%?lnRC|~ZX&>ugU)KuwUur%KIIGJAR>FAIlp28TTix|(P$GK&=5g_ zR}rdG@enOuW()AYa5=T{YXB_BWUnRvOqcI~9frf9?HxrgQg4A+oIIEaR!HKjXHN*R zrV#%YA{GS|o1Xpln#Px_J3g;uEztjCtxBlZJgQzmrIxr!dAQ{yWe=O_NT=2l*}0_t zB8f>+Fm3AG3_>>KFw`jW?1^4AD3qsGd&}Zs7_5 zm)J%r0%KeQ$0l(;+orb`5cx~=!UTW$cRwx{UDPi8drQTCkwq1N6d49Q-vxM;{i2?H z^r{_&ZgLQn99T@D5X`M zGx_&dG1IcA4PKmA{POBPQz4IOh1yqQdDn7=%)G*L?*32xb$?CiKv_o0cvyQ>4OLXQ zmLLO)N-3R-7odP@1f3G_SfNenNg;BeWtG%d6Iyr!)nN)G!~L)a_}l(G^#(#@SJ7s_ z4@{nYi9jWV2nN;jxX==rnsq9o(?%ieJeze*A@3Af{yD=yGkuP5N#`$PfbSuG*mQPGsT2Tc%j zNNcms!?(Gap88@7Gd-fnB=nO&{u`O&P?mV%%y;qTpll!#(vx-4rvodLLuLD7ZW#pQ zfL)>sTDL3^8E*^&GvOyc^F=u z35?HN;+!r%5b$GpUf2kdK%q~w>OTK=g5umMm`+zA?f)dUo+(by7{wQ^j6Ph_06{Y@T=u3;E~kzk17B3s3z^#+ z?u-@-hR*3_gZdE4Mi)8>2S^c!Gcpn|Bs1nm6-EIav!RYuOcE15^dq4Sv=19{~u zk310c*@_xNhqSN~(fI?o3VrAx$^`GSB>!5+(jye_vGeXLX{}z(F)!<{xqQB&oO7MB zDvOX0oLU*6F+iEXYDfmUjoqt;({f4>$DO^=6&EL~{+sNeefF$6U#tBELIb!4iSyxG zT-KePET7U65~zsdKBZ}1N=jFHM_alMR_i+J0p$;op*;o-GX=YKx81d4CEX&}q1&pA znU2+Z-kIy{?B(m~BGiwq{V{+!1hGRpJ#BO{NBA%f>TVi4yG1vk+)^ph zu>xc7R4@eCI44P8nqRYJqqKgTjGkt9gfRT*uF2jTN+mqVS1b-6498n|_L zclKmE-*NottL1VlfM=vx_+R~P-o^h^pvW^b{zv&MfP8O~Kny`IoE77)Y$A{R)e628(zMt9v9=243>hH?vZ9vYp)6`knzJM zx!E3xt)RNnnrAB5RF^EJgS1?hg)$1Vv06&hiQ-$VL2LW%SnYg?Y41@M@H(0s00gNm z;!jy-A0}d?*Z)9*wdM`*E~a+MTtwZ!MzR4y)-6+Kvrnph=9ZOlaY;y_zj3nrn+NIt=xQ2E}SUP@$w%(;9vgrF+#lF+^K~OVB{*=lUzu z3~+$&_qK*f8>gqSXmJXeb(27~v;P1`wtk4^c3}F%@`cELk8=rL{2TGhc1gC>pM3|A zo;aCUG|qnDo{A~Ec3wSOCX4(TFHw~tW7#kq6}DjQJl7Yy7y3GwdH`jxUN)lMna%hb zH5DYpf%s?+G)wlV1YX7q8EhbEz-P9RR-jBkC0NmHS-F`cy->;$vp&|buN6fDRmu?J z#ucQ-iPYWQhJ4%xf#uTM*U~4EUI!3#D{xG8B9B0}a979SDX%MmsE2v;rK0GUU?hSI zNZvzr3n8Xl2hSmmp3!u#?^ujQKubHMobfQRrB3dTw_x;cO=^46L@%SKDY#m71IqhSM^nUe>akmGFcbZ(k=O}0QcSfN2hb@97z8=*GBk=TRl}2K->Tv8X~s> zPttHqR>wR#ggjmxk-=L$_m~_IjxZINW!W9Oc%d(SEkh1gleY_~JXE=xTVukN+atk_ z%X7R%mgUP1jHD;k6+iMBpWKhSSjjt@ty1eba}bq=aQGMsHXS?Ou1g{I=PL3PcVD!G zCb@`u4KUZzyahcF)sg1lqiqy;JOPllY zjqvQlRkFeAw(SC{OO2|aUBW_gvU%t0`6<7#hgeAgt^MkWbej3X~4_rGgi(-~;hLEPRv1Cd6RfWpp<4cH6(;0`D zbLtNbS1VlRKUE-&uTQW}glyY!VEvtp3rJlZvS7LzwgbS&NkZnt-*mS=HC!y{RGlyo z%O!w`yPeQLVvcXZOltS<>}{H!vVf(mRS+V2CAQu)Ij>BcrN~1;-sXcT(;T`jq6aHg zGGT456kZ=HIxsY2hcFe!Gta_C4MiWg8cTz-B+yuEhmmwM<(8)8aSJZ4FH>cG&UynxB-*wl22&gkA$H4Mzs1Gac}k)-r&h z_yn1<`cL)=WLMKZtJIGHUd2R)2|p8rV-hdlb`d~9MDDj6UIjTlw1{fm-A=h&!mvpK z(B&dnbvNyv6|pmws8BwDpJ6E^n3QlNPf!#$`(3Rg+VVe6V7$AhO#a}aq^8l8;>(!8 zQ9pRxJ|xRxx032V$kVBWmLY3QT^0+fAfOM$(*O(3iG1W0_Q=0jklEh{&i^YZdBw&LvCE{52)Ps)8+64>icG7g?&5rt4- z(NrCo!MtCAmh#?k}=vUG?F0gSu^kf@GbA1X9 z>hoWJFljI|HBN1#!3xL}C@S&=evXGZO5l`0oC4vi?ypk}Q)DK5VU8vFG6Cq`%H|r* z;8hs&W1~u}DzE2}$X|O@*ew7N9kqUO6?x6Bf?bso2N@4;%O;`^FU$DChf2a9cU z`!GH&e9kCkXaCHTg_Y-1e)taGST-QH+n!vi~j!-H2*Ru zXo&mh(GaXP0hxcGiVeUIBWbnEI6UH|aWum*s!O}ulNfpM8M4wAK+j2a&T_P#*UM8z z!D-WTg5RjNo8lur#ia%#oBkW7`&8?1qpg~cVyg=KDAv;zYAg^O1Cv2i}(eTsyR4xRjD_?%YS9no+*j$kYzZ`(rqsC{(qb$F}g2oxXLOL zJGY^<5DUEGY8%*cen@F|irev;ZF?&H^~QxyX1kLsX&W&^pL%;;7V# zg;GqdPr4<%$McojglOf3ZW+tizs!(vrKuw?4?PErB>+Cn$|XW}vPm(S=6PlyzDn*l z{e{_~Ln)JS_5YY0ilJG>e^qHnRS1)^^T%6b`{O`ceI%|*{&=QX@BlaD2#3Qa53RrG znm?ddRK9CSJDbDe*)Wi3@+Qy~O0se|K4~65jCFN8f{(i(_{%-;=JW2?^4aR;lrxcD zLOq>rX#kjBbjeiF_%WhOA)vHGp^zlR-T6B0cq&!T# z7)v^=3-)Xx1n50ce~}RGu;R$W`W&GuEKK-XSY%hq4Je5PpTP4&Ts>i=E^XuGtH$Ra zu~qMs6tX0kBc`|o2nXcw=`RJ_#9EI-sr~go^ZjPq`t~|C^Djcwo6+7&AOkK}9DT6% z1jyveO<4dt1YuGtlqgjoMB{8wJoJCB6m0_V{_elo2yptP+D}MY$Tfmpm!Z;!%!B&O zbXL9-Fi-^RQX5-uaD4Y(7uaU@Pw;2|K{_9m0~C8@eXw!L}8{Bo=DU%P%! z<`58&vyo@DlBN9fC0K~@c0xS*%pEW<3s839Wn3;ukA?42^W?Qq5J~RF@VJz_R2~Ai zm$v@D?KP3%<8OaV8~$&smdO&+$zZ@cFsa8wxaQ%EB?~G8Y#EG^*#m$7%_$2*BZY_+ z5i;y@ItUQj`lbG9PcM--##c5diDu%8?_+&<7d|Mm@WkjvR8aHRZa{V5MK+P7$3#58 zdaVG85SAp*tcK9?dkw}4ZV_vEN8(7IEJlpa&49iFao-4yX{UWpc?Yi@i_FK;{t4@g zt(-uq4Lv@!EZV(dv$8_bNwymWm?)>9!%_3HYb^hHiC;UVl52oPB-sT}q{VsKkF?MN zb_`&eecydz{71Ng_=VN}Nhft&qEEVS2)ufyhEk#oQCy#MaUzK0;x>-WL+1Ny)H zFUBu}WoPf)oglgYc@img1EYiDQDZstD0uErKg+Bu2o|&tP<6gh0ENKO;lq5v(rbnC7AP%-{EADT-FI6{S5LaG1 z>xwhzj0W?jtVA=l7*9$GB@B6QVsX~$BvAW>xdpE07sSOnGLecBbjZ=p=^?FOr&@<=wonNNZ^27#VOt7)MAi6}}T40GBY7nS3a%O)=eK)0G$X zGXo6<8lV8fcj9oGOiWY2Y2t5}d$ZO#v0^;p4@TC*LBGZD?k*i##s`ra$+gt?A;d

abUt+Ktk3R> zx14;U3S@N>S(zl1HyNY{tR>pl7D@6Tt7)=gT6*2MXl)VnSTg^Aq)z^Ji9bL@FjNgh z1O@NY7C=NWhi$;C85GzsxiQWHLH?;kG!5W{X2{MKXFLadvU#x4g;(`LSLOqdiY%

?#HQau8yf_Azx)|P1d_>K@855c{8y$-aM3>*X=f$#uz`k&Eu z%kyZA+4<=^_H#3TlL$PS$8phC13Gww!+J{YmHPg9dmDJW0V4Ir`E;F;Y)NIJ1kuAb z-3J*=tf{sv#@l`Nty)YN+GYRM!-1*hFVR+MpK1b$bQu=I>GO8ybx;6iIwZ$>`}(%r zpqeNH^RT7cOHho$bOK<|L(@X3|3c|k@?eM|0mm91>(9sGi5oju9%Q5w z(@VG9SZehHR6XdbTfVtd)aD0|BW-`7sE%Ad@l+ODf<^W@5+k5g6Lk^i3=X=Pco%kk zx~$uVM;JMQ9y<(5W=upq%5v-L$K{XfVyUkkJF@co>a;2{R6$m*j+4RK)(Lj?y2;M* z=;!O7i_Ax8x5HgO*x?5|V3BQl`Sq(U31prRK|RdM zN#;W!5Yh{*sn`Kv8LI{Uq+D58BTQgzqCJ|})pn0H&ajZLBf*hL(PK-46`>2DDqtzF zux+W^)ud!>K-x!sAPL8V*_+)%IUo!hjS^j^ZYqH%nW6~qKz7{KPI}$3{LR4b!KHL` z)M6u5vR<~N;Ba&2pJ!c|)U8N$c}Spy9d!23@Df5~%GKL- z%%PD_zFGIpQO{7Cr{1S6bJIG`iqU+%xP0v&ga5=$hsBo%n=%CNsPpITY5wM&bIPkJ zFryNcqWx$JSv#aP; zjB!!)RUWLAjydqU#c6q!oJ)UfvrhiTv-x)I_LMF%x$8wq1#YV6+@s~$)J@-ZdB~(t zbEW>n^~d%V@)Ek^A(`l}Lxz_}}QtEeNKD3eudPYgAYcj@|N^#S5eeI>Y4*Rpd zqy8?(-WJUah|Y4*RSW-#?Du_kF~$gJ4b1AbC-QNJpuwAgQ9coXj^_2+e z43LrIFi7@er2_dpc@SBcjfa=e)on?DxHt$^3|I6SS=IUN;Vp==JqX-%gx+@{st8=h zdcn93E*Y0izbB_f)~RLn4%^7yB=?_mR7kijUZs$YnGa)0kC-E`H3k(?hVr zVLb=Na}>RM`a6Ez|9Y|{SF^&LE~`%e`T63$%X#h)p3n9TNd-%5v9jRbh)!PvHp2d$ zhwl3<^~~-Ok>ZFqO~MxYaX~t77U1v$?`2t|U1-#~N~lb9_(w$JwrnaohzyMuP3l8( zMzaz}-M;_ca{{p_f+Y%^MVVZT7EJ0N9>@ypreOy22;Wm^9ZOpt7j}mb*e=@aEYK2v z1)oss3k5l0>hopAMJJfP;Gqb>lK+H^Ee(%ylBzbRhiC0(XZ58dxcwMKgwT}sZMbvg zLvWIMla{7kQzK|TMt3zKEuR^wwb@a1cEP)wgfc8Wp12MEfE4i|gJ}L7tWMcvDna%(bl0mxkKlv7o z=6rF1@@{xWiR@Kg54N+*am{vUb`Q%Kj;@NL>Dhrg(=KuyuTI0apl9}{cSe@0fx5>c zjnsn`*<`1jw)US`%q^+0`X`Q)vs^7{@&gUn61ydj{A7Rb3DPdJHAMMPyyceu_QGXZ zITCSp-fahfEqD@5`5ysD#`jS#=Hv3iY$uMObvQ7cH%W6{1vGTjElxwDR+dkbd5N|# zEF+R1>ir-rIw9%)eCDvsFNj)TL8Sq}RITqVkp8h3W-8XkCoF?e0?xTGDjHhQuV6u2@)^s#UB=GycVu2AA7enQ*{rp%yZ6u zc`(ebAHLgryuEy_RK;0k&5S&MG|j}veqTS9J#Vbl#m(&z`Cuf`?RrK38Al04boVF1 z*)-(^v9{e`PA3FZo+Du{8g87tIkOVZkH4r6z`|A5?wi>?+-ZoMtcUx$=v1t+%t)l% zQ`}anjC4_x=gr&k3SEe#z#RXL?mb8Tj#m&pC<#1*uPUq9f^sSllV+`KAQ3oBhaNo- z@<|XRrV~h7Gxs>0`x7n5mzn9qwB-oOP)U+`_z*#M6k7mLt`qn;-V6-5jyjx2uv*bv zpzq!+oV*xSW=EVAL67O|`Xg2?uFsF9!ALYpmX$L~1=n8z#d966AxK15Y|u0_gRV%2g)YTW`U!#rm;o|X1v^J>qBvgJDu0Z2Hke6rn_!2;&OYgw2hqRsET@ATe`u9Oh@W# zk`_d{wpxY9uiY()f*KZOMmO4CJsJQKl(O8fRFYnMbtpzJ^_VjFaUpN*q%QHS)o3u>`$9gq93G<5D9^}bg z2Na1O6Y!l3iHb}7c-;4(+Ke~gjiC%=SaO%zXAW2!is8lhAK6V0^D$-d2;Kaxv|KL_S~3J!XP8 z-k)C|Wn&47O!9fw1i(0z_ftSa2Hz?RduRkpX)A@EL`!IpL0G_g5(c#;kKm4>|^ z=_fkXlA*oHuWg%&W8EC-xPb)VC`@C2w^E{f_&8{+LsCG;>X z0n*C`$%It)1*vx>r-_eyX$q|i-^>bv3M$l_7&j|*>3Spt8%FXwzC?y4a%J5NAXyjE zS6UEATUxIj5EU29C3}on|ArI{fe`d7m^gOy)Rqv=D=GKUBQ&Hh7#@x|K&Sn_{01C# zdWvmV^uFp;Am)1DOvHr2ogdggy0+`kwrOa@1z^DG)F)C`&cmeAhCG3MHtrDQiq1OROB~ZV&!95b~KnYPzKjf=~NZyrf~bb|Eb;$ zBtY?_azm1l$G{T8_6VxUH$~7Qj{~T*+%;CF!?(PbxJcK?lu~H92org?b3@z-o8og@ zw<-m0hXyMf)3O4J3*T7QTUK!ju-(!MZ%PgSvfPmIj9r5+AHN*Og_X_CL0e?7Y&UcE zSFkz=0sjp^^Gp>G^8Y*IctLT7*rz4aY-I(d#nx<8+yH|%a?{Nk`gp9y10>jXqSmVB zCm*KjwcKC9@8rTuQo5tTtA=-zmZGWFPAXQ9xv zFfq`o3dM3EDFe=t!L16jLIL?KmjI-y~;>TP1{dVJi8IA4yD0J2}sHtq7mK%5X zd5I2{hdSS^s+uB1dU)J91%Mibt-;*^%bdAlkTI|_!dBL!0O{gAMRU$Yz6H_Adv%1jVSfI}Lsl*Gd zvXHT|_F^_P+2^1%tOy9ZdZyHHd%h|6sS?A)p=ZeIHvE{pOt1Qb04(Ze18Twxg`7$U zgFmJ7=$FhLlH7F>EMsn!wLii&5h+44Hq8~gDx;{_;j_{8wkSq&8(gs7Tk1jfqJpIh z3sgpJet?t_A~XUY8&7$w8<$B)G88Jvl(sR^070C5LhSH$g5h__wgrqfr54QBfT}TA zjEHwm=$8Ib2EW8U04ji3q0}Lvx=r#n1qg6WdK3jw0@T4q!9_&Wbf@uQI>KDJITFfI zq0&rSMD-mesYbk1`vBz~!AJMGHS%7Q22+i*vVF5g72NYVB^2 zu{&yZ@UcHnOS%}Vgn>*5`G`+M!@&K4iLHahc|UzwLSc9TtOq6T5&!mk`(FMM^fk9d zflTSQf%cEQS0RrncGyM2rbi746fUj?jlVVWp_{NV4EASbS!fTws4N{YCH43-ub7r} zVy|jxpNOWT6@Y=Da4&)^ghP~;3s2!PBWDW+b`45v9G%4K)5A=?eiCoEIj{d_t( zxvsMDoV4^<2tZFePMKSZh)#`woX^rJvt?NE|7a1Px;QvKD09^L_iGC=;Z*3*RCyY8 zq_Yi}(g%`U1(s#jtg^a*e}rCaAGT41A4=Q(mHkt_-yU!?I-V0O*9EsVMR_8P5@l<=Z$%+FX#WFL| z@`xa3HQvG zVtt~VA;NPoiQz}bvjy%={v$!(s==%wI+_g~)XLn_VV3H97f5L>lI&rY(Yg4a3&Pom zFM+}ij!bL9o|isxY`M9u2gFPTnWwrt!2(q#9lwu#(51E8a`gdceUNQ3QT3}$Yjt&i zS|h;K@1vusye;OuUyk!WA6xI2w|RMMMx7n|$0n}}!d)Q;Q=Q^YThBM%1fS8d?~OwW zePcFOeL}yl<+YoLvPddh9Q>D%l2?ujMt#)q+4ZXl?n#Tt62U}hmeQ~ovy9&^KK{JF zp`~AwE}^SUvFa&!g!7ictRF-pp@|0oN>@oWWY%IVT_{-qnb{#$7-he;pM+ra>xQ!E z$x@_?!!Z~3=0n=f9W`O!%l`4i^-yazqXoC`fWQ{vJA}@QxA6i-JJzr7`UEktVgAyH|q;WdBsD zz(wXN)VzkllRtlhp9U|#?R?bd~nQ=I#%M)PA>z5A}N*LEP1E`o?(yWB3~^yb4qQ`-4)UIOc8r0ct zJ*k|ekFuV(%@D6HyZaccJznz2(~rtZK)Vj!EuE)rHuePOVy`an?Kgw7Tzi!_D6N#@ zFr7SBdUuhBK17cc%+TrrMLZ*3zd>`HL)a%Rm7+NgpVV68Zc`Y)%ft!*IZJ*=Rox9+ zY6&R+Pj6ot7G)Q;J41JO!@v;I-3mjuq@*AM(jhG{Af1v9jnt5mLw8CFQWDY<3MdRB zAPQ&nP0u;+&+nV-dVW36y4St;+I#K2){fEFmsG3vASfa@zQ1K3*seq+ETubXKz2|X z+W6=W?0rZzE{SLcmlqmtGhCrpRaMd8;6vp~Qj1-k*5ivt=GU?Q!;hc2RSG`lx|eA> zIKRj5oRd-YaqVO}E$Z^gt1iLnDYA|~!?KR~gUNxGv-#5-sC+kp#zhCw8=t*(7}`bK zjc&thuXP#5z}SjK#rS7>7RS{P@D(KSELwaAHABu%raLb?>C)^Wt>>qJj*n!$o|oPw zHSO+P(_A9h<{l~|7(ojKS$&{3I@4gLD$IvCn=stxb0kThK$!Fr77bznj`VV{_}38HItP*7RDKAdO~CPfp?S^f~`F&{ZcQ0w433>zIkQQu)P3c4La~=0uQHz z@mG*UpK$SckNV0(tvALIlD0H)k9GtdSTtVN-`3EBX3qkMjy1oS5l5UyTMuzfQ|fCa z8bCOu+X~A4Mr@Z;<&zY(2@K}hCHqU5Fq)Uyz$63VsocC}TqUWlOu0H@a&~cqG>cCm ztjl;TM&I(XL&&8Av!xYb$_B8~xL7?8QKFeA@_9?AQErNB)7Vs}T46o9rL`jFHCk2< z%9Kvf2q8sNzaK(ZCn1l0&pmB#@F8nbUfHnOAE>LZEep;@_9I`p60xx3=lX7pBt+9W zbGm-qd?2kDXGoa7n~Mpg@vqko#LYnj(h#P#-Gc#p>+HO}mNY_1%dgo}$|fr+Sdr6< z^S8|;bVZuwjRr`lNldG)0yWAkntDGAeXD&2)dQz=vVC(kl|@XCbCgo0$~KK?OJm{U z9!XVgJ(Khabu*h4Kf_o)%r>p}RP^Iakh; zm-Vrgchh>e?%|!8@7-d5i<$=7{>b&n@YDA?d=u0pL9ia>qv&LF>`~FMPWhELX0$An zAV|; zyNfcigJaqu?HpXWAQ8=nx@wjD=xJvzX)!T5?@IEnC&Hk}ERIeXkdWY?-3IbDry-x{ z+=$9cbvvBoBa{=%clO?9`%u(ET|vD2+RrwtiWpjY?)xFv0C2ws%}d2dcg3o&v>m)5{TqhiQt~ zDKpgOIcVv}+qZWd43O~gK|YNVVn>!>&)Kl!l75LBj6q|u8-DdxY5`ATekk}@QN*8F zV{-bA8(QViRUz3v&=nhvFg_B~h3u}#S)usCawTp`OyGv$OsGNI#9U@)4=U_pO?6OO zjY=r@^JeKmJk(li=^E>t7_*=GK{riWN23)~_QZw4^|AIx4TFIp+eYV;R#?NA_}eYe z;QQ-xA(!7fuUD4F2Mo@U^3ZF>)h}o-^e}UMxyl)c2^Uh9TQ?tswI9?SZc5EyycCkf zrfc|IO*X%)#*KEHe*XLO@jT`16Xu%%o6VTJdDD3Jo^R-Yq%hpvO6BrC$aU_6AbYKm z%rObHIhFUdyPIEV(p|sT2-_XBUXlFtz6ooGO*rbF(d=z?sxPnErcWE8HXqdNKQgQ? zD7&s?$+1%RC)X{l#5=P!oLH2alk;9*EbfxTIDMR`vA}kV6S|O#a<-=|$Ql1sczx2^ zed!u}Iaf^Qb?NY^u+%_;sG12bN)Re3hKkB^oMc7sK^$|4sT&DONyVOwQt>XRW!+GQ zzw^M@3!x~D7R1+sU(cC9zwGdi$I9QmBpIz9yGs*I@>iUq&|=~qPgTXJ3we>% z1%}p=tdT2=y0_05y-`Nmrg|)*Wr?2at6Ro|vW!jJmCTQ!F{1HGj_8N0uOeV>@@YOo z2EwMjsr}Vf*iIpuig2NJ@UufhU8dT+dm7u|yO%E&#Jq%v#aW9Ic)1%zx@i0av>SaFv^5-OTJmk@T2bBMk4wnV4o zcm7zTu6@m0-1uo?XO+JEBHHX=G^RcSDWlV`c$-rqq50gW;HDRRPqbw&{LZ4bf;&Tn z`A~+)v_~1@)Ydr~mBv$XbynQ=Wu?i*025B{VK~RkI?6z4>v8koTQ>jHvF1~OyZz!>Y9n0%r#kv^cVw|)9 ztp|$-SQ0pCdxvY|1D(V`9*suL>)^B;> zrM{Pl<6+?$b)(S$qmC;1$Itpb`#`18_Muyckg4Ff zpv1PY;z>i5mMu}(QHMUnJFfWDPF7%t>R3NN8qz7hqGf?`D<{K#Uew6`Aeo*hXb+6A z_ES&MI?5Dg?Zk_&U6=2a{k}jr=_BwgRjHObER86o73H`r)1TlMMr{{W_w5qsV(C}K zY{){>1vd4@OgK9S%r%-R-OygTq-B5Qh`>DAH8*-nIGgEh>^-`cVb!PJPlcHTo?_K? ztk>Y%98)$$epO8~RK{UH4K!hB)NIxRUNU(?iw}*BGS{fj5_)xIO=Bk%3E|;#pF$`%i@2zWk46pDOHw>Jl6{W! zS?Au~3#V#BrSd0FQQTd#Tv4ffc8F?LhYp$XF%o?sE5N^KZRc9E8%Z*XyS3a^ll_#5 z6h1tOb(=i?O?s&YKNhV*TpAu}3Bq)YxcgiL4KrL1s3dIvA zkytT)#9aqo;$*|*Ledf!ZPw^Df#=i`lU*bD8;EcNUsNx?<+wsXUBEVJ8NEMXKHAlt zA8nL8qLqqApKqw2ZpC|*!Z|iP4VjhFD-l;bb{C{_hTD(c(gwLw#9k0$W>lE}pN+T#;t|;`ryVG>)tjpl! zcgQ-b*l#wa-0tIOm!tc+1}R?kq*KqK)I5*_-nX%4Rc_MAp+yclH&T+^Ya~H?X@4e^diF{pxyT`0kpws5B!9SFILQpFh zz$3Shn=rAR4sOPf>_Un(rN4@eB$}Dv?H3c!DxF~|kyY?AHajpi?U2p=3T$|LuxtlM zXJyns5M0v=^DBo2G43YNLMv&e*LQcnZCAw~Tvbg%p`F1?AxDBURiD5?*WdDJHb3(D zE-s4N90sSDpjLlgkDW|E=z95*o`0c1NW!%B|?Id4e$QsJ{Uj<;2yMr%CU;|&>5Y;q9aUG&>}D7NCG;rsXv`J@yXW~2&4WG2GFy;e+rGH2 zkPnRyKYTvjn^S(gc5G2CM?Nwwiij536IgFKzkjtbyoRSg4X;8Oqsj26F^s8E(fO-J z>CT+g73gy1<+x(uLo(1&@6%C`b1F<%Q5EpP>}hiZ?s_0?4>pKz!`e6`i9DqYk6?CW z%jeE^{Z-M6@qr6qGQD{6zzZ5K-t~e<^hRZ5B^zOrqTg8tM7)l5oC>%|y2~@Bd`2{m z=1SVVecb6KLAQj`-Q)K_F69B;3$Ob}86JC!oI_)Is}Dd&mMIQKw2D$A$`0%1^s==A z>ucY)w}*UmYeLRWkd9ZiXG5p8E4o4xB9q{iyXm184XBl#M=_$0Sx6#%C<0JJbS7$u z=34-E2o4N!diBCpf{{q@(_7tzttZKP49=&K#<|=9homo0Y{#|t3zZ74^*^QW&U;Ck zL)k6sg>Rsj(;nCTAJ%U*B@Q2uv6+Asm9v2S_5Ddtj{s(Tp`TA!?`tAjb$Msh0{!&n zN54ItVF$?YEj@CAuTp6n8Qx|K&)CPG4qRBO!FeAPv22XJYVImxQsc6s8qDB1y@6Zj zkHn7iO^1k1wG*qA1zIaqUznTqf$(b z(?i)~CrZxIQZh#g9GgkB0@gmLHl+97qGt?Ntx0szlEMCR)~)3SSRpFd5CiukXutSE zdf!7*m4F!JOpqj~2sCB7k`WQ{t-a3FycW;k3rA6f%}j3x5n;G3akXGeD|qo8Aq6j;XS<@5>?e>Tk@hYFU0Qe)OfHAvQ* zjY>}fpo)gG3zxt9i&6g#CuA#P6xyUnNTCB4HRNV4L!dK`(eB;svdDP^o;@O0nC zD@;mx9xG9r4i+m@qXykm8OL#W)ZP#`8ejabX9UFVc@+>&tos_vWpKdAC?kJvZhYAg zwSlWJv-lfc(jf7kQpBdz{SG`u8gkROos@QQJXOnm0p+IB#9_2m!L(R{&~~ea@a;B+ z#y5}ax~vwhgh5jMq5T+B(kz?9kocx<{xMVmvU>&iHm}l`mAK4zc1QYMGW~EAG1`HI zQ?G~&DkQV?qIuDYbqKh~t@RHCL^0BcUR4^u$F+pcgaakMZ#9ctB-8K+Cm9>`r(Yj; z@N)&cFl)X8Av5U;+>nu^yL(mmLv%8o_bm3l~Z*oZ<`yq zMt-VqK1HxRuii8Rpd0R2S@IosYjg7RLaz3Fp-eo!D2UC_pDfTD87}#Z&aWJ;G*@=N zrN_O1ih(*r(8&fBg;$TFtl<;PUx_Nr+D7vT=Jj|d)yaEpF)ip5<(HxF$TjMi##U0Klr?l4B3a(?GxZgf&S+-fSaqJ79KpN;BLtwrgyZ{gJ4Hxw$e__990 ze#L0zWow&xo@Ea-dMx#%iI_Sad$uS$oH_EN zqVA-7+>)ek<|_kdchUUc({XR$tqT>t9vSUeMbAV<$+q^st44lJhe3;}5JJX(3 zE?LWpa@E-lPi0RYb=pxH$iyeoGFpMz79cOs;C`F_XbMm-Zao{#p)wq0v&6w`p=M## zuvIJFR3ZWR>yg(>aD7k);Qqz+r_>k?SidRfAQjJoalS2Q#OBs#RY~8mYw%??`ltz2P5~lJ0?(s@>90I(4d!wjKPd&~ z1`HKpBKy7E&=gML7&nf>gRa+W6e*Lqf{2?Qu#38E*C5sNBGD463V<>x9dlZnof?(6 ziwHE+MH875croT4I>*N!Sjt2xZ+(c3S-@g;jc3N;u**%l(8`h%Jx&krHFct%;0unq z(nG4nISTG|@l;LBS2fhhjlPPORKM!(8;f#M@3bWiaIN2YA=i2?*D34XbF&9K3zmrg zVpLUM8Z#Ax!=9OqCn@HO?K{SFZsVCm&kwct8BV2qA~vId0AtiFyO>U@lZa&FZNns-l@u<@? zPMAZE6{}-^R@X9}3}}mWGFyX3D!NHeXeh(`wuBHt(UAkJ<)3(Sg?L%L*9fQL< zq9m&^BVm(CQV1@!0&h^oV=?e}CoPf97nY1Zsd*qx&8V#XBjeVrcvBW)(U&rLWBB`5 z#&wY;KDo53InRPYQEYit@!1+z7`g61=a?ZCv^(s5mF)Wg|NUQ|+smEOpsnJSO zN`-{`cVi>T@FG>$Tx8!^Q9Gk)a}6hFa*sq$2*o6^M~2<7y}a5&1V=DY@Ifzft$c@N zmPamQX@ra}Zj%u0Sn*4{{=Fs%xuMsR#~ko=!w$;li$oi0hoTCCt+1>M$%|im-;p@`u-B9ViDg-)idBpj)U7 zV*+vB`RK=Pg@tM!69-qZyFEuzY9brby#>2Rl>3g77Snzm-+CA=Du|>^2juSJV2Tk* z9!+b>FflBgxAI2C>t-aD&e~IHD{NLssRpU2GXa-WnR{Mwu#X%| zR}Kn0IOdknMdF02kw9OCnJcVFs3xXUNhq?q5vaCNV{0}{+`>I4hZH7MzQs+;N7xrF zJg0hw+&6#q{6j~@jaSObnviZbE}f~0cx`OC-G|sSPe}0=bs?ZB6O;or!rSa|ssGvds(Nr@s&^>K2bJ`FR(s6ltO|5|M?1;Zw=7-&I z2YY96j;LMWVWt&PPqh4-FR|)_^Evp&9UpOGV~#2@rQ1I_%GNTse3t+I<>R$6iJA=| zYTTcE6+RHC1e^B|0;N5DZ>_;`46Jo^62iqFdi0|zb4-d7+D7X4vhRL!gVe&kQ^#eG z{`G-*K(SKTbOYr%PaM_4Mzz_-T6z5($)!$_FUj#GsF>b7tmFsYn4Ha6v6A7DK^8d1 z-&VFoe62f@g0ni=LnUo~rtkIKVH?kt^c30Qq4ce5Sn;k&Yw6p^1-*>KeCLyt2b~ix zO*}c^D$P4lP@jtkk)`>`+wxWx=hAR1ucjYwzinNq0Znbn-c)8X^*mU^y-zCnhc zOV@$UDd#|Q@WoVMV@4;Ss@z&Uay2vWcl@XVL^is7^w@0V6jQ>B!W2#x6S%gR~P;VqlFuEV;aDxl?| zt9v|ago%~+?m%Hi9`2uuo%6!`ov=>||7m|yMyniUpq+d!K97hd{Repw`pSt5y;oEL z?)$UvU5zCg8IX`du<#EZ*OKTs?P@#9ktQ`2U)R^`HR~Za$jk9>d+t3y7Fd;DIG;t6 z5Ky8*Noe??zsJ4L`wg`GyMhU6`J5I>nB_X0Ix|wO(Hzo8y#?eD>&>yp9&A6j8j7<) zO!7q&`2`&05K5fPnwf}9OfFN4h==Hn!5*H}7rOUx)`ZVrK7x0^M&7kf6uoCos z;3G-YPQkpa_@WPXh8>x;-MNr}Eqw9;6B8KhGxm^w2|P_j61D=n9auUi)Pq0HgY`lS z7nQ+=FEW065*HzSgj%W^i)ks|G{H*Y9U31H;w-sJ&LuY8A|#k36~PxN1T0-VZ=M^` z2-H=QB%SRm43I#c#3b=kqhmki>+@1mrYk;)IQ1`OA%mVziMr8y_41M zI0EtgrtzJ`ZB{>l@|svr6C3BVy+O!S1pqKYi=B4=J~d_?000n$og@JH)4tab;YX<9 zIHZ7Z9V|F;)28%!j64}h!Y}A)V$hOUSrzoaYOe@bp5HO(k0C)FYMYwZj%!Xruuc#mE`ptkWxu=dnpXL;tzv-y@KbZvP&2a)N?RQujdg`44Q*Zq z`=_R45N@N=JnH7ipG?GlF@d>t0m*;8{2!+Q>-PZ4|HY#P+Y`7$kA@-`rY{6zP6Sf@ zFOgtP0!sf);z1Hn2>36%z~oVXlJmbrBqtdt^*51~WS|P`FCrp;m_>XDNcwLg_WvWT z1AuBRKr{+;3RHUl0AgG;U>c1;ar|Tw9EYC|41^0yX#p}2qTZM?9tS>4Kz&64L;U+2 zRI~Z@4NSHP$OKe@2_k?XSV$9)_OG)2ddp&+pkew?s{{aK04zUM{`w)pgcxCc2q51- za(|+-z|>lRbZGQUFd+nxBJH&S6*{U7|3qYAz>n#b6hq1TqaN_T&`QF@nSY`&!wy@3 zROo;6V{HX8p{+B+6k7jj0RMk((*Ht3gavc{;+FQplIAai{83n9)xcGUJ~ zH~Nzw!~aua@!wEwxc?~eVH=R*H`rftJH51V3PJ$Dc_#qC_nVvw&(Er0gMI4&lKt&L z{!^#qZ?b3>f9U*8_OJT+rT1SR3&8!G><5cqdVh0V|EX5=H&Fp>80jF8?>EuEw8D71 zfK2FQIKZ^9C#?VYqW?q|`wdy0=qEBi%)RTMUi*h_0{T&~e8hji{_S1<6ZZFdGP(7O z@NZt}57@u~6s$b&AFzM>ivNWDy&mfLe!|}V&DyZXgDAu_{yz}^?)3kODDqqRY4!df c`nTNAYSkG6(hyMrr~uFL0Dvn!AgX)(A7p3w4gdfE From c32a4e8cd3dc3bac393c2fc792e6a47105574542 Mon Sep 17 00:00:00 2001 From: wfy1997 <60631776+wfy1997@users.noreply.github.com> Date: Mon, 21 Oct 2024 13:39:51 -0400 Subject: [PATCH 09/23] Update cds-model-props.yml --- model-desc/cds-model-props.yml | 10 ++++++---- 1 file changed, 6 insertions(+), 4 deletions(-) diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index 35a2cdf..cb30860 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -5130,13 +5130,14 @@ PropDefinitions: - G2 - G3 - G4 - - GX - GB + - GX - High Grade - Intermediate Grade - Low Grade - - Unknown + - Not Applicable - Not Reported + - Unknown Term: - Origin: caDSR Original Source: DSS @@ -5146,6 +5147,7 @@ PropDefinitions: tumor_stage_clinical_t: Desc: Extent of the primary cancer based on evidence obtained from clinical assessment parameters determined prior to treatment. Enum: + - Not Reported - T0 - T1 - T1a @@ -5174,14 +5176,14 @@ PropDefinitions: - T4c - T4d - T4e - - TX + - T5 - Ta - Tis - Tis (DCIS) - Tis (LCIS) - Tis (Paget's) + - TX - Unknown - - Not Reported Term: - Origin: caDSR Original Source: TCGA From 187f595d4308520a27c1b99b67a22ae7a005a57a Mon Sep 17 00:00:00 2001 From: wfy1997 <60631776+wfy1997@users.noreply.github.com> Date: Tue, 22 Oct 2024 11:20:00 -0400 Subject: [PATCH 10/23] Update to replace "Data Hub" with "CRDC Submission Portal" --- model-desc/cds-model-props.yml | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index cb30860..0d21f0a 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -1,7 +1,7 @@ PropDefinitions: # crdc_id crdc_id: - Desc: The crdc_id is a unique identifier that is generated by Data Hub + Desc: The crdc_id is a unique identifier that is generated by CRDC Submission Portal Type: string Tags: Template: 'No' From c1064108024b0469645a50c0cc1269dd4d1640ad Mon Sep 17 00:00:00 2001 From: wfy1997 <60631776+wfy1997@users.noreply.github.com> Date: Mon, 28 Oct 2024 11:36:02 -0400 Subject: [PATCH 11/23] add pvs for analytical_fractions and primary diagnosis --- model-desc/cds-model-props.yml | 28 +++++++++++++++++++++++++++- 1 file changed, 27 insertions(+), 1 deletion(-) diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index 0d21f0a..b5beb51 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -2913,6 +2913,25 @@ PropDefinitions: primary_diagnosis: Desc: Primary disease diagnosed for this diagnosis and subject Enum: + - Infiltrating ductular carcinoma + - Triple-Negative Breast Carcinoma + - Infiltrating duct carcinoma, NOS + - Infiltrating lobular carcinoma, NOS + - Infiltrating duct and lobular carcinoma + - Mucinous Carcinoma + - Infiltrating duct and mucinous carcinoma + - Adenocarcinoma + - Lung Squamous Cell Carcinoma, NOS + - Lung Adenocarcinoma, NOS + - Endometrioid carcinoma, NOS + - Clear Cell Renal Cell Carcinoma + - Non-Clear Cell Renal Cell Carcinoma + - Colon Adenocarcinoma + - High-grade serous carcinoma + - Pancreas-Adenocarcinoma Ductal Type + - Pancreas-Adenosquamous Carcinoma + - Pancreas-Undifferentiated Carcinoma + - Mucinous Non-Cystic Carcinoma - Papillary Intralymphatic Angioendothelioma - Atypical Smooth Muscle Neoplasm - Medulloblastoma, WHO Grade 4 @@ -11007,7 +11026,14 @@ PropDefinitions: Value: Specimen Aliquot Identifier analytical_fractions: Desc: The portion of a specimen that was isolated from the whole and collected via a fractionation process to be subjected to further analysis. - Type: string + Enum: + - Acetylome + - Glycoproteome + - Lipidome + - Metabolome + - Phosphoproteome + - Proteome + - Ubiquitylome Term: - Origin: caDSR Original Source: CRDC From 1e7fcdf4bfa28c29e2d04becee570cc686dfb761 Mon Sep 17 00:00:00 2001 From: wfy1997 <60631776+wfy1997@users.noreply.github.com> Date: Mon, 28 Oct 2024 16:46:33 -0400 Subject: [PATCH 12/23] remove treatment outcome and update Enum values for response --- model-desc/cds-model-props.yml | 11 +---------- model-desc/cds-model.yml | 1 - 2 files changed, 1 insertion(+), 11 deletions(-) diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index b5beb51..d8ccdf2 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -5930,14 +5930,6 @@ PropDefinitions: Version: '1.00' response: Desc: Text term that describes the patient's final outcome after the treatment was administered. - Type: string - Term: - - Origin: caDSR - Code: "13383448" - Value: Disease Response Assessment Outcome - Version: '1.00' - treatment_outcome: - Desc: Text term that describes the patient's final outcome after the treatment was administered Enum: - Complete Remission - Minor Response @@ -5955,8 +5947,7 @@ PropDefinitions: - Very Good Partial Response Term: - Origin: caDSR - Original Source: TCGA - Code: '13383448' + Code: "13383448" Value: Disease Response Assessment Outcome Version: '1.00' treatment_type: diff --git a/model-desc/cds-model.yml b/model-desc/cds-model.yml index 7236b59..f9347d0 100644 --- a/model-desc/cds-model.yml +++ b/model-desc/cds-model.yml @@ -132,7 +132,6 @@ Nodes: Props: - treatment_id - treatment_type - - treatment_outcome - days_to_treatment - therapeutic_agents - response From 298fb00f60e32b7a789a876134e889074d74d69d Mon Sep 17 00:00:00 2001 From: wfy1997 <60631776+wfy1997@users.noreply.github.com> Date: Mon, 28 Oct 2024 16:53:47 -0400 Subject: [PATCH 13/23] Update cds-model-props.yml --- model-desc/cds-model-props.yml | 9 +++------ 1 file changed, 3 insertions(+), 6 deletions(-) diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index d8ccdf2..383fdf5 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -5931,20 +5931,17 @@ PropDefinitions: response: Desc: Text term that describes the patient's final outcome after the treatment was administered. Enum: - - Complete Remission - - Minor Response - - Mixed Response + - Complete Response - No Evidence of Disease - - Non-Response + - No Response - Not Applicable - - Not Done - Not Evaluable - Not Reported - Partial Response + - Persistent Disease - Progressive Disease - Stable Disease - Unknown - - Very Good Partial Response Term: - Origin: caDSR Code: "13383448" From 6e3834485f2fae171e2247cbb957414c60e6a6fb Mon Sep 17 00:00:00 2001 From: wfy1997 <60631776+wfy1997@users.noreply.github.com> Date: Wed, 30 Oct 2024 13:13:13 -0400 Subject: [PATCH 14/23] remove duplicate properties --- model-desc/cds-model-props.yml | 9 --------- 1 file changed, 9 deletions(-) diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index 383fdf5..b12fb98 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -221,15 +221,6 @@ PropDefinitions: Type: string Req: true Key: true - acquisition_method_type: - Desc: Records the method of acquisition or source for the specimen under consideration - Type: string - Term: - - Origin: caDSR - Original Source: MCL/HTAN - Code: '6626651' - Value: Biospecimen Acquisition Method Type - Version: '2.00' tumor_tissue_type: Desc: Text that describes the kind of disease present in the tumor specimen as related to a specific timepoint (add rows to select multiple values along with timepoints) Type: string From acbf20f472621ffa20010f6fb5a680dd5f7bce39 Mon Sep 17 00:00:00 2001 From: wfy1997 <60631776+wfy1997@users.noreply.github.com> Date: Wed, 30 Oct 2024 13:20:06 -0400 Subject: [PATCH 15/23] remove duplicated properties tumor_tissue_type --- model-desc/cds-model-props.yml | 9 --------- 1 file changed, 9 deletions(-) diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index b12fb98..0912012 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -1142,15 +1142,6 @@ PropDefinitions: Code: '6626651' Value: Biospecimen Acquisition Method Type Version: '2.00' - tumor_tissue_type: - Desc: Text that describes the kind of disease present in the tumor specimen as related to a specific timepoint (add rows to select multiple values along with timepoints) - Type: string - Term: - - Origin: caDSR - Original Source: HTAN - Code: '3288124' - Value: Tumor Tissue Disease Description Type - Version: '1.00' tissue_fixative: Desc: A compound that preserves tissues and cells for microscopic study. Req: true From 2537f5d128447d8d0f711f14392b9ffc3d072c14 Mon Sep 17 00:00:00 2001 From: wfy1997 <60631776+wfy1997@users.noreply.github.com> Date: Wed, 30 Oct 2024 13:22:34 -0400 Subject: [PATCH 16/23] remove duplicated properties tissue_fixative --- model-desc/cds-model-props.yml | 33 --------------------------------- 1 file changed, 33 deletions(-) diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index 0912012..7d26d74 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -230,39 +230,6 @@ PropDefinitions: Code: '3288124' Value: Tumor Tissue Disease Description Type Version: '1.00' - tissue_fixative: - Desc: A compound that preserves tissues and cells for microscopic study. - Req: true - Enum: - - 95% Ethanol - - Acetone - - Alcohol - - Carbodiimide - - Carnoy's Solution - - CryoStor - - Diimidoester - - Dimethylacetamide - - Formalin - - Glutaraldehyde - - Methacarn - - Not applicable - - Not recorded - - NP40 Lysis Buffer - - OCT media - - Other - - Para-benzoquinone - - PAXgene Tissue - - Poloxamer - - RNAlater - - Saline - - TCL Lysis Buffer - - Unknown - Term: - - Origin: caDSR - Original Source: NCI Standard - Code: '65078' - Value: Specimen Fixative Type - Version: '4.00' embedding_medium: Desc: A material that infiltrates and supports a specimen and preserves its shape and structure for sectioning and microscopy. Req: true From bafcb8dc8326cb80e13c830f8356e4960371f3d6 Mon Sep 17 00:00:00 2001 From: wfy1997 <60631776+wfy1997@users.noreply.github.com> Date: Wed, 30 Oct 2024 13:26:50 -0400 Subject: [PATCH 17/23] remove duplicated properties --- model-desc/cds-model-props.yml | 75 ---------------------------------- 1 file changed, 75 deletions(-) diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index 7d26d74..cf48db1 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -230,81 +230,6 @@ PropDefinitions: Code: '3288124' Value: Tumor Tissue Disease Description Type Version: '1.00' - embedding_medium: - Desc: A material that infiltrates and supports a specimen and preserves its shape and structure for sectioning and microscopy. - Req: true - Enum: - - Paraffin wax - - Carbowax - - Methacrylate - - Epoxy Resin (Araldite) - - Agar embedding - - Celloidin media - - Gelatin - - Other - - None - - Unknown - Term: - - Origin: caDSR - Original Source: HTAN - Code: '8037927' - Value: Biospecimen Collection Medium Type - Version: '1.00' - staining_method: - Desc: Any of the various methods that use a dye, reagent, or other material for producing coloration in tissues or microorganisms for microscopic examination. - Req: true - Enum: - - CODEX - - GeoMX-DSP - - H&E - - IHC - - IMC - - MIBI - - mIHC - - MxIF - - SABER - - t-CyCIF - Term: - - Origin: caDSR - Original Source: HTAN - Code: '7789196' - Value: Imaging Assay Technology Type - Version: '1.00' - objective: - Desc: "An\_objective\_is an optical element that gathers light from an object being observed and\_focuses\_the\_light rays\_from it to produce a\_real image\_of the object." - Type: string - Term: - - Origin: caDSR - Code: '7788935' - Value: Microscope Device Objective Lens Text - Version: '1.00' - nominal_magnification: - Desc: The magnification of the lens as specified by the manufacturer - i.e. '60' is a 60X lens. floating point value > 1(no units) - Type: string - Term: - - Origin: caDSR - Original Source: HTAN - Code: '7788940' - Value: Microscope Device Nominal Magnification Float Value - Version: '1.00' - immersion: - Desc: Immersion medium - Type: string - Term: - - Origin: caDSR - Original Source: HTAN - Code: '8058286' - Value: Microscope Device Immersion Medium Type - Version: '1.00' - lens_numerical_aperture: - Desc: The numerical aperture of the lens. Floating point value > 0. - Type: string - Term: - - Origin: caDSR - Original Source: HTAN - Code: '7788942' - Value: Microscope Device Lens Numerical Aperture Float Value - Version: '1.00' working_distance: Desc: The working distance of the lens, expressed as a floating point number. Floating point > 0. Size needs to be specified in microns (um) Type: string From e2ee315f4a877873eea5cc8266b2c5c1e2780edd Mon Sep 17 00:00:00 2001 From: wfy1997 <60631776+wfy1997@users.noreply.github.com> Date: Wed, 30 Oct 2024 13:29:06 -0400 Subject: [PATCH 18/23] Update cds-model-props.yml --- model-desc/cds-model-props.yml | 1 - 1 file changed, 1 deletion(-) diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index cf48db1..88252c2 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -2796,7 +2796,6 @@ PropDefinitions: - Infiltrating duct and mucinous carcinoma - Adenocarcinoma - Lung Squamous Cell Carcinoma, NOS - - Lung Adenocarcinoma, NOS - Endometrioid carcinoma, NOS - Clear Cell Renal Cell Carcinoma - Non-Clear Cell Renal Cell Carcinoma From 52778c7f6894a964f23eee1392e0afe3b5fc3d93 Mon Sep 17 00:00:00 2001 From: wfy1997 <60631776+wfy1997@users.noreply.github.com> Date: Wed, 30 Oct 2024 13:33:07 -0400 Subject: [PATCH 19/23] Update cds-model-props.yml --- model-desc/cds-model-props.yml | 1 - 1 file changed, 1 deletion(-) diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index 88252c2..259f421 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -2801,7 +2801,6 @@ PropDefinitions: - Non-Clear Cell Renal Cell Carcinoma - Colon Adenocarcinoma - High-grade serous carcinoma - - Pancreas-Adenocarcinoma Ductal Type - Pancreas-Adenosquamous Carcinoma - Pancreas-Undifferentiated Carcinoma - Mucinous Non-Cystic Carcinoma From 1577c86d0cae21ed1c5f581b6f65e872a1cd8a2e Mon Sep 17 00:00:00 2001 From: wfy1997 <60631776+wfy1997@users.noreply.github.com> Date: Wed, 30 Oct 2024 13:48:52 -0400 Subject: [PATCH 20/23] Update cds-model-props.yml --- model-desc/cds-model-props.yml | 1 - 1 file changed, 1 deletion(-) diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index 259f421..ca41fbf 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -2802,7 +2802,6 @@ PropDefinitions: - Colon Adenocarcinoma - High-grade serous carcinoma - Pancreas-Adenosquamous Carcinoma - - Pancreas-Undifferentiated Carcinoma - Mucinous Non-Cystic Carcinoma - Papillary Intralymphatic Angioendothelioma - Atypical Smooth Muscle Neoplasm From eeafb2c8cec0c7453eda45ccebcd3b5fa449b385 Mon Sep 17 00:00:00 2001 From: wfy1997 <60631776+wfy1997@users.noreply.github.com> Date: Wed, 30 Oct 2024 13:59:20 -0400 Subject: [PATCH 21/23] remove duplicate enum values for primary_diagnosis --- model-desc/cds-model-props.yml | 1509 ++++++++++++++++---------------- 1 file changed, 752 insertions(+), 757 deletions(-) diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index ca41fbf..5bb2732 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -2787,810 +2787,805 @@ PropDefinitions: primary_diagnosis: Desc: Primary disease diagnosed for this diagnosis and subject Enum: - - Infiltrating ductular carcinoma - - Triple-Negative Breast Carcinoma - - Infiltrating duct carcinoma, NOS - - Infiltrating lobular carcinoma, NOS - - Infiltrating duct and lobular carcinoma - - Mucinous Carcinoma - - Infiltrating duct and mucinous carcinoma - - Adenocarcinoma - - Lung Squamous Cell Carcinoma, NOS - - Endometrioid carcinoma, NOS - - Clear Cell Renal Cell Carcinoma - - Non-Clear Cell Renal Cell Carcinoma - - Colon Adenocarcinoma + - Astroblastoma, Other, Other CNS Tumor, NOS Or NEC + - Medulloblastoma; Hypercellular Lesion With Marked Atypia + - Ependymoma, NOS, Posterior Fossa Ependymoma, NOS Or NEC + - Neoplasm, Uncertain Whether Benign Or Malignant, Dysembryoplastic Neuroepithelial Tumor, Glioneuronal And Neuronal Tumors + - Neuroma, NOS + - Precursor Cell Lymphoblastic Leukemia, NOS + - Hypercellular Neuroepithelial Tumor With Some Features Of Glioma, Possibly High Grade + - Acute Leukemia, NOS + - Oligoastrocytoma, NOS, Glioneuronal And Neuronal Tumors, Papillary Glioneuronal Tumor - High-grade serous carcinoma - - Pancreas-Adenosquamous Carcinoma - - Mucinous Non-Cystic Carcinoma - - Papillary Intralymphatic Angioendothelioma - - Atypical Smooth Muscle Neoplasm - - Medulloblastoma, WHO Grade 4 - - Acute Monoblastic And Monocytic Leukemia - - Adenocarcinoma In Situ, Non-Mucinous - - Ganglioneuroma, Maturing Type, Favorable Histology - - T-Lymphoblastic Leukemia + - Myeloid Leukemia, NOS + - Choriocarcinoma, NOS + - Embryonal Carcinoma, NOS, Embryonal Tumor With Multilayered Rosettes, C19MC Altered, Other CNS Embryonal Tumors + - Giant Cell Tumor Of Bone, NOS + - Adenocarcinoma, Intestinal Type + - Not Specified In Data + - Neoplasm, Uncertain Whether Benign Or Malignant, Choroid Plexus Tumors, Choroid Plexus Papilloma + - Ductal Carcinoma NOS + - Renal Cell Carcinoma, NOS + - B Lymphoblastic Leukemia/Lymphoma With T(1;19)(Q23;P13.3); E2A-PBX1 (TCF3-PBX1) + - Myelodysplastic Syndrome, NOS + - Low Grade Fibromyxoid Sarcoma + - Benign Cystic Nephroma + - Glial Neoplasm + - Papillary Adenocarcinoma, NOS + - Telangiectatic Osteosarcoma + - Ganglioglioma, NOS, Malignant Peripheral Nerve Sheath Tumor, NOS + - Central Neurocytoma + - Giant Cell Tumor Of Soft Parts, NOS + - Giant Cell Tumor Of Bone, Malignant + - Sertoli-Leydig Cell Tumor, Poorly Differentiated + - Glioma, Malignant, Dysembryoplastic Neuroepithelial Tumor, Glioneuronal And Neuronal Tumors + - Acute Megakaryoblastic Leukemia + - Germinoma, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor + - Dysembryoplastic Neuroepithelial Tumor With Adjacent Cortical Dysplasia, WHO Grade 1 + - Supratentorial Ependymoma, NOS - Myxoid Liposarcoma - - Clear Cell Meningioma, Meningioma, Other - - Meningeal Melanomatosis - - Hepatoblastoma, NOS - - Teratocarcinoma - - Smooth Muscle Tumor Of Uncertain Malignant Potential - - Solid Pseudopapillary Neoplasm Of Pancreas - - Mast Cell Leukemia - - Medulloblastoma, NOS, Medulloblastoma, NOS Or NEC - - Glioblastoma Multiforme - - Giant Cell Glioblastoma - - Juvenile Myelomonocytic Leukemia, NOS - - Spindle Cell Sarcoma - - Chondroid Chordoma - - Chondrosarcoma, NOS - - Hepatoblastoma - - Sex Cord-Gonadal Stromal Tumor, Incompletely Differentiated - - Glioma, Malignant, Astrocytoma, IDH-Mutant, High-Grade Glioma - - High Grade Glioma With Necrosis, WHO Grade 4 - - Lung Adenocarcinoma, NOS - - Malignant Tumor - - Ependymoma, NOS, Supratentorial Ependymoma, ZFTA Fusion-Positive - - Atypical Choroid Plexus Papilloma - - Small Round Blue Cell Tumor + - Acute Lymphoblastic Leukemia + - Combined Small Cell-Squamous Cell Carcinoma + - High Grade Spindle Cell Sarcoma + - Medulloblastoma, Group 3 Subtype (WHO Grade 4) - Acute Monocytic Leukemia - - Lactotroph Adenoma - - Medulloblastoma By Morphology, NON-WNT By Immunohistochemistry - - Astrocytoma, NOS, Low-Grade Glioma, Pilocytic Astrocytoma - - Hypercellular Neuroepithelial Tumor With Some Features Of Glioma, Possibly High Grade - - Sertoli-Leydig Cell Tumor, Poorly Differentiated, With Heterologous Elements - - Astrocytoma, NOS, Angiocentric Glioma, Low-Grade Glioma - - Inflammatory Myofibroblastic Tumor With An Associated Odontogenic Keratocyst - - Inflammatory Carcinoma - - Diffuse Large B-Cell Lymphoma, NOS - - Acute Myeloid Leukemia With Abnormal Marrow Eosinophils - - Signet Ring Cell Carcinoma - - Myxopapillary Ependymoma, Anaplastic - - Acute Myeloid Leukemia Without Maturation - - Lymphoepithelial Carcinoma - - Malignant Rhabdoid Tumor - - Germinoma - - Precursor T-Cell Lymphoblastic Leukemia - - Telangiectatic Osteosarcoma - - Desmoplastic Nodular Medulloblastoma - - Papillary Glioneuronal Tumor - - Diffuse Glioma, Favor High Grade - - Papillary Glioneuronal Tumor, WHO Grade 1 - - Ganglioneuroma, Other, Schwannoma - - Medulloblastoma, NOS, Medulloblastoma, Group 4 - - Unclassified Sarcoma With Round Cell Morphology - - Papillary Serous Adenocarcinoma - - Malignant Melanocytic Neoplasm - - B Lymphoblastic Leukemia/Lymphoma With T(1;19)(Q23;P13.3); E2A-PBX1 (TCF3-PBX1) - - Oxyphilic Adenocarcinoma - - Favor Pilocytic Astrocytoma, CNS WHO Grade 1 - - High-Grade Neuroepithelial Tumor - - Precursor Cell Lymphoblastic Leukemia, NOS - - Therapy Related Myeloid Neoplasm - - Schwannoma, NOS - - Glioma, Malignant, Diffuse Midline Glioma, H3 K27-Altered, High-Grade Glioma - - Glioma, Malignant, Low-Grade Glioma, Pilocytic Astrocytoma - - Myofibromatosis - - B Lymphoblastic Leukemia/Lymphoma With Hyperdiploidy - - Fibroma - - Desmoplastic Melanoma, NOS - - Epithelial Tumor, Benign - - Meningioma, Malignant - - Glioblastoma, NOS - - Endometrioid Carcinoma, NOS - - Neoplasm, Malignant - - Embryonal Tumor With Multilayered Rosettes C19MC-Altered - - Subependymal Giant Cell Astrocytoma, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC - Neoplasm, NOS - - Hodgkin Lymphoma, Nodular Sclerosis, NOS - - Papillary Microcarcinoma - - Tumor Cells, Malignant, Medulloblastoma, Medulloblastoma, NOS Or NEC - - Hypocellular Low Grade Lesion - - Mixed Phenotype Acute Leukemia With T(V;11q23); MLL Rearranged - - Oligodendroglioma, NOS, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - - Acute Myeloid Leukemia, NOS, Juvenile Myelomonocytic Leukemia, NOS - - Rhabdoid Tumor, NOS - - B Lymphoblastic Leukemia/Lymphoma With T(V;11q23); MLL Rearranged - - Malignant Sarcoma With DICER1 Mutation, Favor Primary Intracranial Sarcoma, DICER1 Mutant - - Kidney Clear Cell Renal Carcinoma - - Neuroblastoma, Undifferentiated Type - - Synovial Sarcoma, NOS - - Primary Cutaneous Follicle Center Lymphoma - - Embryonal Rhabdomyosarcoma, NOS - - Neoplasm, Malignant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype And IDH-Wildtype, High-Grade Glioma - - Papillary Urothelial Carcinoma, Non-Invasive - - Embryonal Tumor With Multi-Layered Rosettes - - Precursor Cell Lymphoblastic Lymphoma, NOS - - Epithelioid Hemangioendothelioma, NOS - - Metaplastic Carcinoma, NOS - - Invasive Carcinoma - - Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, SHH-Activated And TP53-Wildtype - - HHV8 Positive Diffuse Large B-Cell Lymphoma - - Mesenchymal Chondrosarcoma - - Pineoblastoma - - Neoplasm, Malignant, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - - Mixed Germ Cell Tumor, CNS Germ Cell Tumors, CNS Germinoma - - Lymphoproliferative Disorder, NOS - - Solid Pseudopapillary Tumor Of Ovary - - Papillary Carcinoma, NOS - - Choriocarcinoma Combined With Other Germ Cell Elements - - Secretory Carcinoma + - Retinoblastoma, Grade 3 + - Yolk Sac Tumor, NOS, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor + - Myofibroblastic Tumor, NOS + - Sex Cord-Gonadal Stromal Tumor, Mixed Forms + - Adamantinomatous Craniopharyngioma - Mesoblastic Nephroma - - Neoplasm, Uncertain Whether Benign Or Malignant - - Rhabdomyosarcoma, Favor Alveolar Type - - Dedifferentiated Liposarcoma - - Myoepithelial Carcinoma - - Hemangioendothelioma, NOS - - Pilomyxoid Astrocytoma - - Oligoastrocytoma, NOS, Other, Other CNS Tumor, NOS Or NEC - - Anaplastic Ependymoma - - Medulloblastoma, NOS, Diffuse Hemispheric Glioma, H3 G34-Mutant, High-Grade Glioma - - Low-Grade Glioneuronal, Neuronal Tumor - - Pilocytic Astrocytoma, Low-Grade Glioma, Pleomorphic Xanthoastrocytoma - - CPNET - - Serous Surface Papillary Carcinoma - - Adenocarcinoma In Adenomatous Polyposis Coli - - Embryonal Carcinoma, NOS - - Neoplasm, Uncertain Whether Benign Or Malignant, Ependymoma, Posterior Fossa Ependymoma, Group PFA - - Neoplasm, Uncertain Whether Benign Or Malignant, Diffuse Midline Glioma, H3 K27-Altered, High-Grade Glioma - - Glial Neoplasm - - Adrenal Cortical Tumor, NOS - - Ganglioglioma, NOS, Diffuse Astrocytoma, MYB- Or MYBL1-Altered, Low-Grade Glioma - - Undifferentiated Sarcoma - - Sertoli-Leydig Cell Tumor, Intermediate Differentiation, With Heterologous Elements - - Gliomatosis Cerebri - - Spindle Cell Melanoma, Type B + - Dysembryoplastic Neuroepithelial Tumor, Low-Grade Glioma, Polymorphous Low-Grade Neuroepithelial Tumor Of The Young + - Astrocytoma, NOS, High-Grade Glioma, Infant-Type Hemispheric Glioma + - Rhabdomyosarcoma, NOS - Mucinous Adenocarcinoma, Endocervical Type - - Acute Myelomonocytic Leukemia, NOS - - Follicular Adenocarcinoma, Well Differentiated, Neuroblastoma, NOS - - Renal Cell Carcinoma, NOS - - Papillary Tumor Of Pineal Region - - Sex Cord Stromal Tumor NOS - - Hemangioblastoma, CNS WHO Grade 1 - - Fibrosarcoma, NOS - - Acute Myeloid Leukemia, T(8;21)(Q22;Q22) - - Papillary Lesion With Atypical/High Grade Features + - Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH + - Ganglioglioma, NOS, Glioneuronal And Neuronal Tumors + - Dermoid Cyst + - Adenocarcinoma Combined With Other Types Of Carcinoma + - Precursor Cell Lymphoblastic Lymphoma, NOS + - Posterior Fossa Ependymoma, CNS WHO Grade 2 + - Pituitary Adenoma, NOS + - Neoplasm, Malignant, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor + - Sex Cord-Gonadal Stromal Tumor, Incompletely Differentiated + - High Grade Follicular Derived Thyroid Carcinoma + - Desmoplastic Fibroma + - Perineuroma + - Diffuse Midline Glioma, H3K27M-Mutant, CNS WHO Grade 4 + - Ganglioglioma + - Pancreatobiliary-Type Carcinoma + - Paratesticular Rhabdomyosarcoma With Diffuse Anaplasia + - Hemangioblastoma + - Colorectal Carcinoma + - Acute Myelomonocytic Leukemia + - Diffuse Midline Glioma, H3 K27-Altered + - T-Lymphoblastic Lymphoma + - Lymphangioma, NOS + - Neoplasm, Benign + - Papillary Intralymphatic Angioendothelioma + - Ependymoma, NOS, Supratentorial Ependymoma, ZFTA Fusion-Positive + - Unclassified Sarcoma With Round Cell Morphology + - Glioma + - Medulloblastoma, Classic (Biphasic) Histologic Type, Non-SHH/Non-WNT Molecular Group, CNS WHO Grade 4 + - Soft Tissue Sarcoma - Xanthogranuloma - - Neoplasm, Metastatic - - Pancreas-Adenocarcinoma Ductal Type - - Myeloid Sarcoma - - Yolk Sac Tumor - - Carcinoma In Situ, NOS - - Dysembryoplastic Neuroepithelial Tumor, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - - Anaplastic Large Cell Lymphoma, T-Cell And Null-Cell Type - - Dysembryoplastic Neuroepithelial Tumor With Adjacent Cortical Dysplasia, WHO Grade 1 + - Neoplasm, Malignant, Diffuse Midline Glioma, H3 K27-Altered, High-Grade Glioma + - Bronchio-Alveolar Carcinoma, Mucinous + - Hepatocellular Carcinoma, Fibrolamellar + - Pancreatic Neuroendocrine Tumor, Nonfunctioning + - Myxopapillary Ependymoma + - Chondrosarcoma, NOS + - Favor Ganglioglioma + - Papillary Tumor Of Pineal Region + - Acute Myeloid Leukemia With Mutated NPM1 + - Epithelioid Hemangioendothelioma, NOS + - Neuroblastoma, NOS + - Chondroid Chordoma + - Infiltrating Duct And Lobular Carcinoma + - Mitotically Active Glial/ Glioneuronal Neoplasm + - Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, NOS Or NEC + - CPNET + - Mycosis Fungoides, Langerhans Cell Histiocytosis, NOS + - T-Lymphoblastic Leukemia + - Medulloblastoma, NOS, Medulloblastoma, Non-WNT/Non-SHH + - Clear Cell Meningioma, Meningioma, Other + - Ameloblastic Carcinosarcoma + - Dysembryoplastic Neuroepithelial Tumor, Glioneuronal And Neuronal Tumors + - Meningothelial Meningioma + - Epithelioid Cell Melanoma + - Prostate Cancer + - Paraganglioma, Malignant + - Small Cell Sarcoma + - Cystosarcoma Phyllodes, NOS + - Seminoma, NOS + - Yolk Sac Tumor, NOS + - Intraductal Carcinoma NOS + - Adenocarcinoma, Endocervical Type + - Neurofibroma, NOS + - Astroblastoma, Astroblastoma, MN1-Altered, High-Grade Glioma + - Meningothelial Meningioma, Grade 1 - Neoplasm, Uncertain Whether Benign Or Malignant, Ependymoma, Supratentorial Ependymoma, NOS Or NEC - - Adenocarcinoma,NOS, Glioblastoma, NOS - - Myeloid Leukemia Associated With Down Syndrome - - Lipoblastomatosis - - Metastatic Neuroblastoma - - Hepatocellular Carcinoma, NOS, Nephroblastoma, NOS - - Combined Small Cell-Squamous Cell Carcinoma - - Tubular Adenocarcinoma - - Acute Monoblastic Leukemia - - Neurocytoma - - Astrocytoma, NOS, Low-Grade Glioma, Pleomorphic Xanthoastrocytoma - - Merkel Cell Tumor - - Astrocytoma, IDH-Mutant, WHO Grade 2 - - Craniopharyngioma, NOS - - Astrocytoma, IDH-Mutant, CNS WHO Grade 3 - - Glioma, Malignant, Malignant Peripheral Nerve Sheath Tumor, NOS - - B Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34;Q11.2); BCR-ABL1 - - Tumor Cells, Malignant, Other, Pineal Parenchymal Tumor Of Intermediate Differentiation - - Embryonal Rhabdomyosarcoma - - Pinealoma - - Ependymoma NOS - - Pigmented Dermatofibrosarcoma Protuberans - - Hemangioendothelioma, Malignant - - Adenocarcinoma, Pancreatobiliary Type - - Precursor B-Cell Lymphoblastic Leukemia - - Thymic Carcinoma, NOS - - Lobular Carcinoma, NOS - - Ganglioglioma, NOS - - Atypical Teratoid/Rhabdoid Tumor, ATRT, NOS Or NEC - - Choroid Plexus Carcinoma, WHO Grade 3 - - Rhabdomyosarcoma, Most Likely An Embryonal Carcinoma - - Squamous Cell Carcinoma, Small Cell, Nonkeratinizing - - Embryonal Carcinoma, NOS, Embryonal Tumor With Multilayered Rosettes, C19MC Altered, Other CNS Embryonal Tumors - - Colorectal Carcinoma - - Liposarcoma, NOS - - Primary Mediastinal (Thymic) Large B-Cell Lymphoma - - Meningeal Melanocytoma - - Dysembryoplastic Neuroepithelial Tumor, Angiocentric Glioma, Low-Grade Glioma - - Leukemia, NOS - - Periosteal Osteosarcoma - - Myelodysplastic Syndrome, NOS - - Central Neurocytoma, Glioneuronal And Neuronal Tumors - - Medulloblastoma, NOS, Medulloblastoma, SHH-Activated And TP53-Mutant - - Meningioma - - Gastrointestinal Stromal Tumor - - Pancreatobiliary-Type Carcinoma - - Hepatosplenic T-Cell Lymphoma, Precursor Cell Lymphoblastic Leukemia, NOS - Unknown - - Ganglioglioma - - Sertoli-Leydig Cell Tumor, Poorly Differentiated - - Squamous Cell Carcinoma, Keratinizing, NOS - - Invasive Mammary Carcinoma + - Neoplasm, Uncertain Whether Benign Or Malignant, CNS Sarcoma, Ewing Sarcoma + - Glioma, Malignant, Diffuse Hemispheric Glioma, H3 G34-Mutant, High-Grade Glioma + - Endometrioid Adenocarcinoma, NOS + - Pancreas-Adenocarcinoma Ductal Type + - Giant Cell Glioblastoma, Glioblastoma, IDH-Wildtype, High-Grade Glioma + - Angiomyosarcoma + - Carcinoid Tumor + - Adenosquamous Carcinoma + - Metastatic Neuroblastoma + - Clear Cell Sarcoma Of Kidney - Infiltrating Duct Mixed With Other Types Of Carcinoma + - Neoplasm, Uncertain Whether Benign Or Malignant, Diffuse Midline Glioma, H3 K27-Altered, High-Grade Glioma + - Embryonal Carcinoma, NOS, Ependymoma, Supratentorial Ependymoma, NOS Or NEC + - Neoplasm, Uncertain Whether Benign Or Malignant, CNS Germ Cell Tumors, CNS Germinoma + - Astrocytoma, NOS, Low-Grade Glioma, Pleomorphic Xanthoastrocytoma + - Low Cumulative Sun Damage Melanoma + - Supratentorial Ependymoma + - Ossifying Fibromyxoid Tumor, NOS + - Diffuse Large B-Cell Lymphoma, NOS + - Adenocarcinoma With Neuroendocrine Differentiation + - Atypical Meningioma + - Pineoblastoma - Chronic Myeloid Leukemia, NOS - - Acute Leukemia, NOS - - Desmoplastic Small Round Cell Tumor - - Classic Medulloblastoma, CNS WHO Grade 4 - - Well Differentiated Neuroendocrince Tumor, Grade 1 - - Neoplasm, Uncertain Whether Benign Or Malignant, High-Grade Glioma, High-Grade Glioma, NOS Or NEC - - Angiomyofibroblastoma - - Large Cell Medulloblastoma, Embryonal Tumor With Multilayered Rosettes, NOS, Other CNS Embryonal Tumors - - Craniopharyngioma, NOS, Adamantinomatous Craniopharyngioma - - Glioblastoma, NOS, High-Grade Glioma, High-Grade Glioma, NOS Or NEC - - Oligodendroglioma, NOS, Other, Other CNS Tumor, NOS Or NEC - - Oligodendroglioma - - Acute Myelomonocytic Leukemia - - Mesenchymal Chondrosarcoma, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - - Meningothelial Meningioma - - Ductal Carcinoma NOS - - Astroblastoma - - Merkel Cell Carcinoma - - Desmoplastic/Nodular Medulloblastoma (Histologically Defined), CNS WHO Grade 4 - - Hamartoma - - Choroid Plexus Papilloma, NOS, Other CNS Embryonal Tumors, Pineoblastoma - - Not Reported - - Reactive Connective Tissue - - Nephroblastoma (Wilms Tumor) - - Neoplasm, Uncertain Whether Benign Or Malignant, Adamantinomatous Craniopharyngioma, Craniopharyngioma - - Mixed Phenotype Acute Leukemia, T/Myeloid, NOS - - Neoplasm, Malignant, Astrocytoma, IDH-Mutant, Low-Grade Glioma - - Pancreas-Undifferentiated Carcinoma - - Epithelioid Mesothelioma, Malignant - - Multiple Myeloma - - Low Grade Glial/ Glioneuronal Tumor - - Mucous Adenocarcinoma - - Craniopharyngioma, Adamantinomatous, Adamantinomatous Craniopharyngioma - - Basal Cell Adenocarcinoma - - Ependymoma, NOS, Medulloblastoma, Medulloblastoma, NOS Or NEC - - Malignant Melanoma, NOS - - Acute Erythroid Leukemia - - Atypical Teratoid/Rhabdoid Tumor - - Olfactory Neuroblastoma - - Medullary Carcinoma - - Carcinoid Tumor - - Neoplasm, Uncertain Whether Benign Or Malignant, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - - Lobular And Ductal Carcinoma - - Medulloblastoma, NOS, Medulloblastoma, Non-WNT/Non-SHH - - Alveolar Soft Part Sarcoma - - Mesothelioma, Biphasic, Malignant, B Lymphoblastic Leukemia/Lymphoma, NOS - - Neoplasm, Malignant, Diffuse Midline Glioma, H3 K27-Altered, High-Grade Glioma - - Myofibroblastic Tumor, NOS - - Cavernoma - - Tenosynovial Giant Cell Tumor, NOS + - Atypical Choroid Plexus Papilloma + - Ependymoma, NOS, Posterior Fossa Ependymoma, Group PFB + - Pleomorphic Xanthoastrocytoma, NOS, High-Grade Glioma + - Oxyphilic Adenocarcinoma + - Favor Pilocytic Astrocytoma, CNS WHO Grade 1 + - Poorly Differentiated, Intermediate Mitotic-Karyorrhectic Index + - Clear Cell Meningioma + - Medulloblastoma, Classic Histologic Type, CNS WHO Grade 4 - Appearances Consistent With Alveolar Soft Part Sarcoma - - Craniopharyngioma, Adamantinomatous - - Choroid Plexus Carcinoma, Choroid Plexus Tumors - - Melanotic Schwannoma, Other - - Myofibroblastic Tumor - - Diffuse Midline Glioma, H3K27M-Mutant, CNS WHO Grade 4 - - Neoplasm, Uncertain Whether Benign Or Malignant, Low-Grade Glioma, Pilocytic Astrocytoma - - Embryonal Rhabdomyosarcoma, NOS, CNS Embryonal Tumor, NOS - - Dysembryoplastic Neuroepithelial Tumor, Glioneuronal And Neuronal Tumors - - Lobular Adenocarcinoma - - Medulloblastoma, NOS, Medulloblastoma, Group 3 - - Pilocytic Astrocytoma, Diffuse Leptomeningeal Glioneuronal Tumor, Glioneuronal And Neuronal Tumors - - Histologically Low-Grade Glioma - - Anaplastic Large Cell Lymphoma, ALK Positive - - Spindled And Epithelioid Tumor With Features Of Intracranial Mesenchymal Tumor - - Central Neurocytoma, Low-Grade Glioma, Subependymal Giant Cell Astrocytoma - - Intraductal Papillary Carcinoma - - Papillary Carcinoma, Columnar Cell - - Acute Myeloid Leukemia, T(16;16)(P 13;Q 11) - - Embryonal Sarcoma - - Central Neuroblastoma - - Paratesticular Rhabdomyosarcoma With Diffuse Anaplasia - - Carcinoma, Diffuse Type - - Neuroepithelioma, NOS - - Leiomyosarcoma, NOS - - Malignant Neoplasm Of Prostate - - Choroid Plexus Papilloma, NOS, Choroid Plexus Tumors - - Embryonal Carcinoma, NOS, Ependymoma, Supratentorial Ependymoma, NOS Or NEC - - Glioma, Malignant, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH - - Neoplasm, Uncertain Whether Benign Or Malignant, Low-Grade Glioma, Subependymal Giant Cell Astrocytoma + - Dedifferentiated Liposarcoma + - Neoplasm, Uncertain Whether Benign Or Malignant, Low-Grade Glioma, Oligodendroglioma, IDH-Mutant, And 1p/19q-Codeleted + - Neoplasm, Uncertain Whether Benign Or Malignant, ATRT, NOS Or NEC, Atypical Teratoid/Rhabdoid Tumor + - Tubular Adenocarcinoma + - Rhabdomyosarcoma, Most Likely An Embryonal Carcinoma + - Adenocarcinoma, NOS + - Pleuropulmonary Blastoma + - Basaloid Squamous Cell Carcinoma + - Oligodendroglioma, Anaplastic, NOS + - Pilocytic Astrocytoma, WHO Grade 1 - Not Applicable - - Precursor B-Cell Acute Lymphoblastic Leukemia With Hyperdiploidy - - Neoplasm - - B Lymphoblastic Leukemia/Lymphoma With Hypodiploidy - - Adenocarcinoma - - Ganglioneuroblastoma, Nodular Type - - Subependymoma - - Astroblastoma, Other, Other CNS Tumor, NOS Or NEC - - Low Grade Neoplasm. Features Suggestive Of Pilocytic Astrocytoma. - - Transitional Cell Carcinoma, NOS - - Ganglioneuroma - - Angiomatoid Fibrous Histiocytoma - - Squamous Cell Carcinoma, Metastatic, NOS - - Astrocytoma, NOS, Other, Other CNS Tumor, NOS Or NEC - - Papillary Thyroid Carcinoma - - Diffuse Midline Glioma, H3 K27 Altered, WHO Grade 4 - - Chronic Eosinophilic Leukemia - - Myxoid Spindle Cell Tumor - - Tumor Cells, Malignant, Diffuse Leptomeningeal Glioneuronal Tumor, Glioneuronal And Neuronal Tumors - - Neoplasm, Malignant, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC - - Neoplasm, Malignant, Uncertain Whether Primary Or Metastatic - - Melanoma In Situ - - Acinar Cell Carcinoma - - Squamous Cell Carcinoma, Large Cell, Nonkeratinizing, NOS - - Medulloblastoma, NOS, Medulloblastoma, WNT-Activated - - Bland Myofibroblastic Proliferation With Associated Florid Lymphoplasmacytic Inflammation - - Ependymoma, NOS, Choroid Plexus Tumors, Choroid Plexus Papilloma - - Neuroma, NOS - - Acral Lentiginous Melanoma, Malignant - - Melanotic Neuroectodermal Tumor - - Adenocarcinoma With Neuroendocrine Differentiation - - Combined Small Cell-Large Carcinoma - - Glioma, Malignant, Diffuse Hemispheric Glioma, H3 G34-Mutant, High-Grade Glioma - - Myxopapillary Ependymoma - - Prostate Cancer - - Cholangiocarcinoma - - Medulloblastoma, Classic Variant, WHO Grade 4 - - Malignant Melanoma, NOS, Meningeal Melanocytic Neoplasms (Includes Melanoma), Other + - Abdominal Fibromatosis + - Hamartoma + - Neoplasm, Malignant, Low-Grade Glioma, Pilocytic Astrocytoma + - Choroid Plexus Papilloma, NOS, Choroid Plexus Tumors + - Burkitt Lymphoma, NOS + - Lymphoepithelial Carcinoma + - Bronchiolo-Alveolar Carcinoma, Non-Mucinous + - Kidney Clear Cell Renal Carcinoma + - Pilocytic Astrocytoma, Low-Grade Glioma + - Adenocarcinoma In Situ In Adenomatous Polyp + - Neoplasm, Uncertain Whether Benign Or Malignant + - Small Blue Cell Tumor. Favor Medulloblastoma + - B Lymphoblastic Leukemia/Lymphoma, NOS + - Embryonal Tumor With Multi-Layered Rosettes + - Chronic Eosinophilic Leukemia + - Mixed Glioma + - Basal Cell Adenocarcinoma + - Olfactory Neuroblastoma + - Transitional Cell Carcinoma, NOS + - Clear Cell Sarcoma, NOS + - Embryonal Rhabdomyosarcoma, High-Grade + - Angiocentric Glioma + - Diffuse Midline Glioma, H3 K27 Altered, WHO Grade 4 - Osteoblastoma, NOS - - Acute Myeloid Leukemia (Megakaryoblastic) With T(1;22)(P13;Q13); RBM15-MKL1 - - Hepatocellular Carcinoma, Fibrolamellar - - Adenocarcinoma, NOS - - Myeloid Leukemia, NOS - - CNS Embryonal Tumor, NOS - - Adenocarcinoma In Situ, NOS - - Dermatofibrosarcoma Protuberans, NOS + - Malignant Neoplasm With Rhabdomyoblastic Differentiation, High Grade + - Myxopapillary Ependymoma (CNS WHO Grade II) + - Melanoma In Situ + - Secretory Carcinoma + - Pilocytic Astrocytoma, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC + - Rhabdomyosarcoma, Favor Alveolar Type + - Adenocarcinoma, Metastatic NOS + - Fibrosarcoma, NOS + - Glioblastoma + - Atypical Choroid Plexus Papilloma, Choroid Plexus Tumors + - Ganglioneuroma, High-Grade Glioma, High-Grade Glioma, NOS Or NEC + - Desmoplastic Melanoma, NOS + - Choroid Plexus Carcinoma + - Soft Tissue Tumor, Benign + - Medulloblastoma, NOS + - Glioblastoma, NOS, Medulloblastoma, NOS + - Residual Astrocytoma + - B Lymphoblastic Leukemia/Lymphoma With T(V;11q23); MLL Rearranged + - Extra Adrenal Paraganglioma + - Mucoepidermoid Carcinoma + - Mixed Germ Cell Tumor, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor + - Choroid Plexus Papilloma, NOS + - Glioma, Malignant, Astrocytoma, IDH-Mutant, Low-Grade Glioma + - B-Lymphoblastic Leukemia/Lymphoma, NOS + - Hodgkin Lymphoma, Nodular Sclerosis, NOS + - Fibroma + - Craniopharyngioma, NOS, Adamantinomatous Craniopharyngioma + - T-Cell/Histiocyte Rich Large B-Cell Lymphoma + - Astrocytoma, IDH-Mutant, CNS WHO Grade 4 + - Acute Erythroid Leukemia + - Glioma, Histologically Low Grade + - Mucous Adenocarcinoma + - Glioma, Malignant, Ganglioglioma, Glioneuronal And Neuronal Tumors + - Nodular Melanoma + - Synovial Sarcoma, Biphasic + - Neoplasm, Metastatic - Neoplasm, Uncertain Whether Benign Or Malignant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype And IDH-Wildtype, High-Grade Glioma - - Metastatic Secondary Tumors - - Myelodysplastic Syndrome With Multilineage Dysplasia - - Neoplasm, Malignant, Medulloblastoma, Medulloblastoma, NOS Or NEC - - Serous Cystadenocarcinoma, NOS - - Angiocentric Glioma - - Pancreatoblastoma - - Diffuse Glioma - - Papillary Carcinoma, Follicular Variant - - Astrocytoma, NOS, Low-Grade Glioma, Subependymal Giant Cell Astrocytoma - - Low Grade Fibromyxoid Sarcoma - Thymoma, NOS - - Ependymoma, NOS, Atypical Meningioma - - Diffuse Midline Glioma, H3 K27-Altered - - Teratoma, NOS - - Adenosquamous Carcinoma - - Nuclear Protein In Testis (NUT)-Associated Carcinoma - - Mitotically Active Glial/ Glioneuronal Neoplasm - - Atypical Lymphoid Infiltrate - - Bronchiolo-Alveolar Carcinoma, Non-Mucinous - - Acute Myeloid Leukemia, NOS - - Glial Neoplasm Showing High-Grade Features - - Astroblastoma, Astroblastoma, MN1-Altered, High-Grade Glioma - - Ependymoma, NOS - - High Grade Malignant Peripheral Nerve Sheath Tumor With Heterologous Rhabdomyoblastic Differentiation (Malignant Triton Tumor) - - Serous Adenocarcinoma, NOS - - Acute Myeloid Leukemia With Myelodysplasia-Related Changes + - Neoplasm, Uncertain Whether Benign Or Malignant, Ependymoma, Posterior Fossa Ependymoma, Group PFA + - Desmoplastic/Nodular Medulloblastoma + - Papillary Glioneuronal Tumor + - Mixed Phenotype Acute Leukemia, T/Myeloid, NOS + - Cholangiocarcinoma + - Astroblastoma, MN1-Altered. Histologically High-Grade + - Sertoli-Leydig Cell Tumor, Poorly Differentiated, With Heterologous Elements + - Glioma, Malignant, High-Grade Glioma, Infant-Type Hemispheric Glioma + - Juvenile Myelomonocytic Leukemia, NOS - Embryonal Neoplasm With INI-1 Loss By Immunohistochemistry + - Myeloid Leukemia With Myelodysplasia-Related Changes + - Primary Cutaneous Follicle Center Lymphoma + - Choroid Plexus Carcinoma, WHO Grade 3 + - Infiltrating Duct Carcinoma NOS + - T Lymphoblastic Leukemia/Lymphoma + - Glioma, Malignant, Other, Other CNS Tumor, NOS Or NEC + - Mixed Germ Cell Tumor, Myelodysplastic Syndrome With Excess Blasts + - Clear Cell Adenocarcinoma, NOS + - Cutaneous T-Cell Lymphoma, NOS + - Germinoma + - Neoplasm, Malignant, ATRT, NOS Or NEC, Atypical Teratoid/Rhabdoid Tumor + - Meningeal Melanocytoma + - Neoplasm, Malignant, Medulloblastoma, Medulloblastoma, NOS Or NEC + - Acute Promyelocytic Leukemia, T(15;17)(Q22;Q11-12) + - Alveolar Soft Part Sarcoma + - Astrocytoma, NOS, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Mixed Epithelioid And Spindle Cell Melanoma + - CNS Embryonal Tumor, NOS, CNS Embryonal Tumor, NOS Or NEC, Other CNS Embryonal Tumors + - Malignant Tumor, Spindle Cell Type - Glioma, Malignant, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC - - Endometrioid Adenocarcinoma, NOS - - Sertoli-Leydig Cell Tumor Of Intermediate Differentiation, NOS - - Giant Cell Tumor Of Bone, Malignant - - Low Cumulative Sun Damage Melanoma - - Neoplasm, Uncertain Whether Benign Or Malignant, Meningioma, Other - - Dysembryoplastic Neuroepithelial Tumor, Low-Grade Glioma, Polymorphous Low-Grade Neuroepithelial Tumor Of The Young - - Atypical Teratoid/Rhabdoid Tumor, ATRT-MYC - - Paraganglioma, NOS - - Malignant Neoplasm With Rhabdomyoblastic Differentiation, High Grade + - Glioma, Malignant, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Endometrioid Carcinoma, NOS + - Lung Squamous Cell Carcinoma, NOS + - Papillary Urothelial Carcinoma, Non-Invasive + - Neuroblastoma, Undifferentiated Type + - Periosteal Osteosarcoma + - Mixed Phenotype Acute Leukemia, B/Myeloid, NOS + - Inflammatory Carcinoma + - Glioblastoma, NOS + - Carcinoma, NOS, Medulloblastoma, Medulloblastoma, NOS Or NEC + - Squamous Cell Carcinoma, NOS + - Hypocellular Low Grade Lesion + - Glioblastoma Multiforme + - Pancreas-Undifferentiated Carcinoma + - Differentiating Neuroblastoma + - Myxoid Spindle Cell Tumor + - Merkel Cell Tumor + - Malignant Peripheral Nerve Sheath Tumor, NOS, CNS Sarcoma, CNS Sarcoma, NOS Or NEC + - Hemangioma, NOS + - Acute Myeloid Leukemia With Abnormal Marrow Eosinophils + - Well Differentiated Neuroendocrince Tumor, Grade 1 + - Ganglioglioma, Anaplastic + - Ependymoma WHO Grade 2 + - Synovial Sarcoma, NOS + - Thymic Carcinoma, NOS + - Tumor Cells, Malignant + - Pilomyxoid Astrocytoma + - Papillary Carcinoma, Columnar Cell + - Plexiform Fibrohistiocytic Tumor + - Astrocytoma, NOS, Angiocentric Glioma, Low-Grade Glioma + - Carcinoma, Undifferentiated, NOS + - Dermatofibrosarcoma Protuberans, NOS + - High Grade Glioma With Necrosis, WHO Grade 4 + - Infiltrating ductular carcinoma + - Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Juvenile Myelomonocytic Leukemia, NOS + - Infiltrating Duct And Mucinous Carcinoma + - Intraductal Papillary Carcinoma + - Serous Surface Papillary Carcinoma + - Invasive Carcinoma + - High Grade Malignant Epithelioid Neoplasm + - Favor Pilocytic Astrocytoma With Increased Proliferation Indices + - Medulloblastoma, Classic Morphology, CNS WHO Grade 4, NON-WNT/NON-SHH, Group 4 Subtype By Methylation + - Composite Hodgkin And Non-Hodgkin Lymphoma + - Atypical Teratoid/Rhabdoid Tumor, ATRT, NOS Or NEC + - Atypical Teratoid/Rhabdoid Tumor, ATRT-TYR + - Primary Cutaneous CD30 Positive T-Cell Lymphoproliferative Disorder + - Hemangioendothelioma, NOS + - Hypercellular Lesion With Atypia + - Embryonal Carcinoma, NOS + - Subependymoma, Ependymoma, Supratentorial Ependymoma, NOS Or NEC + - Germ Cell Tumor, Nonseminomatous + - Adrenal Cortical Carcinoma + - Olfactory Neurocytoma + - Large Cell Medulloblastoma, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH + - Nuclear Protein In Testis (NUT)-Associated Carcinoma - Epithelial-Myoepithelial Carcinoma + - Squamous Cell Carcinoma, Keratinizing, NOS + - Ganglioneuroma, Other, Schwannoma + - Glomus Tumor, Malignant + - Neoplasm, Malignant, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - Malignant Lymphoma, Non-Hodgkin, NOS - - Undiagnosed Spindle Cell Tumor - - Meningothelial Meningioma, Meningioma, Other - - Oligodendroglioma, Anaplastic, NOS - - Large Cell Medulloblastoma, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH - - Neuroblastoma, NOS - - Ependymoma, NOS, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH - - Tumor Cells, Uncertain Whether Benign Or Malignant - - High Grade Spindle Cell Sarcoma - - Diffuse Midline Glioma, H3 K27M-Mutant - - Meningioma, NOS, Embryonal Tumor With Multilayered Rosettes, NOS, Other CNS Embryonal Tumors - - Malignant Peripheral Nerve Sheath Tumor (Mpnst) - - Ganglioglioma, NOS, Malignant Peripheral Nerve Sheath Tumor, NOS - - Transient Abnormal Myelopoiesis - - Supratentorial Ependymoma, NOS - - Retinoblastoma, Grade 3 - - Medulloblastoma WHO Grade 4 - - Follicular Adenocarcinoma, NOS - - Sertoli Cell Tumor, NOS - - Ganglioglioma, NOS, Glioneuronal And Neuronal Tumors - - Medulloblastoma - - Combined Small Cell-Adenocarcinoma - - Ependymoma, NOS, Posterior Fossa Ependymoma, Group PFA - - Pleuropulmonary Blastoma - - Mucinous Carcinoma - - Epithelioid Sarcoma, NOS - - Pilocytic Astrocytoma, Low-Grade Glioma - - Spinal Ependymoma, WHO Grade 2 - - Embryonal Rhabdomyosarcoma With Anaplastic Features - - Astrocytoma, NOS, High-Grade Glioma, High-Grade Glioma, NOS Or NEC - - Lymphoma, NOS - - Spindle Cell Melanoma, NOS - - Adenocarcinoma, Endocervical Type - - Colon Adenocarcinoma - - High Grade Follicular Derived Thyroid Carcinoma - - Medulloblastoma, Nodular/Desmoplastic With Anaplastic/Large Cell Features, Non-WNT/Non-SHH; WHO Grade 4 - - Neoplasm, Malignant, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor - - Morphologically Consistent With Pilocytic Astrocytoma, WHO Grade 1 - - Nephroblastoma, NOS - - Nodular Melanoma - - Residual Astrocytoma - - Astroblastoma, MN1-Altered. Histologically High-Grade - - Mixed Type Rhabdomyosarcoma - - Craniopharyngioma - - Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, Group 4 - - Granulosa Cell Tumor, Malignant - - Adrenal Cortical Adenoma, NOS - - Alveolar Rhabdomyosarcoma - - Adenocarcinoma, Pancreatobiliary Type, Pancreatobiliary-Type Carcinoma - - CNS Embryonal Tumor With Rhabdoid Features - - Invasive Lobular Carcinoma - - Pinealoblastoma - - Glial Tumor - - Gliosarcoma - - Medulloblastoma, Classic (Biphasic) Histologic Type, Non-SHH/Non-WNT Molecular Group, CNS WHO Grade 4 - - Ductal Carcinoma In Situ, NOS - - Solitary Fibrous Tumor, NOS - - Ependymoma, NOS, Posterior Fossa Ependymoma, NOS Or NEC - - Malignant Peripheral Nerve Sheath Tumor, NOS, CNS Sarcoma, CNS Sarcoma, NOS Or NEC - - Neoplasm, Uncertain Whether Benign Or Malignant, Astrocytoma, IDH-Mutant, Low-Grade Glioma - - Choroid Plexus Papillary Tumor - - Ependymoma, Anaplastic - - Leydig Cell Tumor, NOS - - Synovial Sarcoma, Biphasic - - Medulloblastoma, SHH-Activated And TP53-Wildtype - - Glioma, Malignant, Angiocentric Glioma, Low-Grade Glioma - - Neoplasm, Malignant, ATRT-SHH, Atypical Teratoid/Rhabdoid Tumor - - Micropapillary Carcinoma, NOS + - Embryonal Rhabdomyosarcoma, NOS, CNS Embryonal Tumor, NOS + - Tenosynovial Giant Cell Tumor, NOS + - Histologically Low-Grade Glioma + - Chordoma, NOS, Ganglioneuroblastoma + - Ependymoma, NOS + - Invasive Mammary Carcinoma + - Rhabdoid Tumor, Malignant + - Medulloblastoma, Classic Histology + - Adenocarcinoma In Villous Adenoma + - Undifferentiated Sarcoma + - Papillary Thyroid Carcinoma + - Renal Cell Adenocarcinoma + - Hodgkin Lymphoma, NOS + - Malignant Histiocytosis - Desmoplastic Nodular Medulloblastoma, Medulloblastoma, Medulloblastoma, SHH-Activated And TP53-Wildtype + - Solid Pseudopapillary Tumor Of Ovary - Astrocytic Glioma, Histologically Low-Grade, Most Compatible With Pilocytic Astrocytoma + - Inflammatory Myofibroblastic Tumor With An Associated Odontogenic Keratocyst + - Myofibromatosis + - Small Round Blue Cell Tumor - Meningioma, Atypical, CNS WHO Grade 2 - - High Grade Malignant Epithelioid Neoplasm - - Astrocytoma, NOS, High-Grade Glioma, Infant-Type Hemispheric Glioma - - Meningioma, NOS - - Gangliocytoma, NOS - - Low Grade Glial Neoplasm - - Mucinous Adenocarcinoma - - Malignant Glioma - - Lung Squamous Cell Carcinoma, NOS - - Soft Tissue Sarcoma - - Meningioangiomatosis - - Adenocarcinoma In Villous Adenoma - - Squamous Cell Carcinoma In Situ, NOS - - Malignant Peripheral Nerve Sheath Tumor, NOS - - Desmoplastic Infantile Astrocytoma - - Medulloblastoma, SHH-Activated And TP53-Mutant - - Subependymal Giant Cell Astrocytoma - - Glioma, Malignant, Astrocytoma, IDH-Mutant, Low-Grade Glioma - - Glioma, Malignant, Ganglioglioma, Glioneuronal And Neuronal Tumors - - Hepatocellular Carcinoma, NOS - - Ameloblastic Carcinosarcoma - - Squamous Cell Carcinoma, NOS - - Glioma, Malignant, Other, Other Low-Grade B-Cell Lymphomas Of The CNS - - Atypical Meningioma - - Ependymoma, NOS, Posterior Fossa Ependymoma, Group PFB - - Sclerosing Stromal Tumor - - Gastrointestinal Stromal Tumor, Benign - - Large Cell Medulloblastoma - - Acute Myeloid Leukemia, NOS, Myeloproliferative Neoplasm, Unclassifiable - - Synovial Sarcoma, Spindle Cell - - Pituitary Adenoma, NOS - - Astrocytoma, NOS, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - - Familial Adenomatous Polyposis - - Not Specified In Data - - Medulloblastoma; Hypercellular Lesion With Marked Atypia - - Seminoma, NOS - - Malignant Lymphoma, NOS - - High Grade Carcinosarcoma - - Plasmacytoma, Extramedullary - - Abdominal Fibromatosis + - Neoplasm, Uncertain Whether Benign Or Malignant, Adamantinomatous Craniopharyngioma, Craniopharyngioma + - Pilocytic Astrocytoma + - Lobular And Ductal Carcinoma + - Desmoplastic/Nodular Medulloblastoma (Histologically Defined), CNS WHO Grade 4 + - Malignant Peripheral Nerve Sheath Tumor With Rhabdomyoblastic Differentiation + - Tumor Cells, Malignant, Diffuse Leptomeningeal Glioneuronal Tumor, Glioneuronal And Neuronal Tumors + - Malignant Tumor - Brain Tumor - - Giant Cell Tumor Of Soft Parts, NOS - - Oligodendroglioma, NOS - - Tumor Cells, Malignant - - Glioneuronal Tumor With Focal Increased Atypia - - Adenosarcoma - - Atypical Teratoid/Rhabdoid Tumor, ATRT-TYR - - Carcinoma, Metastatic, NOS - - Glioma, Malignant - - Neurofibroma, NOS - - Neoplasm, Uncertain Whether Benign Or Malignant, Dysembryoplastic Neuroepithelial Tumor, Glioneuronal And Neuronal Tumors + - Gastrointestinal Stromal Tumor, Benign + - Rasmussen Encephalitis + - Medulloblastoma, NOS, Diffuse Hemispheric Glioma, H3 G34-Mutant, High-Grade Glioma + - Adenocarcinoma,NOS, Glioblastoma, NOS + - Malignant Peripheral Nerve Sheath Tumor (Mpnst) + - Embryonal Sarcoma + - Neoplasm, Malignant, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC + - Anaplastic Large Cell Lymphoma, T-Cell And Null-Cell Type + - Teratoma, NOS + - Pleomorphic Xanthoastrocytoma, NOS + - Infiltrating duct and lobular carcinoma + - Sclerosing Stromal Tumor + - Tumor Cells, Uncertain Whether Benign Or Malignant + - Acute Myeloid Leukemia, NOS, Juvenile Myelomonocytic Leukemia, NOS + - Lobular Carcinoma, NOS + - Schwannoma, NOS, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - Sarcoma, NOS - - Neoplasm, Malignant, High-Grade Glioma, High-Grade Glioma, NOS Or NEC - - Blue Nevus, Malignant - - Neoplasm, Malignant, Low-Grade Glioma, Pilocytic Astrocytoma - - Clear Cell Sarcoma Of Kidney - - Malignant Tumor, Spindle Cell Type - - Epithelioid Cell Melanoma - - Small Cell Sarcoma - - Subependymoma, Ependymoma, Supratentorial Ependymoma, NOS Or NEC - - Glioma, Malignant, Embryonal Tumor With Multilayered Rosettes, C19MC Altered, Other CNS Embryonal Tumors - - Brain Tumor, Low Grade Glioma + - CNS Embryonal Tumor With Rhabdoid Features - Glial Neoplasm, Astrocytoma - - Vascular Lesion, Consistent With Hemangioma - - Juvenile Granulosa Cell Tumor - - Malignant Peripheral Nerve Sheath Tumor With Rhabdomyoblastic Differentiation - - Carcinoma, NOS, Medulloblastoma, Medulloblastoma, NOS Or NEC - - Neoplasm, Uncertain Whether Benign Or Malignant, ATRT, NOS Or NEC, Atypical Teratoid/Rhabdoid Tumor - - Favor Anaplastic Ependymoma - - Schwannoma, NOS, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - - Oligodendroglioma, NOS, Low-Grade Glioma, Oligodendroglioma, IDH-Mutant, And 1p/19q-Codeleted - - Atypical Teratoid/Rhabdoid Tumor, INI1/SMARCB1-Altered, WHO Grade 4 - - Yolk Sac Tumor, NOS - - Small Cell Carcinoma, NOS - - Carcinosarcoma NOS - - Mixed Germ Cell Tumor, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor - - Juvenile Myelomonocytic Leukemia - - Myofibroma - - Posterior Fossa Ependymoma, CNS WHO Grade 2 - - Renal Cell Adenocarcinoma - - Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Juvenile Myelomonocytic Leukemia, NOS - - High Grade Neuroepithelial Tumor - - Neoplasm, Malignant, Medulloblastoma, Medulloblastoma, WNT-Activated - - Pleomorphic Xanthoastrocytoma, NOS, High-Grade Glioma - - Pilocytic Astrocytoma, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC - - Lymphoid Leukemia, NOS - - Atypical Choroid Plexus Papilloma, Choroid Plexus Tumors - - Benign Cystic Nephroma + - Pancreas-Adenosquamous Carcinoma + - Mesenchymal Lesion + - Serous Adenocarcinoma, NOS + - Hepatoblastoma, NOS + - Astrocytoma, NOS, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype And IDH-Wildtype, High-Grade Glioma - Sex Cord-Gonadal Stromal Tumor, NOS - - Neoplasm, Benign - - Glioblastoma - - Pilocytic Astrocytoma, WHO Grade 1, KIAA1549-BRAF Fusion - - Acute Myeloid Leukemia With T(9;11)(P22;Q23); MLLT3-MLL - - Glioma, Malignant, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - - Hypercellular Lesion With Atypia - - Myxopapillary Ependymoma, Ependymoma - - Neoplasm, Malignant, CNS Neuroblastoma, FOXR2-Activated, Other CNS Embryonal Tumors - - Head & Neck Squamous Cell Carcinoma - - Giant Cell Tumor Of Bone, NOS - - Neuroepithelial Tumor With Glioneuronal-Like Features - - Neuroepithelial Tumor - - Leydig Cell Tumor, Benign - - Adenocarcinoma With Mixed Subtypes - - Parosteal Osteosarcoma - - Acute Lymphoblastic Leukemia - - Infantile Fibrosarcoma - - Langerhans Cell Histiocytosis, Disseminated - Adenoid Cystic Carcinoma + - Embryonal Tumor + - Acute Myeloid Leukemia, T(8;21)(Q22;Q22) + - Spindled And Epithelioid Tumor With Features Of Intracranial Mesenchymal Tumor + - Cavernoma + - Malignant Tumor, Small Cell Type + - Mixed Germ Cell Tumor, CNS Germ Cell Tumors, CNS Germinoma + - Low Grade Neoplasm. Features Suggestive Of Pilocytic Astrocytoma. + - Neoplasm, Malignant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype And IDH-Wildtype, High-Grade Glioma + - Serous Carcinoma, NOS + - Metastatic Secondary Tumors + - Yolk Sac Tumor + - Morphologically Consistent With Pilocytic Astrocytoma, WHO Grade 1 - Neuroendocrine Tumor, NOS - - Glioma, Histologically Low Grade - - Rhabdomyoma, NOS - - Rhabdomyosarcoma, Embryonal Subtype - - Glioma, Malignant, Low-Grade Glioma, Polymorphous Low-Grade Neuroepithelial Tumor Of The Young - - Ganglioglioma, NOS, Other, Other CNS Tumor, NOS Or NEC - - Pancreas-Adenosquamous Carcinoma - - Germinoma, CNS Germ Cell Tumors, CNS Germinoma - - Control - - Undifferentiated Small Round Cell Sarcoma - - Medulloepithelioma, NOS - - Glioma, Malignant, Other, Other CNS Tumor, NOS Or NEC - - Choroid Plexus Papilloma, NOS - - Glioma, Malignant, Dysembryoplastic Neuroepithelial Tumor, Glioneuronal And Neuronal Tumors - - Acute Myeloid Leukemia With Mutated CEBPA - - Intraductal Carcinoma NOS - - Hemangioma, NOS - - Perineuroma - - Pilocytic Astrocytoma - - Poorly Differentiated, Intermediate Mitotic-Karyorrhectic Index - - Astrocytoma, IDH-Mutant, CNS WHO Grade 4 + - Mixed Germ Cell Tumor, Acute Megakaryoblastic Leukemia + - Juvenile Myelomonocytic Leukemia + - Acute Myeloid Leukemia With T(9;11)(P22;Q23); MLLT3-MLL + - Glioma, Malignant, High-Grade Glioma, Pleomorphic Xanthoastrocytoma + - Papillary Glioneuronal Tumor, WHO Grade 1 + - Central Neuroblastoma + - Dysembryoplastic Neuroepithelial Tumor + - Mixed Adenocarcinoma And Squamous Cell Carcinoma, Pancreatobiliary-Type Carcinoma + - Subcutaneous Panniculitis-Like T-Cell Lymphoma + - Myofibroblastic Tumor + - Nephroblastoma, NOS + - Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, SHH-Activated And TP53-Wildtype + - Malignant Melanoma, NOS, Meningeal Melanocytic Neoplasms (Includes Melanoma), Other + - Carcinoma, Metastatic, NOS - Follicular Carcinoma, Minimally Invasive - - Glioma, Malignant, High-Grade Glioma, High-Grade Glioma, NOS Or NEC - - Burkitt Lymphoma, NOS - - Ependymoma, NOS, Supratentorial Ependymoma, NOS Or NEC - - Neoplasm, Uncertain Whether Benign Or Malignant, CNS Germ Cell Tumors, CNS Germinoma - - Mixed Germ Cell Tumor - - Medulloblastoma, Classic Histologic Type, CNS WHO Grade 4 - - Central Neurocytoma + - Angiomyofibroblastoma + - Classic Medulloblastoma, CNS WHO Grade 4 + - Neoplasm, Uncertain Whether Benign Or Malignant, Low-Grade Glioma, Subependymal Giant Cell Astrocytoma + - Atypical Teratoid/Rhabdoid Tumor, ATRT-MYC + - Astroblastoma + - Meningothelial Meningioma, Meningioma, Other + - Poorly Differentiated Chordoma + - Chronic Myelogenous Leukemia + - Pleomorphic Sarcoma + - Supratentorial Ependymoma CNS WHO Grade 3 + - Leydig Cell Tumor, NOS + - Adenosarcoma + - Pigmented Dermatofibrosarcoma Protuberans + - Astrocytoma, NOS, Other, Other CNS Tumor, NOS Or NEC + - Astrocytoma, NOS, High-Grade Glioma, High-Grade Glioma, NOS Or NEC + - Astrocytoma, NOS, Astrocytoma, IDH-Mutant, Low-Grade Glioma + - Myxofibrosarcoma + - Precursor T-Cell Lymphoblastic Leukemia + - Neurocytoma + - Adrenal Cortical Tumor, NOS + - Neoplasm, Malignant, ATRT-SHH, Atypical Teratoid/Rhabdoid Tumor + - Acute Myeloid Leukemia (Megakaryoblastic) With T(1;22)(P13;Q13); RBM15-MKL1 + - Neoplasm, Malignant, CNS Neuroblastoma, FOXR2-Activated, Other CNS Embryonal Tumors + - Infiltrating duct and mucinous carcinoma + - Adenocarcinoma In Situ, NOS + - Mucinous Adenocarcinoma + - Retinoblastoma, NOS + - Anaplastic Ependymoma + - Germ Cell Tumor, Nonseminomatous, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor + - Acute Monoblastic And Monocytic Leukemia + - Hemangioblastoma, CNS WHO Grade 1 + - Alveolar Rhabdomyosarcoma - Medullary Carcinoma, NOS - - Proliferative Dermal Lesion In Congenital Nevus - - Glioma, Malignant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype And IDH-Wildtype, High-Grade Glioma - - Neuroendocrine Carcinoma, NOS - - Glioblastoma, NOS, Medulloblastoma, NOS - - Astrocytoma, Benign - - Ganglioneuroblastoma - - Astrocytoma, NOS, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype And IDH-Wildtype, High-Grade Glioma - - Medulloblastoma, NOS - - Favor Ganglioglioma - - Chronic Myeloid Leukemia, BCR-ABL1-Positive - - Schwannian Stroma Poor Peripheral Neuroblastic Tumor, Consistent With Neuroblastoma - - Adrenal Cortical Carcinoma - - Astrocytoma - - Neoplasm, Uncertain Whether Benign Or Malignant, Choroid Plexus Tumors, Choroid Plexus Papilloma - - Favor Posterior Fossa Ependymoma, WHO GRADE 3 - - Leiomyoma, NOS - - Sex Cord-Gonadal Stromal Tumor, Mixed Forms + - Adult Granulosa Cell Tumor Of Testis + - Medulloblastoma, WHO Grade 4 + - Craniopharyngioma, Adamantinomatous + - High Grade Malignant Peripheral Nerve Sheath Tumor With Heterologous Rhabdomyoblastic Differentiation (Malignant Triton Tumor) + - Spindle Cell Rhabdomyosaroma + - Diffuse Midline Glioma, H3 K27M-Mutant + - Epithelioid Sarcoma, NOS + - Myoepithelial Carcinoma + - Multiple Myeloma + - Triple-Negative Breast Carcinoma + - Hepatocellular Carcinoma, NOS, Nephroblastoma, NOS - Neuroblastoma, Schwannian Stroma Poor, Poorly Differentiated, Low MKI, Favorable Histology - - Poorly Differentiated Neuroblastoma - - T-Lymphoblastic Lymphoma + - Sertoli Cell Tumor, NOS + - Ossifying Fibroma + - Pleomorphic Liposarcoma + - Amelanotic Melanoma + - Liposarcoma, NOS + - Non-Germinomatous Germ Cell Tumor + - Lactotroph Adenoma + - Transient Abnormal Myelopoiesis + - Favor Posterior Fossa Ependymoma, WHO GRADE 3 + - Dysembryoplastic Neuroepithelial Tumor, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Carcinoma In Situ, NOS + - Ependymoma, NOS, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH + - Ependymoma, Anaplastic + - Glial Neoplasm, Favor Pilocytic Astrocytoma + - Gastrointestinal Stromal Tumor, NOS + - Serous Cystadenocarcinoma, NOS + - Papillary Lesion With Atypical/High Grade Features + - Spinal Ependymoma, WHO Grade 2 + - Ductal Carcinoma In Situ, NOS + - Infiltrating Ductal Carcinoma + - Mixed Type Rhabdomyosarcoma + - Medulloblastoma, SHH-Activated And TP53-Mutant + - Precursor B-Cell Acute Lymphoblastic Leukemia With Hyperdiploidy + - Mesenchymal Chondrosarcoma, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Cribriform Carcinoma, NOS + - Myxopapillary Ependymoma, Anaplastic + - Ependymoma, Anaplastic, Supratentorial Ependymoma, NOS Or NEC + - Astrocytoma, IDH-Mutant, WHO Grade 2 + - Meningioangiomatosis + - Acute Myeloid Leukemia, NOS, Myeloproliferative Neoplasm, Unclassifiable + - Endometrioid carcinoma, NOS + - Adenocarcinoma In Situ, Non-Mucinous + - Medulloblastoma, NOS, Medulloblastoma, Group 4 + - Papillary Carcinoma, Follicular Variant + - Metaplastic Carcinoma, NOS + - Choroid Plexus Carcinoma, Choroid Plexus Tumors + - Poorly Differentiated Sertoli-Leydig Cell Tumor With Heterologous Rhabdomyosarcomatous Differentiation + - Low Grade Glioma + - Sex Cord Stromal Tumor NOS - Stroma Poor, Poorly Differentiated Neuroblastoma With Low MKI, Favorable Histology - - Low Grade Glioneuronal Tumor - - Adenocarcinoma Combined With Other Types Of Carcinoma - - Germ Cell Tumor, Nonseminomatous - - Tumor Cells, Benign - - Dysembryoplastic Neuroepithelial Tumor - - Soft Tissue Tumor, Benign - - Malignant Histiocytosis - - Chronic Myelogenous Leukemia - - Yolk Sac Tumor, NOS, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor - - Carcinoma NOS + - Residual Low Grade Neuroendocrine Tumor (Typical Carcinoid) + - Melanotic Neuroectodermal Tumor + - Ependymoma, NOS, Medulloblastoma, Medulloblastoma, NOS Or NEC + - Glioma, Malignant, Angiocentric Glioma, Low-Grade Glioma + - Malignant Lymphoma, NOS + - Medulloblastoma WHO Grade 4 + - Choroid Plexus Papillary Tumor + - Follicular Adenocarcinoma, Well Differentiated, Neuroblastoma, NOS + - Neuroepithelial Tumor + - Myelodysplastic Syndrome With Multilineage Dysplasia + - Primary Mediastinal (Thymic) Large B-Cell Lymphoma + - Mast Cell Leukemia + - Ganglioneuroblastoma + - Pheochromocytoma, NOS + - Papillary Serous Adenocarcinoma + - Mixed Germ Cell Tumor + - Lymphoid Leukemia, NOS + - Ependymoma NOS + - Smooth Muscle Tumor Of Uncertain Malignant Potential + - Combined Small Cell-Large Carcinoma + - Sertoli Leydig Cell Tumor + - Anaplastic Large Cell Lymphoma, ALK Positive + - Meningioma, Malignant + - Rhabdoid Tumor, NOS + - Merkel Cell Carcinoma + - Neoplasm, Uncertain Whether Benign Or Malignant, Meningioma, Other + - Lymphoma, NOS + - Gangliocytoma, NOS + - Glioblastoma, NOS, High-Grade Glioma, High-Grade Glioma, NOS Or NEC + - Mucinous Non-Cystic Carcinoma + - Mucinous Carcinoma + - Astrocytoma, NOS, Low-Grade Glioma, Pilocytic Astrocytoma + - Ganglioglioma, NOS, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - High Grade Carcinosarcoma + - Subependymal Giant Cell Astrocytoma, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC + - Squamous Cell Carcinoma, Metastatic, NOS + - Myeloid Leukemia Associated With Down Syndrome + - Meningeal Melanomatosis + - Neuroepithelial Tumor With Glioneuronal-Like Features + - Squamous Cell Carcinoma, Large Cell, Nonkeratinizing, NOS - Meningiomatosis, NOS - - Spindle Cell Rhabdomyosaroma - - Pleomorphic Sarcoma - - Cutaneous T-Cell Lymphoma, NOS - - Chordoma, NOS, Ganglioneuroblastoma - - Clear Cell Sarcoma, NOS - - Langerhans Cell Histiocytosis - - Supratentorial Ependymoma - - B Lymphoblastic Leukemia/Lymphoma, NOS - - Ganglioglioma, Anaplastic - - Giant Cell Glioblastoma, Glioblastoma, IDH-Wildtype, High-Grade Glioma - - Supratentorial Ependymoma CNS WHO Grade 3 + - Neoplasm, Uncertain Whether Benign Or Malignant, High-Grade Glioma, High-Grade Glioma, NOS Or NEC + - Oligodendroglioma, NOS, Low-Grade Glioma, Oligodendroglioma, IDH-Mutant, And 1p/19q-Codeleted + - Ependymoma, NOS, Posterior Fossa Ependymoma, Group PFA + - CNS Embryonal Tumor, NOS + - Favor Anaplastic Ependymoma + - Diffuse Glioma - Adamantinomatous Craniopharyngioma (CNS WHO Grade 1) - - Chordoma, NOS, Chordoma (Including Poorly Differentiated Chordoma), Other - - Hemangiosarcoma - - Adenoma, NOS - - Oligoastrocytoma, NOS, Glioneuronal And Neuronal Tumors, Papillary Glioneuronal Tumor - - Germinoma, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor - - Mycosis Fungoides, Langerhans Cell Histiocytosis, NOS - - Malignant Tumor, Small Cell Type - - Neoplasm, Malignant, ATRT, NOS Or NEC, Atypical Teratoid/Rhabdoid Tumor - - Ganglioglioma, NOS, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - - Embryonal Rhabdomyosarcoma, High-Grade - - Differentiating Neuroblastoma - - Malignant Tumor, Spindle Cell Type, CNS Sarcoma, CNS Sarcoma, NOS Or NEC - - Ganglioglioma, NOS, Ependymoma, Supratentorial Ependymoma, NOS Or NEC - - CNS Primative Neuroectodermal Tumor (PNET) - - Ossifying Fibroma - - B Lymphoblastic Leukemia/Lymphoma With T(12;21)(P13;Q22); TEL-AML1 (ETV6-RUNX1) - - Hodgkin Lymphoma, NOS - - Desmoplastic/Nodular Medulloblastoma - - Malignant Peripheral Nerve Sheath Tumor - - Glomus Tumor, Malignant - - Pleomorphic Xanthoastrocytoma, NOS - - Glioma, Malignant, High-Grade Glioma, Infant-Type Hemispheric Glioma - - Papillary Transitional Cell Carcinoma + - Medulloblastoma, Classic Variant, WHO Grade 4 + - Neoplasm, Uncertain Whether Benign Or Malignant, Astrocytoma, IDH-Mutant, Low-Grade Glioma + - Glioneuronal Tumor With Focal Increased Atypia + - High Grade Neuroepithelial Tumor + - Squamous Cell Carcinoma, Small Cell, Nonkeratinizing + - Mixed Phenotype Acute Leukemia With T(V;11q23); MLL Rearranged + - Acute Myeloid Leukemia, Minimal Differentiation + - Fibrillary Astrocytoma - Chordoma, NOS - - Rhabdoid Tumor, Malignant - - Ossifying Fibromyxoid Tumor, NOS - - CNS Embryonal Tumor, NOS, CNS Embryonal Tumor, NOS Or NEC, Other CNS Embryonal Tumors + - Undifferentiated Leukemia + - Myofibroma + - Neoplasm, Malignant + - Pleomorphic Xanthoastrocytoma, NOS, Low-Grade Glioma - Invasive Ductal Carcinoma - - High-Grade Serous Carcinoma - - Pleomorphic Liposarcoma - - Aggressive Fibromatosis - - Spindle Cell Carcinoma, NOS + - Subependymal Giant Cell Astrocytoma + - Embryonal Rhabdomyosarcoma With Anaplastic Features + - High-Grade Neuroepithelial Tumor + - Low Grade Glioneuronal Tumor + - Neoplasm, Malignant, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH + - Acute Myeloid Leukemia Without Maturation + - Adenocarcinoma With Mixed Subtypes + - B Lymphoblastic Leukemia/Lymphoma With Hyperdiploidy + - Malignant Peripheral Nerve Sheath Tumor, NOS + - Hemangiosarcoma + - Paraganglioma, NOS + - Medulloblastoma, Nodular/Desmoplastic With Anaplastic/Large Cell Features, Non-WNT/Non-SHH; WHO Grade 4 + - Signet Ring Cell Carcinoma + - Spindle Cell Melanoma, NOS + - Lobular Adenocarcinoma + - Undiagnosed Spindle Cell Tumor + - Pilocytic Astrocytoma, WHO Grade 1, KIAA1549-BRAF Fusion + - Meningioma + - Hepatosplenic T-Cell Lymphoma, Precursor Cell Lymphoblastic Leukemia, NOS + - Mesenchymal Chondrosarcoma + - Anaplastic Ganglioglioma + - Osteosarcoma, NOS + - Oligoastrocytoma, NOS, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC + - Ependymoma WHO Grade 3 + - Lung Adenocarcinoma, NOS + - Lymphoproliferative Disorder, NOS + - Atypical Lymphoid Infiltrate - Medulloblastoma, NOS, Medulloblastoma, SHH-Activated And TP53-Wildtype - - Neoplasm, Uncertain Whether Benign Or Malignant, Low-Grade Glioma, Oligodendroglioma, IDH-Mutant, And 1p/19q-Codeleted - - Chronic Myelogenous Leukemia, BCR/ABL Positive - - Ewing Sarcoma - - Dermatofibrosarcoma Protuberans, Fibrosarcomatous - - Malignant Epithelioid And Myxoid Neoplasm - - Poorly Differentiated Chordoma - - Oligoastrocytoma, NOS + - Genital Rhabdomyoma - Chondroblastic Osteosarcoma + - Neuroepithelioma, NOS + - Malignant Epithelioid And Myxoid Neoplasm + - Pancreatoblastoma + - Nephroblastoma (Wilms Tumor) + - Malignant Glioma + - Ewing Sarcoma + - Atypical Smooth Muscle Neoplasm + - Acute Myelomonocytic Leukemia, NOS + - Neoplasm, Uncertain Whether Benign Or Malignant, Low-Grade Glioma, Pilocytic Astrocytoma + - Epithelial Tumor, Benign - Favor Teratoma - - Metastatic Signet Ring Cell Carcinoma - - Rhabdomyosarcoma, NOS + - Malignant Neoplasm Of Prostate + - Non-Clear Cell Renal Cell Carcinoma + - Meningioma, NOS, Embryonal Tumor With Multilayered Rosettes, NOS, Other CNS Embryonal Tumors + - Melanotic Schwannoma, Other + - Medulloblastoma, NOS, Medulloblastoma, WNT-Activated + - Carcinosarcoma NOS + - Plasmacytoma, Extramedullary + - Infantile Fibrosarcoma + - Glioma, Malignant, High-Grade Glioma, High-Grade Glioma, NOS Or NEC + - CNS Primative Neuroectodermal Tumor (PNET) + - Infiltrating duct carcinoma, NOS + - Precursor B-Cell Lymphoblastic Leukemia + - Squamous Cell Carcinoma In Situ, NOS + - Acute Myeloid Leukemia, T(16;16)(P 13;Q 11) + - Papillary Transitional Cell Carcinoma + - Atypical Teratoid/Rhabdoid Tumor + - Low-Grade Glioneuronal, Neuronal Tumor + - Combined Small Cell-Adenocarcinoma + - Hepatocellular Carcinoma, NOS + - Spindle Cell Carcinoma, NOS + - Carcinoma, Diffuse Type + - Lentiginous Melanocytic Nevus + - Glioma, Malignant, Embryonal Tumor With Multilayered Rosettes, C19MC Altered, Other CNS Embryonal Tumors + - Solitary Fibrous Tumor, NOS + - Glioma, Malignant, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH + - Granulosa Cell Tumor, Malignant + - Ganglioneuroma, Maturing Type, Favorable Histology + - Invasive Lobular Carcinoma + - Ganglioglioma, NOS, Other, Other CNS Tumor, NOS Or NEC + - Bland Myofibroblastic Proliferation With Associated Florid Lymphoplasmacytic Inflammation + - Medulloblastoma + - Hepatoblastoma + - Low Grade Glial/ Glioneuronal Tumor + - Atypical Teratoid Rhabdoid Tumor, CNS WHO Grade 4 + - Oligoastrocytoma, NOS, Other, Other CNS Tumor, NOS Or NEC + - Diffuse Glioma, Favor High Grade + - Reactive Connective Tissue + - Medulloblastoma, NOS, Medulloblastoma, SHH-Activated And TP53-Mutant + - Tumor Cells, Malignant, Medulloblastoma, Medulloblastoma, NOS Or NEC + - Glioma, Malignant, Malignant Peripheral Nerve Sheath Tumor, NOS + - Melanoma, NOS + - Malignant Melanocytic Neoplasm + - Chronic Myelogenous Leukemia, BCR/ABL Positive + - Vascular Lesion, Consistent With Hemangioma + - Small Cell Neuroendocrine Carcinoma + - Medullary Carcinoma + - Anaplastic Astrocytoma, IDH-Wildtype, Glioblastoma, IDH Wildtype + - Rhabdomyosarcoma, Embryonal Subtype + - Medulloblastoma By Morphology, NON-WNT By Immunohistochemistry + - Glioma, Malignant, Astrocytoma, IDH-Mutant, High-Grade Glioma + - Ganglioglioma, NOS + - Dysembryoplastic Neuroepithelial Tumor, Angiocentric Glioma, Low-Grade Glioma + - Neoplasm, Uncertain Whether Benign Or Malignant, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Angiomatoid Fibrous Histiocytoma + - Micropapillary Carcinoma, NOS + - Infiltrating Lobular Carcinoma, NOS + - Gastrointestinal Stromal Tumor + - Desmoplastic Nodular Medulloblastoma, Medulloblastoma, Medulloblastoma, Group 4 + - Craniopharyngioma + - Sertoli-Leydig Cell Tumor, Intermediate Differentiation, With Heterologous Elements + - Acute Myeloid Leukemia, Inv(16)(P13;Q22) + - Subependymoma + - Gliomatosis Cerebri + - Infiltrating lobular carcinoma, NOS + - Schwannoma, NOS + - Oligodendroglioma, NOS, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Dysplasia + - Malignant Rhabdoid Tumor + - Blue Nevus, Malignant + - Adenocarcinoma, Pancreatobiliary Type + - Ependymoma, NOS, Choroid Plexus Tumors, Choroid Plexus Papilloma + - Ganglioneuroblastoma, Nodular Type - Granulosa Cell Tumor, Juvenile - - Pheochromocytoma, NOS - - Adenocarcinoma In Situ In Adenomatous Polyp - - Anaplastic Ganglioglioma - - Extra Adrenal Paraganglioma - - Lentiginous Melanocytic Nevus - - B-Lymphoblastic Leukemia/Lymphoma, NOS - - Osteosarcoma, NOS - - Angiomyosarcoma - - Neoplasm, Uncertain Whether Benign Or Malignant, CNS Sarcoma, Ewing Sarcoma - - Pancreatic Neuroendocrine Tumor, Nonfunctioning - - Mesenchymal Lesion - - Ganglioneuroma, High-Grade Glioma, High-Grade Glioma, NOS Or NEC - - Papillary Adenocarcinoma, NOS - - Adult Granulosa Cell Tumor Of Testis + - Juvenile Granulosa Cell Tumor + - Chronic Myeloid Leukemia, BCR-ABL1-Positive + - Head & Neck Squamous Cell Carcinoma + - Astrocytoma, NOS, Low-Grade Glioma, Subependymal Giant Cell Astrocytoma + - Medulloblastoma, SHH-Activated And TP53-Wildtype + - Ganglioglioma, NOS, Ependymoma, Supratentorial Ependymoma, NOS Or NEC - Intraductal Papillary Mucinous Neoplasm With An Associated Invasive Carcinoma - - Infiltrating Lobular Carcinoma, NOS - - Undifferentiated Leukemia - - Hemangioblastoma, Other - - Serous Carcinoma, NOS - - Neoplasm, Malignant, CNS Embryonal Tumor, NOS Or NEC, Other CNS Embryonal Tumors - - Pilocytic Astrocytoma, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC - - Atypical Teratoid Rhabdoid Tumor, CNS WHO Grade 4 - - Small Blue Cell Tumor. Favor Medulloblastoma - - Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, NOS Or NEC - - Rasmussen Encephalitis - - Adenocarcinoma, Metastatic NOS - - Primary Cutaneous CD30 Positive T-Cell Lymphoproliferative Disorder - - Astrocytoma, NOS, Astrocytoma, IDH-Mutant, Low-Grade Glioma - - Small Cell Neuroendocrine Carcinoma - - Infiltrating Duct And Mucinous Carcinoma - - Acute Myeloid Leukemia With Mutated NPM1 - - Subcutaneous Panniculitis-Like T-Cell Lymphoma - - Retinoblastoma, NOS - - Clear Cell Adenocarcinoma, NOS - - Mixed Germ Cell Tumor, Myelodysplastic Syndrome With Excess Blasts + - Adrenal Cortical Adenoma, NOS + - Adenocarcinoma, Pancreatobiliary Type, Pancreatobiliary-Type Carcinoma + - Lipoblastomatosis + - Central Neurocytoma, Glioneuronal And Neuronal Tumors + - Control + - HHV8 Positive Diffuse Large B-Cell Lymphoma + - Pilocytic Astrocytoma, Low-Grade Glioma, Pleomorphic Xanthoastrocytoma + - Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, Group 4 + - Large Cell Medulloblastoma + - B Lymphoblastic Leukemia/Lymphoma With T(12;21)(P13;Q22); TEL-AML1 (ETV6-RUNX1) + - Central Osteosarcoma, NOS - Chordoma - - Cribriform Carcinoma, NOS - - Mixed Germ Cell Tumor, Acute Megakaryoblastic Leukemia - - Desmoplastic Fibroma - - Genital Rhabdomyoma - - Infiltrating Duct And Lobular Carcinoma - - Residual Low Grade Neuroendocrine Tumor (Typical Carcinoid) - - Plexiform Fibrohistiocytic Tumor - - Neoplasm, Uncertain Whether Benign Or Malignant, ATRT-SHH, Atypical Teratoid/Rhabdoid Tumor - - Oligoastrocytoma, NOS, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC - - Pilocytic Astrocytoma, WHO Grade 1 - - Choriocarcinoma, NOS - - Myxofibrosarcoma + - Pilocytic Astrocytoma, Diffuse Leptomeningeal Glioneuronal Tumor, Glioneuronal And Neuronal Tumors + - Pilocytic Astrocytoma, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Dermatofibrosarcoma Protuberans, Fibrosarcomatous + - Neuroendocrine Carcinoma, NOS + - Glioma, Malignant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype And IDH-Wildtype, High-Grade Glioma + - Oligodendroglioma, NOS + - Acute Monoblastic Leukemia + - Glioma, Malignant, Low-Grade Glioma, Polymorphous Low-Grade Neuroepithelial Tumor Of The Young + - Neoplasm + - Medulloepithelioma, NOS + - Oligodendroglioma, NOS, High-Grade Glioma, Oligodendroglioma, IDH-Mutant, And 1p/19q-Codeleted + - Not Reported + - Aggressive Fibromatosis + - Acute Myeloid Leukemia With Myelodysplasia-Related Changes + - Langerhans Cell Histiocytosis, Disseminated + - Glioma, Malignant, Low-Grade Glioma, Pilocytic Astrocytoma + - Oligoastrocytoma, NOS + - Undifferentiated Nasopharyngeal Carcinoma + - Small Cell Carcinoma, NOS + - Chordoma, NOS, Chordoma (Including Poorly Differentiated Chordoma), Other + - Mesothelioma, Biphasic, Malignant, B Lymphoblastic Leukemia/Lymphoma, NOS + - Central Neurocytoma, Low-Grade Glioma, Subependymal Giant Cell Astrocytoma + - Undifferentiated Small Round Cell Sarcoma + - Rhabdomyoma, NOS + - Glioblastoma, IDH Wildtype + - Neoplasm, Malignant, Astrocytoma, IDH-Mutant, Low-Grade Glioma + - Therapy Related Myeloid Neoplasm + - Acute Myeloid Leukemia, NOS + - Malignant Tumor, Spindle Cell Type, CNS Sarcoma, CNS Sarcoma, NOS Or NEC + - Leydig Cell Tumor, Benign - Myelodysplastic Syndrome With Single Lineage Dysplasia - - Bronchio-Alveolar Carcinoma, Mucinous - - Medulloblastoma, Classic Histology - - Non-Germinomatous Germ Cell Tumor - - Poorly Differentiated Sertoli-Leydig Cell Tumor With Heterologous Rhabdomyosarcomatous Differentiation - - Pleomorphic Rhabdomyosarcoma, Adult Type - - Infiltrating Ductal Carcinoma - - Acute Megakaryoblastic Leukemia - - Myxopapillary Ependymoma (CNS WHO Grade II) - - Mucoepidermoid Carcinoma - - Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH - - Carcinoma, Undifferentiated, NOS - - Marginal Zone B-Cell Lymphoma, NOS - - Central Osteosarcoma, NOS - - Olfactory Neurocytoma - - T Lymphoblastic Leukemia/Lymphoma - - Mixed Glioma - - Medulloblastoma, Group 3 Subtype (WHO Grade 4) - - Cystosarcoma Phyllodes, NOS - - Amelanotic Melanoma - - Pleomorphic Xanthoastrocytoma, NOS, Low-Grade Glioma - - Meningothelial Meningioma, Grade 1 - - Low Grade Glioma - - Clear Cell Meningioma + - Germinoma, CNS Germ Cell Tumors, CNS Germinoma + - Glial Tumor + - Synovial Sarcoma, Spindle Cell + - Spindle Cell Melanoma, Type B + - Familial Adenomatous Polyposis + - Giant Cell Glioblastoma + - Teratocarcinoma + - Adenoma, NOS + - Acral Lentiginous Melanoma, Malignant + - Carcinoma NOS + - Papillary Carcinoma, NOS + - Poorly Differentiated Neuroblastoma + - Solid Pseudopapillary Neoplasm Of Pancreas - Nasopharyngeal Carcinoma - - Spinal Ependymoma, Histologically Low Grade (CNS WHO Grade 2) - - Infiltrating Duct Carcinoma NOS - - Lymphangioma, NOS - - Mixed Adenocarcinoma And Squamous Cell Carcinoma, Pancreatobiliary-Type Carcinoma - - Glioma - - T-Cell/Histiocyte Rich Large B-Cell Lymphoma - - Desmoplastic Nodular Medulloblastoma, Medulloblastoma, Medulloblastoma, Group 4 - - Mixed Phenotype Acute Leukemia, B/Myeloid, NOS - - Acute Myeloid Leukemia, Minimal Differentiation - - Favor Pilocytic Astrocytoma With Increased Proliferation Indices - - Acute Promyelocytic Leukemia, T(15;17)(Q22;Q11-12) - - Oligodendroglioma, NOS, High-Grade Glioma, Oligodendroglioma, IDH-Mutant, And 1p/19q-Codeleted - - Ependymoma, Anaplastic, Supratentorial Ependymoma, NOS Or NEC - - Dermoid Cyst + - Adenocarcinoma In Adenomatous Polyposis Coli + - Leiomyoma, NOS + - Embryonal Rhabdomyosarcoma, NOS + - Choroid Plexus Papilloma, NOS, Other CNS Embryonal Tumors, Pineoblastoma + - Tumor Cells, Benign + - Marginal Zone B-Cell Lymphoma, NOS + - Tumor Cells, Malignant, Other, Pineal Parenchymal Tumor Of Intermediate Differentiation + - Pinealoma + - Atypical Teratoid/Rhabdoid Tumor, INI1/SMARCB1-Altered, WHO Grade 4 + - Metastatic Signet Ring Cell Carcinoma + - Astrocytoma + - Desmoplastic Infantile Astrocytoma + - Malignant Sarcoma With DICER1 Mutation, Favor Primary Intracranial Sarcoma, DICER1 Mutant + - B Lymphoblastic Leukemia/Lymphoma With Hypodiploidy + - Colon Adenocarcinoma + - Ependymoma, NOS, Supratentorial Ependymoma, NOS Or NEC + - Proliferative Dermal Lesion In Congenital Nevus + - Neoplasm, Malignant, Medulloblastoma, Medulloblastoma, WNT-Activated - Arteriovenous Malformation - - Glioma, Malignant, High-Grade Glioma, Pleomorphic Xanthoastrocytoma - - Mixed Epithelioid And Spindle Cell Melanoma - - Anaplastic Astrocytoma, IDH-Wildtype, Glioblastoma, IDH Wildtype - - Germ Cell Tumor, Nonseminomatous, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor - - Melanoma, NOS - - Glioblastoma, IDH Wildtype - - Medulloblastoma, Classic Morphology, CNS WHO Grade 4, NON-WNT/NON-SHH, Group 4 Subtype By Methylation - - Paraganglioma, Malignant - - Fibrillary Astrocytoma - - Ependymoma WHO Grade 3 - - Dysplasia - - Sertoli Leydig Cell Tumor - - Embryonal Tumor - - Undifferentiated Nasopharyngeal Carcinoma - - Adamantinomatous Craniopharyngioma - - Central Primitive Neuroectodermal Tumor - - Ependymoma WHO Grade 2 - - Neoplasm, Malignant, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH - - Adenocarcinoma, Intestinal Type + - Glioma, Malignant + - Acinar Cell Carcinoma + - Spinal Ependymoma, Histologically Low Grade (CNS WHO Grade 2) + - Leukemia, NOS + - Hemangioblastoma, Other + - High-Grade Serous Carcinoma + - Medulloblastoma, NOS, Medulloblastoma, Group 3 + - Schwannian Stroma Poor Peripheral Neuroblastic Tumor, Consistent With Neuroblastoma + - Acute Myeloid Leukemia With Mutated CEBPA + - Parosteal Osteosarcoma + - Epithelioid Mesothelioma, Malignant + - Meningioma, NOS + - Neoplasm, Uncertain Whether Benign Or Malignant, ATRT-SHH, Atypical Teratoid/Rhabdoid Tumor + - Choriocarcinoma Combined With Other Germ Cell Elements + - Brain Tumor, Low Grade Glioma + - Ganglioglioma, NOS, Diffuse Astrocytoma, MYB- Or MYBL1-Altered, Low-Grade Glioma + - Embryonal Tumor With Multilayered Rosettes C19MC-Altered + - Neoplasm, Malignant, Uncertain Whether Primary Or Metastatic + - Desmoplastic Small Round Cell Tumor + - Embryonal Rhabdomyosarcoma + - Langerhans Cell Histiocytosis + - Glial Neoplasm Showing High-Grade Features + - Oligodendroglioma + - Malignant Melanoma, NOS + - Myxopapillary Ependymoma, Ependymoma + - Medulloblastoma, NOS, Medulloblastoma, NOS Or NEC + - Neoplasm, Malignant, CNS Embryonal Tumor, NOS Or NEC, Other CNS Embryonal Tumors + - Adenocarcinoma + - B Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34;Q11.2); BCR-ABL1 + - Hemangioendothelioma, Malignant - Choroid Plexus Neoplasm - - Glial Neoplasm, Favor Pilocytic Astrocytoma - - Gastrointestinal Stromal Tumor, NOS - - Acute Myeloid Leukemia, Inv(16)(P13;Q22) - - Composite Hodgkin And Non-Hodgkin Lymphoma - - Myeloid Leukemia With Myelodysplasia-Related Changes - - Hemangioblastoma - - Choroid Plexus Carcinoma - - Basaloid Squamous Cell Carcinoma + - Craniopharyngioma, Adamantinomatous, Adamantinomatous Craniopharyngioma + - Pinealoblastoma + - Large Cell Medulloblastoma, Embryonal Tumor With Multilayered Rosettes, NOS, Other CNS Embryonal Tumors + - Spindle Cell Sarcoma + - Gliosarcoma + - Central Primitive Neuroectodermal Tumor + - Astrocytoma, IDH-Mutant, CNS WHO Grade 3 + - Astrocytoma, Benign + - Pleomorphic Rhabdomyosarcoma, Adult Type + - Myeloid Sarcoma + - Glioma, Malignant, Other, Other Low-Grade B-Cell Lymphomas Of The CNS + - Ganglioneuroma + - Neoplasm, Malignant, High-Grade Glioma, High-Grade Glioma, NOS Or NEC + - Clear Cell Renal Cell Carcinoma + - Ependymoma, NOS, Atypical Meningioma + - Oligodendroglioma, NOS, Other, Other CNS Tumor, NOS Or NEC + - Malignant Peripheral Nerve Sheath Tumor + - Glioma, Malignant, Diffuse Midline Glioma, H3 K27-Altered, High-Grade Glioma + - Sertoli-Leydig Cell Tumor Of Intermediate Differentiation, NOS + - Desmoplastic Nodular Medulloblastoma + - Papillary Microcarcinoma + - Craniopharyngioma, NOS + - Low Grade Glial Neoplasm + - Leiomyosarcoma, NOS + - Follicular Adenocarcinoma, NOS Req: true Term: - Origin: caDSR From 48a3e69f35477aced2e6e2167fd98b14e0113b10 Mon Sep 17 00:00:00 2001 From: wfy1997 <60631776+wfy1997@users.noreply.github.com> Date: Wed, 30 Oct 2024 14:13:17 -0400 Subject: [PATCH 22/23] Update cds-model-props.yml --- model-desc/cds-model-props.yml | 3 ++- 1 file changed, 2 insertions(+), 1 deletion(-) diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index 5bb2732..db1ef6d 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -10870,7 +10870,7 @@ PropDefinitions: Version: '1.00' # proteomic aliquot_id: - Desc: Software that was used to de-identify the images (if used) + Desc: One or more characters used to identify a portion of a sample. Req: true Key: true Term: @@ -10878,6 +10878,7 @@ PropDefinitions: Original Source: CRDC Code: "15105438" Value: Specimen Aliquot Identifier + Version: '1.00' analytical_fractions: Desc: The portion of a specimen that was isolated from the whole and collected via a fractionation process to be subjected to further analysis. Enum: From 9000832a5d2b0881430dbc2b9551f7424d43ba5b Mon Sep 17 00:00:00 2001 From: wfy1997 <60631776+wfy1997@users.noreply.github.com> Date: Wed, 30 Oct 2024 14:15:45 -0400 Subject: [PATCH 23/23] Update aliquote_id --- model-desc/cds-model-props.yml | 1 + 1 file changed, 1 insertion(+) diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index db1ef6d..f463ccc 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -10873,6 +10873,7 @@ PropDefinitions: Desc: One or more characters used to identify a portion of a sample. Req: true Key: true + Type: string Term: - Origin: caDSR Original Source: CRDC